LEVINE (1984)
(Lish)
DRAFT COPY
DOC #22

920

Contract No. DAMD17-79-C-9161
IITRI Project No. L6121
Study No. 7

DETERMINATION OF THE CHRONIC MAMMALIAN TOXICOLOGICAL EFFECTS OF RDX

B

TWENTY-FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE (RDX) IN THE B6C3F1 HYBRID MOUSE

Levine, B.S., et al. 1984
DAMD-IIT Res. Rpt.

PHASE VI FINAL REPORT
Volume 3

Prepared by:

Barry S. Levine
E. Marianna Furedi
John M. Sagartz
Vladislava S. Rac
Paul M. Lish

IIT Research Institute
10 West 35th Street
Chicago, IL 60616

Supported by:

U.S. Army Medical Research
and Development Command
Fort Detrick, Frederick, MD 21701

Project Officer: Jesse J. Barkley, Jr.

April 1984

Approved for public release: Distribution Unlimited

The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.

286 Q MICE

LEVINE (1984)
(Lish)
Draft Copy
DOC #22

920

Contract No. DAMD17-79-C-9161
IITRI Project No. L6121
Study No. 7

DETERMINATION OF THE CHRONIC MAMMALIAN TOXICOLOGICAL EFFECTS OF RDX

B

TWENTY-FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE (RDX) IN THE B6C3F1 HYBRID MOUSE

Levine, B.S., et al. 1984

DAMD-IIT Restricted

PHASE VI FINAL REPORT
Volume 3

Prepared by:

Barry S. Levine
E. Marianna Furedi
John M. Sagartz
Vladislava S. Rac
Paul M. Lish

IIT Research Institute
10 West 35th Street
Chicago, IL 60616

Supported by:

U.S. Army Medical Research
and Development Command
Fort Detrick, Frederick, MD 21701

Project Officer: Jesse J. Barkley, Jr.

April 1984

Approved for public release: Distribution Unlimited

The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.

LC

APPENDIX XI

PATHOLOGY REPORT

FINAL PATHOLOGY REPORT

of Twenty-four Month Chronic Toxicity-Carcinogenicity Study of Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) in B6C3F1 Hybrid Mice

March 26, 1984

IITRI Project Number L6121

Study Number 7

IIT RESEARCH INSTITUTE

QUALITY ASSURANCE STATEMENT
L6121 SN 7

Necropsy and histology procedures were inspected on January 1, August 4, and November 11, 1981; February 10, April 21, and November 29, 1982; and January 26, February 8, April 25 and May, 19, 1983. Draft Pathology Reports were audited January 21, May 3, and August 19 and 20, 1982; January 12 to 17, and October 6, 1983; and January 12 to 18, February 29 to March 2 and March 28 to 30, 1984. Inspections and audits were performed by Josephine M. Reed and Julie McPhilips. The study was found to meet Life Sciences Quality Assurance criteria. Specimens and raw data generated during the study will be retained in the IITRI Life Sciences Archives as specified in standard operating procedures.

Josephine M. Reed
Supervisor, Quality Assurance

TABLE OF CONTENTS

MATERIAL AND METHODS 601

1. Gross Pathology 601

2. Histopathology 602

PATHOLOGY RESULTS 602

1. Gross Observations 602

Six Month Observations 603
Twelve Month Observations 603
Twenty-four Month Observations 603

2. Histopathology 604

Six Month Interim Sacrifice 604
Twelve Month Interim Sacrifice 604
Twenty-four Month Terminal Sacrifice 604

3. Summary and Conclusions 605

PATHOLOGY APPENDIX I: 607

Six Month Interim Sacrifice 608

A Gross Pathology Table I 609
B Histopathology Incidence Tables 628
C Incidence Comparison Tables 667
D Incidence of Lesions Considered to be Treatment-Related ... 672

PATHOLOGY APPENDIX II: 673

Twelve Month Interim Sacrifice 673

A Gross Pathology Table II 675
B Histopathology Incidence Tables 690
C Incidence Comparison Tables 718

PATHOLOGY APPENDIX III: 725

Twenty-four Month Terminal Sacrifice 725

A Gross Pathology Table III A, III B 727
B Histopathology Incidence Tables 771
C Incidence Comparision Tables 1153
D Incidence of Lesions Considered to be Treatment-Related .. 1181

TABLE OF CONTENTS (Continued)

PATHOLOGY APPENDIX IV: 1182

Statistical Evaluation 1182

1. Statistical Evaluation of Histopathologic Lesions MALE B6C3F1 HYBRID MOUSE - Table IV 1182

2. Statistical Evaluation of Histopathologic Lesions FEMALE B6C3F1 HYBRID MOUSE - Table V 1186

3. Statistical Evaluation of Histopathologic Lesions MALE B6C3F1 HYBRID MOUSE (LIVER, Adenoma and Carcinoma) - Table VI 1188

PATHOLOGY APPENDIX V: 1189

Addendum - Histopathology Report - Lung Sections From 1.5, 7.0 and 35.0 mg/kg/day Dose Groups 1189

FINAL PATHOLOGY REPORT
of Twenty-four Month Chronic Toxicity-Carcinogenicity
Study of Hexahydro-1,3,5-trinitro-1,3,5-triazine
(RDX) in B6C3F1 Hybrid Mice

MATERIAL AND METHODS

In accordance with the amended experimental protocol gross and histopathologic examinations were performed on organs and tissues of B6C3F1 hybrid mice for IITRI Project L6121, Study Number 7.

The mice were divided into five groups, each consisting of 85 males and 85 females. Four of the five groups were each treated with different doses of HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE (RDX) for twenty-four months. The mice of the fifth group did not receive RDX and did serve as a control group. The group number, treatment, number of mice per group, and the corresponding dose levels are outlined below.

Treatment Group	Treatment	Number of Males	Number of Females	Dose Level mg/kg/day
I	-	85	85	0.0
II	RDX	85	85	1.5
III	RDX	85	85	7.0
IV	RDX	85	85	35.0
V	RDX	85	85	175.0/100*

* Due to high mortality, dose level of 175 mg/kg was reduced for both sexes to 100 mg/kg, commencing on 4/20/81 (Week 11 of the Study).

In accordance with the experimental design, 10 mice per sex, per dose level were sacrificed after six months and twelve months of the study. All surviving mice were sacrificed after twenty-four months of the study.

1. Gross Pathology All mice were anesthetized by carbon dioxide inhalation and exanguinated from the orbital sinus or abominal aorta. Mice that died or were sacrificed moribund were also necropsied. At necropsy thoracic, abdominal, and cranial cavities of each mouse were opened and organs were examined and collected in buffered neutral 10% formalin. The lungs were fixed by intratracheal perfusion of formalin. Eyes were fixed in 3% glutaraldehyde, testes were fixed in Bouin's solution for 24 hours, and then placed in 70% ethanol before processing. The brain, heart, kidneys, liver, spleen, testes were weighed at necropsy before fixation except for spontaneous deaths and moribund sacrifices.

The following tissues were collected.

2 *adrenals	2 ovaries
3 *brain (frontal, parietal, cerebellar)	1 *pancreas
1 *cecum	1 pituitary
1 *colon	1 *prostate -M
1 costobrondial junction, rib	1 rectum
1 *duodenum	1 salivary gland
2 *epididymes	2 seminal vesicles
1 *esophagus	1 sciatic nerve
2 *eyes and optic nerves	2 *skin/mammary gland
1 gall bladder	3 *spinal cord (cerival, thoracic, lumbar)
1 *heart	1 *spleen
1 *ileum	1 *sternum with marrow
1 *jejunum	1 *stomach
2 *kidneys	2 testes
1 *larynx	1 thymus
2 *liver	2 *thyroids/parathyroids
2 *lungs with mainstem bronchi	1 *trachea
lymph nodes:	1 *uterus
1 mandibular	1 *urinary bladder
1 *mesenteric	0 bone marrow smear
1 muscle, skeletal	2 *tissue masses
3 nasal turbinates	

and any other tissues with *gross lesions.

56 - 5 = 51

2. Histopathology Tissues marked with an asterisk from control and high dose level(175/100 mg/kg) were paraffin embedded, sectioned at 5 μ, stained with hematoxylin and eosin and examined microscopically. The liver, brain, spinal cord, kidneys, heart, spleen, gonads, lungs, gross lesions and tissue masses were examined microscopically for all remaining test mice.

The grading system and abbreviations used in the tables are as follows.

Grade 1 = minimal severity
Grade 2 = mild severity
Grade 3 = moderate severity
Grade 4 = marked severity
N = Within Normal Limits
M = Tissue Not Present
- = Tissue Not Applicable
P = Lesion Present, No Grade

PATHOLOGY RESULTS

1. Gross Observations A summary of gross observations is presented by group and sex for Six Month Interim Sacrifice, Pathology Appendix I - Table I; Twelve Month Interim Sacrifice, Pathology Appendix II - Table II; and Twenty-Four Month Terminal Sacrifice, Pathology Appendix III - Tables IIIA and IIIB.

SIX MONTH OBSERVATIONS - TABLE I

There was fighting among the male mice, especially at the 175/100 mg/kg/day dosage level. This fighting induced damage to external genitalia and induced skin lesions. These lesions were considered to be only secondary to the compound administration. Crusty and dark red skin was observed at these fighting wounds.

Thirty male and 36 female mice that died during the first six months of the study at the 175/100 mg/kg/day dose level had dark red mottled lungs, dark red spleen and dark red liver. Distended with red, yellow and brown fluid urinary bladder was observed in 14/39 male mice at the 175/100 mg/kg/day dose level. These lesions observed at necropsy were considered to be induced by the RDX administration.

TWELVE MONTH OBSERVATIONS - TABLE II

Mice that died or were sacrificed moribund between six and twelve months and all mice that were sacrificed at twelve month interim period and were treated with RDX did not have lesions observed at necropsy in greater frequency than those observed in the control group.

TWENTY-FOUR MONTH TERMINAL SACRIFICE - TABLE III A, III B

Lesions observed at necropsy in mice that died spontaneously or those sacrificed as moribund between twelve and twenty-four months are present in Pathology Appendix III in Tables IIIA and IIIB. Mice which were treated with RDX when compared with the control group, appear to have higher incidences of liver nodules or masses and enlarged livers than the control group.

Gross observations at terminal sacrifice are presented in Table III B. Lesions observed at necropsy in female mice as liver nodules or masses appear to occur in higher incidences in RDX treated female mice which was probably related to the compound administration.

All other lesions observed at necropsy at six month interim sacrifices, twelve month sacrifce and in mice that were sacrificed at the twenty-four month of the study and all mice that died spontaneously or were sacrificed as moribund during the study were considered to be spontaneously occurring inflammatory, degenerative and/or neoplastic lesions which are commonly observed in this strain of mice and were considered to be unrelated to the administration of RDX.

2. Histopathology

SIX MONTH INTERIM SACRIFICE

Microscopic examination of tissues from mice sacrificed after six months, mice that died spontaneously or were sacrificed moribund during this study period, revealed renal tubular cytoplasmic vacuolization in male mice at all dose levels. Renal tubular cytoplasmic vacuolization was seen in one control mouse, 10 mice receiving 1.5 mg/kg/day, 12 mice receiving 7.0 mg/kg/day, 11 mice receiving 35.0 mg/kg/day and 12 mice receiving 175/100 mg/kg/day. In this lesion, single or multiple sharply delineated cytoplasmic vacuoles were found in renal tubular epithelium. Renal tubular cytoplasmic vacuolization was considered to be compound-induced at six month interim sacrifice but was not considered to be RDX-induced at the twelve month interim sacrifice and at the twenty-four month terminal sacrifice. There was excessive fighting in male mice causing cutaneous trauma and an increased incidence of dermatitis in male mice. This increased incidence of skin lesions is a secondary compound effect.

TWELVE MONTH INTERIM SACRIFICE

No compound-related microscopic lesions were observed in male and female mice sacrificed after twelve months of the study, mice that died spontaneously nor in mice which were sacrificed moribund. The increased incidence of dermal lesions reflects compound-induced behavioral changes (fighting wounds) rather than specific effects on the skin as a target organ.

TWENTY-FOUR MONTH TERMINAL SACRIFICE

Microscopic examination of tissues from mice after the terminal sacrifice revealed statistically significant (at $p < 0.05$) compound-induced testicular degeneration at the 35 and 175/100 mg/kg/day dose level (Pathology Appendix IV - Table IV). There was necrosis of germinal epithelium, interstitial fibrosis and aspermia in male mice. The statistically significant increase of the hepatocellular adenoma/carcinoma was observed in female mice at the 7.0, 35, and 175/100 mg/kg/day dose level (Pathology Appendix IV - Tables V and VI). Chronic dermatitis observed in male mice was a compound-induced hyperesthesia and fight-induced dermal lesion.

Historical control data from the National Toxicology Program (NTP Bulletin #10) were therefore included in the analyses as the female concurrent control group demonstrated a low incidence of liver tumors. When this was performed (Pathology Appendix IV - Table VI) female mice receiving 35 mg/kg/day still showed a significant increase in hepatocarcinomas. A p value of $\simeq 0.09$ was, however, seen for 175/100 mg/kg/day-treated females when compared to historical controls. The small number of surviving animals in this high dose group (31) compared to 60-65 for the other groups may have contributed to this statistic as the actual incidence (9.7%) was greater than that seen at 35 mg/kg/day (9.4%). When combined adenoma/carcinoma data were analyzed, statistically significant increases were observed for both 35 and 175/100 mg/kg/day females compared to either concurrent or historical control data. This was apparent even though concurrent controls had a significantly lower incidence than historical controls. The data therefore suggest that RDX is a suspect carcinogen.

The incidence of alveolar/bronchiolar carcinoma in male mice (Pathology Appendix IV - Table IV) was statistically significant only at the 175/100 mg/kg/day dose level.

All other lesions observed microscopically in tissues from the twenty-four month chronic toxicity/carcinogenicity study of HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE (RDX) were considered spontaneous, naturally occuring degenerative, inflammatory and/or neoplastic diseases which commonly occur in an aging mouse population of the B6C3F1 strain (see References 1 and 2).

SUMMARY AND CONCLUSIONS

Gross lesions observed at six months of the study for the 175/100 mg/kg/day dosage level as red lungs, dark red spleen, dark red liver, distended with red fluid urinary bladder were considered to be induced by RDX. Compound-related lesions observed in kidneys for male mice as renal tubular cytoplasmic vacuolization (Six Month Interim Report) at all dosage levels was not observed in male mice at the Twelve Month nor the Twenty-four Month Histopathologic Examination at any dosage level. Increased incidence of dermatitis in male mice was considered to be a secondary compound effect.

No compound-related gross nor histopathologic lesions were observed at the Twelve Month Interim Sacrifice. The increased incidence of dermal lesions during this study period reflect compound-induced behavioral changes (fighting wounds) rather than specific effects on the skin as a target organ.

Lesions observed at necropsy at the terminal sacrifice for female mice as liver nodules and masses were considered to be compound-induced. Microscopic examination revealed statistically significant increased incidence of hepatocellular adenomas and carcinomas in female mice for 7.0, 35.0, and 175/100 mg/kg/day dose levels which was a carcinogenic effect of RDX in the B6C3F1 strain when treated for twenty-four months. In male mice testicular degeneration was considered to be induced by RDX at the 35 and 175/100 mg/kg/day dosage levels. The occurrence of combined alveolar-bronchial carcinoma/adenoma in male mice was statistically significant (at $p < 0.05$) only at the 175/100 mg/kg/day dose level.

On the basis of compound-induced histopathologic lesions observed in this study, no effect levels for RDX in B6C3F1 Hybrid Mice were 7.0 mg/kg/day for male mice and 1.5 mg/kg/day dose level for female mice.

Vladislava S. Rac

Vladislava S. Rac, D.V.M., M.S.
Head, Pathology
Pathology Section
Life Sciences Research

IIT RESEARCH INSTITUTE

REFERENCES

Benirschke, K., et al. Pathology of Laboratory Animals, Vols. I & II. Springer-Verlag, New York. 1978.

Turuson, V. S. Pathology of Tumours in Laboratory Animals, Vol. II: Tumours of the Mouse. WHO.IARX, Lyon. 1979.

PATHOLOGY APPENDIX I:

Six Month Interim Sacrifice

FINAL PATHOLOGY REPORT

of Twenty-Four Month Chronic Toxicity-Carcinogenicity Study of Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) in B6C3F1 Hybrid Mice

IITRI Project No. L6121
Study Number 7

Six Month Interim Report
NECROPSY OBSERVATIONS

Carol A. Thompson, D.V.M., M.S.
Senior Veterinary Pathologist
Pathology Section
Life Sciences Research

L06121 SN 7
Six Month Interim Sacrifice
and Deaths 0-6 Months
B6C3F1 Hybrid Mouse

Table I

NECROPSY OBSERVATIONS

ORGAN Lesion	MALES 0.0	1.5	7.0	35	175/ 100	FEMALES 0.0	1.5	7.0	35	175/ 100
Number of Mice Examined	11	12	13	13	46	10	11	10	10	44
No Gross Lesions	7	7	5	7	7	5	3	6	4	15
SKIN/Subcutis										
Hair loss, focal/multifocal			1	1	1	2	2		3	
Dark red, focal/diffuse			1							
Firm, focal			1		1					
Dry				1						
Nodule					2					
Mass			1		1		1			
Crusty, dark red/fighting wounds			3		7					
Thickened					1					
THYMUS										
Dark red			1							
HEART										
Soft/spongy			1		2					

L06121 SN 7
Six Month Interim Sacrifice
and Deaths 0-6 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS

ORGAN Lesion	MALES 0.0	1.5	7.0	35	175/ 100	FEMALES 0.0	1.5	7.0	35	175/ 100
LUNG										
Mottled	1	1	1	2	8		1			5
Dark red/mottled red		1	1		15					15
Dark					1					2
Spotted										1
Mottled black										1
Oozed red material					1					4
LIVER										
Mottled red/dark red	1		1		2					3
Light brown/pale/tan	2	1	1	1	3	3	4	3	2	1
Soft										1
White, focal/multifocal			1		1					
Dark brown					2					1
Oozed red material					2					3
SPLEEN										
Dark red/purple/ dark	1				7					7
Enlarged/round edges	1	1	2	2	2	1	2	2	2	1

L06121 SN 7
Six Month Interim Sacrifice
and Deaths 0-6 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS

ORGAN Lesion	MALES 0.0	1.5	7.0	35	175/ 100	FEMALES 0.0	1.5	7.0	35	175/ 100
SPLEEN (continued)										
Soft		1		1						
Black, focal/diffuse			1		1					3
Oozed red material										1
Brown/dark brown		1								
Pale/light red			1							
PANCREAS										
Dark red					3					2
KIDNEY										
Light brown/tan/pale		1			1					
Soft		1								
Mottled red				1	1					
Nodule(s)		1								
URINARY BLADDER										
Distended with fluid, red/yellow/brown	3	3	2	2	13					
Mass(es)			1							

L06121 SN 7
Six Month Interim Sacrifice
and Deaths 0-6 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS

ORGAN Lesion	MALES 0.0	1.5	7.0	35	175/ 100	FEMALES 0.0	1.5	7.0	35	175/ 100
URINARY BLADDER (continued)										
Firm					4					
TESTES										
Small				1						
SEMINAL VESICLES										
Yellow					3					
Small					1					
Enlarged					1					
PENIS										
Crusted/crusted red	1		1		1					
Swollen/enlarged	1		1		1					
Firm	1	1			1					
Dark red	1	1			1					
Discharge, white/red/yellow			1		1					
Irritation		1		1	1					
Extended from prepuce				1						

L06121 SN 7
Six Month Interim Sacrifice
and Deaths 0-6 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS

ORGAN Lesion	MALES 0.0	1.5	7.0	35	175/ 100	FEMALES 0.0	1.5	7.0	35	175/ 100
PREPUCE										
Abscess				1						
PREPUTIAL GLAND										
Cyst		1			2					
SCROTUM										
Lesion			1							
UTERUS										
Swollen/distended						1	1	1	2	1
Segmented						1	1			
Dark red										2
Contained red material										1
Mass							1			
OVARIES										
Mass							1			
Cyst										1

L06121 SN 7
Six Month Interim Sacrifice
and Deaths 0-6 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS

ORGAN Lesion	MALES 0.0	1.5	7.0	35	175/100	FEMALES 0.0	1.5	7.0	35	175/100
STOMACH										
Distended					3					1
Firm					2					1
DUODENUM										
Red foci					1					
Flaccid					2					
Contained red material					1					
Distended with gas										1
JEJUNUM										
Flaccid					2					
Distended with gas										1
Contained red material					1					
ILEUM										
Contained red material					1					
Flaccid					2					
Distended with gas										1

L06121 SN 7
Six Month Interim Sacrifice
and Deaths 0-6 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS

ORGAN Lesion	MALES 0.0	1.5	7.0	35	175/ 100	FEMALES 0.0	1.5	7.0	35	175/ 100
MESENTERIC LYMPH NODE										
Dark red		1	1	1						
Black				1						
RECTUM										
Dark red					1					
ANUS										
Red discharge					1					
Irritated			1							
EYES										
White/opaque					1					
Soft										1
PITUITARY GLAND										
Dark red					1					

L06121 SN 7
Six Month Interim Sacrifice
and Deaths 0-6 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS

ORGAN Lesion	MALES 0.0	1.5	7.0	35	175/100	FEMALES 0.0	1.5	7.0	35	175/100
RESPIRATORY LYMPH NODE										
Enlarged							1			
Red							1			
LUMBAR LYMPH NODE										
Enlarged					1		1			
INGUINAL REGION										
Mass				1			1			
SUBCUTANEOUS LYMPH NODE										
Enlarged				1						
Black				1						
NOSE										
Red discharge					1					
MOUTH										
Red discharge					1					

L06121 SN 7
Six Month Interim Sacrifice
and Deaths 0-6 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS

ORGAN Lesion	MALES 0.0	1.5	7.0	35	175/ 100	FEMALES 0.0	1.5	7.0	35	175/ 100
ABDOMINAL CAVITY										
Contained red material										1
INGUINAL LYMPH NODE										
Enlarged							1			
PELVIC REGION										
Mass				1						

Final

Histopathology Report

Chronic Toxicity/Carcinogenicity Study

RDX in B6C3F1 Mice

6 Month Interim Sacrifice

I.I.T.R.I. Project No. L 06121, Study No. 7

Sponsor Project No. DAMD-17-79-C-9161

Submitted by

John W. Sagartz, D.V.M.

January 4, 1984

Histopathology Narrative Report

Histopathologic Evaluation Methods

Microslides, prepared by I.I.T.R.I., were examined by John W. Sagartz, D.V.M. Histopathologic observations for each mouse were recorded on standard forms provided by I.I.T.R.I. Tissue counts were recorded on a second standard form. Both forms were signed by the pathologist and were initialled by Barbara E. Sagartz who transcribed observations and tissue counts.

These data were transferred to a handwritten Histopathology Incidence Table and submitted for typing. Accuracy of the typed Histopathology Incidence Table was verified by a reviewer who initialled the individual animal data forms.

Personnel Record

Study: I.I.T.R.I. Project No. L 06121 SN 7
Sponsor Project No. DAMD-17-79-C9161
Chronic Toxicity/Carcinogenicity Study
RDX - B6C3F1 Mice
6 Month Interim Sacrifice

The personnel listed below have participated in the technical and/or clerical activities of this study:

Name	Signature	Initials	Date
John W. Sagartz, D.V.M.	John W. Sagartz	JWS	1/14/82
Barbara E. Sagartz	Barbara E. Sagartz	BES	1-14-82
John E. Sagartz	John E. Sagartz	JES	1-14-82
William M. Sagartz	William M. Sagartz	WMS	1/14/82

In this experiment, 425 male and 425 female B6C3F1 mice were randomly divided into 5 dosage groups. The groups are identified as follows:

Group	Dose (mg/kg/day)	Number of Animals	
		Male	Female
I	0.0	85	85
II	1.5	85	85
III	7.0	85	85
IV	35.0	85	85
V	175.0/100(1)	85	85

In accordance with the experimental design, 10 mice per sex per treatment group were sacrificed after 26 weeks on test.

Microscopic examination was performed on hematoxylin and eosin-stained sections from all mice in the control and highest dose (175/100 mg/kg) groups, including those mice which died or were sacrificed prior to scheduled sacrifice. The following tissues were examined: adrenals, brain (3 sections), cecum, colon, duodenum, epididymides, esophagus, eyes, optic nerves, gonads, gross lesions, heart, ileum, jejunum, kidneys, liver, lungs, mammary gland, mesenteric lymph node, pancreas, prostate, rectum, skin, spinal cord (3 sections), spleen, sternum & bone marrow, stomach, thyroid/parathyroid, tissue masses, trachea, urinary bladder, and uterus.

---

(1)Due to high mortality, daily dosage of 175 mg/kg was reduced for both sexes to 100 mg/kg, commencing on 4/20/81 (week 11). Four high dose males (82-1082, 82-1089, 82-1109, and 82-1113) died after this reduction in daily dosage.

For mice in the 2 intermediate dose groups, gonads, liver, brain (3 sections), spinal cord (3 sections), kidneys, heart, spleen, and gross lesions were examined microscopically.

In the Histopathology Incidence Tables, the presence or absence of a tissue is expressed by the following symbols:

N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Lesions were graded from 1 to 4, according to severity on the following scale:

1 = Minimal
2 = Mild
3 = Moderate
4 = Marked

P = presence of a lesion which cannot be graded according to severity. Examples include neoplasia and urinary calculi.

The incidences of various lesions in each treatment group were summarized in Incidence Comparison Tables. Lesions considered treatment-related were extracted from these tables and placed in a separate table entitled "Incidence of Lesions Considered to be Treatment-Related".

There was a spontaneous and random occurrence of a variety of nonneoplastic lesions in controls and treated groups. Some lesions occurred solely, or with greater frequency, in mice of treated groups as compared with controls. These lesions, however, are not uncommon in the untreated mice of this strain.

In the first six months of this study, there were numerous spontaneous deaths and moribund sacrifices among males and females receiving the highest dose (175/100 mg/kg). The incidences of early deaths in various treatment groups are as follows:

Group	(Dose) (mg/kg/day)	Males	Females
I	0.0	1	0
II	1.5	2	1
III	7.0	3	0
IV	35.0	3	0
V	175.0/100	34	36

Because of high mortality among males and females receiving 175.0 mg/kg, the number of tissues examined from this group greatly exceeds that from controls and lower dosage groups. Consequently, precise comparison of incidences is not possible; this situation was taken into account in preparing this report.

Male Mice

Among males receiving 175/100 mg/kg, pulmonary congestion was observed in 27 mice. This lesion is a common agonal change and does not, in my opinion, indicate that the lung is a target organ of compound toxicity.

Renal tubular cytoplasmic vacuolization was seen in one control, 10 receiving 1.5 mg/kg, 12 mice receiving 7.0 mg/kg, 11 mice receiving 35.0 mg/kg, and 12 receiving 175/100 mg/kg. In this lesion, single or multiple sharply delineated cytoplasmic vacuoles were found in renal tubular epithelium. These vacuoles occurred most frequently in cortical tubules.

Acute or chronic dermatitis was found in 2 controls, 3 males receiving 7.0 mg/kg (one mouse had dermatitis in two sites), and 14 males receiving 175/100 mg/kg. These lesions consisted of accumulations of leukocytes in the epidermis and superficial dermis; in some instances, there was focal epidermal necrosis and ulceration. In each of the 2 affected controls, the dermatitis was found in routinely-taken skin sections in the absence of gross lesions. The dermatitis found in each of the 3 males receiving 7.0 mg/kg occurred in grossly observed lesions. Among the 14 affected males receiving 175/100 mg/kg, 7 mice had dermatitis in the routinely-taken sections; the remaining 7 males had dermatitis in sections taken from gross lesions.

Female Mice

The most important occurrence among females was the high rate of spontaneous deaths in mice receiving 175.0 mg/kg. These early deaths were generally accompanied by pulmonary congestion, seen in 31 mice. As noted in the males, this is a nonspecific agonal change.

The remaining histopathologic lesions occurred sporadically and were not related to compound administration.

Discussion

At this stage of the study, there is clearly a toxic compound effect among males and females receiving the 175.0 mg/kg dose of RDX.

In males, the renal tubule is a likely site of test compound effect. This effect was manifested by increased incidence of

renal tubular cytoplasmic vacuolization in all treatment groups. This change was however not accompanied by cellular necrosis or inflammatory response, and is regarded as a mild, reversible effect.

There was an increased incidence of dermatitis in males receiving 175/100 mg/kg. I have been advised by I.I.T.R.I. that the 175/100 mg/kg males exhibited clinical signs of hyperesthesia which resulted in excessive fighting and cutaneous trauma. Although the increased incidence of dermatitis is treatment-related, the relationship is apparently due primarily to abnormal behavior rather than a specific compound effect on the skin as a target organ.

Conclusions

In the first 6 months of this 2-year study, the test substance, RDX, caused numerous deaths among male and female mice receiving 175.0 mg/kg.

In males, the urinary tract is a probable target of toxic compound action as evidenced by pyelonephritis, renal tubular cytoplasmic vacuolization and urinary calculi. At the 175/100 mg/kg dose, there was an increased incidence of dermatitis in males. This increased incidence is a secondary compound effect on behavior caused by hyperesthesia and excessive fighting.

In females, the target organ for compound toxicity was undetermined.

John W. Sagartz, D.V.M. 1/4/84
(Date)

Veterinary Pathologist

Histopathology Tables

I.I.I.K.I.
Study No.: L 06121 SN 7
Compound: RDX
~~Dose (mg/kg/day)~~: 0.0

** Died after week 11 and dose reduction.

HISTOPATHOLOGY INCIDENCE TABLE

* Died on Study
or
Moribund Sacrifice

Male Mice - Controls
Group 1

ORGAN Lesion	Accession Number 81-0482	81-1197	81-1198	81-1199	81-1200	81-1201	81-1202	81-1203	81-1204	81-1205	81-1206	Incidence
BRAIN	N	N	N	N	N	N	N	N	N	N	N	
SPINAL CORD	N	N	N	N	N	N	N	N	N	N	N	
EYES	N	N	N	N	N	N	N	N	N	N	N	
OPTIC NERVES	N	N	N	N	N	N	N	N	N	N	N	
ADRENALS	N	N	N	N	N	N	N	N	N	N	N	
SPLEEN	N	N	N	N	N	N	N	N	N	N	N	
PANCREAS	N	N	N	N	N	N	N	N	N	N	N	
MESENTERIC LYMPH NODE	N	N	N	N	N	N	M	N	N	N	N	
TESTES	N	N	N	N	N	N	N	N	N	N	N	
PROSTATE	N	N	N	N	N	N	N	N	N	N	N	
EPIDIDYMIDES	N	N	N	N	N	N	N	N	N	N	N	
URINARY BLADDER	N	N	L	N	N	N	N	N	N	N	N	
Calculus			P									1/11
LUNGS	N	N	N	N	N	N	N	N	N	N	N	
ESOPHAGUS	M	M	N	N	N	N	N	N	N	N	N	
TRACHEA	M	N	N	N	M	N	N	N	N	N	N	
HEART	N	N	N	N	N	N	N	N	N	N	N	
LIVER	N	N	N	N	N	N	N	N	N	N	N	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 0.0

HISTOPATHOLOGY INCIDENCE TABLE

* Died on Study or Moribund Sacrifice

Male Mice - Controls (Con't.)
Group 1

ORGAN Lesion	Accession Number: 81-0482 *	81-1197	81-1198	81-1199	81-1200	81-1201	81-1202	81-1203	81-1204	81-1205	81-1206	Incidence
KIDNEYS	L	L	N	N	N	N	N	N	N	N	N	
Pyelitis, diffuse, acute	3											1/11
Cytoplasmic Vacuolization, diffuse		2										1/11
STOMACH	N	N	N	N	N	N	N	N	N	N	N	
DUODENUM	N	N	N	N	N	N	N	N	N	N	N	
JEJUNUM	M	N	N	N	N	N	N	N	N	N	N	
ILEUM	M	N	N	N	M	N	N	N	N	N	N	
COLON	N	N	N	N	N	N	N	N	N	N	N	
STERNUM	N	N	N	N	N	N	N	N	N	N	N	
BONE MARROW	N	N	N	N	N	N	N	N	N	N	N	
THYROIDS	M	N	N	N	M	N	N	N	N	N	N	
PARATHYROIDS	M	N	N	M	M	M	M	M	N	M	M	
CECUM	N	N	N	N	N	N	N	N	N	N	N	
RECTUM	M	N	N	N	N	N	N	N	N	N	N	
SKIN	N	N	L	N	N	N	N	N	N	L	N	
Dermatitis, multifocal, acute										2		1/11
Dermatitis, multifocal, chronic			2									1/11
MAMMARY GLAND	M	M	M	M	M	M	M	M	M	M	M	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 0.0

HISTOPATHOLOGY INCIDENCE TABLE

Male Mice → Controls (Con't.)
Group I

* Died on Study or Moribund Sacrifice

ORGAN / Lesion	Accession Number	81-0482 *	81-1197	81-1198	81-1199	81-1200	81-1201	81-1202	81-1203	81-1204	81-1205	81-1206	Incidence
LESIONS (TISSUES NOT SPECIFICALLY													
REQUIRED BY PROTOCOL)													
LARYNX		-	-	N	N	-	N	N	N	N	N	N	
GALL BLADDER		N	-	-	-	-	-	N	-	-	-	-	
THYMUS		N	-	-	-	-	-	-	-	-	-	-	
PENIS		L	-	-	-	-	-	-	-	-	-	-	
Balanitis, diffuse, chronic, active		4											1/1
URETHRA		L	-	-	-	-	L	-	-	-	-	L	
Urethritis, diffuse, chronic		4											1/3
Calculus		P					P					P	3/3
SEMINAL VESICLES		N	N	N	N	N	N	N	N	N	N	N	
PERIPHERAL NERVE		N	-	-	-	-	-	-	-	-	-	-	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 1.5

** Died after week 11 and dose reduction.

HISTOPATHOLOGY INCIDENCE TABLE

* Died on Study
or
Moribund Sacrifice

Male Mice
Group II

ORGAN Lesion	Accession Number	81-0639*	81-0645*	81-1217	81-1218	81-1219	81-1220	81-1221	81-1222	81-1223	81-1224	81-1225	81-1226									Incidence
BRAIN		N	N	N	N	N	N	N	N	N	N	N	N									
SPINAL CORD		N	N	N	N	N	N	N	N	N	N	N	N									
LIVER		N	N	N	N	N	N	N	N	N	N	N	N									
KIDNEYS		L	L	L	L	L	L	L	L	L	L	L	L									
Pyelonephritis, diffuse, acute			4																			1/12
Pyelonephritis, multifocal, acute		3																				1/12
Cytoplasmic vacuolization, diffuse				2	2	2	2	2	2	2	2	2	2									10/12
HEART		N	N	N	N	N	N	N	N	N	N	N	N									
SPLEEN		N	N	N	N	N	N	N	N	N	N	N	N									
TESTES		N	N	N	N	N	N	N	N	N	N	N	N									
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
PANCREAS		-	-	-	-	N	-	-	-	-	-	-	-									
PENIS		L	-	-	-	-	-	-	-	-	-	-	-									
Balanitis, diffuse, chronic		3																				1/1
PREPUCE		L	-	-	-	-	-	-	-	-	-	-	-									
Posthitis, diffuse, chronic		3																				1/1

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 1.5

HISTOPATHOLOGY INCIDENCE TABLE

* Died on Study
or
Moribund Sacrifice

Male Mice (Con't.)
Group II

ORGAN / Lesion	Accession Number: 81-0639*	81-0645*	81-1217	81-1218	81-1219	81-1220	81-1221	81-1222	81-1223	81-1224	81-1225	81-1226	Incidence
EPIDIDYMIDES	-	N	-	-	-	-	-	-	-	-	-	-	
PREPUTIAL GLANDS	-	-	L	-	-	-	-	-	-	-	-	-	
Cysts, multiple			2										1/1

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

I.I .I.
Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 7.0

* Died after week 11 and dose reduction.

HISTOPATHOLOGY INCIDENCE TABLE

* Died on Study
or
Moribund Sacrifice

Male Mice
Group III

ORGAN Lesion	Accession Number	81-0766	81-0785*	81-0818*	81-1237	81-1238	81-1239	81-1240*	81-1241	81-1242	81-1243	81-1244	81-1245	81-1246								Incidence
BRAIN		N	N	N	N	N	N	N	N	N	N	N	N	N								
SPINAL CORD		N	N	N	N	N	N	N	N	N	N	N	N	N								
LIVER		N	N	N	N	N	N	N	N	N	N	N	N	N								
KIDNEYS		L	L	L	L	L	L	L	L	L	L	L	L	L								
Pyelonephritis, multifocal, acute			4					4														2/13
Cytoplasmic vacuolization, diffuse		2		1	2	2	1	2	2	2	2	2	1	2								12/13
HEART		N	N	N	N	N	N	N	N	N	N	N	N	N								
SPLEEN		N	N	N	N	N	N	N	N	N	N	N	N	N								
TESTES		N	N	N	N	N	N	N	N	N	N	N	N	N								
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
PANCREAS		N	-	-	-	N	-	-	-	N	-	-	-	-								
PENIS		-	L	-	-	-	-	-	-	-	-	-	-	-								
Calculus			P																			1/1
PREPUCE		-	L	-	-	-	-	-	-	-	-	-	-	-								
Posthitis, diffuse, chronic			4																			1/1
SCROTUM		-	L	-	-	-	-	-	-	-	-	-	-	-								
Cellulitis, multifocal, chronic			3																			1/1

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 7.0

** Died after week 11 and dose reduction.

HISTOPATHOLOGY INCIDENCE TABLE

Male Mice (Con't.)
Group III

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0766	81-0785*	81-0818*	81-1237	81-1238	81-1239	81-1240*	81-1241	81-1242	81-1243	81-1244	81-1245	81-1246								Incidence
SKIN		-	-	-	-	L	L	L	-	-	-	-	-	-								
Dermatitis, focal, acute							4															1/3
Dermatitis, focal, acute, perianal area						4																1/3
Dermatitis, multifocal, chronic, perianal area								3														1/3
Dermatitis, focal, chronic								3														1/3
SUBCUTIS		-	-	-	-	-	-	-	L	-	-	-	-	-								
Hematoma, solitary									3													1/1

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

..I.T...I.
Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 35.0

** Died after week 11 and dose reduction.

HISTOPATHOLOGY INCIDENCE TABLE

* Died on Study
or
Moribund Sacrifice

Male Mice
Group IV

ORGAN Lesion	Accession Number	81-0916*	81-0959	81-0971*	81-1257	81-1258	81-1259	81-1260	81-1261	81-1262	81-1263**	81-1264	81-1265	81-1266								Incidence
BRAIN		N	N	N	N	N	N	N	N	N	N	N	N	N								
SPINAL CORD		N	N	N	N	N	N	N	N	N	N	N	N	N								
LIVER		N	N	N	N	N	N	N	N	N	N	N	N	N								
KIDNEYS		N	L	L	L	L	L	L	L	L	L	L	L	L								
Pyelonephritis, multifocal, acute				4							3											2/13
Cytoplasmic vacuolization, diffuse			2		2	3	2	1	2	2	2	2	1	2								11/13
HEART		N	N	N	N	N	N	N	N	N	N	N	N	N								
SPLEEN		M	N	N	N	N	N	N	N	N	N	N	N	N								
TESTES		N	N	N	N	N	N	N	N	N	N	N	N	N								
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
PANCREAS		-	-	-	-	-	-	N	-	-	-	N	-	-								
PREPUCE		-	-	L	-	-	-	-	-	-	-	-	-	-								
Abscess, solitary, chronic				3																		1/1
SKIN		-	-	N	-	-	-	-	-	-	-	-	-	-								
SUBCUTANEOUS FAT		-	-	-	-	-	L	-	-	-	-	-	-	-								
Steatitis, focal, chronic, active							3															1/1
MESENTERIC LYMPH NODE		-	-	N	-	-	-	-	-	-	-	-	-	-								

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 175.0/100

** Died after week 11 and dose reduction.

HISTOPATHOLOGY INCIDENCE TABLE

* Died on Study
or
Moribund Sacrifice

Male Mice
Group V

ORGAN Lesion / Accession Number	81-1049*	81-1051*	81-1054*	81-1055*	81-1057*	81-1059*	81-1060*	81-1061*	81-1063*	81-1066*	81-1070*	81-1072*	81-1074	81-1078*	81-1080*	81-1081*	81-1082**	81-1087*	81-1089**	81-1090	Incidence
BRAIN	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
SPINAL CORD	N	N	N	N	N	N	N	N	N	N	N	N	N	M	N	N	N	N	N	N	
EYES	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
OPTIC NERVES	N	N	N	N	N	M	N	N	N	N	N	N	N	M	N	N	N	N	N	N	
ADRENALS	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
SPLEEN	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
PANCREAS	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
MESENTERIC LYMPH NODE	N	N	N	N	N	M	N	M	L	N	M	N	N	N	M	N	N	N	N	N	
Hyperplasia, lymphoid, diffuse									3												
TESTES	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
PROSTATE	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	L	N	N	N	
Prostatitis, diffuse,chronic,active																	4				
EPIDIDYMIDES	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
URINARY BLADDER	L	N	L	N	N	N	N	N	N	L	N	N	N	N	N	N	L	N	N	N	
Cystitis, diffuse, chronic, active																	4				
Cystitis, diffuse, chronic										3											
Calculi, multiple																	P				
Calculus	P		P																		

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

T.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 175.0/100

** Died after week 11 and dose reduction.

HISTOPATHOLOGY INCIDENCE TABLE

Male Mice (Con't.)
Group V

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion / Accession Number	81-1091*	81-1092*	81-1094	81-1095*	81-1096*	81-1104*	81-1107*	81-1109**	81-1110*	81-1111*	81-1112	81-1113**	81-1115	81-1116	81-1118*	81-1120*	81-1277*	81-1278*	81-1279*	81-1280	Incidence
BRAIN	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
SPINAL CORD	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
EYES	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
OPTIC NERVES	N	N	N	N	N	N	N	N	M	M	N	N	N	N	N	M	M	N	N	N	
ADRENALS	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
SPLEEN	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
PANCREAS	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
MESENTERIC LYMPH NODE	N	N	N	N	N	N	N	N	M	N	M	M	N	M	N	M	N	N	M	M	
Hyperplasia, lymphoid, diffuse																					
TESTES	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
PROSTATE	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Prostatitis, diffuse, chronic, active																					
EPIDIDYMIDES	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
URINARY BLADDER	N	N	N	N	N	N	L	N	N	N	N	N	N	L	N	L	N	N	N	N	
Cystitis, diffuse, chronic, active																					
Cystitis, diffuse, chronic														2							
Calculi, multiple																					
Calculus							P									P					

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
\- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 175.0/100

** Died after week 11 and dose reduction.

HISTOPATHOLOGY INCIDENCE TABLE

*Died on Study
or
Moribund Sacrifice

Male Mice (Con't.)
Group V

ORGAN Lesion	Accession Number 81-1281*	81-1282	81-1283	81-1284	81-1285	81-1286	Incidence
BRAIN	N	N	N	N	N	N	
SPINAL CORD	N	N	N	N	N	N	
EYES	N	N	N	N	N	N	
OPTIC NERVES	N	N	N	N	N	N	
ADRENALS	N	N	N	N	N	N	
SPLEEN	N	N	N	N	N	N	
PANCREAS	N	N	N	N	N	N	
MESENTERIC LYMPH NODE	N	N	N	N	N	N	
Hyperplasia, lymphoid, diffuse							1/35
TESTES	N	N	N	N	N	N	
PROSTATE	N	N	N	N	N	N	
Prostatitis, diffuse, chronic, active							1/46
EPIDIDYMIDES	N	N	M	N	N	N	
URINARY BLADDER	L	N	N	N	N	N	
Cystitis, diffuse, chronic, active							1/46
Cystitis, diffuse, chronic	2						3/46
Calculi, multiple							1/46
Calculus							4/46

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 175.0/100

Died after week 1 and due to reduction.

HISTOPATHOLOGY INCIDENCE TABLE

*Died on Study
or
Moribund Sacrifice

Male Mice (Con't.)
Group V

ORGAN Lesion	Accession Number	81-1049*	81-1051*	81-1054*	81-1055*	81-1057*	81-1059*	81-1060*	81-1061*	81-1063*	81-1066*	81-1070*	81-1072*	81-1074	81-1078*	81-1080*	81-1081*	81-1082*	81-1087*	81-1089*	81-1090	Incidence
LUNGS		L	L	N	L	L	L	L	L	N	N	L	L	N	L	L	L	L	L	L	N	
Congestion, diffuse		3	4		2	2	3	2	3			3	2		2	2	3	2	2	4		
ESOPHAGUS		M	M	N	M	N	M	N	N	N	N	N	N	N	N	N	N	M	N	N	N	
TRACHEA		N	M	N	M	N	M	N	N	N	N	N	N	N	M	N	N	N	N	N	N	
HEART		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
LIVER		N	N	N	N	N	N	N	L	N	L	N	N	N	N	N	N	N	N	N	N	
Hepatitis, diffuse, acute											2											
Hepatitis, multifocal, acute, necrotic									2													
KIDNEYS		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	L	N	N	N	
Pyelonephritis, multifocal, acute																		2				
Cytoplasmic vacuolization, diffuse																						
STOMACH		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
DUODENUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
JEJUNUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
ILEUM		N	N	M	N	N	N	N	N	N	M	N	M	N	N	N	N	N	N	N	N	
COLON		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
STERNUM		N	N	N	N	N	N	N	N	N	N	M	N	N	N	N	N	N	N	N	N	
BONE MARROW		N	N	N	N	N	N	N	N	N	N	M	N	N	N	N	N	L	N	N	N	
Hyperplasia, myeloid, diffuse																		3				

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 175.0/100

HISTOPATHOLOGY INCIDENCE TABLE

*Died on Study
or
Moribund Sacrifice

Male Mice (Con't.)
Group V

ORGAN Lesion	Accession Number	81-1091*	81-1092*	81-1094	81-1095*	81-1096*	81-1104*	81-1107*	81-1109*	81-1110*	81-1111*	81-1112	81-1113*	81-1115	81-1116	81-1118*	81-1120*	81-1277*	81-1278*	81-1279*	81-1280	Incidence
LUNGS		N	L	N	L	N	L	L	L	L	L	N	N	N	N	L	L	N	L	L	N	
Congestion, diffuse			2		2		4	2	3	3	3					2	3		3	2		
ESOPHAGUS		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
TRACHEA		N	N	N	N	N	N	N	N	N	N	M	N	N	N	N	N	N	N	N	N	
HEART		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
LIVER		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Hepatitis, diffuse, acute																						
Hepatitis,multifocal,acute,necrotic																						
KIDNEYS		N	N	L	N	N	N	N	L	N	N	L	N	L	L	L	N	N	N	N	L	
Pyelonephritis, multifocal, acute																						
Cytoplasmic vacuolization, diffuse				3					2			3		2	2	2					2	
STOMACH		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
DUODENUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
JEJUNUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	M	N	N	N	N	
ILEUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	M	N	N	N	N	
COLON		N	N	N	N	N	N	N	N	M	N	N	N	N	N	N	N	N	N	N	N	
STERNUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
BONE MARROW		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Hyperplasia, myeloid, diffuse																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

HISTOPATHOLOGY INCIDENCE TABLE

*Died on Study
or
Moribund Sacrifice

Male Mice (Con't.)
Group V

ORGAN Lesion / Accession Number	81-1049*	81-1051*	81-1054*	81-1055*	81-1057*	81-1059*	81-1060*	81-1061*	81-1063*	81-1066*	81-1070*	81-1072*	81-1074	81-1078*	81-1080*	81-1081*	81-1082**	81-1087*	81-1089**	81-1090	Incidence
LUNGS	L	L	N	L	L	L	L	L	N	N	L	L	N	L	L	L	L	L	L	N	
Congestion, diffuse	3	4		2	2	3	2	3			3	2		2	2	3	2	2	4		
ESOPHAGUS	M	M	N	M	N	M	N	N	N	N	N	N	N	N	N	N	M	N	N	N	
TRACHEA	N	M	N	M	N	M	N	N	N	N	N	N	N	M	N	N	N	N	N	N	
HEART	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
LIVER	N	N	N	N	N	N	N	L	N	L	N	N	N	N	N	N	N	N	N	N	
Hepatitis, diffuse, acute										2											
Hepatitis,multifocal,acute,necrotic								2													
KIDNEYS	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	L	N	N	N	
Pyelonephritis, multifocal, acute																	2				
Cytoplasmic vacuolization, diffuse																					
STOMACH	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
DUODENUM	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
JEJUNUM	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
ILEUM	N	N	M	N	N	N	N	N	N	M	N	M	N	N	N	N	N	N	N	N	
COLON	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
STERNUM	N	N	N	N	N	N	N	N	N	N	M	N	N	N	N	N	N	N	N	N	
BONE MARROW	N	N	N	N	N	N	N	N	N	N	M	N	N	N	N	N	L	N	N	N	
Hyperplasia, myeloid, diffuse																	3				

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

I.I.....I.
Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 175.0/100

** Died after week 11 and dose reduction.

HISTOPATHOLOGY INCIDENCE TABLE

Male Mice (Con't.)
Group V

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion / Accession Number	81-1281*	81-1282	81-1283	81-1284	81-1285	81-1286	Incidence
LUNGS	L	N	N	N	N	N	
Congestion, diffuse	2						27/46
ESOPHAGUS	N	N	N	N	N	N	
TRACHEA	N	N	N	N	N	N	
HEART	N	N	N	N	N	N	
LIVER	N	N	N	N	N	N	
Hepatitis, diffuse, acute							1/46
Hepatitis,multifocal,acute,necrotic							1/46
KIDNEYS	N	L	L	L	L	L	
Pyelonephritis, multifocal, acute							1/46
Cytoplasmic vacuolization, diffuse		2	2	2	2	2	12/46
STOMACH	N	N	N	N	N	N	
DUODENUM	N	N	N	N	N	N	
JEJUNUM	N	N	N	N	N	N	
ILEUM	N	N	N	N	N	M	
COLON	N	N	N	N	N	N	
STERNUM	N	N	N	N	N	N	
BONE MARROW	N	N	N	N	N	N	
Hyperplasia, myeloid, diffuse							1/45

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Symbols: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 175.0/100

*** Died after week 11 and dose reduction.

HISTOPATHOLOGY INCIDENCE TABLE

* Died on Study
or
Moribund Sacrifice

Male Mice (Con't.)
Group V

ORGAN / Lesion	Accession Number	81-1049*	81-1051*	81-1054*	81-1055*	81-1057*	81-1059*	81-1060*	81-1061*	81-1063*	81-1066*	81-1070*	81-1072*	81-1074	81-1078*	81-1080*	81-1081*	81-1082**	81-1087*	81-1089**	81-1090	Incidence
THYROIDS		N	M	N	M	N	N	N	N	N	N	N	N	N	M	N	N	N	N	N	N	
PARATHYROIDS		M	M	M	M	N	M	N	N	M	M	N	M	M	M	M	N	M	N	N	M	
CECUM		N	N	N	N	N	N	N	N	N	M	N	N	N	N	N	N	N	N	N	N	
RECTUM		N	N	N	N	N	N	N	N	M	N	N	N	N	M	N	N	N	N	N	N	
SKIN		N	L	N	N	N	N	N	L	N	L	N	N	N	N	N	L	N	N	N	L	
Dermatitis, multifocal, acute																						
Dermatitis,multifocal,chronic,active			3																		2	
Dermatitis, diffuse, chronic											2						3					
Dermatitis, multifocal, chronic									2													
Dermatitis, focal, chronic																						
MAMMARY GLAND		M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
LARYNX		-	-	-	-	-	N	-	-	N	-	-	-	N	-	-	-	N	-	-	N	
THYMUS		-	N	-	N	N	N	N	N	N	N	-	N	-	N	N	N	-	N	N	-	
PENIS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	
Balanitis, focal, acute																		4				
Calculus																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 175.0/100

* Died on Study or Moribund Sacrifice

HISTOPATHOLOGY INCIDENCE TABLE

Male Mice (Con't.)

Group V

ORGAN Lesion	Accession Number	81-1091*	81-1092*	81-1094	81-1095*	81-1096*	81-1104*	81-1107*	81-1109*	81-1110*	81-1111*	81-1112	81-1113*	81-1115	81-1116	81-1118*	81-1120*	81-1277*	81-1278*	81-1279*	81-1280	Incidence
THYROIDS		N	N	N	N	N	N	N	N	N	N	M	N	N	N	N	N	N	N	N	N	
PARATHYROIDS		M	M	M	M	N	M	M	N	N	N	M	N	M	M	M	N	M	M	N	M	
CECUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
RECTUM		N	N	N	N	N	N	N	N	M	N	N	N	N	N	N	N	N	N	N	N	
SKIN		N	N	N	N	M	N	L	L	N	N	L	L	N	L	N	N	N	N	L	N	
Dermatitis, multifocal, acute															3							
Dermatitis,multifocal,chronic,active																						
Dermatitis, diffuse, chronic												3										
Dermatitis, multifocal, chronic								2	2				3							2		
Dermatitis, focal, chronic																						
MAMMARY GLAND		M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
LARYNX		-	-	N	-	-	-	-	N	-	-	-	N	N	N	-	-	-	-	-	N	
THYMUS		N	-	-	N	N	N	N	-	N	N	-	-	-	-	N	-	N	N	N	-	
PENIS		-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	
Balanitis, focal, acute																						
Calculus													P									

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 175.0/100

* Died on Study
or
Moribund Sacrifice

HISTOPATHOLOGY INCIDENCE TABLE
Male Mice (Con't.)
Group V

ORGAN Lesion	Accession Number	81-1281*	81-1282	81-1283	81-1284	81-1285	81-1286	Incidence
THYROIDS		N	N	N	N	N	N	
PARATHYROIDS		N	M	N	N	M	N	
CECUM		N	N	N	N	N	N	
RECTUM		N	N	N	N	N	N	
SKIN		L	N	L	N	L	N	
Dermatitis, multifocal, acute								1/45
Dermatitis,multifocal,chronic,active								2/45
Dermatitis, diffuse, chronic								3/45
Dermatitis, multifocal, chronic		2		2				7/45
Dermatitis, focal, chronic						3		1/45
MAMMARY GLAND		M	M	M	M	M	M	
LESIONS (TISSUES NOT SPECIFICALLY								
REQUIRED BY PROTOCOL)								
LARYNX		-	N	N	N	N	N	
THYMUS		N	-	-	-	-	-	
PENIS		-	-	-	-	-	-	
Balanitis, focal, acute								1/2
Calculus								1/2

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 175.0/100

** Died after week 11 and dose reduction.

* Died on Study
or
Moribund Sacrifice

HISTOPATHOLOGY INCIDENCE TABLE

Male Mice (Con't.)

Group V

ORGAN Lesion	Accession Number	81-1049*	81-1051*	81-1054*	81-1055*	81-1057*	81-1059*	81-1060*	81-1061*	81-1063*	81-1066*	81-1070*	81-1072*	81-1074	81-1078*	81-1080*	81-1081*	81-1082**	81-1087*	81-1089**	81-1090	Incidence
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL) Con't.																						
URETHRA		-	-	-	L	-	-	-	L	-	L	-	-	-	-	-	-	-	L	-	-	
Calculus					P				P		P								P			
SEMINAL VESICLES		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	L	N	N	N	
Seminal vesiculitis,diffuse,chronic,																						
active																		4				
PERIPHERAL NERVE		N	N	N	N	N	N	N	N	N	N	N	N	-	-	N	N	-	N	N	-	
SALIVARY GLAND		-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	
LUMBAR LYMPH NODES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	
Hyperplasia, lymphoid, diffuse																		3				
PREPUTIAL GLAND		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	
Adenitis, focal, acute																		4				
Cysts, multiple																						
SUBCUTIS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	
Abscess, solitary																		3				
MANDIBULAR LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
GALL BLADDER		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 175.0/100

HISTOPATHOLOGY INCIDENCE TABLE

* Died on Study
or
Moribund Sacrifice

Male Mice (Con't.)
Group V

ORGAN / Lesion	Accession Number	81-1091*	81-1092*	81-1094	81-1095*	81-1096*	81-1104*	81-1107*	81-1109**	81-1110*	81-1111*	81-1112	81-1113**	81-1115	81-1116	81-1118*	81-1120*	81-1277*	81-1278*	81-1279*	81-1280	Incidence
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL) Con't.																						
URETHRA		-	-	-	-	L	-	-	-	L	L	L	-	L	-	-	L	-	-	-	-	
Calculus						P				P	P	P		P			P					
SEMINAL VESICLES		N	N	N	-	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Seminal Vesiculitis, diffuse,chronic,																						
active																						
PERIPHERAL NERVE		N	N	-	N	N	N	N	-	N	N	-	-	-	-	N	N	N	N	N	-	
SALIVARY GLAND		-	N	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
LUMBAR LYMPH NODES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Hyperplasia, lymphoid, diffuse																						
PREPUTIAL GLAND		-	-	L	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	
Adenitis, focal, acute																						
Cysts, multiple				2											2							
SUBCUTIS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Abscess, solitary																						
MANDIBULAR LYMPH NODE		-	N	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
GALL BLADDER		N	N	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 175.0/100

** Died after week 11 and dose reduction.

* Died on Study.
or
Moribund Sacrifice

HISTOPATHOLOGY INCIDENCE TABLE

Male Mice (Con't.)
Group V

ORGAN Lesion / Accession Number	81-1281*	81-1282	81-1283	81-1284	81-1285	81-1286	Incidence
LESIONS (TISSUES NOT SPECIFICALLY							
REQUIRED BY PROTOCOL) Con't.							
URETHRA	L	-	-	L	-	-	
Calculus	P			P			12/12
SEMINAL VESICLES	N	N	N	N	N	N	
Seminal vesiculitis,diffuse,chronic							
active							1/45
PERIPHERAL NERVE	N	-	-	-	-	-	
SALIVARY GLAND	-	-	-	-	-	-	
LUMBAR LYMPH NODES	-	-	-	-	-	-	
Hyperplasia, lymphoid, diffuse							1/1
PREPUTIAL GLAND	-	-	-	-	-	-	
Adenitis, focal, acute							1/3
Cysts, multiple							2/3
SUBCUTIS	-	-	-	-	-	-	
Abscess, solitary							1/1
MANDIBULAR LYMPH NODE	-	-	-	-	-	-	
GALL BLADDER	-	-	-	-	-	N	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 175.0/100

** Died after week 11 and dose reduction.

* Died on Study
or
Moribund Sacrifice

HISTOPATHOLOGY INCIDENCE TABLE

Male Mice (Con't.)

Group V

ORGAN Lesion	Accession Number	81-1049*	81-1051*	81-1054*	81-1055*	81-1057*	81-1059*	81-1060*	81-1061*	81-1063*	81-1066*	81-1070*	81-1072*	81-1074	81-1078*	81-1080*	81-1081*	81-1082**	81-1087*	81-1089**	81-1090	Incidence
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL) Con't.																						
PREPUCE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Posthitis, multifocal, chronic																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 175.0/100

** Died after week 11 and dose reduction.

HISTOPATHOLOGY INCIDENCE TABLE

Male Mice (Con't.)
Group V

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1091*	81-1092*	81-1094	81-1095*	81-1096*	81-1104*	81-1107*	81-1109**	81-1110*	81-1111*	81-1112	81-1113**	81-1115	81-1116	81-1118*	81-1120*	81-1277*	81-1278*	81-1279*	81-1280	Incidence
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL) Con't.																						
PREPUCE		-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	
Posthitis, multifocal, chronic													3									

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

I.I.T.R.I.
Study No : L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 175.0/100

... Died after week 11 and dose reduction.

HISTOPATHOLOGY INCIDENCE TABLE

* Died on Study
or
Moribund Sacrifice

Male Mice (Con't.)
Group V

ORGAN Lesion	Accession Number	81-1281*	81-1282	81-1283	81-1284	81-1285	81-1286															Incidence
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL) Con't.																						
PREPUCE		-	-	-	-	-	-															
Posthitis, multifocal, chronic																						1/1

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No. L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 0.0

... Died after week 11 and dose reduction.

HISTOPATHOLOGY INCIDENCE TABLE

* Died on Study
or
Moribund Sacrifice

Female Mice - Controls
Group I

ORGAN Lesion	Accession Number 81-1207	81-1208	81-1209	81-1210	81-1211	81-1212	81-1213	81-1214	81-1215	81-1216	Incidence
BRAIN	N	N	N	N	N	N	N	N	N	N	
SPINAL CORD	N	N	N	N	N	N	N	N	N	N	
EYES	N	N	N	N	N	N	N	N	N	N	
OPTIC NERVES	N	N	N	N	N	N	N	N	N	N	
ADRENALS	N	N	N	N	N	N	N	N	N	N	
SPLEEN	N	N	N	N	N	N	N	N	N	N	
PANCREAS	N	N	N	N	N	N	N	N	N	N	
MESENTERIC LYMPH NODE	N	N	M	N	M	N	N	N	N	N	
OVARIES	N	N	N	N	N	N	N	N	N	N	
UTERUS	L	L	N	N	N	L	N	L	L	N	
Hyperplasia,cystic,glandular,diffuse	2	2				2			3		4/10
Hyperplasia,cystic,glandular,focal								2			1/10
URINARY BLADDER	N	N	L	N	N	N	N	N	L	N	
Cystitis, diffuse, chronic			2						2		2/10
LUNGS	N	N	N	N	N	N	N	N	N	N	
ESOPHAGUS	N	N	N	N	N	N	N	N	N	N	
TRACHEA	N	N	N	N	N	N	N	N	N	N	
HEART	N	N	N	N	N	N	N	N	N	N	
LIVER	N	N	N	N	N	N	N	N	N	N	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No : L 06121 SN 7
Compound RDX
Dose (mg/kg/day): 0.0

* Died on Study
or
Moribund Sacrifice

HISTOPATHOLOGY INCIDENCE TABLE

Female Mice - Controls (Con't.)

Group 1

ORGAN Lesion / Accession Number	81-1207	81-1208	81-1209	81-1210	81-1211	81-1212	81-1213	81-1214	81-1215	81-1216	Incidence
KIDNEYS	N	L	N	N	N	N	N	N	N	N	
Lymphocytosis, interstitial, multifocal		2									1/10
STOMACH	N	N	N	N	N	N	N	N	N	N	
DUODENUM	N	N	N	N	N	N	N	N	N	N	
JEJUNUM	N	N	N	N	N	N	N	N	N	N	
ILEUM	N	N	N	N	N	N	N	N	N	N	
COLON	N	N	N	N	N	N	N	N	N	N	
STERNUM	N	N	N	N	N	N	N	N	N	N	
BONE MARROW	N	N	N	N	N	N	N	N	N	N	
THYROIDS	N	N	N	N	N	N	N	N	N	N	
PARATHYROIDS	N	N	M	N	M	N	N	N	N	M	
CECUM	N	N	N	N	N	N	N	M	M	N	
RECTUM	N	N	N	N	N	N	N	N	N	N	
SKIN	L	N	N	N	N	N	N	L	N	N	
Dermatitis, focal, chronic	3							2			2/10
MAMMARY GLAND	N	N	N	N	N	N	N	N	N	N	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

N.I.H. 1.
Study .: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 0.0

** Died after week 11 and dose reduction.

HISTOPATHOLOGY INCIDENCE TABLE

Female Mice - Controls (Con't.)
Group I

* Died on Study
or
Moribund Sacrifice

ORGAN / Lesion	Accession Number	81-1207	81-1208	81-1209	81-1210	81-1211	81-1212	81-1213	81-1214	81-1215	81-1216	Incidence
LESIONS (TISSUES NOT SPECIFICALLY												
REQUIRED BY PROTOCOL)												
LARYNX		N	N	N	N	N	N	N	N	N	N	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study # : L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 1.5

** Died after week 11 and dose reduction.

HISTOPATHOLOGY INCIDENCE TABLE

Female Mice
Group 11

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0715*	81-1227	81-1228	81-1229	81-1230	81-1231	81-1232	81-1233	81-1234	81-1235	81-1236	Incidence
BRAIN		N	N	N	N	N	N	N	N	N	N	N	
SPINAL CORD		N	N	N	N	N	N	N	N	N	N	N	
LIVER		L	N	N	N	N	N	N	N	N	N	N	1/11
Hepatitis, diffuse, acute		3											1/11
KIDNEYS		L	N	N	N	N	N	N	N	N	N	N	
Pyelonephritis, multifocal, acute		3											1/11
HEART		N	N	N	N	N	N	N	N	N	N	N	
SPLEEN		N	N	N	N	N	N	N	N	N	N	N	
OVARIES		M	N	N	N	N	N	N	N	N	N	N	
LESIONS (TISSUES NOT SPECIFICALLY													
REQUIRED BY PROTOCOL)													
PANCREAS		-	-	-	-	N	-	-	N	N	-	-	
URINARY BLADDER		N	-	-	-	-	-	-	-	-	-	-	
MESENTERIC LYMPH NODE		L	-	-	-	-	-	-	-	-	-	-	
Lymphadenitis, diffuse, acute													
bacterial etiology		4											1/1

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study : L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 1.5

** Died after week 11 and do[illegible] reduction.

HISTOPATHOLOGY INCIDENCE TABLE

Female Mice - Con't.
Group II

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion / Accession Number	81-0715*	81-1227	81-1228	81-1229	81-1230	81-1231	81-1232	81-1233	81-1234	81-1235	81-1236	Incidence
LESIONS (TISSUES NOT SPECIFICALLY												
REQUIRED BY PROTOCOL) Con't.												
MEDIASTINAL LYMPH NODE	L	-	-	-	-	-	-	-	-	-	-	
Lymphadenitis, diffuse, acute,												
bacterial etiology	4											1/1
ABDOMINAL CAVITY	L	-	-	-	-	-	-	-	-	-	-	
Abscess,multiocular,acute,bact. et.	4											1/1
SKIN	-	-	-	N	-	-	L	-	-	-	-	
Dermatitis, diffuse, chronic							2					1/2
MAMMARY GLAND	-	-	-	N	-	-	-	-	-	-	-	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

I.I.T.R.I.
Study .: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 7.0

HISTOPATHOLOGY INCIDENCE TABLE

Female Mice
Group III

ORGAN Lesion / Accession Number	81-1247	81-1248	81-1249	81-1250	81-1251	81-1252	81-1253	81-1254	81-1255	81-1256	Incidence
BRAIN	N	N	N	N	N	N	N	N	N	N	
SPINAL CORD	N	N	N	N	N	N	N	N	N	N	
LIVER	N	N	N	N	N	N	N	N	N	N	
KIDNEYS	N	N	N	N	N	N	N	N	N	N	
HEART	N	N	N	N	N	N	N	N	N	N	
SPLEEN	N	N	N	N	N	N	N	N	N	N	
OVARIES	N	N	N	N	N	N	N	N	N	N	
LESIONS (TISSUES NOT SPECIFICALLY											
REQUIRED BY PROTOCOL)											
PANCREAS	N	-	-	-	-	-	-	N	-	-	
URINARY BLADDER	-	-	-	-	-	-	-	-	-	N	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 35.0

*** Died after week 11 and dos reduction.

HISTOPATHOLOGY INCIDENCE TABLE

Female Mice
Group IV

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1267	81-1268	81-1269	81-1270	81-1271	81-1272	81-1273	81-1274	81-1275	81-1276	Incidence
BRAIN		N	N	N	N	N	N	N	N	N	N	
SPINAL CORD		N	N	N	N	N	N	N	N	N	N	
LIVER		N	N	N	N	N	N	N	N	N	N	
KIDNEYS		N	N	N	N	N	N	N	N	N	N	
HEART		N	N	N	N	N	N	N	N	N	N	
SPLEEN		N	N	N	N	N	N	N	N	N	N	
OVARIES		N	N	N	N	N	N	N	N	N	N	
LESIONS (TISSUES NOT SPECIFICALLY												
REQUIRED BY PROTOCOL)												
PANCREAS		-	N	-	-	-	-	-	-	-	-	
UTERUS		-	-	-	N	-	-	-	-	-	-	
SKIN		-	-	-	N	-	N	L	-	-	-	
Dermatitis, multifocal, chronic								3				1/3
MAMMARY GLAND		-	-	-	-	-	N	-	-	-	-	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No. : L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 175.0

** Died after week 11 and dose reduction.

HISTOPATHOLOGY INCIDENCE TABLE

Female Mice
Group V

*Died on Study
or
Moribund Sacrifice

ORGAN / Lesion	Accession Number	81-1123*	81-1125*	81-1126*	81-1131*	81-1132	81-1133*	81-1134*	81-1141*	81-1142*	81-1143*	81-1144*	81-1149*	81-1150	81-1153*	81-1154	81-1155*	81-1156*	81-1158*	81-1159*	81-1162*	Incidence
BRAIN		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
SPINAL CORD		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
EYES		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
OPTIC NERVES		N	M	N	N	N	N	N	M	M	N	N	N	N	M	N	M	M	N	N	N	
ADRENALS		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
SPLEEN		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
PANCREAS		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Pancreatitis, focal, acute																						
MESENTERIC LYMPH NODE		N	N	N	N	N	N	N	N	M	N	N	N	N	N	N	N	N	N	M	M	
OVARIES		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
UTERUS		N	N	N	N	L	N	N	N	N	N	N	N	N	N	L	N	N	N	N	N	
Hyperplasia,cystic,glandular,diffuse						2																
Hyperplasia, cystic, glandular, multifocal																2						
URINARY BLADDER		M	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
LUNGS		L	L	L	N	N	L	L	L	L	L	L	N	N	N	N	L	L	L	L	L	
Congestion, diffuse		3	2	3			4	2	3	2	2	3					3	3	2	2	3	
ESOPHAGUS		N	N	M	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
TRACHEA		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

I.I.T.R(
Study No.. L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 175.0/100

** Died after week 11 and dose/ luction.

HISTOPATHOLOGY INCIDENCE TABLE

* Died on Study
or
Moribund Sacrifice

Female Mice (Con't.)
Group V

ORGAN Lesion	Accession Number	81-1164*	81-1166*	81-1167*	81-1168*	81-1170*	81-1173*	81-1174*	81-1175*	81-1182*	81-1184*	81-1190	81-1191*	81-1192*	81-1195*	81-1287	81-1288*	81-1289*	81-1290	81-1291*	81-1292	Incidence
BRAIN		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
SPINAL CORD		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
EYES		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
OPTIC NERVES		N	N	N	M	M	N	M	M	N	N	N	M	N	M	N	M	M	M	N	N	
ADRENALS		N	N	N	M	N	N	N	N	N	N	N	N	M	N	N	N	N	N	N	N	
SPLEEN		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
PANCREAS		N	N	N	N	N	N	N	N	N	N	N	N	N	M	N	N	N	N	N	N	
Pancreatitis, focal, acute																						
MESENTERIC LYMPH NODE		N	N	N	M	N	M	N	M	N	N	M	N	N	M	N	N	M	M	N	N	
OVARIES		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
UTERUS		N	N	N	N	N	N	N	N	N	N	N	N	N	M	N	N	N	N	N	N	
Hyperplasia,cystic,glandular,diffuse																						
Hyperplasia, cystic, glandular, multifocal																						
URINARY BLADDER		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	M	N	N	N	
LUNGS		L	L	L	L	L	L	L	L	L	L	N	L	L	L	N	L	L	N	N	N	
Congestion, diffuse		3	2	2	3	3	2	3	2	3	3		3	3	3		2	2				
ESOPHAGUS		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
TRACHEA		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

I.I.T.R.I.
Study N/ L 06121 SN 7
Compound. RDX
Dose (mg/kg/day): 175.0/100

** Died after week 11 and dose reduction.

HISTOPATHOLOGY INCIDENCE TABLE

Female Mice (Con't.)
Group V

* Died on Study
or
Moribund Sacrifice

099

ORGAN Lesion	Accession Number	81-1293*	81-1294	81-1295*	81-[redacted]	Incidence
BRAIN		N	N	N	N	
SPINAL CORD		N	N	N	N	
EYES		N	N	N	N	
OPTIC NERVES		M	N	N	N	
ADRENALS		N	N	N	N	
SPLEEN		N	N	N	N	
PANCREAS		N	L	N	N	
Pancreatitis, focal, acute			2			1/43
MESENTERIC LYMPH NODE		M	N	N	N	
OVARIES		N	N	N	N	
UTERUS		N	N	N	N	
Hyperplasia,cystic,glandular,diffuse						1/43
Hyperplasia, cystic, glandular, multifocal						1/43
URINARY BLADDER		N	N	N	N	
LUNGS		N	N	L	L	
Congestion, diffuse				2	2	31/44
ESOPHAGUS		N	N	N	N	
TRACHEA		N	N	N	N	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

I.I.T.R.
Study No. L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 175.0/100

** Died after week 11 and dose reduction.

* Died on Study
or
Moribund Sacrifice

HISTOPATHOLOGY INCIDENCE TABLE

Female Mice (Con't.)
Group V

ORGAN Lesion	Accession Number	81-1123*	81-1125*	81-1126*	81-1131*	81-1132	81-1133*	81-1134*	81-1141*	81-1142*	81-1143*	81-1144*	81-1149*	81-1150	81-1153*	81-1154	81-1155*	81-1156*	81-1158*	81-1159*	81-1162*	Incidence
HEART		N	N	N	N	M	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
LIVER		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
KIDNEYS		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
STOMACH		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
DUODENUM		N	M	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
JEJUNUM		N	M	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
ILEUM		N	M	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
COLON		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
STERNUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
BONE MARROW		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
THYROIDS		N	N	N	N	N	N	N	N	N	N	N	M	N	N	N	N	N	N	N	N	
PARATHYROIDS		N	N	M	N	M	M	M	M	M	M	M	M	N	M	M	N	M	N	M	N	
CECUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
RECTUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
SKIN		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
MAMMARY GLAND		N	M	M	N	N	M	M	N	N	M	N	M	N	M	N	M	M	M	M	M	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No.: L 06121 SN 7
Compound: DX
Dose (mg/kg/day): 175.0/100

** Died after week 11 and dose reduction.

HISTOPATHOLOGY INCIDENCE TABLE
Female Mice (Con't.)
Group V

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion / Accession Number	81-1164*	81-1166*	81-1167*	81-1168*	81-1170*	81-1173*	81-1174*	81-1175*	81-1182*	81-1184*	81-1190	81-1191*	81-1192*	81-1195*	81-1287	81-1288*	81-1289*	81-1290	81-1291*	81-1292	Incidence
HEART	N	N	N	N	N	N	N	N	N	N	N	N	M	N	N	N	N	N	N	N	
LIVER	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
KIDNEYS	N	N	N	N	N	N	N	N	N	N	N	N	M	N	N	N	N	N	N	N	
STOMACH	N	N	N	N	N	N	N	N	N	N	N	N	M	N	N	N	N	N	N	N	
DUODENUM	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
JEJUNUM	N	N	N	N	N	N	N	N	N	N	N	N	N	M	N	N	N	N	N	N	
ILEUM	N	N	N	N	N	N	N	M	N	N	N	N	N	N	N	N	N	N	N	N	
COLON	N	N	N	N	N	N	N	N	M	N	M	N	M	N	N	N	N	N	N	N	
STERNUM	N	N	N	N	N	N	N	N	N	N	N	N	M	M	N	N	N	N	N	N	
BONE MARROW	N	N	N	N	N	N	N	N	N	N	N	N	M	M	N	N	N	N	N	N	
THYROIDS	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
PARATHYROIDS	M	M	N	M	M	N	M	N	M	M	M	M	N	N	N	M	M	M	M	M	
CECUM	N	N	N	N	N	N	N	N	N	N	N	N	M	N	N	N	N	N	N	N	
RECTUM	N	N	N	N	N	N	N	N	N	N	N	N	M	M	N	N	N	M	N	N	
SKIN	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
MAMMARY GLAND	M	N	M	N	M	N	M	M	N	N	N	N	N	M	N	M	M	M	M	N	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

I.I.T.R.
Study No(L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 175.0/100

*~ Died after week 11 and dose reduction.

HISTOPATHOLOGY INCIDENCE TABLE

Female Mice (Con't.)
Group V

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1293*	81-1294	81-1295*	81-1296*~																	Incidence
HEART		N	N	N	N																	
LIVER		N	N	N	N																	
KIDNEYS		N	N	N	N																	
STOMACH		N	N	N	N																	
DUODENUM		N	N	N	N																	
JEJUNUM		N	N	N	N																	
ILEUM		N	N	N	N																	
COLON		N	N	N	N																	
STERNUM		N	N	N	N																	
BONE MARROW		N	N	N	N																	
THYROIDS		N	N	N	N																	
PARATHYROIDS		M	M	M	M																	
CECUM		N	N	N	N																	
RECTUM		N	N	N	M																	
SKIN		N	N	N	N																	
MAMMARY GLAND		N	N	M	M																	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study N : L 06121 SN 7
Compou RDX
Dose (mg/kg/day): 175.0/100

HISTOPATHOLOGY INCIDENCE TABLE

Female Mice (Con't.)
Group V

* Died on Study
or
Moribund Sacrifice

ORGAN / Lesion	Accession Number	81-1123*	81-1125*	81-1126*	81-1131*	81-1132	81-1133*	81-1134*	81-1141*	81-1142*	81-1143*	81-1144*	81-1149*	81-1150	81-1153*	81-1154	81-1155*	81-1156*	81-1158*	81-1159*	81-1162*	Incidence
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
LARYNX		-	-	-	-	N	-	-	-	-	-	-	-	N	-	N	-	-	-	-	-	
THYMUS		N	N	N	N	-	-	N	N	N	N	N	N	-	N	-	N	N	N	N	N	
PERIPHERAL NERVE		N	N	N	N	-	N	N	N	N	N	N	N	-	N	-	N	N	N	N	N	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

I.I.T.R.
Study No L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 175.0/100

* Died on Study
or
Moribund Sacrifice

** Died after week 11 and dose / uction.

HISTOPATHOLOGY INCIDENCE TABLE

Female Mice (Con't.)
Group V

ORGAN / Lesion	Accession Number	81-1164*	81-1166*	81-1167*	81-1168*	81-1170*	81-1173*	81-1174*	81-1175*	81-1182*	81-1184*	81-1190	81-1191*	81-1192*	81-1195*	81-1287	81-1288*	81-1289*	81-1290	81-1291*	81-1292	Incidence
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
LARYNX		-	-	-	-	-	-	-	-	-	-	N	-	-	-	N	-	-	-	-	N	
THYMUS		N	N	N	N	N	N	N	N	N	N	-	N	-	N	-	N	N	-	N	-	
PERIPHERAL NERVE		N	N	N	N	N	N	N	N	N	N	-	N	-	N	-	N	-	-	N	-	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No. : L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 175.0/100

** Died after week 11 and dose reduction.

HISTOPATHOLOGY INCIDENCE TABLE

Female Mice (Con't.)
Group V

* Died on Study
or
Moribund Sacrifice

999

ORGAN / Lesion	Accession Number	81-1293*	81-1294	81-1295*	81-1296**	Incidence
LESIONS (TISSUES NOT SPECIFICALLY						
REQUIRED BY PROTOCOL)						
LARYNX		-	N	-	-	
THYMUS		N	-	N	-	
PERIPHERAL NERVE		N	-	N	N	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group MALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35.0 mg/kg/day	RDX 175/100 mg/kg/day*	FEMALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35.0 mg/kg/day	RDX 175/100 mg/kg/day*
URINARY BLADDER		(11)	-	-	-	(46)		(10)	(1)	(1)	-	(42)
Cystitis, chronic		0/11	-	-	-	4/46		2/10	0/1	0/1	-	0/42
Calculus		1/11	-	-	-	5/46		0/10	0/1	0/1	-	0/42
LUNGS		(11)	-	-	-	(46)		(10)	-	-	-	(44)
Congestion**		0/11	-	-	-	27/46		0/10	-	-	-	31/44
LIVER		(11)	(12)	(13)	(13)	(46)		(10)	(11)	(10)	(10)	(44)
Hepatitis, acute		0/11	0/12	0/13	0/13	1/46		0/10	1/11	0/10	0/10	0/44
Hepatitis, necrotic, acute		0/11	0/12	0/13	0/13	1/46		0/10	0/11	0/10	0/10	0/44
KIDNEYS		(11)	(12)	(13)	(13)	(46)		(10)	(11)	(10)	(10)	(43)
Pyelitis, acute		1/11	0/12	0/13	0/13	0/46		0/10	0/11	0/10	0/10	0/43
Pyelonephritis, acute		0/11	2/12	2/13	2/13	1/46		0/10	1/11	0/10	0/10	0/43
Lymphocytosis, interstitial		0/11	0/12	0/13	0/13	0/46		1/10	0/11	0/10	0/10	0/43
Cytoplasmic vacuolization		1/11	10/12	12/13	11/13	12/46		0/10	0/11	0/10	0/10	0/43
SKIN		(11)	-	(3)	(1)	(45)		(10)	(2)	-	(3)	(44)
Dermatitis, acute		1/11	-	2/3	0/1	1/45		0/10	0/2	-	0/3	0/44
Dermatitis, chronic		1/11	-	1/3	0/1	13/45		2/10	1/2	-	1/3	0/44

* Due to high mortality, daily dosage of 175 mg/kg was reduced for both sexes to 100 mg/kg, commencing on 4/20/81 (week 11). Four high dose males (82-1082, 82-1089, 82-1109, and 82-1113) died after this reduction in daily dosage.

** Agonal phenomenon, not specifically related to treatment.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group	MALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35.0 mg/kg/day	RDX 175/100 mg/kg/day*	FEMALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35.0 mg/kg/day	RDX 175/100 mg/kg/day*
PANCREAS		(11)	(1)	(3)	(2)	(46)	(10)	(3)	(2)	(1)	(43)
Pancreatitis, acute		0/11	0/1	0/3	0/2	0/46	0/10	0/3	0/2	0/1	1/43
BONE MARROW		(11)	-	-	-	(45)	(10)	-	-	-	(42)
Hyperplasia, myeloid		0/11	-	-	-	1/45	0/10	-	-	-	0/42
MESENTERIC LYMPH NODE		(10)	-	-	(1)	(35)	(8)	(1)	-	-	(33)
Hyperplasia, lymphoid		0/10	-	-	0/1	1/35	0/8	0/1	-	-	0/33
Lymphadenitis, bacterial et., acute		0/10	-	-	0/1	0/35	0/8	1/1	-	-	0/33
PROSTATE		(11)	-	-	-	(46)	-	-	-	-	-
Prostatitis, chronic		0/11	-	-	-	1/46					
UTERUS		-	-	-	-	-	(10)	-	-	(1)	(43)
Hyperplasia, cystic, glandular							5/10	-	-	0/1	2/43

* Due to high mortality, daily dosage of 175 mg/kg was reduced for both sexes to 100 mg/kg, commencing on 4/20/81 (week 11). Four high dose males (82-1082, 82-1089, 82-1109, and 82-1113) died after this reduction in daily dosage.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group	MALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35.0 mg/kg/day	RDX 175/100 mg/kg/day*	FEMALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35.0 mg/kg/day	RDX 175/100 mg/kg/day*
LESIONS (TISSUES NOT SPECIFICALLY											
REQUIRED BY PROTOCOL)											
MEDIASTINAL LYMPH NODE		-	-	-	-	-	-	(1)	-	-	-
Lymphadenitis, bacterial et., acute		-	-	-	-	-	-	1/1	-	-	-
SEMINAL VESICLES		(11)	-	-	-	(45)	-	-	-	-	-
Seminal vesiculitis, chronic		0/11	-	-	-	1/45					
PENIS		(1)	(1)	(1)	-	(2)	-	-	-	-	-
Balanitis, acute		0/1	0/1	0/1	-	1/2					
Balanitis, chronic		1/1	1/1	0/1	-	0/2					
Calculus		0/1	0/1	1/1	-	1/2					
URETHRA		(3)	-	-	-	(12)	-	-	-	-	-
Urethritis, chronic		1/3	-	-	-	1/12					
Calculus		3/3	-	-	-	12/12					
PREPUCE		(0)	(1)	(1)	(1)	(1)	-	-	-	-	-
Posthitis, chronic		0/0	1/1	1/1	0/1	1/1					

* Due to high mortality, daily dosage of 175 mg/kg was reduced for both sexes to 100 mg/kg, commencing on 4/20/81 (week 11). Four high dose males (82-1082, 82-1089, 82-1109, and 82-1113) died after this reduction in daily dosage.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group	MALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35.0 mg/kg/day	RDX 175/100 mg/kg/day*	FEMALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35.0 mg/kg/day	RDX 175/100 mg/kg/day*
PREPUCE (Con't.)		(0)	(1)	(1)	(1)	(1)	-	-	-	-	-
Abscess, chronic		0/0	0/1	0/1	1/1	0/1					
PREPUTIAL GLAND		(0)	(1)	-	-	(3)	-	-	-	-	-
Adenitis, acute		0/0	0/1	-	-	1/3					
Cysts		0/0	1/1	-	-	2/3					
SCROTUM		-	-	(1)	-	-	-	-	-	-	-
Cellulitis, chronic		-	-	1/1	-	-					
LUMBAR LYMPH NODES		-	-	-	-	(1)	-	-	-	-	-
Hyperplasia, lymphoid		-	-	-	-	1/1	-	-	-	-	-
SUBCUTANEOUS FAT		-	-	-	(1)	-	-	-	-	-	-
Steatitis, chronic		-	-	-	1/1	-	-	-	-	-	-
SUBCUTIS		-	-	(1)	-	(1)	-	-	-	-	-
Abscess		-	-	0/1	-	1/1	-	-	-	-	-
Hematoma		-	-	1/1	-	0/1	-	-	-	-	-

* Due to high mortality, daily dosage of 175 mg/kg was reduced for both sexes to 100 mg/kg, commencing on 4/20/81 (week 11). Four high dose males (82-1082, 82-1089, 82-1109, and 82-1113) died after this reduction in daily dosage.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group MALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35.0 mg/kg/day	RDX 175/100 mg/kg/day*	FEMALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35.0 mg/kg/day	RDX 175/100 mg/kg/day*
ABDOMINAL CAVITY		-	-	-	-	-	-	(1)	-	-	-
Abscess, bacterial et., acute		-	-	-	-	-	-	1/1	-	-	-

* Due to high mortality, daily dosage of 175 mg/kg was reduced for both sexes to 100 mg/kg, commencing on 4/20/81 (week 11).

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE OF LESIONS CONSIDERED TO BE TREATMENT RELATED

ORGAN Lesion	Group	MALES RDX 0.0 mg/kg/day	MALES RDX 1.5 mg/kg/day	MALES RDX 7.0 mg/kg/day	MALES RDX 35.0 mg/kg/day	MALES RDX 175/100 mg/kg/day*	FEMALES RDX 0.0 mg/kg/day	FEMALES RDX 1.5 mg/kg/day	FEMALES RDX 7.0 mg/kg/day	FEMALES RDX 35.0 mg/kg/day	FEMALES RDX 175/100 mg/kg/day*
KIDNEYS		(11)	(12)	(13)	(13)	(46)	(10)	(11)	(10)	(10)	(43)
Cytoplasmic vacuolization		1/11	10/12	12/13	11/13	12/46	0/10	0/11	0/10	0/10	0/43

* Due to high mortality, daily dosage of 175 mg/kg was reduced for both sexes to 100 mg/kg, commencing on 4/20/81 (week 11).

PATHOLOGY APPENDIX II:

Twelve Month Interim Sacrifice

FINAL PATHOLOGY REPORT

of Twenty-Four Month Chronic Toxicity-Carcinogenicity Study of Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) in B6C3F1 Hybrid Mice

IITRI Project No. L6121
Study Number 7

Twelve Month Interim Report
NECROPSY OBSERVATIONS

Carol A. Thompson, D.V.M., M.S.
Senior Veterinary Pathologist
Pathology Section
Life Sciences Research

L06121 SN 7
Twelve Month Interim Sacrifice
and Deaths 6-12 Months
B6C3F1 Hybrid Mouse

Table II

NECROPSY OBSERVATIONS

ORGAN Lesion	MALES 0.0	1.5	7.0	35	175/ 100	FEMALES 0.0	1.5	7.0	35	175/ 100
Number of Mice Examined	11	13	10	13	12	10	12	10	11	10
No Gross Lesions	3	5	7	9	4	3	7	6	7	3
SKIN/Subcutis										
Hair loss, focal/multifocal	2	4	1	1	5	3	2	1	4	1
Dark red, focal/diffuse	1									
Mass		1		1						
Crust formation	1	2		1	1					
Abscess	1	1			1					
Crusty, dark red/fighting wounds		1		1						
Thickened	1				2					
Black focus		1								
LUNG										
Red/mottled red				1	1		1			
Mottled		1								
LIVER										
Mottled red/dark red		1		1	1					

LO6121 SN 7
Twelve Month Interim Sacrifice
and Deaths 6-12 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS

ORGAN Lesion	MALES 0.0	1.5	7.0	35	175/ 100	FEMALES 0.0	1.5	7.0	35	175/ 100
LIVER (continued)										
Light brown/pale/tan	1	1					2			
Firm							1			
Dark brown				1						
Nodule	1		1		1					
Enlarged							1			
Mass					1					
GALL BLADDER										
Red				1						
Distended									1	
ADRENAL GLANDS										
Mass							1			
SPLEEN										
Dark red/purple/dark		1					1			
Enlarged/round edges			1	2			1			
Black, focal/diffuse					1		1			

LO6121 SN 7
Twelve Month Interim Sacrifice
and Deaths 6-12 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS

ORGAN Lesion	MALES 0.0	1.5	7.0	35	175/ 100	FEMALES 0.0	1.5	7.0	35	175/ 100
SPLEEN (continued)										
Dark brown				1						
Pale/light red				1						
PANCREAS										
Firm							1			
KIDNEYS										
Light brown/tan/pale	1	1	1	1			1		1	
Soft				2						
Mottled red				1						
Small			1							
Dilated pelvis				1						
Nodule				1						
URINARY BLADDER										
Distended with fluid, red/yellow/brown	2	3	2	1				2	1	
Dark red, focal/diffuse					1					

L06121 SN 7
Twelve Month Interim Sacrifice
and Deaths 6-12 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS

ORGAN Lesion	MALES 0.0	1.5	7.0	35	175/ 100	FEMALES 0.0	1.5	7.0	35	175/ 100
TESTES										
Small					1					
Firm					1					
Tan					1					
SEMINAL VESICLES										
Yellow		1		1	1					
Enlarged		1								
Firm					1					
PENIS										
Swollen/enlarged		1								
Dark red		1								
Discharge, white/red	1									
Irritation	1	2		2						
Extended from prepuce		1	1							

LO6121 SN 7
Twelve Month Interim Sacrifice
and Deaths 6-12 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS

ORGAN Lesion	MALES 0.0	1.5	7.0	35	175/ 100	FEMALES 0.0	1.5	7.0	35	175/ 100
PREPUTIAL GLAND										
Enlarged	1									
Abscess		1	1							
UTERUS										
Swollen/distended						4	1			4
Dark red						1		4		
OVARIES										
Cyst						1	1	2		2
Firm							1			1
MESENTERIC LYMPH NODE										
Dark red				1						
Enlarged							1			
Small				1						
Dark brown				1						

LO6121 SN 7
Twelve Month Interim Sacrifice
and Deaths 6-12 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS

ORGAN Lesion	MALES 0.0	1.5	7.0	35	175/ 100	FEMALES 0.0	1.5	7.0	35	175/ 100
EYE										
White/opaque/gray					1		1			
Small							1			
Firm					1					
SKULL										
Contained red material				1						
PITUITARY GLAND										
Dark red				1						
TAIL										
Nodule			1							
PELVIC REGION										
Mass							1			
RESPIRATORY LYMPH NODE										
Enlarged				1			1			

L06121 SN 7
Twelve Month Interim Sacrifice
and Deaths 6-12 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS

ORGAN Lesion	MALES 0.0	1.5	7.0	35	175/ 100	FEMALES 0.0	1.5	7.0	35	175/ 100
LUMBAR LYMPH NODE										
Enlarged		2		1					1	
Dark red/black		2								
INGUINAL LYMPH NODE										
Enlarged	3	1								
Brown	1									
Dark red	1	1								
PERINEAL REGION										
Swollen				1						
Red				1						
RENAL LYMPH NODE										
Enlarged							1			
ABDOMINAL FAT										
Yellow	1									
Firm	1									

L06121 SN 7
Twelve Month Interim Sacrifice
and Deaths 6-12 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS

ORGAN Lesion	MALES 0.0	1.5	7.0	35	175/ 100	FEMALES 0.0	1.5	7.0	35	175/ 100
THORACIC CAVITY										
Multiple masses					1					
ABDOMINAL CAVITY										
Multiple masses					1					
Contained red fluid				1						

Final

Histopathology Report

Chronic Toxicity/Carcinogenicity Study

RDX in B6C3F1 Mice

12 Month Interim Sacrifice

I.I.T.R.I. Project No. L 06121, Study No. 7

Sponsor Project No. DAMD-17-79-C-9161

Submitted by

John W. Sagartz, D.V.M.

January 4, 1984

Histopathology Narrative Report

Histopathologic Evaluation Methods

Histopathologic examination was performed by John W. Sagartz, D.V.M. Histopathologic findings for each mouse were recorded on a standard form provided by I.I.T.R.I. Tissue counts were recorded on a second form. Both forms were signed by the pathologist and were initialled by Barbara E. Sagartz who transcribed the observations and tissue counts.

These data were transferred to a handwritten Histopathology Incidence Table and submitted for typing. Accuracy of the typed Histopathology Incidence Table was verified by reviewers who initialled the individual animal data forms.

Following verification of the data on the Histopathology Incidence Table, incidences of various histopathologic lesions were calculated on an Incidence Comparison Table. These calculations were verified by the pathologist who then used the Incidence Comparison Tables as the basis for preparation of the Histopathology Narrative Report.

Personnel Record

Study: I.I.T.R.I. Project No. L 06121 SN 7
Sponsor Project No. DAMD-17-79-C9161
Chronic Toxicity/Carcinogenicity Study
RDX - B6C3F1
12 Month Interim Sacrifice

The personnel listed below have participated in the technical and/or clerical activities of this study:

Name	Signature	Initials	Date
John W. Sagartz, D.V.M.	John W. Sagartz	JWS	7/28/82
Barbara E. Sagartz	Barbara E. Sagartz	BES	7-28-82
Michael J. Sagartz	Michael J. Sagartz	MJS	7/25/82
William M. Sagartz	William M. Sagartz	WMS	7/25/82
LaKen Heinrichs	LaKen Heinrichs	LH	7/26/82

In the second six months of this study, there were occasional spontaneous deaths and moribund sacrifices among treated and control mice of both sexes. The incidences of early deaths in various groups are as follows:

Group	Dose (mg/kg/day)	Males	Females
I	0.0	1	0
II	1.5	3	2
III	7.0	0	0
IV	35.0	3	1
V	175.0/100	2	0

Male Mice

Noteworthy microscopic changes were found in the brain and in various cutaneous sites.

Corpora amylacea were observed in the midbrains of 8 mice receiving 1.5 mg/kg, 2 mice receiving 7.0 mg/kg, 6 mice receiving 35.0 mg/kg, and 7 mice receiving 175/100 mg/kg. No corpora amylacea were seen in male controls. Morphologically, these structures consist of multiple basophilic, granular, mineralized foci which were not accompanied by local tissue damage or cellular reaction. These bodies are frequently seen in adult mice and, in this instance, their occurrence among treated mice is regarded as spontaneous.

A variety of cutaneous lesions were found in controls and treated males. These lesions included chronic dermatitis, dermal and subcutaneous abscess, hyperkeratosis, ulceration, granuloma, and hematoma. Also external genital lesions such as preputial gland

adenitis, posthitis, blanitis, and penile calculi were found among control and treated males.

The incidence of chronic dermatitis was increased among males receiving 1.5 and 175/100 mg/kg of test compound. Throughout this study, there has reportedly been increased fighting and cutaneous trauma among treated males. This behavior is probably due to compound-induced hyperesthesia.

Female Mice

Corpora amylacea were found in the brains of several treated females. These structures were noted in 4 mice receiving 1.5 mg/kg, 4 mice receiving 7.0 mg/kg, 5 mice receiving 35.0 mg/kg, and 7 mice receiving 175/100 mg/kg. No corpora amylacea were found in female controls. As with males, the occurrence of these aggregates is considered random.

Discussion

In comparing this experimental phase with the 6 month interim sacrifice, the increased incidence of renal tubular cytoplasmic vacuolization seen among treated males at 6 months was not detected at this 12 month sacrifice.

The presence of corpora amylacea in brains of several treated mice of both sexes is, at this stage, regarded as a spurious, random finding in view of the small sample size from each group and the historically frequent identification of these apparently harmless structures in adult mice.

Conclusions

In the second 6 months of this study, the test compound apparently continued to cause hyperesthesia and excessive fighting among males. The increased incidences of various cutaneous lesions reflect compound-induced behavioral changes rather than specific effects on the skin as a target organ.

At this stage, there is no apparent target organ for compound toxicity in either sex.

John W. Sagartz 1/4/83

John W. Sagartz, D.V.M. (Date)
Veterinary Pathologist

Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 0.0

HISTOPATHOLOGY INCIDENCE TABLE

Male Mice
Group I

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0450	81-0460	81-0461*	81-0467	81-0471	81-0493	81-0494	81-0503	81-0504	81-0507	81-0508										Incidence
BRAIN		N	N	L	N	N	N	N	N	N	N	N										
Hemorrhage, multifocal				2																		1/11
SPINAL CORD		N	N	L	N	N	N	N	N	N	N	N										
Hemorrhage, focal				2																		1/11
EYES		N	N	N	N	N	N	N	N	N	N	N										
OPTIC NERVES		N	N	N	N	N	M	N	N	N	N	N										
ADRENALS		N	N	N	N	N	N	N	N	N	N	N										
SPLEEN		N	N	N	N	N	N	N	N	N	N	N										
PANCREAS		N	N	N	N	N	N	N	N	N	N	N										
MESENTERIC LYMPH NODE		N	L	N	N	N	N	N	N	N	N	N										
Hyperplasia, lymphoid, diffuse			3																			1/11
TESTES		N	N	N	N	N	N	N	L	N	N	N										
Hyperplasia, interstitial cell,																						
multifocal									2													1/11
PROSTATE		N	N	N	N	N	N	N	N	N	N	N										
EPIDIDYMIDES		N	N	N	N	L	N	N	N	N	N	N										
Sperm granulomata, multiple						3																1/11
URINARY BLADDER		N	N	N	N	L	N	N	N	L	L	L										
Calculus						P				P	P	P										4/11

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

I.L. H.I.
Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 0.0

HISTOPATHOLOGY INCIDENCE TABLE

Male Mice
Group I (Con't.)

* Died on Study
or

ORGAN Lesion / Accession Number	81-0450	81-0460	81-0461*	81-0467	81-0471	81-0493	81-0494	81-0503	81-0504	81-0507	81-0508	Incidence
LUNGS	N	N	L	N	N	N	N	N	N	N	N	
Congestion, diffuse			2									1/11
ESOPHAGUS	N	N	N	N	N	N	N	N	N	N	N	
TRACHEA	N	N	N	N	N	N	N	N	N	N	N	
THYROIDS	N	N	N	N	N	N	N	N	N	N	N	
PARATHYROIDS	M	N	N	N	N	M	M	M	N	M	N	
HEART	N	N	N	N	N	N	N	N	N	N	N	
LIVER	N	N	L	N	N	N	N	N	N	L	N	
Hepatocellular adenoma, solitary										P		1/11
Necrosis, coagulative, multifocal			2									1/11
KIDNEYS	L	L	L	N	L	L	L	L	L	L	L	
Pyelonephritis, multifocal, acute,												
bacterial etiology			3									1/11
Hyperplasia, tubular, multifocal						2	2					2/11
Cytoplasmic vacuolization, diffuse	2	2	1		2	2	3	1	2	2	2	10/11
Nephrocalcinosis, multifocal			2									1/11
STOMACH	N	N	L	N	N	N	N	N	N	N	N	
Mineralization, multifocal(glandular)			2									1/11
DUODENUM	N	N	N	N	N	N	N	N	N	N	N	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No.: L 06121 SN 7
Comp[illegible]d: RDX
Dose [illegible]g/kg/day): 0.0

HISTOPATHOLOGY INCIDENCE TABLE

Male Mice
Group I (Con't.)

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0450	81-0460	81-0461*	81-0467	81-0471	81-0493	81-0494	81-0503	81-0504	81-0507	81-0508										Incidence
JEJUNUM		N	N	N	N	N	N	N	N	N	N	N										
ILEUM		N	N	N	N	N	N	N	N	N	N	N										
CECUM		N	N	N	N	N	N	N	N	N	N	N										
COLON		N	N	N	N	N	N	N	N	N	N	N										
RECTUM		N	N	N	N	N	N	N	N	N	N	N										
SKIN		L	L	N	N	N	N	N	L	N	N	N										
Dermatitis, focal, chronic, active			3																			1/11
Dermatitis, focal, chronic									2													1/11
Abscess, solitary		4																				1/11
MAMMARY GLAND		M	M	M	M	M	M	N	M	M	M	M										
STERNUM		N	N	N	N	N	N	M	N	N	N	N										
BONE MARROW		N	N	N	N	N	N	M	N	N	N	N										
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
PREPUTIAL GLAND		-	N	-	-	-	-	-	-	-	L	-										
Adenitis, diffuse, chronic, active											3											1/2
PREPUCE		-	-	L	-	-	-	-	-	-	-	-										
Posthitis, focal, acute, bacterial																						
etiology				4																		1/1

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

I.I[illegible] R.I.
Stud[illegible] No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 0.0

HISTOPATHOLOGY INCIDENCE TABLE

* Died on Study
or
Moribund Sacrifice

Male Mice
Group I (Con't.)

ORGAN Lesion	Accession Number	81-0450	81-0460	81-0461*	81-0467	81-0471	81-0493	81-0494	81-0503	81-0504	81-0507	81-0508	Incidence
LESIONS (TISSUES NOT SPECIFICALLY													
REQUIRED BY PROTOCOL) (Con't.)													
URETHRA		-	-	-	-	-	-	-	-	-	-	L	
Calculus												P	1/1
SUBCUTIS		-	-	-	L	-	-	-	-	-	-	L	
Granuloma, solitary					3								1/2
Hematoma, focal												4	1/2
SEMINAL VESICLES		N	N	N	N	N	N	N	N	N	N	N	
INGUINAL LYMPH NODE		L	-	-	-	-	-	-	-	-	L	-	
Lymphadenitis, diffuse, chronic		3											1/2
Hyperplasia, lymphoid, diffuse											4		1/2
ABDOMINAL FAT		L	-	-	-	-	-	-	-	-	-	-	
Steatitis, focal, chronic		3											1/1

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No.: L 06121 SN 7
Com nd: RDX
Dose mg/kg/day): 1.5

694

HISTOPATHOLOGY INCIDENCE TABLE

Male Mice
Group II

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0600	81-0610	81-0614	81-0615*	81-0621	81-0637	81-0640*	81-0641	81-0642*	81-0655	81-0659	81-0662	81-0664								Incidence
BRAIN		N	L	N	N	N	L	L	N	L	L	L	L	L								
Corpora amylacea, multifocal			2				2	2		2	2	2	2	2								8/13
SPINAL CORD		N	N	N	N	N	N	N	N	N	N	N	N	N								
SPLEEN		N	N	N	N	N	N	N	N	N	L	N	N	N								
Hyperplasia, lymphoid, diffuse											3											1/13
HEART		N	N	N	N	N	N	N	N	N	N	N	N	N								
LIVER		N	N	N	N	N	N	N	N	N	N	N	N	N								
KIDNEYS		N	N	N	N	L	L	L	L	L	L	N	L	L								
Pyelonephritis, diffuse, chronic,																						
active, bilateral										4												1/13
Pyelitis, multifocal, chronic							2															1/13
Hyperplasia, tubular, multifocal									1													1/13
Cytoplasmic vacuolization, diffuse						1			1		1		2	1								5/13
Nephrocalcinosis, multifocal								2														1/13
TESTES		N	N	N	N	N	N	N	L	N	N	N	N	N								
Oligospermia									2													1/13

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

I.I. R.I.
Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 1.5

HISTOPATHOLOGY INCIDENCE TABLE

Male Mice
Group II (Con't.)

* Died on Study
or

ORGAN Lesion	Accession Number	81-0600	81-0610	81-0614	81-0615*	81-0621	81-0637	81-0640*	81-0641	81-0642*	81-0655	81-0659	81-0662	81-0664								Incidence
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
SKIN		-	L	-	L	L	L	L	L	L	-	-	-	-								
Dermatitis, multifocal, chronic,																						
active, ulcerative									4													1/7
Dermatitis, focal, chronic, active,																						
ulcerative, penile area								4														1/7
Dermatitis, diffuse, chronic,																						
ulcerative			3																			1/7
Dermatitis, multifocal, chronic,																						
ulcerative								3														1/7
Dermatitis, multifocal, chronic						2	1															2/7
Abscess, solitary, penile area								3		4												2/7
Hyperkeratosis, multifocal, penile area				3																		1/7
INGUINAL LYMPH NODE		-	-	L	-	-	-	-	-	-	-	-	-	-								
Hyperplasia, lymphoid, diffuse				2																		1/1
Hemosiderosis, multifocal				2																		1/1
MESENTERIC FAT		-	-	-	L	-	-	-	-	-	-	-	-	-								
Steatitis, focal, chronic					3																	1/1

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

T.R.T.R.P.
Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 1.5

969

HISTOPATHOLOGY INCIDENCE TABLE

* Died on Study
or

Male Mice
Group II (Con't.)

ORGAN / Lesion	Accession Number	81-0600	81-0610	81-0614	81-0615*	81-0621	81-0637	81-0640*	81-0641	81-0642*	81-0655	81-0659	81-0662	81-0664								Incidence
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL) (Con't.)																						
PREPUTIAL GLAND		-	-	-	L	-	-	-	-	-	-	-	-	-								
Adenitis, diffuse, chronic					3																	1/1
PENIS		-	-	-	-	L	L	-	-	-	-	-	-	-								
Balanitis, diffuse, chronic, active,																						
ulcerative							3															1/2
Balanitis, diffuse, chronic						3																1/2
SUBCUTIS		-	-	-	-	-	L	-	-	-	-	-	-	-								
Abscess, solitary, penile area							4															1/1
SEMINAL VESICLES		-	-	-	-	-	N	-	-	-	-	-	-	-								
LUMBAR LYMPH NODE		-	-	-	-	-	-	L	-	-	-	-	-	-								
Hyperplasia, lymphoid, diffuse								2														1/1
URINARY BLADDER		-	-	-	N	-	-	-	-	-	-	-	-	-								

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 7.0

HISTOPATHOLOGY INCIDENCE TABLE

* Died on Study
or
Moribund Sacrifice

Male Mice
Group III

ORGAN Lesion	Accession Number	81-0751	81-0755	81-0772	81-0780	81-0783	81-0800	81-0801	81-0803	81-0808	81-0819	Incidence
BRAIN		N	L	N	N	L	N	N	N	N	N	
Corpora amylacea, multifocal			2			1						2/10
SPINAL CORD		N	N	N	N	N	N	N	N	N	N	
SPLEEN		N	N	N	N	L	N	N	N	N	N	
Hematopoiesis,extramedullary,diffuse						4						1/10
HEART		N	N	N	N	N	N	N	N	N	N	
LIVER		N	N	L	N	N	L	N	L	N	N	
Hepatocellular adenoma, solitary							P		P			2/10
Focal cellular alteration							P		P			2/10
Fatty change,periacinar,multifocal				1								1/10
KIDNEYS		N	L	L	L	L	N	L	N	L	L	
Pyelitis, multifocal, chronic											2	1/10
Hyperplasia, tubular, multifocal				2	2			2				3/10
Cytoplasmic vacuolization, diffuse			1	2	2			1		2	1	6/10
Infarct, solitary						4						1/10
TESTES		N	N	N	N	N	N	N	N	N	N	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 7.0

869

HISTOPATHOLOGY INCIDENCE TABLE

Male Mice
Group III (Con't.)

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0751	81-0755	81-0772	81-0780	81-0783	81-0800	81-0801	81-0803	81-0808	81-0819	Incidence
LESIONS (TISSUES NOT SPECIFICALLY												
REQUIRED BY PROTOCOL)												
SKIN		-	-	-	-	L	-	-	-	-	-	
Dermatitis, multifocal, chronic						2						1/1
Ulcer,focal,acute,penile area						3						1/1
SUBCUTIS		-	-	-	-	-	-	-	L	-	-	
Abscess, solitary, tail area									3			1/1
URINARY BLADDER		-	-	-	-	L	N	-	-	-	-	
Cystitis, multifocal, chronic						2						1/2
PREPUTIAL GLAND		-	-	-	-	L	-	-	-	-	-	
Abscess, solitary						4						1/1
PROSTATE		-	-	-	-	L	-	-	-	-	-	
Prostatitis, diffuse, acute						2						1/1

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

N.I.H.
Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 35.0

HISTOPATHOLOGY INCIDENCE TABLE

Male Mice
Group IV

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0899	81-0901	81-0908	81-0911	81-0925	81-0939	81-0942	81-0948*	81-0953	81-0958	81-0963	81-0967*	81-0968*								Incidence
BRAIN		N	N	N	L	N	N	L	L	L	N	L	N	L								
Corpora amylacea, multifocal					2			1	2	1		2		2								6/13
SPINAL CORD		N	N	N	N	N	N	N	N	N	N	N	N	N								
SPLEEN		N	N	N	N	N	N	N	L	N	N	N	N	L								
Splenitis, diffuse, acute														3								1/13
Hematopoiesis,extramedullary,diffuse									4					4								2/13
Hyperplasia, lymphoid, diffuse														3								1/13
HEART		N	N	N	N	N	N	N	N	N	N	N	N	N								
LIVER		N	N	N	N	N	N	N	N	N	N	N	N	L								
Hepatitis, diffuse, acute														3								1/13
Focal cellular alteration														P								1/13
KIDNEYS		L	L	N	N	L	L	N	L	L	N	L	L	L								
Pyelonephritis, multifocal, acute, bilateral													3									1/13
Pyelonephritis, diffuse, acute, unilateral, bacterial etiology														4								1/13
Hyperplasia, tubular, multifocal							2		2			1										3/13
Cytoplasmic vacuolization, diffuse		2	1			2	1		1	1		1	2									8/13
TESTES		N	N	N	N	N	N	N	N	N	N	N	N	N								

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 35.0

700

HISTOPATHOLOGY INCIDENCE TABLE

Male Mice
Group IV (Con't.)

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number 81-0899	81-0901	81-0908	81-0911	81-0925	81-0939	81-0942	81-0948*	81-0953	81-0958	81-0963	81-0967*	81-0968*								Incidence
LESIONS (TISSUES NOT SPECIFICALLY																					
REQUIRED BY PROTOCOL)																					
SKIN	-	-	-	-	-	-	L	L	-	-	-	-	-								
Dermatitis, focal, chronic, active,																					
ulcerative							4	4													2/2
SUBCUTIS	-	-	-	-	-	-	-	-	-	-	-	-	L								
Abscess, solitary, perianal area,																					
bacterial etiology													4								1/1
LUMBAR LYMPH NODE	-	-	-	-	-	-	-	-	-	-	-	-	L								
Lymphadenitis, diffuse, acute													3								1/1
Hyperplasia, lymphoid, diffuse													3								1/1
LUNGS	-	-	-	-	-	-	-	L	-	-	-	-	-								
Congestion, diffuse								2													1/1
PREPUCE	-	-	-	-	-	-	-	-	-	-	-	-	L								
Posthitis, multifocal, acute, ulcerative													4								1/1
URINARY BLADDER	-	-	-	-	-	-	-	-	-	-	-	-	L								
Cystitis, diffuse, acute													4								1/1
PENIS	-	-	-	-	-	-	-	N	-	-	-	L	-								
Calculus												P									1/2

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Stu. No.: 061 SN
Com nd: RDX
Dose mg/kg/day): 35.0

HISTOPATHOLOGY INCIDENCE TABLE

Male Mice
Group IV (Con't.)

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0899	81-0901	81-0908	81-0911	81-0925	81-0939	81-0942	81-0948*	81-0953	81-0958	81-0963	81-0967*	81-0968*								Incidence
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL) (Con't.)																						
COLON		-	-	-	-	-	-	-	-	-	-	-	-	N								
PROSTATE		-	-	-	-	-	-	-	N	-	-	-	N	-								
PITUITARY		-	-	-	-	-	-	-	N	-	-	-	-	-								
MESENTERIC LYMPH NODE		-	-	-	-	-	-	-	N	-	-	-	N	-								
GALL BLADDER		-	-	-	-	-	-	-	-	-	-	-	N	-								
SEMINAL VESICLES		-	-	-	-	-	-	-	-	-	-	-	N	-								

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

HISTOPATHOLOGY INCIDENCE TABLE

Male Mice
Group V

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1048	81-1052	81-1062	81-1065*	81-1067	81-1068*	81-1069	81-1073	81-1084	81-1103	81-1114	81-1117									Incidence
BRAIN		L	L	N	N	N	N	N	L	L	L	L	L									
Corpora amylacea, multifocal		2	1						2	2	2	2	2									7/12
SPINAL CORD		N	N	N	N	N	N	N	N	N	N	N	N									
EYES		N	N	N	L	N	N	N	N	N	N	N	N									
Phthisis bulbi, unilateral					4																	1/12
OPTIC NERVES		N	N	N	M	N	M	N	N	N	N	N	N									
ADRENALS		N	L	N	N	N	N	N	L	N	N	L	N									
Pheochromocytoma, solitary,																						
unilateral									P													1/12
Hyperplasia, multifocal (medulla)			2																			1/12
Hyperplasia, focal												2										1/12
SPLEEN		N	N	N	N	N	N	N	N	N	N	N	N									
PANCREAS		N	N	N	L	N	N	N	N	N	N	N	N									
Undifferentiated Sarcoma					P																	1/12
MESENTERIC LYMPH NODE		N	N	N	L	L	N	M	N	N	N	L	N									
Undifferentiated Sarcoma					P																	1/11
Hyperplasia, lymphoid, diffuse						2						3										2/11
TESTES		N	N	N	N	N	N	N	N	N	L	N	N									
Degeneration, diffuse, unilateral											4											1/12

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No. 06 SN
Compound: RDX
Dose (mg/kg/day): 175/100

HISTOPATHOLOGY INCIDENCE TABLE

Male Mice
Group V (Con't.)

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1048	81-1052	81-1062	81-1065*	81-1067	81-1068*	81-1069	81-1073	81-1084	81-1103	81-1114	81-1117									Incidence
PROSTATE		N	N	N	N	N	N	N	N	N	N	N	N									
EPIDIDYMIDES		N	N	N	N	N	N	N	N	N	N	N	N									
URINARY BLADDER		N	N	N	N	N	L	N	N	N	L	L	N									
Cystitis, diffuse, acute							4															1/12
Calculus											P	P										2/12
LUNGS		N	N	N	L	N	L	N	N	N	N	N	N									
Undifferentiated Sarcoma,metastatic					P																	1/12
Congestion, diffuse							3															1/12
ESOPHAGUS		N	N	N	N	N	N	N	N	N	N	N	N									
TRACHEA		N	N	N	N	N	N	N	N	N	N	N	N									
THYROIDS		N	N	N	N	N	N	N	N	N	N	N	N									
PARATHYROIDS		M	N	M	N	N	N	N	N	N	N	M	M									
HEART		N	N	N	N	N	N	N	N	N	N	N	N									
LIVER		N	N	N	L	L	N	N	L	N	N	N	N									
Undifferentiated Sarcoma					P																	1/12
Hemangioma, solitary						P																1/12
Hepatitis, periacinar, multifocal,																						
chronic					3																	1/12
Clear-cell focus									P													1/12

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

T.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 175/100

HISTOPATHOLOGY INCIDENCE TABLE

* Died on Study
or
Moribund Sacrifice

Male Mice
Group V (Con't.)

ORGAN Lesion	Accession Number 81-1048	81-1052	81-1062	81-1065*	81-1067	81-1068*	81-1069	81-1073	81-1084	81-1103	81-1114	81-1117								Incidence
KIDNEYS	L	L	L	L	N	L	L	L	L	L	L	L								
Undifferentiated Sarcoma (Serosa)				P																1/12
Pyelitis,diffuse,acute,unilateral						4														1/12
Hyperplasia, tubular, multifocal							1		2		2	2								4/12
Nephrocalcinosis, multifocal									1			1								2/12
Cytoplasmic vacuolization, diffuse	2	2	2	3			2	1	2	2	2	2								10/12
STOMACH	N	N	N	N	N	N	N	N	N	N	N	N								
DUODENUM	N	N	N	N	N	N	N	N	N	N	N	N								
JEJUNUM	N	N	N	M	N	N	N	N	N	N	N	N								
ILEUM	N	N	N	N	N	N	N	N	N	N	N	N								
CECUM	N	N	N	M	N	N	N	N	N	N	N	N								
COLON	N	N	N	N	N	N	N	N	N	N	N	N								
RECTUM	N	N	N	N	N	N	N	N	N	N	N	N								
SKIN	L	N	L	N	M	N	L	N	N	L	L	N								
Dermatitis,multifocal,chronic,active										2										1/11
Dermatitis, diffuse, chronic	3																			1/11
Dermatitis, multifocal, chronic			2				2				2									3/11
MAMMARY GLAND	M	M	M	N	M	M	M	M	M	M	M	M								

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 175/100

HISTOPATHOLOGY INCIDENCE TABLE

Male Mice
Group V (Con't.)

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1048	81-1052	81-1062	81-1065*	81-1067	81-1068*	81-1069	81-1073	81-1084	81-1103	81-1114	81-1117									Incidence
STERNUM		N	N	N	L	N	N	N	N	N	N	N	N									
Undifferentiated Sarcoma					P																	1/12
BONE MARROW		N	N	N	L	N	N	N	N	N	N	N	N									
Undifferentiated Sarcoma					P																	1/12
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
PLEURA		-	-	-	L	-	-	-	-	-	-	-	-									
Undifferentiated Sarcoma					P																	1/1
SUBCUTIS		-	-	-	L	-	-	-	-	-	-	-	-									
Abscesses, multiple, penile area					3																	1/1
SEMINAL VESICLES		N	N	N	N	N	N	N	N	N	N	N	N									
PREPUTIAL GLAND		-	-	-	-	-	-	-	-	-	N	-	-									

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No.: L 06121 SN 7
Com[illegible]nd: RDX
Dose (mg/kg/day): 0.0

706

30

HISTOPATHOLOGY INCIDENCE TABLE

Female Mice
Group I

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion / Accession Number	81-0522	81-0526	81-0532	81-0535	81-0541	81-0547	81-0556	81-0565	81-0577	81-0585											Incidence
BRAIN	N	N	N	N	N	N	N	N	N	N											
SPINAL CORD	N	N	N	N	N	N	N	N	N	N											
EYES	N	N	N	N	N	N	N	N	N	N											
OPTIC NERVES	N	N	N	N	N	N	N	N	N	N											
ADRENALS	N	N	N	N	N	N	N	N	N	N											
SPLEEN	N	N	N	N	N	L	N	N	N	N											
Hyperplasia, lymphoid, diffuse						2															1/10
PANCREAS	N	N	N	N	N	N	N	N	N	N											
MESENTERIC LYMPH NODE	N	N	N	N	N	N	N	N	N	N											
OVARIES	N	L	N	N	N	N	N	N	N	N											
Parovarian cyst, solitary		3																			1/10
UTERUS	L	N	L	L	N	L	L	N	L	L											
Endometritis, diffuse, acute						3															1/10
Endometritis, multifocal, acute			2																		1/10
Hyperplasia, cystic, glandular, diffuse			2	2			3			2											4/10
Hyperplasia,cystic,glandular,multifocal									2												1/10
Hyperplasia, cystic, glandular, focal	2																				1/10
URINARY BLADDER	N	N	M	N	N	N	N	N	N	N											

12 Moritxs

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
\- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

T.T. T.T.
Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 0.0

HISTOPATHOLOGY INCIDENCE TABLE

Female Mice
Group I (Con't.)

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0522	81-0526	81-0532	81-0535	81-0541	81-0547	81-0556	81-0565	81-0577	81-0585										Incidence
LUNGS		N	N	N	L	N	N	N	N	N	N										
Hemorrhage, focal					2																1/10
ESOPHAGUS		N	N	N	N	N	N	N	N	N	N										
TRACHEA		N	N	N	N	N	N	N	N	N	N										
THYROIDS		N	N	N	N	N	N	N	N	N	N										
PARATHYROIDS		M	M	N	M	M	N	M	M	N	N										
HEART		N	N	N	N	N	N	N	N	N	N										
LIVER		N	N	N	N	N	N	N	N	N	N										
KIDNEYS		N	N	N	N	N	N	N	N	N	N										
STOMACH		N	N	N	N	N	N	N	N	N	N										
DUODENUM		N	N	N	N	N	N	N	N	N	N										
JEJUNUM		N	N	N	N	N	N	N	N	N	N										
ILEUM		N	N	M	N	N	N	N	N	N	N										
CECUM		N	N	N	N	N	N	N	N	N	N										
COLON		N	N	N	N	N	N	N	N	N	N										
RECTUM		N	M	N	N	N	N	N	N	N	N										
SKIN		L	N	N	N	L	N	L	N	N	N										
Dermatitis, diffuse, chronic		2				2		1													3/10
Dermatitis, focal, chronic								2													1/10

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicalbe

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 0.0

708

HISTOPATHOLOGY INCIDENCE TABLE

* Died on Study
or
Moribund Sacrifice

Female Mice
Group I (Con't.)

ORGAN Lesion	Accession Number	81-0522	81-0526	81-0532	81-0535	81-0541	81-0547	81-0556	81-0565	81-0577	81-0585	Incidence
MAMMARY GLAND		N	N	N	N	M	M	N	N	N	N	
STERNUM		N	N	N	N	N	N	N	N	N	N	
BONE MARROW		N	N	N	N	N	N	N	N	N	N	
LESIONS (TISSUES NOT SPECIFICALLY												
REQUIRED BY PROTOCOL)												
VAGINA		N	N	N	N	-	-	-	N	N	N	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 1.5

HISTOPATHOLOGY INCIDENCE TABLE

* Died on Study
or
Moribund Sacrifice

Female Mice
Group II

ORGAN / Lesion	Accession Number	81-0672*	81-0673	81-0681	81-0685	81-0687	81-0701	81-0705	81-0717	81-0721*	81-0734	81-0741	81-0744	Incidence
BRAIN		N	L	N	N	N	L	N	L	N	L	N	N	
Corpora amylacea, multifocal			2				1		2		2			4/12
SPINAL CORD		N	N	N	N	N	N	N	N	N	N	N	N	
SPLEEN		L	N	N	N	N	L	N	N	N	N	N	N	
Malignant Lymphoma, lymphocytic type		P												1/12
Hyperplasia, lymphoid, diffuse							3							1/12
OVARIES		L	N	N	N	N	L	N	N	N	N	N	N	
Malignant Lymphoma, lymphocytic type		P												1/12
Cyst, follicular, solitary							3							1/12
HEART		N	N	N	N	N	N	N	N	N	N	N	N	
LIVER		L	N	N	N	N	N	L	N	N	N	N	N	
Malignant Lymphoma, lymphocytic type		P												1/12
Microabscess, solitary								2						1/12
KIDNEYS		L	N	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, lymphocytic type		P												1/12
Nephropathy, chronic, multifocal		2												1/12

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 1.5

HISTOPATHOLOGY INCIDENCE TABLE

* Died on Study
or
Moribund Sacrifice

Female Mice
Group II (Con't.)

ORGAN Lesion	Accession Number	81-0672*	81-0673	81-0681	81-0685	81-0687	81-0701	81-0705	81-0717	81-0721*	81-0734	81-0741	81-0744	Incidence
LESIONS (TISSUES NOT SPECIFICALLY														
REQUIRED BY PROTOCOL)														
SKIN		L	L	-	-	-	-	-	-	-	-	-	-	
Dermatitis, chronic, diffuse		2	2											2/2
MAMMARY GLAND		N	-	-	-	-	-	-	-	-	-	-	-	
UTERUS		-	-	-	-	-	-	-	-	-	L	-	-	
Hyperplasia,cystic,glandular,multifocal											2			1/1
PANCREAS		N	-	-	-	-	-	-	-	-	-	-	-	
ADRENAL		N	-	-	-	-	-	-	-	-	-	-	-	
MESENTERIC LYMPH NODE		L	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type		P												1/1
RENAL LYMPH NODES		L	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type		P												1/1
RESPIRATORY LYMPH NODES		L	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type		P												1/1
LUNGS		L	-	-	-	-	-	-	-	-	-	-	-	
Congestion, multifocal		4												1/1
PELVIC BONE		-	-	-	-	-	-	-	-	L	-	-	-	
Osteosarcoma										P				1/1

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 1.5

HISTOPATHOLOGY INCIDENCE TABLE

* Died on Study
or
Moribund Sacrifice

Female Mice
Group II (Con't.)

ORGAN Lesion	Accession Number	81-0672*	81-0673	81-0681	81-0685	81-0687	81-0701	81-0705	81-0717	81-0721*	81-0734	81-0741	81-0744									Incidence
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL) (Con't.)																						
EYE		-	-	-	-	-	-	-	-	L	-	-	-									
Phthisis bulbi, unilateral										P												1/1

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 7.0

HISTOPATHOLOGY INCIDENCE TABLE

* Died on Study
or
Moribund Sacrifice

Female Mice
Group III

ORGAN Lesion	Accession Number	81-0835	81-0842	81-0845	81-0854	81-0865	81-0870	81-0884	81-0886	81-0887	81-0891	Incidence
BRAIN		L	N	N	L	L	N	N	N	L	N	
Corpora amylacea, multifocal		2			2	2				2		4/10
SPINAL CORD		N	N	N	N	N	N	N	N	N	N	
SPLEEN		N	N	N	N	N	N	N	N	N	N	
OVARIES		L	N	N	N	N	N	N	N	N	N	
Parovarian cyst, hemorrhagic,solitary		3										1/10
HEART		L	N	N	N	N	N	N	N	N	N	
Myocarditis, multifocal, chronic		2										1/10
LIVER		N	N	N	N	N	N	N	N	N	N	
KIDNEYS		N	N	N	N	N	N	N	N	N	N	
LESIONS (TISSUES NOT SPECIFICALLY												
REQUIRED BY PROTOCOL)												
SKIN		-	-	L	-	-	-	-	-	-	-	
Dermatitis, multifocal, chronic				1								1/1
URINARY BLADDER		-	-	N	-	-	-	-	-	-	L	
Hemangioma, solitary											P	1/2
UTERUS		L	L	L	-	-	-	-	-	-	L	
Hyperplasia,cystic,glandular,multifocal		2	2	3							2	4/4

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 7.0

HISTOPATHOLOGY INCIDENCE TABLE

Female Mice
Group III (Con't.)

* Died on Study
or
Moribund Sacrifice

ORGAN / Lesion	Accession Number: 81-0835	81-0842	81-0845	81-0854	81-0865	81-0870	81-0884	81-0886	81-0887	81-0891										Incidence
LESIONS (TISSUES NOT SPECIFICALLY																				
REQUIRED BY PROTOCOL) (Con't.)																				
VAGINA	N	N	N	-	-	-	-	-	-	N										
PERIPHERAL NERVE	-	-	-	-	-	-	-	-	-	N										

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 35.0

714

HISTOPATHOLOGY INCIDENCE TABLE

Female Mice
Group IV

* Died on Study
or
Moribund Sacrivice

ORGAN Lesion	Accession Number	81-0979	81-0984	81-0997	81-1002	81-1009	81-1011	81-1030	81-1033	81-1034	81-1038	81-1046*	Incidence
BRAIN		N	L	N	L	N	L	L	N	N	L	N	
Corpora amylacea, multifocal			2		2		2	2			2		5/11
SPINAL CORD		N	N	N	N	N	N	N	N	N	N	N	
SPLEEN		N	N	N	N	N	N	N	N	N	N	N	
OVARIES		N	N	N	N	N	N	N	N	N	N	N	
HEART		N	N	N	N	N	N	N	N	N	N	N	
LIVER		N	N	N	N	N	L	N	N	N	N	N	
Fatty change, periportal, diffuse							1						1/11
KIDNEYS		N	N	N	L	N	N	N	N	N	N	L	
Nephropathy, diffuse, chronic												3	1/11
Lymphocytosis, multifocal					2								1/11
LESIONS (TISSUES NOT SPECIFICALLY													
REQUIRED BY PROTOCOL)													
SKIN		L	-	-	-	-	-	-	-	L	N	N	
Dermatitis, multifocal, chronic		2								1			2/4
MAMMARY GLAND		N	-	-	-	-	-	-	-	-	N	-	
URINARY BLADDER		-	-	-	-	-	-	-	-	N	-	-	
LUMBAR LYMPH NODES		-	-	-	-	-	-	-	-	-	-	N	
GALL BLADDER		-	-	-	-	-	-	-	-	-	-	N	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No.: [illegible] 86121 BN 7
Compound: RDX
Dose (mg/kg/day): 175/100

HISTOPATHOLOGY INCIDENCE TABLE

* Died on Study or Moribund Sacrifice

Female Mice
Group V

ORGAN Lesion	Accession Number 81-1148	81-1157	81-1160	81-1161	81-1163	81-1165	81-1181	81-1187	81-1188	81-1196	Incidence
BRAIN	L	L	L	L	L	L	N	N	L	N	
Corpora amylacea, multifocal	2	2	2	2	2	2			2		7/10
SPINAL CORD	N	N	N	N	M	N	N	N	N	N	
EYES	N	N	N	N	N	N	N	N	N	N	
OPTIC NERVES	N	N	N	N	N	N	N	N	N	N	
ADRENALS	N	N	N	N	N	N	N	N	N	N	
SPLEEN	N	N	N	N	N	N	N	N	N	N	
PANCREAS	N	N	N	N	N	N	N	N	N	N	
MESENTERIC LYMPH NODE	N	N	N	N	M	N	N	N	L	N	
Hyperplasia, lymphoid, diffuse									3		1/9
OVARIES	N	N	N	N	N	N	L	N	N	L	
Parovarian cyst, solitary							3				1/10
Cyst, follicular, solitary										3	1/10
UTERUS	L	L	L	L	L	L	N	L	N	L	
Hyperplasia, cystic, glandular, diffuse	3							2			2/10
Hyperplasia, cystic, glandular, multifocal		2		2	2	2				1	5/10
Hyperplasia, cystic, glandular, focal			1								1/10
URINARY BLADDER	N	N	N	N	N	N	N	N	N	N	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study No.: L 06121 SN 7
Compound: RDX
Dose (mg/kg/day): 175/100

HISTOPATHOLOGY INCIDENCE TABLE

Female Mice
Group V (Con't.)

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number 81-1148	81-1157	81-1160	81-1161	81-1163	81-1165	81-1181	81-1187	81-1188	81-1196	Incidence
LUNGS	N	N	N	N	N	N	L	N	N	N	
Pneumonia,interstitial,focal,chronic							1				1/10
ESOPHAGUS	N	N	N	N	N	N	N	N	N	N	
TRACHEA	N	N	N	N	N	N	N	N	N	N	
THYROIDS	N	L	N	N	N	N	N	N	N	N	
Follicular adenoma, solitary		P									1/10
PARATHYROIDS	M	M	N	N	M	M	N	N	N	N	
HEART	N	N	N	N	N	N	N	N	N	N	
LIVER	L	N	N	N	N	N	N	N	N	N	
Periarteritis, focal, chronic	1										1/10
KIDNEYS	N	N	N	N	N	N	N	N	N	N	
STOMACH	N	N	N	N	N	N	N	N	N	N	
DUODENUM	N	N	N	N	N	N	N	N	N	N	
JEJUNUM	N	N	N	N	N	N	N	N	N	N	
ILEUM	N	N	N	N	N	N	N	N	N	N	
CECUM	N	N	N	N	N	N	N	N	N	N	
COLON	N	N	N	N	N	N	N	N	N	N	
RECTUM	N	N	N	N	N	N	N	N	N	N	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

Study : 5121 7
Compound: RDX
Dose (mg/kg/day): 175/100

HISTOPATHOLOGY INCIDENCE TABLE

Female Mice
Group V (Con't.)

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion / Accession Number	81-1148	81-1157	81-1160	81-1161	81-1163	81-1165	81-1181	81-1187	81-1188	81-1196											Incidence
SKIN	L	N	N	N	N	N	N	N	N	N											
Dermatitis, focal, chronic	2																				1/10
MAMMARY GLAND	N	N	N	N	N	N	N	N	N	N											
STERNUM	N	N	N	N	N	N	N	N	N	N											
BONE MARROW	N	N	N	N	N	N	N	N	N	N											
LESIONS (TISSUES NOT SPECIFICALLY																					
REQUIRED BY PROTOCOL)																					
VAGINA	-	N	N	N	-	N	-	N	N	N											

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group MALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35.0 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35.0 mg/kg/day	RDX 175/100 mg/kg/day
BRAIN		(11)	(13)	(10)	(13)	(12)	(10)	(12)	(10)	(11)	(10)
Corpora amylacea		0/11	8/13	2/10	6/13	7/12	0/10	4/12	4/10	5/11	7/10
Hemorrhage		1/11	0/13	0/10	0/13	0/12	0/10	0/12	0/10	0/11	0/10
SPINAL CORD		(11)	(13)	(10)	(13)	(12)	(10)	(12)	(10)	(11)	(9)
Hemorrhage		1/11	0/13	0/10	0/13	0/12	0/10	0/12	0/10	0/11	0/9
EYES		(11)	-	-	-	(12)	(10)	(*1)	-	-	(10)
Phthisis bulbi		0/11	-	-	-	1/12	0/10	1/1	-	-	0/10
ADRENALS		(11)	-	-	-	(12)	(10)	(*1)	-	-	(10)
Pheochromocytoma		0/11	-	-	-	1/12	0/10	0/1	-	-	0/10
Hyperplasia, medulla		0/11	-	-	-	1/12	0/10	0/1	-	-	0/10
Hyperplasia, cortex		0/11	-	-	-	1/12	0/10	0/1	-	-	0/10
SPLEEN		(11)	(13)	(10)	(13)	(12)	(10)	(12)	(10)	(11)	(10)
Malignant Lymphoma, lymphocytic type		0/11	0/13	0/10	0/13	0/12	0/10	1/12	0/10	0/11	0/10
Splenitis, acute		0/11	0/13	0/10	1/13	0/12	0/10	0/12	0/10	0/11	0/10
Hyperplasia, lymphoid		0/11	1/13	0/10	1/13	0/12	0/10	1/12	0/10	0/11	0/10
Hematopoiesis, extramedullary		0/11	0/13	1/10	2/13	0/12	0/10	0/12	0/10	0/11	0/10
PANCREAS		(11)	-	-	-	(12)	(10)	(*1)	-	-	(10)
Undifferentiated Sarcoma		0/11	-	-	-	1/12	0/10	0/1	-	-	0/10

* Tissues not specifically required by protocol.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group MALES: RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35/0 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES: RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35.0 mg/kg/day	RDX 175/100 mg/kg/day
MESENTERIC LYMPH NODE	(11)	-	-	(*2)	(11)	(10)	(*1)	-	-	(9)
Undifferentiated Sarcoma	0/11	-	-	0/2	1/11	0/10	0/1	-	-	0/9
Malignant Lymphoma, lymphocytic type	0/11	-	-	0/2	0/11	0/10	1/1	-	-	0/9
Hyperplasia, lymphoid	1/11	-	-	0/2	2/11	0/10	0/1	-	-	1/9
TESTES	(11)	(13)	(10)	(13)	(12)	-	-	-	-	-
Hyperplasia, interstitial cell	1/11	0/13	0/10	0/13	0/12					
Oligospermia	0/11	1/13	0/10	0/13	0/12					
Degeneration	0/11	0/13	0/10	0/13	1/12					
OVARIES	-	-	-	-	-	(10)	(12)	(10)	(11)	(10)
Malignant Lymphoma, lymphocytic type						0/10	1/12	0/10	0/11	0/10
Parovarian cyst						1/10	0/12	0/10	0/11	1/10
Parovarian cyst, hemorrhagic						0/10	0/12	1/10	0/11	0/10
Cyst, follicular						0/10	1/12	0/10	0/11	1/10
EPIDIDYMIDES	(11)	-	-	-	(12)	-	-	-	-	-
Sperm granulomata	1/11	-	-	-	0/12					
UTERUS	-	-	-	-	-	(10)	(*1)	(*4)	-	(10)
Endometritis, acute						2/10	0/1	0/4	-	0/10
Hyperplasia, cystic, glandular						6/10	1/1	4/4	-	8/10

* Tissues not specifically required by protocol.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group MALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35.0 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35.0 mg/kg/day	RDX 175/100 mg/kg/day
URINARY BLADDER		(11)	(*1)	(*2)	(*1)	(12)		(9)	-	(*2)	(*1)	(10)
Hemangioma		0/11	0/1	0/2	0/1	0/12		0/9	-	1/2	0/1	0/10
Cystitis, acute		0/11	0/1	0/2	1/1	1/12		0/9	-	0/2	0/1	0/10
Cystitis, chronic		0/11	0/1	1/2	0/1	0/12		0/9	-	0/2	0/1	0/10
Calculus		4/11	0/1	0/2	0/1	2/12		0/9	-	0/2	0/1	0/10
LUNGS		(11)	-	-	(*1)	(12)		(10)	(*1)	-	-	(10)
Undifferentiated Sarcoma, metastatic		0/11	-	-	0/1	1/12		0/10	0/1	-	-	0/10
Pneumonia, interstitial, chronic		0/11	-	-	0/1	0/12		0/10	0/1	-	-	1/10
Hemorrhage		0/11	-	-	0/1	0/12		1/10	0/1	-	-	0/10
Congestion		1/11	-	-	1/1	1/12		0/10	1/1	-	-	0/10
THYROIDS		(11)	-	-	-	(12)		(10)	-	-	-	(10)
Follicular adenoma		0/11	-	-	-	0/12		0/10	-	-	-	1/10
HEART		(11)	(13)	(10)	(13)	(12)		(10)	(12)	(10)	(11)	(10)
Myocarditis, chronic		0/11	0/13	0/10	0/13	0/12		0/10	0/12	1/10	0/11	0/10
LIVER		(11)	(13)	(10)	(13)	(12)		(10)	(12)	(10)	(11)	(10)
Undifferentiated Sarcoma		0/11	0/13	0/10	0/13	1/12		0/10	0/12	0/10	0/11	0/10
Hepatocellular adenoma		1/11	0/13	0/10	0/13	0/12		0/10	0/12	0/10	0/11	0/10
Malignant Lymphoma, lymphocytic type		0/11	0/13	0/10	0/13	0/12		0/10	1/12	0/10	0/11	0/10
Hemangioma		0/11	0/13	0/10	0/13	1/12		0/10	0/12	0/10	0/11	0/10
Focal cellular alteration		0/11	0/13	2/10	1/13	0/12		0/10	0/12	0/10	0/11	0/10

* Tissues not specifically required by protocol.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group MALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35.0 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35.0 mg/kg/day	RDX 175/100 mg/kg/day
LIVER (Continued)											
Clear-cell focus		0/11	0/13	0/10	0/13	1/12	0/10	0/12	0/10	0/11	0/10
Hepatitis, acute		0/11	0/13	0/10	1/13	0/12	0/10	0/12	0/10	0/11	0/10
Hepatitis, chronic		0/11	0/13	0/10	0/13	1/12	0/10	0/12	0/10	0/11	0/10
Necrosis, coagulative		1/11	0/13	0/10	0/13	0/12	0/10	0/12	0/10	0/11	0/10
Fatty change		0/11	0/13	1/10	0/13	0/12	0/10	0/12	0/10	1/11	0/10
Microabscess		0/11	0/13	0/10	0/13	0/12	0/10	1/12	0/10	0/11	0/10
Periarteritis, chronic		0/11	0/13	0/10	0/13	0/12	0/10	0/12	0/10	0/11	1/10
KIDNEYS		(11)	(13)	(10)	(13)	(12)	(10)	(12)	(10)	(11)	(10)
Undifferentiated Sarcoma (Serosa)		0/11	0/13	0/10	0/13	1/12	0/10	0/12	0/10	0/11	0/10
Malignant Lymphoma, lymphocytic type		0/11	0/13	0/10	0/13	0/12	0/10	1/12	0/10	0/11	0/10
Pyelonephritis, acute		0/11	0/13	0/10	1/13	0/12	0/10	0/12	0/10	0/11	0/10
Pyelonephritis, acute, bacterial et.,		1/11	0/13	0/10	1/13	0/12	0/10	0/12	0/10	0/11	0/10
Pyelonephritis, chronic		0/11	1/13	0/10	0/13	0/12	0/10	0/12	0/10	0/11	0/10
Pyelitis, acute		0/11	0/13	0/10	0/13	1/12	0/10	0/12	0/10	0/11	0/10
Pyelitis, chronic		0/11	1/13	1/10	0/13	0/12	0/10	0/12	0/10	0/11	0/10
Nephropathy, chronic		0/11	0/13	0/10	0/13	0/12	0/10	1/12	0/10	1/11	0/10
Hyperplasia, tubular		2/11	1/13	3/10	3/13	4/12	0/10	0/12	0/10	0/11	0/10
Cytoplasmic vacuolization		10/11	5/13	6/10	8/13	10/12	0/10	0/12	0/10	0/11	0/10
Nephrocalcinosis		1/11	1/13	0/10	0/13	2/12	0/10	0/12	0/10	0/11	0/10

* Tissues not specifically required by protocol.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group MALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35.0 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35.0 mg/kg/day	RDX 175/100 mg/kg/day
KIDNEYS (Continued)											
Infarct		0/11	0/13	1/10	0/13	0/12	0/10	0/12	0/10	0/11	0/10
Lymphocytosis		0/11	0/13	0/10	0/13	0/12	0/10	0/12	0/10	1/11	0/10
STOMACH		(11)	-	-	-	(12)	(10)	-	-	-	(10)
Mineralization		1/11	-	-	-	0/12	0/10	-	-	-	0/10
SKIN		(11)	(*7)	(*1)	(*2)	(11)	(10)	(*2)	(*1)	(*4)	(10)
Dermatitis, chronic		2/11	6/7	1/1	2/2	5/11	4/10	2/2	1/1	2/4	1/10
Abscess		1/11	2/7	0/1	0/2	0/11	0/10	0/2	0/1	0/4	0/10
Hyperkeratosis		0/11	1/7	0/1	0/2	0/11	0/10	0/2	0/1	0/4	0/10
Ulcer		0/11	0/7	1/1	0/2	0/11	0/10	0/2	0/1	0/4	0/10
STERNUM		(10)	-	-	-	(12)	(10)	-	-	-	(10)
Undifferentiated Sarcoma		0/10	-	-	-	1/12	0/10	-	-	-	0/10
BONE MARROW		(10)	-	-	-	(12)	(10)	-	-	-	(10)
Undifferentiated Sarcoma		0/10	-	-	-	1/12	0/10	-	-	-	0/10
LESIONS (TISSUES NOT SPECIFICALLY											
REQUIRED BY PROTOCOL)											
URETHRA		(1)	-	-	-	-	-	-	-	-	-
Calculus		1/1	-	-	-	-	-	-	-	-	-

* Tissues not specifically required by protocol.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group MALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35.0 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35.0 mg/kg/day	RDX 175/100 mg/kg/day
LESIONS (TISSUES NOT SPECIFICALLY											
REQUIRED BY PROTOCOL) (Con't.)											
INGUINAL LYMPH NODE		(2)	(1)	-	-	-	-	-	-	-	-
Lymphadenitis, chronic		1/2	0/1	-	-	-	-	-	-	-	-
Hyperplasia, lymphoid		1/2	1/1	-	-	-	-	-	-	-	-
Hemosiderosis		0/2	1/1	-	-	-	-	-	-	-	-
LUMBAR LYMPH NODE		-	(1)	-	(1)	-	-	-	-	(1)	-
Lymphadenitis, acute		-	0/1	-	1/1	-	-	-	-	0/1	-
Hyperplasia, lymphoid		-	1/1	-	1/1	-	-	-	-	0/1	-
RENAL LYMPH NODE		-	-	-	-	-	-	(1)	-	-	-
Malignant Lymphoma, lymphocytic type		-	-	-	-	-	-	1/1	-	-	-
SUBCUTIS		(2)	(1)	(1)	(1)	(1)	-	-	-	-	-
Abscess		0/2	1/1	1/1	1/1	1/1					
Granuloma		1/2	0/1	0/1	0/1	0/1					
Hematoma		1/2	0/1	0/1	0/1	0/1					
PREPUTIAL GLAND		(2)	(1)	(1)	-	(1)	-	-	-	-	-
Adenitis, chronic		1/2	1/1	0/1	-	0/1					
Abscess		0/2	0/1	1/1	-	0/1					
PREPUCE		(1)	-	-	(1)	-	-	-	-	-	-
Posthitis, acute		1/1	-	-	1/1	-					

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion / Group	MALES RDX 0.0 mg/kg/day	MALES RDX 1.5 mg/kg/day	MALES RDX 7.0 mg/kg/day	MALES RDX 35.0 mg/kg/day	MALES RDX 175/100 mg/kg/day	FEMALES RDX 0.0 mg/kg/day	FEMALES RDX 1.5 mg/kg/day	FEMALES RDX 7.0 mg/kg/day	FEMALES RDX 35.0 mg/kg/day	FEMALES RDX 175/100 mg/kg/day
LESIONS (TISSUES NOT SPECIFICALLY										
REQUIRED BY PROTOCOL) (Con't.)										
PENIS	-	(2)	-	(2)	-	-	-	-	-	-
Balanitis, chronic	-	2/2	-	0/2	-					
Calculus	-	0/2	-	1/2	-					
RESPIRATORY LYMPH NODE	-	-	-	-	-	-	(1)	-	-	-
Malignant Lymphoma, lymphocytic type							1/1			
PLEURA	-	-	-	-	(1)	-	-	-	-	-
Undifferentiated Sarcoma					1/1					
PELVIC BONE	-	-	-	-	-	-	(1)	-	-	-
Osteosarcoma							1/1			
ABDOMINAL FAT	(1)	-	-	-	-	-	-	-	-	-
Steatitis, chronic	1/1									
MESENTERIC FAT	-	(1)	-	-	-	-	-	-	-	-
Steatitis, chronic		1/1								
PROSTATE	(11)	-	(1)	(2)	(12)	-	-	-	-	-
Prostatitis, acute	0/11		1/1	0/2	0/12					

PATHOLOGY APPENDIX III:

Twenty-four Month Terminal Sacrifice

FINAL PATHOLOGY REPORT

of Twenty-Four Month Chronic Toxicity-Carcinogenicity Study of Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) in B6C3F1 Hybrid Mice

IITRI Project No. L6121
Study Number 7

Twenty-Four Month Interim Report
NECROPSY OBSERVATIONS

Carol A. Thompson, D.V.M., M.S.
Senior Veterinary Pathologist
Pathology Section
Life Sciences Research

L6121 SN 7

Table III, A

Deaths 12-24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Scheduled Sacrifices

ORGAN Lesion	Dosage: mg/kg/day	MALES 0.0	1.5	7.0	35.0	175/100	FEMALES 0.0	1.5	7.0	35.0	175/100
NUMBER OF MICE EXAMINED		44	41	40	36	21	48	44	49	43	25
NO GROSS LESIONS		2	1	3	3	5	0	1	0	0	0
SKIN/Subcutis											
Hairloss		11	14	14	7	7	26	19	31	17	7
Crusted/crusted red/fight wounds/											
lesions		15	15	10	11	7	-	-	1	-	-
Dry		2	2	2	2	-	-	-	-	-	-
Abscess		3	-	-	1	-	-	-	-	-	-
Nodule(s)		2	-	1	-	1	-	-	-	-	-
Mass(es)		10	10	5	4	3	-	2	2	1	3
Mass(es), ulcerated/crusted											
surface		6	7	4	6	-	-	1	2	-	-
Edema		-	2	-	-	-	-	-	-	-	-
MANDIBULAR SALIVARY GLAND											
Mass		-	-	-	-	-	-	-	-	1	-

L6121 SN 7

Deaths 12-24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Scheduled Sacrifices

ORGAN Lesion	Dosage: mg/kg/day	MALES 0.0	1.5	7.0	35.0	175/100	FEMALES 0.0	1.5	7.0	35.0	175/100
MANDIBULAR LYMPH NODE											
Enlarged		-	-	-	-	-	4	-	1	-	2
Firm		-	-	-	-	-	1	-	-	-	-
Tan		-	-	-	-	-	-	-	1	-	1
MAMMARY GLAND											
STERNUM											
COSTOCHONDIAL JUNCTION/RIBS											
THORACIC CAVITY											
Red fluid		-	1	-	-	-	-	-	2	-	2
THYMUS											
Enlarged/mass		-	-	-	-	-	-	-	1	-	-
HEART											

L6121 SN 7

Deaths 12-24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Scheduled Sacrifices

ORGAN Lesion	Dosage: mg/kg/day	MALES 0.0	1.5	7.0	35.0	175/100	FEMALES 0.0	1.5	7.0	35.0	175/100
LUNGS											
Red foci/ diffuse		-	2	-	1	-	1	-	1	-	1
Tan foci / diffuse		1	-	-	1	1	1	-	1	-	1
Pale		-	1	-	-	-	-	-	2	-	-
Nodule(s)		1	2	1	4	1	1	-	2	-	1
Mass(es)		-	1	-	-	-	1	-	-	-	1
ABDOMINAL CAVITY											
Contained red/brown fluid		-	1	-	-	2	-	-	-	-	1
Contained clear fluid		-	1	-	-	-	-	-	-	-	-
Contained "milky" fluid		-	-	1	-	-	-	-	-	-	-
Mass(es)		-	1	1	-	1	-	-	-	-	-
DIAPHRAGM											
LIVER											
Enlarged		-	1	-	-	-	1	-	-	-	2
Nodule(s)		8	6	6	5	2	2	1	4	3	2
Mass(es)		7	16	9	11	8	1	6	5	6	4

L6121 SN 7

Deaths 12-24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Scheduled Sacrifices

ORGAN Lesion	Dosage: mg/kg/day	MALES 0.0	1.5	7.0	35.0	175/100	FEMALES 0.0	1.5	7.0	35.0	175/100
LIVER (continued)											
Tan foci/mottled tan		5	2	1	1	2	3	-	6	2	2
Red foci		2	-	1	-	1	2	3	3	-	2
Pale/tan, diffuse		-	-	-	-	-	3	1	1	3	1
Brown, diffuse/foci		-	-	-	-	-	-	-	-	3	-
Red/mottled red		-	1	-	-	-	-	-	-	-	-
Granular		-	1	-	-	-	1	-	-	-	2
Cyst(s)		1	1	-	1	-	-	-	-	1	-
Soft		-	-	-	-	-	-	-	-	1	-
Focus		1	-	-	1	1	-	-	-	-	-
GALL BLADDER											
Encompassed in mass		-	1	1	-	2	-	1	-	-	1
ADRENAL GLANDS											
Red, diffuse/foci/mottled red		-	-	-	-	-	-	-	-	-	1
Tan		-	-	-	-	-	-	-	1	-	1
Enlarged		-	-	1	1	-	-	-	1	1	1

Deaths 12-24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Scheduled Sacrifices

ORGAN Lesion	Dosage: mg/kg/day	MALES 0.0	1.5	7.0	35.0	175/100	FEMALES 0.0	1.5	7.0	35.0	175/100
SPLEEN											
Enlarged		7	8	7	3	1	15	14	16	9	5
Small		-	1	-	-	-	-	-	-	-	-
Nodule(s)		1	-	1	-	1	1	-	1	2	1
Mass(es)		-	1	1	-	-	-	-	1	-	-
Firm		-	1	-	-	-	-	-	-	-	-
Soft		-	2	-	-	-	-	1	-	-	-
Mottled red/red, diffuse		-	1	2	-	-	3	3	1	1	1
White/tan foci		1	-	1	1	-	1	3	3	2	1
Mottled tan/white, diffuse		2	1	2	-	-	3	2	1	3	1
PANCREAS											
Cyst(s)		-	-	-	-	-	-	-	-	1	-
KIDNEY											
Pale/tan		2	2	3	1	-	-	1	2	2	2
Tan/yellow foci		-	-	1	1	-	-	-	-	-	-
White/grey foci		-	-	2	-	-	-	-	-	-	-
Red, diffuse/foci		-	-	-	-	-	-	-	-	1	-

L6121 SN 7

Deaths 12-24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Scheduled Sacrifices

ORGAN Lesion	Dosage: mg/kg/day	MALES 0.0	1.5	7.0	35.0	175/100	FEMALES 0.0	1.5	7.0	35.0	175/100
KIDNEY (continued)											
Nodule(s)		-	1	-	1	-	-	-	-	-	1
Small		1	-	1	1	-	-	-	-	-	-
Mass		-	-	-	-	-	-	-	1	-	-
URINARY BLADDER											
Distended with yellow/brown fluid		8	4	8	5	-	-	-	-	-	-
Calculi		7	-	2	-	-	-	-	-	-	-
Thickened		1	-	1	-	-	-	-	-	-	-
Firm		1	-	1	-	-	-	-	-	-	-
TESTES											
Small		-	2	-	1	1	-	-	-	-	-
Soft/flaccid		-	-	-	-	-	-	-	-	-	-
Mass(es)		-	1	-	-	-	-	-	-	-	-
Gray/pale/tan		-	1	-	-	-	-	-	-	-	-
EPIDIDYMIS											
Small		-	1	-	-	-	-	-	-	-	-

L6121 SN 7

Deaths 12-24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Scheduled Sacrifices

ORGAN Lesion	Dosage: mg/kg/day	MALES 0.0	1.5	7.0	35.0	175/100	FEMALES 0.0	1.5	7.0	35.0	175/100
SEMINAL VESICLES											
Small		-	1	-	-	-	-	-	-	-	-
PROSTATE											
OVARIES											
Cystic		-	-	-	-	-	14	17	15	12	7
Enlarged		-	-	-	-	-	2	1	-	2	-
Black foci, diffuse		-	-	-	-	-	1	-	-	1	1
Red		-	-	-	-	-	1	-	1	2	1
Tan foci, diffuse		-	-	-	-	-	2	-	1	-	-
Firm		-	-	-	-	-	1	-	-	1	-
Nodule(s)		-	-	-	-	-	1	1	1	1	-
Mass(es)		-	-	-	-	-	1	-	1	1	-
UTERUS											
Distended/enlarged		-	-	-	-	-	40	37	38	35	19
Red foci/focus/endometrium(lumen)		-	-	-	-	-	2	-	2	2	-
Nodule(s)/endometrium (lumen)		-	-	-	-	-	-	-	1	-	-

L6121 SN 7

Deaths 12-24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Scheduled Sacrifices

ORGAN Lesion	Dosage: mg/kg/day	MALES					FEMALES				
		0.0	1.5	7.0	35.0	175/100	0.0	1.5	7.0	35.0	175/100
UTERUS (continued)											
Mass(es)		-	-	-	-	-	-	1	1	-	-
Mass encompassed in		-	-	-	-	-	-	-	-	1	-
Red, diffuse		-	-	-	-	-	-	-	1	-	1
Cyst		-	-	-	-	-	1	1	-	2	-
STOMACH											
Contained green/brown material		-	-	-	-	-	-	-	-	-	1
DUODENUM											
Contained yellow/green material		-	-	-	-	-	-	-	-	1	1
Distended		-	-	-	-	-	-	-	1	-	-
JEJUNUM											
Contained green/black material		-	-	-	-	-	-	-	-	1	1
Firm		-	-	1	-	-	-	-	-	-	-
Nodule(s)		-	-	1	-	-	-	-	-	-	-
Mass		-	1	-	-	-	-	-	-	-	-

L6121 SN 7

Deaths 12-24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Scheduled Sacrifices

ORGAN Lesion	Dosage: mg/kg/day	MALES 0.0	1.5	7.0	35.0	175/100	FEMALES 0.0	1.5	7.0	35.0	175/100
ILEUM											
Contained green material		-	-	-	-	-	-	-	-	1	1
Enlarged Peyer's patches		-	1	-	-	-	1	-	3	-	-
MESENTERIC LYMPH NODE											
Enlarged		9	13	8	9	3	3	5	4	3	3
Red, diffuse/mottled/foci		8	11	8	10	2	1	2	-	2	2
Tan/white, diffuse/mottled		1	3	1	3	1	-	2	3	3	-
Firm		-	-	1	-	-	-	1	-	-	-
Soft		-	-	-	-	-	-	-	-	1	-
Lobulated		-	-	1	-	-	-	1	-	-	-
Cystic		-	-	-	-	-	-	1	-	-	-
CECUM											
EYES											
Opaque/pale/white		-	-	1	1	-	-	-	2	-	2
Small		-	-	1	-	-	1	1	1	-	2
Degenerate		-	1	-	-	-	-	-	-	-	-

L6121 SN 7

Deaths 12-24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Scheduled Sacrifices

ORGAN Lesion	Dosage: mg/kg/day	MALES 0.0	1.5	7.0	35.0	175/100	FEMALES 0.0	1.5	7.0	35.0	175/100
EYES (continued)											
Closed (eye lid)		-	-	1	-	-	-	-	-	-	-
Not apparant		-	-	1	-	-	-	-	-	-	-
BRAIN											
Concaved ventral surface		-	-	-	-	-	1	2	1	-	-
Soft		-	-	-	-	-	-	1	-	-	-
PITUITARY GLAND											
Enlarged		-	-	-	-	-	3	5	3	1	-
Red/black foci, diffuse		-	-	-	-	-	4	7	2	3	-
Clear gray foci		-	-	-	-	-	1	-	1	-	-
Tan foci		-	-	-	1	-	-	-	-	-	-
TAIL											
Nodule		-	-	-	-	1	-	-	-	-	-
LACUMAL GLAND											
Swollen/enlarged		-	-	1	1	1	1	1	1	1	3

L6121 SN 7

Deaths 12-24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Scheduled Sacrifices

ORGAN Lesion	Dosage: mg/kg/day	MALES					FEMALES				
		0.0	1.5	7.0	35.0	175/100	0.0	1.5	7.0	35.0	175/100
LACUMAL GLAND											
Tan		-	-	-	-	-	-	-	-	-	1
ORBRIT											
Nodule(s)		-	-	-	-	-	-	1	-	-	-
AXILLARY LYMPH NODE											
Enlarged		-	-	1	-	-	1	-	-	-	-
RESPIRATORY LYMPH NODE											
Enlarged		-	-	1	-	-	3	2	4	-	1
Tan		-	-	-	-	-	-	-	1	-	-
Red		-	-	-	-	-	-	-	1	-	-
ABDOMINAL/MESENTERIC FAT											
Fat body/necrosis/yellow		2	4	-	3	1	-	2	3	1	-
Cyst		-	-	-	-	-	5	-	-	1	-

L6121 SN 7

Deaths 12-24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Scheduled Sacrifices

ORGAN Lesion	Dosage: mg/kg/day	MALES 0.0	1.5	7.0	35.0	175/100	FEMALES 0.0	1.5	7.0	35.0	175/100
PANCREATIC LYMPH NODE											
Enlarged		1	-	-	1	-	-	1	-	-	-
Red		-	-	-	-	-	-	1	-	-	-
Tan		-	-	-	1	-	-	-	-	-	-
HEPATIC LYMPH NODE											
Enlarged		1	1	-	-	-	-	-	-	-	-
Red, diffuse		-	1	-	-	-	-	-	-	-	-
RENAL LYMPH NODE											
Enlarged		-	1	-	-	-	5	2	4	1	1
Tan/grey		-	-	-	-	-	-	1	1	-	-
Cystic		-	-	-	-	-	1	-	1	-	-
LUMBAR LYMPH NODE											
Enlarged		1	-	-	-	-	2	2	4	-	2
Red, diffuse/mottled		-	-	-	-	-	-	-	2	-	-
Tan, diffuse/mottled		-	-	-	-	-	1	-	1	-	-
Cystic		-	-	-	-	-	-	-	1	-	-

L6121 SN 7

Deaths 12-24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Scheduled Sacrifices

ORGAN Lesion	Dosage: mg/kg/day	MALES					FEMALES				
		0.0	1.5	7.0	35.0	175/100	0.0	1.5	7.0	35.0	175/100
PENIS											
Swollen/enlarged/thickened		7	6	5	2	2	-	-	-	-	-
Red, diffuse/foci		-	3	2	1	1	-	-	-	-	-
Crusted/crusted red		2	1	1	-	1	-	-	-	-	-
Firm		-	1	-	-	-	-	-	-	-	-
White		1	-	-	-	-	-	-	-	-	-
PREPUTIAL GLAND											
Enlarged/swollen		2	-	-	-	-	-	-	-	-	-
Tan		1	-	-	-	-	-	-	-	-	-
INGUINAL LYMPH NODE (Ventral S.C. LN)											
Enlarged		6	2	7	8	1	1	-	1	-	1
Red		-	-	1	2	-	-	-	-	-	1
Tan/gray/white		-	1	1	3	-	1	-	1	-	-

L6121 SN 7
Terminal Sacrifice

B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Moribund Sacrifices and
Spontaneous Deaths

ORGAN Lesion	Dosage: mg/kg/day	MALES 0.0	1.5	7.0	35.0	175/100	FEMALES 0.0	1.5	7.0	35.0	175/100
THYMUS (continued)											
Firm		-	-	-	-	-	-	-	-	1	-
HEART											
Soft/flaccid		-	1	-	-	1	-	-	1	-	-
Firm		-	-	-	-	-	2	-	-	-	-
Nodule		1	-	-	-	-	-	-	-	-	-
Pale		-	-	-	-	-	1	-	-	-	-
White focus		-	-	1	-	-	-	-	-	-	-
Enlarged		-	-	-	1	-	-	-	-	-	-
LUNGS											
Mottled red		1	3	1	2	1	3	2	2	4	-
Red foci, diffuse		1	-	1	-	-	-	4	1	1	-
Pale		2	1	-	-	-	-	1	-	1	-
Mottled		1	-	2	-	1	-	-	-	1	1
Nodule(s)		3	1	-	5	1	1	-	2	2	-
Mass(es)		-	1	1	1	1	3	1	-	1	-
Cystic		1	-	-	-	-	-	-	-	-	-

L6121 SN 7
Terminal Sacrifice
12-24 Months
B6C3F1 Hybrid Mouse

Table III, B

NECROPSY OBSERVATIONS
Moribund Sacrifices and
Spontaneous Deaths

ORGAN Lesion	Dosage: mg/kg/day	MALES 0.0	1.5	7.0	35.0	175/100	FEMALES 0.0	1.5	7.0	35.0	175/100
NUMBER OF MICE EXAMINED		19	19	22	23	6	17	18	15	21	6
NO GROSS LESIONS		0	0	0	0	0	0	0	0	0	0
SKIN/Subcutis											
Hairloss		7	7	8	6	2	6	5	8	5	2
Crusted/crusted red/fight wounds/											
lesions		6	6	5	8	3	1	-	-	-	-
Abscess		-	2	2	1	-	-	-	-	-	-
Thickened area		1	1	2	-	-	-	1	-	-	-
Nodule(s)		1	3	1	3	-	1	-	-	1	-
Mass(es)		3	6	4	7	-	-	4	6	2	1
Mass(es) ulcerated/crusted surface		5	5	9	3	1	-	1	1	1	-
Edema		1	-	1	2	-	-	2	-	-	-
Red, diffuse/foci		-	-	-	-	-	1	1	-	-	-
Yellow		1	-	-	-	-	-	1	-	-	-
Black area		1	-	-	-	-	-	-	1	-	-
MANDIBULAR SALIVARY GLAND											
Enlarged/mass		-	-	1	1	-	2	2	-	-	-

L6121 SN 7
Terminal Sacrifice
12-24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Moribund Sacrifices and
Spontaneous Deaths

ORGAN Lesion	Dosage: mg/kg/day	MALES 0.0	1.5	7.0	35.0	175/100	FEMALES 0.0	1.5	7.0	35.0	175/100
MANDIBULAR SALIVARY GLAND (cont.)											
Tan		1	-	1	-	-	-	-	-	-	-
Red		-	-	-	-	-	1	-	-	1	-
Firm		-	-	1	-	-	1	-	-	-	-
Encompassed in mass		1	-	1	-	-	-	-	-	-	-
MANDIBULAR LYMPH NODE											
Enlarged		-	1	2	1	-	4	5	4	1	-
Firm		-	-	1	-	-	1	-	-	-	-
Red		-	-	1	-	-	2	2	1	1	-
Tan		-	-	1	1	-	-	1	1	-	-
Encompassed in mass		1	-	1	1	-	-	-	-	-	-
MAMMARY GLAND											
Enlarged		-	1	2	1	-	-	-	-	-	-
Nodule		-	-	-	-	-	-	1	-	-	-
Red		-	1	-	1	-	-	-	-	-	-
Black focus		-	-	1	-	-	-	-	-	-	-

L6121 SN 7
Terminal Sacrifice
12-24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Moribund Sacrifices and
Spontaneous Deaths

ORGAN Lesion	Dosage: mg/kg/day	MALES 0.0	1.5	7.0	35.0	175/100	FEMALES 0.0	1.5	7.0	35.0	175/100
STERNUM											
Mass(es)		2	-	1	-	-	-	-	-	-	-
COSTOCHORDIAL JUNCTION/RIBS											
Mass(es)		2	-	1	-	-	-	-	-	-	-
Nodule(s)		-	-	-	1	-	-	-	1	1	-
THORACIC CAVITY											
Red fluid		1	1	2	4	-	5	2	2	1	-
Clear fluid		-	-	-	3	-	1	-	3	1	-
"Milky" fluid		-	-	-	-	-	1	-	-	1	-
Nodule(s)		-	-	-	2	-	-	-	1	2	-
Mass(es)		2	-	1	-	-	-	-	1	-	-
THYMUS											
Enlarged/mass		1	-	-	-	-	3	1	1	5	-
Nodule(s)		-	-	-	1	-	-	-	-	-	-
Encompassed in mass		-	-	1	2	-	1	1	1	-	-
Tan		1	-	-	-	-	-	-	-	2	-

L6121 SN 7
Terminal Sacrifice
12-24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Moribund Sacrifices and
Spontaneous Deaths

ORGAN Lesion	Dosage: mg/kg/day	MALES 0.0	1.5	7.0	35.0	175/100	FEMALES 0.0	1.5	7.0	35.0	175/100
LUNGS (continued)											
Firm		1	-	-	-	-	-	1	-	-	-
Black foci		-	-	-	1	-	-	-	-	-	-
ABDOMINAL CAVITY											
Contained red/brown fluid		2	2	4	3	2	6	5	1	5	-
Contained clear fluid		-	1	-	1	-	1	-	-	-	-
Contained "milky" fluid		-	-	-	-	-	-	-	1	1	-
Mass(es)		-	1	1	2	-	-	1	3	2	-
Nodule(s)		-	-	-	-	-	-	-	-	1	-
DIAPHRAGM											
Nodule(s)		-	-	-	1	-	-	-	-	-	-
LIVER											
Enlarged		-	2	4	4	-	1	6	2	3	1
Lobular		-	1	-	1	-	-	-	-	-	-
Nodule(s)		-	2	2	3	-	1	1	2	3	-
Mass(es)		6	5	3	5	2	-	1	1	3	1

L6121 SN 7
Terminal Sacrifice
12=24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Moribund Sacrifices and
Spontaneous Deaths

ORGAN Lesion	Dosage: mg/kg/day	MALES 0.0	1.5	7.0	35.0	175/100	FEMALES 0.0	1.5	7.0	35.0	175/100
LIVER (continued)											
Tan foci/mottled tan		-	-	4	5	-	-	4	1	1	-
Red foci		1	-	4	-	-	1	-	2	-	-
Pale/tan, diffuse		4	4	6	2	1	3	4	2	3	1
Brown, diffuse/foci		-	2	-	-	-	-	-	-	1	-
Red/mottled red		-	1	2	2	-	2	3	1	1	1
Mottled		-	-	-	1	-	-	1	-	1	-
Firm		-	-	1	1	-	-	-	-	-	-
White/grey foci		-	2	-	2	-	1	-	-	2	-
Granular		-	-	1	1	-	-	-	-	-	-
Ridged edges		-	-	-	-	-	1	-	-	-	-
Soft		-	-	-	1	-	-	1	1	-	-
GALL BLADDER											
Distended/enlarged		1	1	-	-	-	1	-	-	-	-
Contained red fluid		-	-	1	1	-	1	-	-	2	-
Encompassed in mass		3	2	1	1	1	-	-	1	-	-
Red		-	-	-	1	-	-	-	-	-	1

L6121 SN 7
Terminal Sacrifice
12-24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Moribund Sacrifices and
Spontaneous Deaths

ORGAN Lesion	Dosage: mg/kg/day	MALES 0.0	1.5	7.0	35.0	175/100	FEMALES 0.0	1.5	7.0	35.0	175/100
ADRENAL GLANDS											
Red, diffuse/foci/mottled red		-	-	-	-	-	1	-	1	-	-
Tan		-	1	-	2	-	-	-	-	-	1
Enlarged		-	1	-	1	-	-	-	1	1	-
Mass		-	-	-	-	-	-	1	-	-	-
Encompassed in mass		-	-	2	1	-	-	2	2	-	-
Adhesions		-	-	-	1	-	-	-	-	-	-
SPLEEN											
Enlarged		4	5	12	10	2	10	11	8	11	2
Small		-	-	-	-	-	-	1	-	-	-
Pale		3	1	2	-	-	-	1	-	1	-
Nodule(s)		1	-	1	-	-	-	-	-	1	-
Mass(es)		-	-	1	1	-	-	2	1	3	-
Granular		-	-	-	1	-	-	-	-	-	-
Firm		-	-	-	-	-	1	-	-	-	-
Soft		-	-	1	-	-	3	2	-	1	-
Rupture		-	-	-	-	-	1	-	-	2	-
Mottled red/red, diffuse		-	-	1	3	1	7	6	5	3	-

L6121 SN 7
Terminal Sacrifice
12-24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Moribund Sacrifices and
Spontaneous Deaths

ORGAN Lesion	Dosage: mg/kg/day	MALES 0.0	1.5	7.0	35.0	175/100	FEMALES 0.0	1.5	7.0	35.0	175/100
SPLEEN (continued)											
White/tan foci		-	1	-	-	-	2	1	-	2	-
Mottled brown/brown, diffuse		1	1	-	-	1	1	-	-	-	-
Mottled tan/white, diffuse		-	-	1	2	-	1	-	1	2	-
Clear foci/cyst		-	-	1	-	-	-	-	-	-	-
PANCREAS											
White/pale		1	-	-	1	-	-	-	-	-	-
Nodule(s)		-	-	-	1	-	-	1	-	1	-
Mass(es)/encompossed in		-	-	-	-	-	-	1	1	1	-
KIDNEY											
Pale/tan		7	4	9	6	1	3	6	4	3	1
Brown		-	-	-	-	-	-	1	-	-	-
Tan/yellow foci		-	-	-	1	-	-	1	-	-	-
White/grey foci		1	-	-	1	1	-	-	-	-	-
Red, diffuse/foci		-	-	2	1	-	1	-	1	1	1
Pitted/depressions		-	-	1	-	-	-	-	-	-	-
Soft/flaccid		-	-	-	-	-	-	3	1	-	-

L6121 SN 7
Terminal Sacrifice
12-24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Moribund Sacrifices and
Spontaneous Deaths

ORGAN Lesion	Dosage: mg/kg/day	MALES 0.0	1.5	7.0	35.0	175/100	FEMALES 0.0	1.5	7.0	35.0	175/100
KIDNEY (continued)											
Enlarged		-	1	2	1	-	-	-	1	-	-
Nodule(s)		1	-	1	1	-	-	-	-	1	-
Dilated pelvis		-	-	-	-	-	-	1	-	-	-
Small		-	-	1	1	-	-	1	-	-	-
Cyst(s)		-	-	-	-	-	-	1	1	-	2
Covered with white material (foci)		-	1	-	-	-	-	-	-	-	-
Mass encompassed/adhered to		-	-	-	-	-	-	2	2	1	-
Mottled		-	-	-	1	-	-	-	-	1	-
URINARY BLADDER											
Distended with yellow/brown fluid		3	1	1	5	-	-	1	-	-	-
Calculi		-	-	1	2	-	-	-	-	-	-
Distended with red fluid		1	-	-	-	-	1	-	-	-	-
Thickened		-	-	-	3	-	1	-	-	-	-
Firm		-	-	1	-	-	-	-	-	-	-
Red, diffuse/foci		-	-	-	1	-	-	-	-	-	1
Ruptured		-	-	-	-	-	1	-	-	-	-

L6121 SN 7
Terminal Sacrifice
12-24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Moribund Sacrifices and
Spontaneous Deaths

ORGAN Lesion	Dosage: mg/kg/day	MALES 0.0	1.5	7.0	35.0	175/100	FEMALES 0.0	1.5	7.0	35.0	175/100
TESTES											
Small		-	1	-	-	-	-	-	-	-	-
Soft/flaccid		-	-	-	2	-	-	-	-	-	-
Grey/pale/tan		-	1	1	-	-	-	-	-	-	-
Red		-	-	1	-	-	-	-	-	-	-
Enlarged		-	-	-	2	-	-	-	-	-	-
Yellow foci		-	-	-	1	-	-	-	-	-	-
EPIDIDYMIS											
Enlarged		1	-	1	-	-	-	-	-	-	-
Grey/white		-	-	1	-	-	-	-	-	-	-
Red		1	-	-	-	-	-	-	-	-	-
SEMINAL VESICLES											
Distended/enlarged		2	1	-	1	2	-	-	-	-	-
Cyst		-	1	-	-	-	-	-	-	-	-
Adhesion		-	-	-	1	-	-	-	-	-	-
Firm		-	-	-	-	1	-	-	-	-	-

x1

L6121 SN 7
Terminal Sacrifice
12-24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Moribund Sacrifices and
Spontaneous Deaths

ORGAN Lesion	Dosage: mg/kg/day	MALES 0.0	1.5	7.0	35.0	175/100	FEMALES 0.0	1.5	7.0	35.0	175/100
PROSTATE											
Enlarged		-	1	-	1	-	-	-	-	-	-
Nodule(s)		-	1	-	-	-	-	-	-	-	-
Red		-	1	-	-	-	-	-	-	-	-
Adhesion		-	-	-	1	-	-	-	-	-	-
OVARIES											
Cystic		-	-	-	-	-	6	5	4	6	-
Enlarged		-	-	-	-	-	3	4	1	1	-
Black foci, diffuse		-	-	-	-	-	1	-	-	-	-
Red		-	-	-	-	-	1	2	1	1	-
Tan foci, diffuse		-	-	-	-	-	-	1	-	-	-
Grey		-	-	-	-	-	1	-	-	-	-
Nodule(s)		-	-	-	-	-	-	-	1	2	-
Mass(es)		-	-	-	-	-	-	1	3	2	-
Mass encompassed in		-	-	-	-	-	-	1	3	-	-
Small		-	-	-	-	-	-	-	-	1	-

L6121 SN 7
Terminal Sacrifice
12-24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Moribund Sacrifices and
Spontaneous Deaths

ORGAN Lesion	Dosage: mg/kg/day	MALES 0.0	1.5	7.0	35.0	175/100	FEMALES 0.0	1.5	7.0	35.0	175/100
PARAOVARIAN TISSUE											
Mass		-	-	-	-	-	1	-	-	-	-
UTERUS											
Distended/enlarged		-	-	-	-	-	4	8	5	11	4
Red foci/focus/endometrium(lumen)		-	-	-	-	-	-	-	1	-	-
Nodule(s)/endometrium (lumen)		-	-	-	-	-	1	1	2	-	-
Mass(es)		-	-	-	-	-	-	-	-	1	1
Mass encompassed in		-	-	-	-	-	1	1	1	-	-
Red diffuse		-	-	-	-	-	-	2	-	2	1
Tan/grey		-	-	-	-	-	1	-	-	1	-
Firm, diffuse/foci		-	-	-	-	-	1	1	-	1	-
Torsion		-	-	-	-	-	-	2	-	1	-
Cyst		-	-	-	-	-	-	1	-	-	-
STOMACH											
Contained green/brown material		-	1	-	-	-	-	-	-	-	-
Yellow mucosa		-	-	-	-	-	1	-	-	-	-
Red foci		-	1	-	-	-	-	-	-	-	-

L6121 SN 7
Terminal Sacrifice
12-24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Moribund Sacrifices and
Spontaneous Deaths

ORGAN Lesion	Dosage: mg/kg/day	MALES					FEMALES				
		0.0	1.5	7.0	35.0	175/100	0.0	1.5	7.0	35.0	175/100
STOMACH (continued)											
Black foci		-	-	-	-	-	-	1	-	-	-
Nodule(s)		-	-	-	1	-	-	1	-	-	-
Mass		-	-	-	-	-	-	1	-	-	-
DUODENUM											
Contained yellow/green material		-	-	-	1	-	1	-	-	-	-
Red		-	-	-	-	-	1	-	-	-	-
Mass		-	-	1	-	-	-	-	-	-	-
Contained red material		-	-	1	1	-	-	-	-	2	-
JEJUNUM											
Contained green/black material		1	-	-	1	-	-	1	-	-	-
Contained red material		1	-	1	1	-	-	1	-	2	-
Dilated		-	-	1	-	-	-	-	-	-	-
Firm		1	-	-	-	-	-	-	-	-	-
Black area		1	-	-	-	-	-	-	-	-	-
Red		-	-	-	-	-	1	-	-	-	-
Enlarged Peyer's patches		-	-	-	1	-	-	-	-	-	-

L6121 SN 7
Terminal Sacrifice
12-24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Moribund Sacrifices and
Spontaneous Deaths

ORGAN Lesion	Dosage: mg/kg/day	MALES 0.0	1.5	7.0	35.0	175/100	FEMALES 0.0	1.5	7.0	35.0	175/100
JEJUNUM (continued)											
Diverticulum		-	1	-	-	-	-	-	-	-	-
ILEUM											
Contained red material		-	-	-	2	-	-	-	-	2	-
Enlarged Peyer's patches		-	1	-	1	-	-	-	-	1	-
Red		-	-	-	-	-	1	-	-	-	-
MESENTERIC LYMPH NODE											
Enlarged/mass		5	4	7	8	-	4	8	7	5	-
Red, diffuse/mottled/foci		5	4	8	6	-	1	6	2	3	-
Tan/white, diffuse/mottled		1	-	-	1	-	-	3	-	2	-
Firm		1	-	-	2	-	-	1	1	-	-
Mass encompassed in		-	-	1	-	-	1	-	1	1	-
Lobulated		-	-	-	-	-	-	1	-	1	-
CECUM											
Contained red material		-	-	-	-	-	-	-	-	2	-
Small		-	-	-	-	-	1	1	-	-	-

I.6121 SN 7
Terminal Sacrifice
12-24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Moribund Sacrifices and
Spontaneous Deaths

ORGAN Lesion	Dosage: mg/kg/day	MALES 0.0	1.5	7.0	35.0	175/100	FEMALES 0.0	1.5	7.0	35.0	175/100
CECUM (continued)											
Nodule(s)		-	-	-	-	-	-	-	1	-	-
COLON											
Contained red material		-	-	-	-	-	-	-	-	2	-
RECTUM											
Contained red material		-	-	-	-	-	-	-	-	2	-
EYES											
Opaque/pale/white		-	-	-	-	-	1	1	-	-	-
Small		-	-	-	-	-	1	-	-	-	-
Not apparant		-	-	-	-	1	-	-	-	-	-
BRAIN											
Concaved ventral surface		-	-	-	-	-	1	-	-	-	-
Pale		-	1	-	-	-	-	-	-	-	-
Red		-	-	-	-	-	-	-	-	2	-

L6121 SN 7
Terminal Sacrifice
12-24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Moribund Sacrifices and
Spontaneous Deaths

ORGAN Lesion	Dosage: mg/kg/day	MALES 0.0	1.5	7.0	35.0	175/100	FEMALES 0.0	1.5	7.0	35.0	175/100
SKULL											
Red		-	-	1	-	-	-	-	-	-	-
Contained red fluid		-	-	-	1	-	-	-	-	-	-
PITUITARY GLAND											
Enlarged		-	-	-	-	-	2	2	-	-	-
Red/black foci, diffuse		-	-	-	1	-	2	2	1	1	-
Clear/grey foci		-	-	1	-	-	-	-	-	-	-
Mass		-	-	-	-	-	-	1	2	-	-
TAIL											
Nodule		-	-	-	-	-	-	-	-	1	-
BONE MARROW											
Pale		-	-	-	-	-	-	-	1	-	-
HEAD											
Abscess-intramuscular		-	1	-	-	-	-	-	-	-	-

L6121 SN 7
Terminal Sacrifice
12-24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Moribund Sacrifices and
Spontaneous Deaths

ORGAN Lesion	Dosage: mg/kg/day	MALES 0.0	1.5	7.0	35.0	175/100	FEMALES 0.0	1.5	7.0	35.0	175/100
LACUMAL GLAND											
Swollen/enlarged		-	-	-	-	-	-	1	-	-	-
Tan		-	-	-	-	-	-	1	-	-	-
ORBRIT											
Mass(es)		-	1	-	-	-	-	1	1	-	-
HARDARIAN GLAND											
Enlarged		-	-	-	-	-	-	1	-	-	-
Mass(es)		-	-	-	-	-	-	-	1	-	-
NOSE											
Red discharge		-	-	-	-	-	-	-	1	-	-
AXILLARY LYMPH NODE											
Enlarged		-	-	1	1	-	1	3	3	1	-
Tan/white, diffuse		-	-	1	1	-	-	1	-	-	-
Red, diffuse		-	-	-	-	-	-	-	1	-	-
Firm		-	-	-	1	-	1	1	1	-	-

L6121 SN 7
Terminal Sacrifice
12-24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Moribund Sacrifices and
Spontaneous Deaths

ORGAN Lesion	Dosage: mg/kg/day	MALES 0.0	1.5	7.0	35.0	175/100	FEMALES 0.0	1.5	7.0	35.0	175/100
RESPIRATORY LYMPH NODE											
Enlarged		-	-	-	2	-	4	4	6	3	-
Tan		-	-	-	-	-	-	-	1	2	-
Red		-	-	-	-	-	1	2	-	-	-
Firm		-	-	-	-	-	-	1	1	1	-
ABDOMINAL/MESENTERIC FAT											
Fat body/necrosis/yellow		-	1	2	1	-	-	1	-	-	-
Firm		-	-	-	-	-	1	-	-	1	-
Red, diffuse		-	-	-	-	-	1	-	-	-	-
Nodule(s)		-	-	-	-	-	-	-	-	2	-
PANCREATIC LYMPH NODE											
Enlarged		1	-	1	2	-	-	1	-	1	-
Red		-	-	1	-	-	-	-	-	-	-
Tan		-	-	-	2	-	-	1	-	-	-
Firm		-	-	-	1	-	-	-	-	-	-

L6121 SN 7
Terminal Sacrifice
12-24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Moribund Sacrifices and
Spontaneous Deaths

ORGAN Lesion	Dosage: mg/kg/day	MALES 0.0	1.5	7.0	35.0	175/100	FEMALES 0.0	1.5	7.0	35.0	175/100
HEPATIC LYMPH NODE											
Enlarged		-	-	1	2	-	1	2	4	-	-
Red, diffuse		-	-	-	1	-	-	1	-	-	-
Firm		-	-	-	1	-	-	-	1	-	-
White/tan		-	-	1	1	-	-	1	1	-	-
RENAL LYMPH NODE											
Enlarged		1	-	2	3	-	5	4	3	2	1
Tan/grey		-	-	1	-	-	-	1	1	1	-
Firm		-	-	-	-	-	-	-	1	1	-
Cystic		1	-	-	-	-	-	-	-	-	-
Red		-	-	-	-	-	-	1	-	-	-
LUMBAR LYMPH NODE											
Enlarged		2	1	3	9	1	5	6	4	6	2
Red, diffuse/mottled		-	-	-	1	-	-	3	-	-	-
Tan, diffuse/mottled		-	-	1	2	-	-	2	-	-	-
Cystic		-	-	-	-	-	-	-	-	-	-
Firm		-	-	-	1	-	1	-	-	-	-

L6121 SN 7
Terminal Sacrifice
12-24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Moribund Sacrifices and
Spontaneous Deaths

ORGAN Lesion	Dosage: mg/kg/day	MALES 0.0	1.5	7.0	35.0	175/100	FEMALES 0.0	1.5	7.0	35.0	175/100
PENIS											
Swollen/enlarged/thickened		3	3	3	3	1	-	-	-	-	-
Red, diffuse/foci		3	-	3	3	1	-	-	-	-	-
Crusted/crusted red		2	2	1	1	-	-	-	-	-	-
Firm		-	1	3	1	-	-	-	-	-	-
Black/blue		1	-	1	-	-	-	-	-	-	-
Irritated		-	1	-	-	-	-	-	-	-	-
Discharge, white/yellow		-	-	-	1	-	-	-	-	-	-
Bite wounds		-	-	-	-	1	-	-	-	-	-
Urethra - not patent		1	-	-	-	-	-	-	-	-	-
PREPUCE											
Crusted		-	1	-	-	-	-	-	-	-	-
PREPUTIAL GLAND											
Enlarged/swollen		2	-	-	1	1	-	-	-	-	-
Firm		-	-	-	1	-	-	-	-	-	-

L6121 SN 7
Terminal Sacrifice
12-24 Months
B6C3F1 Hybrid Mouse

NECROPSY OBSERVATIONS
Moribund Sacrifices and
Spontaneous Deaths

ORGAN Lesion	Dosage: mg/kg/day	MALES 0.0	1.5	7.0	35.0	175/100	FEMALES 0.0	1.5	7.0	35.0	175/100
PELVIC LYMPH NODE											
Enlarged		-	-	1	-	-	-	1	-	-	-
Red		-	-	1	-	-	-	-	-	-	-
INGUINAL LYMPH NODE (Ventral S.C. LN)											
Enlarged		-	1	-	2	-	2	1	3	-	-
Red		-	-	-	-	-	-	-	1	-	-
Tan/grey/white		-	1	-	1	-	-	-	2	-	-
Firm		-	-	-	1	-	-	-	2	-	-
POPLITEAL LYMPH NODE											
Enlarged		-	-	1	1	-	-	-	-	-	-
Tan		-	-	-	1	-	-	-	-	-	-
Firm		-	-	-	1	-	-	-	-	-	-
CERVICAL LYMPH NODE											
Enlarged		-	-	1	-	-	-	-	-	-	-

Histopathology Report

Chronic Toxicity/Carcinogenicity Study

RDX in B6C3F1 Mice

24 Month Terminal Sacrifice

I.I.T.R.I. Project No. L 06121, Study No. 7

Sponor Project No. DAMD-17-79-C-9161

Submitted by

John W. Sagartz, D.V.M.

Histopathologic Evaluation Methods

Histopathologic examination was performed by John W. Sagartz, D.V.M. Histopathologic findings for each mouse were recorded on a standard form provided by I.I.T.R.I. Tissue counts were recorded on a second form. Both forms were signed by the pathologist and were initialled by Barbara E. Sagartz who transcribed the observations and tissue counts.

These data were transferred to a handwritten Histopathology Incidence Table and submitted for typing. Accuracy of the typed Histopathology Incidence Table was verified by reviewers who initialled the individual animal data forms.

Following verification of the data on the Histopathology Incidence Table, incidences of various histopathologic lesions were calculated on an Incidence Comparison Table. These calculations were verified by the pathologist who then used the Incidence Comparison Tables as the basis for preparation of the Histopathology Narrative Report.

Personnel Record

Study: I.I.T.R.I. Project No. L 06121 SN 7
Sponsor Project No. DAMD-17-79-C9161
Chronic Toxicity/Carcinogenicity Study
RDX - B6C3F1 Mice
24 Month Sacrifice

The personnel listed below have participated in the technical and/or clerical activities of this study:

Name	Signature	Initials	Date
John W. Sagartz, D.V.M.	John W. Sagartz	JWS	9/18/83
Barbara E. Sagartz	Barbara E. Sagartz	BES	9-18-83
Michael J. Sagartz	Michael J. Sagartz	MJS	9/18/83
William M. Sagartz	William M. Sagartz	WMS	9/18/83
Nancy A. Sagartz	Nancy A. Sagartz	NAS	9/18/83
John E. Sagartz	John E. Sagartz	JES	9-18-83
Andrew P. Sagartz	Andrew P. Sagartz	APS	9/18/83
Liesl M. Sagartz	Liesl M. Sagartz	LMS	9-18-83

In the second 12 months of this study, there were several spontaneous deaths and moribund sacrifices among treated and control mice of both sexes. The incidences of early deaths in various groups are as follows:

Group	Dose (mg/kg/day)	Males	Females
I	0.0	20	17
II	1.5	19	18
III	7.0	22	15
IV	35.0	23	21
V	175.0/100	6	6

Male Mice

Treatment-related lesions were observed in the skin of males receiving all doses. These lesions included chronic dermatitis and ulceration. Microscopically, the chronic dermatitis consisted of infiltration of the epidermis and superficial dermis by mononuclear leukocytes and occasional polymorphs. In the ulcers, the continuity of the epidermis was focally disrupted; there were varying degrees of necrosis and variable amounts of inflammatory exudate.

It should be noted that in accordance with the protocol, only gross skin lesions were examined microscopically for mice receiving the 1.5, 7.0, and 35.0 mg/kg doses. At the 175/100 mg dose, the total number of surviving mice was much lower than that of the controls. Taking these observations into account, it is my opinion that, as noted at the 6 and 12 month interim sacrifices, the test compound produced hyperesthesia and fight-induced dermal lesions.

Statistically significant increases in the occurrences of testicular degeneration were found in the 35.0 and 175/100 mg/kg

groups and are considered to be a test compound effect. These lesions are microscopically characterized by necrosis of germinal epithelium, aspermia, and interstitial fibrosis. It is conjectural as to whether the test compound acted directly on the testes or whether the lesions are secondary effects caused by nervous stimulation with resultant hyperesthesia and fighting.

Other noteworthy lesions were found in the following organs:

Brain: Markedly increased incidences of corpora amylacea were seen in the 7.0 and 175/100 mg/kg groups. These mineral deposits are generally located in the thalamus and are not accompanied by inflammatory or degenerative changes in adjacent neural tissue. Corpora amylacea are very commonly found in adult mice of this strain. Although the increased incidences of these deposits in the 7.0 and 175/100 mg/kg groups are statistically significant, they are not regarded as biologically significant.

Adrenal Cortex: Hyperplasia occurred more frequently in the 175/100 mg/kg group. Microscopically these changes appeared as nonneoplastic foci of swollen cells which did not involve the cortical circumference. The possibility that these changes may represent a response to stress was considered. Such histologically well delineated foci have not clearly been shown to reflect hyperfunction, and, although the increased incidence is statistically significant, I consider it to be a spurious finding of no toxicologic significance.

Spleen: The increased incidences of lymphoid hyperplasia in the 1.5 and 7.0 mg/kg groups, although statistically significant, are, in my opinion, spontaneous and not biologically significant. It should be noted that incidences of this change in the 35.0 and 175/100 mg/kg groups are markedly lower than those in the lower dose groups and similar to that of controls. This indicates lack of dose response and further supports the lack of relationship to the test compound.
Liver: The increased incidences of malignant lymphoma in the 7.0 and 35.0 mg/kg groups are considered sporadic.

There were occasional increased incidences of microscopic changes among groups receiving the test substance (i.e., subcapsular cataracts, pancreatic acinar atrophy, mesenteric lymph node lymphoid hyperplasia, pulmonary neoplasms, pulmonary histiocytosis, hepatic neoplasms, and renal malignant lymphoma). These lesions are considered to be spontaneous commonly occurring aging changes.

Females

Treatment-related lesions consisting of hepatocellular adenomas and carcinomas were observed in all dose groups. The combined incidences are dose related. Microscopically, hepatocellular adenomas were expanding masses of swollen neoplastic cells which contained occasional mitosis but did not infiltrate adjacent parenchyma. Hepatocellular carcinomas consist of pleomorphic, enlarged, mitotically active hepatocytes arranged in irregular trabecular and invading contiguous normal hepatic tissue.

Other noteworthy histopathologic lesions were noted in the following organs:

Spleen: The increased frequency of extramedullary hematopoiesis in the 7.0 mg/kg group is regarded as spontaneous and unrelated to the test compound.

Lung: The combined incidences of alveolar/bronchiolar adenomas and carcinomas were increased in the 7.0, 35.0, and 175/100 mg/kg groups. The variability in sample sizes for these groups, along with the moderate increases in incidences lead us, with the Sponsor's authorization, to begin preparation of microslides from all remaining formalin-preserved lung specimens in the 1.5, 7.0, and 35.0 mg/kg dose groups of both sexes. Upon receipt of microslides from these mice, histopathologic findings will be evaluated and presented in an addendum to this report.

The relatively high incidence of pulmonary histiocytosis found in the 175/100 mg/kg group is considered random. This change is commonly seen in untreated mice of this age and strain.

Other lesions which occurred with increased frequency among treated mice included splenic lymphoid hyperplasia, malignant lymphoma in urinary bladder, and chronic dermatitis. These lesions were regarded as spontaneous and unrelated to treatment.

In mice of both sexes, the remaining microscopic changes observed in treated groups were considered due to common, naturally-occurring diseases and were not unusual in type, severity, or incidence.

Summary and Conclusions

Under conditions of this experiment, the test compound produced the following biologically significant effects:

Males

1) Compound-induced physiologic hyperesthesia caused fighting in all dose groups. This fighting resulted in increased occurrences of dermatitis and cutaneous ulcerations. This secondary compound effect was also apparent in the 175/100 mg/kg dose group at the 6 month interim sacrifice and in the 1.5 and 175/100 mg/kg doses at the 12 month interim sacrifice.

2) At the 24 month terminal sacrifice, compound-related testicular degeneration was observed in the 35.0 and 175/100 mg/kg groups.

3) At the 6 month interim sacrifice, the renal tubule was suspected as a target of compound action. This suspicion was not substantiated at the 12 month interim sacrifice or at the 24 month terminal sacrifice.

Females

1) No compound-induced pathologic effects were found at the 6 or 12 month interim sacrifices.

2) At the 24 month terminal sacrifice, the occurrence of hepatocellular neoplasms in all dose groups leads to the conclusion that the test substance, RDX, induces these neoplasms and should be considered carcinogenic in female mice.

Following microscopic evaluation of additional lung sections from the 1.5, 7.0, and 35.0 mg/kg groups of males and females, an addendum covering pulmonary findings will be submitted.

1/6/84

John W. Sagartz, D.V.M. (Date)
Veterinary Pathologist

REFERENCES:

1. Benirschke, K., et al. Pathology of Laboratory Animals, Vol. I & II. Springer-Verlag, New York. 1978.

2. Turuson, V.S. Pathology of Tumours in Laboratory Animals, Vol II - Tumours of the Mouse. WHO.IARX, Lyon. 1979.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0523	81-0524	81-0525*	81-0527	81-0528	81-0529	81-0530	81-0531	81-0533	81-0534	81-0536	81-0537	81-0538	81-0539	81-0540	81-0542	81-0543	81-0544	81-0545*	81-0546	Incidence
BRAIN		L	L	L	L	L	L	L	L	L	N	N	N	N	L	N	N	N	L	L	L	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
Lymphocytosis, multifocal								2														
Lymphocytosis, perivascular, multifocal																						
Hemorrhage, multifocal																						
Compression, focal				3					2													
Corpora amylacea, multifocal		2	2	1	2	2	2			2					1				1	2	2	
SPINAL CORD		L	N	N	N	N	N	L	N	N	N	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, mixed type(Meninges)																						
Lymphocytosis, multifocal (Meninges)		2						2														
Hemorrhage, multifocal																						
EYES		N	N	N	L	N	N	N	N	N	N	N	N	N	L	N	N	N	N	N	N	
Phthisis bulbi, unilateral		.			4																	
Keratitis, chronic, multifocal, bilateral																						
Keratitis, chronic, focal, unilateral															2							
Cataract, subcapsular, bilateral																						
Cataract, subcapsular, unilateral																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0548*	81-0549	81-0550	81-0551*	81-0552	81-0553	81-0554	81-0555	81-0557	81-0558	81-0559*	81-0560*	81-0561	81-0562	81-0563	81-0564	81-0566	81-0567*	81-0568	81-0569	Incidence
BRAIN		L	L	L	N	L	L	L	L	L	L	N	N	N	N	L	L	N	L	L	L	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type		P																				
Lymphocytosis, multifocal																						
Lymphocytosis, perivascular, multifocal																						
Hemorrhage, multifocal																			3			
Compression, focal																						
Corpora amylacea, multifocal		2	2	2		2	2	2	2	1	2					2	2			2	2	
SPINAL CORD		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	L	N	N	
Malignant Lymphoma, mixed type(Meninges)																						
Lymphocytosis, multifocal (Meninges)																						
Hemorrhage, multifocal																			3			
EYES		N	N	N	L	N	N	N	L	L	L	L	N	N	N	N	N	N	N	N	N	
Phthisis bulbi, unilateral																						
Keratitis, chronic, multifocal,																						
bilateral					2																	
Keratitis, chronic, focal, unilateral																						
Cataract, subcapsular, bilateral																						
Cataract, subcapsular, unilateral										2	1											

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.1 ...R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0570	81-0571*	81-0572*	81-0573	81-0574*	81-0575	81-0576	81-0578	81-0579*	81-0580*	81-0581	81-0582	81-0583	81-0584*	81-0586*	81-0587	81-0588*	81-0589	81-0590	81-0591	Incidence
BRAIN		L	L	N	N	N	L	N	N	N	N	N	L	L	L	L	L	L	N	L	L	
Malignant Lymphoma, mixed type													P									
Malignant Lymphoma, lymphocytic type																						
Lymphocytosis, multifocal																						
Lymphocytosis, perivascular, multifocal																					2	
Hemorrhage, multifocal																						
Compression, focal																						
Corpora amylacea, multifocal		2	2				2							2	2	2	2	1		2	2	
SPINAL CORD		N	N	N	N	N	N	N	N	N	N	N	L	N	N	N	N	N	N	N	L	
Malignant Lymphoma, mixed type(Meninges)													P									
Lymphocytosis, multifocal (Meninges)																					1	
Hemorrhage, multifocal																						
EYES		N	N	N	L	N	N	N	L	N	N	L	L	L	N	L	N	N	L	L	N	
Phthisis bulbi, unilateral																4						
Keratitis, chronic, multifocal, bilateral																						
Keratitis, chronic, focal, unilateral																						
Cataract, subcapsular, bilateral													2	1						2		
Cataract, subcapsular, unilateral					2				2			2							2			

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0592*	81-0593	81-0594	81-0595	81-0596*																Incidence
BRAIN		N	L	N	N	L																(65)
Malignant Lymphoma, mixed type																						1/65
Malignant Lymphoma, lymphocytic type																						1/65
Lymphocytosis, multifocal																						1/65
Lymphocytosis, perivascular,multifocal																						1/65
Hemorrhage, multifocal																						1/65
Compression, focal																						2/65
Corpora amylacea, multifocal			2			1																36/65
SPINAL CORD		N	N	N	N	N																(65)
Malignant Lymphoma, mixed type(Meninges)																						1/65
Lymphocytosis, multifocal (Meninges)																						3/65
Hemorrhage, multifocal																						1/65
EYES		N	N	L	L	N																(65)
Phthisis bulbi, unilateral																						2/65
Keratitis, chronic, multifocal, bilateral																						1/65
Keratitis, chronic, focal, unilateral																						1/65
Cataract, subcapsular, bilateral				2																		4/65
Cataract, subcapsular, unilateral					2																	7/65

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0523	81-0524	81-0525*	81-0527	81-0528	81-0529	81-0530	81-0531	81-0533	81-0534	81-0536	81-0537	81-0538	81-0539	81-0540	81-0542	81-0543	81-0544	81-0545*	81-0546	Incidence
EYES (Con't.)		N	N	N	L	N	N	N	N	N	N	N	N	N	L	N	N	N	N	N	N	
Hemorrhage, focal, bilateral																						
Mineralization, focal, unilateral																						
(Cornea)																						
OPTIC NERVES		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	L	N	N	
Neuritis, chronic, diffuse																			3			
ADRENALS		N	N	N	N	L	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Pheochromocytoma, solitary																						
Malignant Lymphoma, histiocytic type																						
Hyperplasia, cortical, focal						2																
SPLEEN		N	L	N	L	L	N	N	N	L	L	L	L	L	L	L	L	L	L	L	L	
Malignant Lymphoma, mixed type														P			P		P			
Malignant Lymphoma, lymphocytic type										P	P											
Malignant Lymphoma, histiocytic type																						
Leukemia, myeloid																				P		
Hyperplasia, lymphoid, diffuse			2		2	3						2	3		2	2		2				
Hyperplasia, reticulum-cell, diffuse																					3	
Hematopoiesis, extramedullary, diffuse																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0548*	81-0549	81-0550	81-0551*	81-0552	81-0553	81-0554	81-0555	81-0557	81-0558	81-0559*	81-0560*	81-0561	81-0562	81-0563	81-0564	81-0566	81-0567*	81-0568	81-0569	Incidence
EYES (Con't.)		N	N	N	L	N	N	N	L	L	L	L	N	N	N	N	N	N	N	N	N	
Hemorrhage, focal, bilateral												3										
Mineralization, focal, unilateral,																						
(Cornea)									2													
OPTIC NERVES		N	N	N	N	N	N	N	L	N	N	N	N	N	N	L	N	N	N	N	N	
Neuritis, chronic, diffuse									2							2						
ADRENALS		N	N	N	N	N	N	N	L	N	N	L	N	N	N	N	N	L	N	N	N	
Pheochromocytoma, solitary																		P				
Malignant Lymphoma, histiocytic type												P										
Hyperplasia, cortical, focal									2													
SPLEEN		L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	N	L	L	
Malignant Lymphoma, mixed type			P			P							P		P			P			P	
Malignant Lymphoma, lymphocytic type		P		P			P			P												
Malignant Lymphoma, histiocytic type												P										
Leukemia, myeloid					P																	
Hyperplasia, lymphoid, diffuse								3	3		2			2		2	2					
Hyperplasia, reticulum-cell, diffuse																						
Hematopoiesis, extramedullary, diffuse															3					3		

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.[illegible].R.]
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0570	81-0571*	81-0572*	81-0573	81-0574*	81-0575	81-0576	81-0578	81-0579*	81-0580*	81-0581	81-0582	81-0583	81-0584*	81-0586*	81-0587	81-0588*	81-0589	81-0590	81-0591	Incidence
EYES (Con't.)		N	N	N	L	N	N	N	L	N	N	L	L	L	N	L	N	N	L	L	N	
Hemorrhage, focal, bilateral																						
Mineralization, focal, unilateral,																						
(Cornea)																						
OPTIC NERVES		N	N	N	N	N	N	N	N	N	N	N	N	N	N	M	N	N	N	N	N	
Neuritis, chronic, diffuse																						
ADRENALS		N	N	N	N	N	N	N	N	N	N	N	N	L	N	N	N	N	N	N	N	
Pheochromocytoma, solitary																						
Malignant Lymphoma, histiocytic type																						
Hyperplasia, cortical, focal														2								
SPLEEN		L	L	L	L	N	L	N	N	N	N	L	L	N	L	M	N	N	L	L	L	
Malignant Lymphoma, mixed type		P	P		P							P	P		P				P			
Malignant Lymphoma, lymphocytic type				P																		
Malignant Lymphoma, histiocytic type																						
Leukemia, myeloid																						
Hyperplasia, lymphoid, diffuse							2													3	2	
Hyperplasia, reticulum-cell, diffuse																						
Hematopoiesis, extramedullary, diffuse																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0592*	81-0593	81-0594	81-0595	81-0596*	Incidence
EYES (Con't.)		N	N	L	L	N	(65)
Hemorrhage, focal, bilateral							1/65
Mineralization, focal, unilateral,							
(Cornea)							1/65
OPTIC NERVES		M	N	N	N	N	(63)
Neuritis, chronic, diffuse							3/63
ADRENALS		N	N	N	N	N	(65)
Pheochromocytoma, solitary							1/65
Malignant Lymphoma, histiocytic type							1/65
Hyperplasia, cortical, focal							3/65
SPLEEN		L	L	L	N	L	(64)
Malignant Lymphoma, mixed type		P	P			P	19/64
Malignant Lymphoma, lymphocytic type							7/64
Malignant Lymphoma, histiocytic type							1/64
Leukemia, myeloid							2/64
Hyperplasia, lymphoid, diffuse				2			18/64
Hyperplasia, reticulum-cell, diffuse							1/64
Hematopoiesis, extramedullary, diffuse							2/64

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.J - ?.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0523	81-0524	81-0525*	81-0527	81-0528	81-0529	81-0530	81-0531	81-0533	81-0534	81-0536	81-0537	81-0538	81-0539	81-0540	81-0542	81-0543	81-0544	81-0545*	81-0546	Incidence
PANCREAS		N	N	N	N	N	N	N	N	N	N	N	L	N	N	N	N	N	N	L	N	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
Leukemia, myeloid																				P		
Islet-cell adenoma, solitary																						
Acinar hyperplasia, multifocal																						
Acinar hyperplasia, focal													2									
Pancreatitis, chronic, multifocal																						
MESENTERIC LYMPH NODE		N	N	N	L	L	N	N	M	L	L	N	L	L	L	L	L	L	L	L	N	
Malignant Lymphoma, mixed type															P		P		P			
Malignant Lymphoma, lymphocytic type										P	P											
Malignant Lymphoma, histiocytic type																						
Leukemia, myeloid																				P		
Hyperplasia, lymphoid, diffuse					2	2							2	2		2		2				
Angiectasis, diffuse																						
Congestion, diffuse																						
OVARIES		N	N	N	N	N	L	L	N	N	L	N	L	N	L	N	L	L	N	L	N	
Hemangiosarcoma, solitary															P							
Malignant Lymphoma, mixed type																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0548*	81-0549	81-0550	81-0551*	81-0552	81-0553	81-0554	81-0555	81-0557	81-0558	81-0559*	81-0560*	81-0561	81-0562	81-0563	81-0564	81-0566	81-0567*	81-0568	81-0569	Incidence
PANCREAS		N	N	N	L	L	N	N	N	N	N	N	L	N	L	N	N	L	L	N	N	
Malignant Lymphoma, mixed type													P		P			P				
Malignant Lymphoma, lymphocytic type																						
Leukemia, myeloid					P																	
Islet-cell adenoma, solitary						P																
Acinar hyperplasia, multifocal																						
Acinar hyperplasia, focal																						
Pancreatitis, chronic, multifocal																			3			
MESENTERIC LYMPH NODE		L	L	L	L	L	L	L	N	L	L	L	L	L	L	N	L	L	N	M	L	
Malignant Lymphoma, mixed type			P			P							P		P			P			P	
Malignant Lymphoma, lymphocytic type		P		P			P			P				P								
Malignant Lymphoma, histiocytic type												P										
Leukemia, myeloid					P																	
Hyperplasia, lymphoid, diffuse								2			3						2					
Angiectasis, diffuse			4																			
Congestion, diffuse																						
OVARIES		L	L	N	L	L	N	N	L	N	L	N	L	N	L	N	N	N	N	N	N	
Hemangiosarcoma, solitary					P																	
Malignant Lymphoma, mixed type													P									

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.[illegible]R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0570	81-0571*	81-0572*	81-0573	81-0574*	81-0575	81-0576	81-0578	81-0579*	81-0580*	81-0581	81-0582	81-0583	81-0584*	81-0586*	81-0587	81-0588*	81-0589	81-0590	81-0591	Incidence
PANCREAS		L	L	L	L	N	N	N	N	L	N	L	N	L	N	M	L	L	L	N	N	
Malignant Lymphoma, mixed type		P	P		P							P					P		P			
Malignant Lymphoma, lymphocytic type				P														P				
Leukemia, myeloid																						
Islet-cell adenoma, solitary										P												
Acinar hyperplasia, multifocal														2								
Acinar hyperplasia, focal																						
Pancreatitis, chronic, multifocal																						
MESENTERIC LYMPH NODE		L	L	L	L	N	L	M	N	N	L	L	L	L	L	N	L	L	L	L	L	
Malignant Lymphoma, mixed type		P	P		P							P	P		P		P		P	P		
Malignant Lymphoma, lymphocytic type				P														P				
Malignant Lymphoma, histiocytic type																						
Leukemia, myeloid																						
Hyperplasia, lymphoid, diffuse							2							2							2	
Angiectasis, diffuse																						
Congestion, diffuse											3											
OVARIES		N	L	L	N	N	N	L	N	N	N	L	L	N	N	N	N	L	N	N	N	
Hemangiosarcoma, solitary																						
Malignant Lymphoma, mixed type													P									

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0592*	81-0593	81-0594	81-0595	81-0596*															Incidence
PANCREAS		N	N	N	N	L															(64)
Malignant Lymphoma, mixed type						P															10/64
Malignant Lymphoma, lymphocytic type																					2/64
Leukemia, myeloid																					2/64
Islet-cell adenoma, solitary																					2/64
Acinar hyperplasia, multifocal																					1/64
Acinar hyperplasia, focal																					1/64
Pancreatitis, chronic, multifocal																					1/64
MESENTERIC LYMPH NODE		L	L	L	N	L															(62)
Malignant Lymphoma, mixed type		P	P	P		P															22/62
Malignant Lymphoma, lymphocytic type																					9/62
Malignant Lymphoma, histiocytic type																					1/62
Leukemia, myeloid																					2/62
Hyperplasia, lymphoid, diffuse																					12/62
Angiectasis, diffuse																					1/62
Congestion, diffuse																					1/62
OVARIES		L	N	N	L	L															(65)
Hemangiosarcoma, solitary																					2/65
Malignant Lymphoma, mixed type		P																			3/65

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I. .R.I
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0523	81-0524	81-0525*	81-0527	81-0528	81-0529	81-0530	81-0531	81-0533	81-0534	81-0536	81-0537	81-0538	81-0539	81-0540	81-0542	81-0543	81-0544	81-0545*	81-0546	Incidence
OVARIES (Con't.)		N	N	N	N	N	L	L	N	N	L	N	L	N	L	N	L	L	N	L	N	
Malignant Lymphoma, lymphocytic type																						
Leukemia, myeloid																				P		
Cystadenoma, solitary																						
Abscess, bilateral																						
Abscess, solitary																						
Hematoma, solitary													4									
Hemorrhagic cyst, solitary																	3					
Parovarian cysts, multiple, unilateral																						
Parovarian cyst, solitary						2											2					
Follicular cysts, multiple, unilateral																3						
Follicular cyst, solitary							3			2		2										
UTERUS		L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	
Hemangiosarcoma, solitary													P									
Endometrial Stromal Sarcoma, solitary																						
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
Squamous metaplasia, multifocal																						
Hyperplasia,cystic,glandular,diffuse		4	3	2	2	4	4	4	2	4	2	2	3	3	2	3	3	3	3	2	4	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0548*	81-0549	81-0550	81-0551*	81-0552	81-0553	81-0554	81-0555	81-0557	81-0558	81-0559*	81-0560*	81-0561	81-0562	81-0563	81-0564	81-0566	81-0567*	81-0568	81-0569	Incidence
OVARIES (Con't.)		L	L	N	L	L	N	N	L	N	L	N	L	N	L	N	N	N	N	N	N	
Malignant Lymphoma, lymphocytic type		P																				
Leukemia, myeloid																						
Cystadenoma, solitary																						
Abscess, bilateral															4							
Abscess, solitary					4																	
Hematoma, solitary																						
Hemorrhagic cyst, solitary																						
Parovarian cysts, multiple, unilateral																						
Parovarian cyst, solitary			2			2					3											
Follicular cysts, multiple, unilateral																						
Follicular cyst, solitary									4													
UTERUS		L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	
Hemangiosarcoma, solitary																						
Endometrial Stromal Sarcoma, solitary																						
Malignant Lymphoma, mixed type													P									
Malignant Lymphoma, lymphocytic type							P															
Squamous metaplasia, multifocal															3							
Hyperplasia, cystic, glandular, diffuse		3	2	4	3	2	4	4	4	4	3	2	3	3	3	2	4	3	3	4	4	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I...R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion / Accession Number	81-0570	81-0571*	81-0572*	81-0573	81-0574*	81-0575	81-0576	81-0578	81-0579*	81-0580*	81-0581	81-0582	81-0583	81-0584*	81-0586*	81-0587	81-0588*	81-0589	81-0590	81-0591	Incidence
OVARIES (Con't.)	N	L	L	N	N	N	L	N	N	N	L	L	N	N	N	N	L	N	N	N	
Malignant Lymphoma, lymphocytic type			P														P				
Leukemia, myeloid																					
Cystadenoma, solitary							P														
Abscess, bilateral																					
Abscess, solitary																					
Hematoma, solitary																					
Hemorrhagic cyst, solitary																					
Parovarian cysts, multiple, unilateral											3										
Parovarian cyst, solitary																					
Follicular cysts, multiple, unilateral		2																			
Follicular cyst, solitary							4														
UTERUS	L	L	L	L	L	L	L	L	L	L	L	L	L	L	N	L	L	L	L	L	
Hemangiosarcoma, solitary																					
Endometrial Stromal Sarcoma, solitary					P																
Malignant Lymphoma, mixed type																					
Malignant Lymphoma, lymphocytic type			P																		
Squamous metaplasia, multifocal																					
Hyperplasia, cystic, glandular, diffuse	4	4	2	4		4	4	3	3	2	4	4	3	2		4	2	2	4	3	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0592*	81-0593	81-0594	81-0595	81-0596*															Incidence
OVARIES (Con't.)		L	N	N	L	L															(65)
Malignant Lymphoma, lymphocytic type																					3/65
Leukemia, myeloid																					1/65
Cystadenoma, solitary																					1/65
Abscess, bilateral																					1/65
Abscess, solitary																					1/65
Hematoma, solitary																					1/65
Hemorrhagic cyst, solitary																					1/65
Parovarian cysts, multiple, unilateral					3																2/65
Parovarian cyst, solitary		3				3															7/65
Follicular cysts, multiple, unilateral																					2/65
Follicular cyst, solitary																					5/65
UTERUS		L	L	L	L	L															(65)
Hemangiosarcoma, solitary																					1/65
Endometrial Stromal Sarcoma, solitary																					1/65
Malignant Lymphoma, mixed type																					1/65
Malignant Lymphoma, lymphocytic type																					2/65
Squamous metaplasia, multifocal																					1/65
Hyperplasia, cystic, glandular, diffuse		3	4	4	4	4															63/65

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I T.R.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0523	81-0524	81-0525*	81-0527	81-0528	81-0529	81-0530	81-0531	81-0533	81-0534	81-0536	81-0537	81-0538	81-0539	81-0540	81-0542	81-0543	81-0544	81-0545*	81-0546	Incidence
UTERUS (Con't.)		L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	
Endometritis, acute, diffuse																	2					
Endometritis, acute, multifocal																						
Endometritis, acute, focal																						
Hemorrhage, focal																						
Hydrometra, diffuse																		4				
URINARY BLADDER		M	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
Malignant Lymphoma, histiocytic type																						
LUNGS		N	N	N	N	N	N	N	N	N	L	N	N	L	L	N	N	N	L	L	L	
Osteosarcoma, solitary																						
Alveolar/bronchiolar carcinoma, solitary															P							
Malignant Lymphoma, mixed type														P					P			
Malignant Lymphoma, lymphocytic type											P											
Malignant Lymphoma, histiocytic type																						
Leukemia, myeloid																				P		
Alveolar/bronchiolar adenoma, solitary																						
Histiocytosis, diffuse																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion / Accession Number	81-0548*	81-0549	81-0550	81-0551*	81-0552	81-0553	81-0554	81-0555	81-0557	81-0558	81-0559*	81-0560*	81-0561	81-0562	81-0563	81-0564	81-0566	81-0567*	81-0568	81-0569	Incidence
UTERUS (Con't.)	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	
Endometritis, acute, diffuse		1												3							
Endometritis, acute, multifocal																	1				
Endometritis, acute, focal																					
Hemorrhage, focal																					
Hydrometra, diffuse																					
URINARY BLADDER	N	N	N	N	N	N	N	N	L	N	L	L	N	L	N	N	N	N	N	N	
Malignant Lymphoma, mixed type												P		P							
Malignant Lymphoma, lymphocytic type									P												
Malignant Lymphoma, histiocytic type											P										
LUNGS	L	L	L	L	N	L	L	N	L	N	L	L	N	N	N	L	N	L	N	N	
Osteosarcoma, solitary																					
Alveolar/bronchiolar carcinoma, solitary																		P			
Malignant Lymphoma, mixed type		P										P									
Malignant Lymphoma, lymphocytic type	P		P			P			P												
Malignant Lymphoma, histiocytic type											P										
Leukemia, myeloid																					
Alveolar/bronchiolar adenoma, solitary			P									P									
Histiocytosis, diffuse				3																	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0570	81-0571*	81-0572*	81-0573	81-0574*	81-0575	81-0576	81-0578	81-0579*	81-0580*	81-0581	81-0582	81-0583	81-0584*	81-0586*	81-0587	81-0588*	81-0589	81-0590	81-0591	Incidence
UTERUS (Con't.)		L	L	L	L	L	L	L	L	L	L	L	L	L	L	N	L	L	L	L	L	
Endometritis, acute, diffuse										3			3									
Endometritis, acute, multifocal																						
Endometritis, acute, focal																						
Hemorrhage, focal																						
Hydrometra, diffuse																						
URINARY BLADDER		N	L	L	L	N	N	N	N	N	N	N	N	N	N	N	N	L	N	N	N	
Malignant Lymphoma, mixed type			P		P																	
Malignant Lymphoma, lymphocytic type				P														P				
Malignant Lymphoma, histiocytic type																						
LUNGS		N	L	L	L	L	N	N	N	N	L	L	N	L	L	L	L	L	L	N	L	
Osteosarcoma, solitary											P											
Alveolar/bronchiolar carcinoma,solitary															P							
Malignant Lymphoma, mixed type			P		P							P					P		P			
Malignant Lymphoma, lymphocytic type				P														P				
Malignant Lymphoma, histiocytic type																						
Leukemia, myeloid																						
Alveolar/bronchiolar adenoma, solitary											P											
Histiocytosis, diffuse																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0592*	81-0593	81-0594	81-0595	81-0596*															Incidence
UTERUS (Con't.)		L	L	L	L	L															(65)
Endometritis, acute, diffuse																					5/65
Endometritis, acute, multifocal			2																		2/65
Endometritis, acute, focal				1																	1/65
Hemorrhage, focal						3															1/65
Hydrometra, diffuse																					1/65
URINARY BLADDER		N	N	N	N	N															(64)
Malignant Lymphoma, mixed type																					4/64
Malignant Lymphoma, lymphocytic type																					3/64
Malignant Lymphoma, histiocytic type																					1/64
LUNGS		N	N	N	L	L															(65)
Osteosarcoma, solitary																					1/65
Alveolar/bronchiolar carcinoma,solitary																					3/65
Malignant Lymphoma, mixed type						P															10/65
Malignant Lymphoma, lymphocytic type																					7/65
Malignant Lymphoma, histiocytic type																					1/65
Leukemia, myeloid																					1/65
Alveolar/bronchiolar adenoma, solitary					P																4/65
Histiocytosis, diffuse																					1/65

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I...R...
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0523	81-0524	81-0525*	81-0527	81-0528	81-0529	81-0530	81-0531	81-0533	81-0534	81-0536	81-0537	81-0538	81-0539	81-0540	81-0542	81-0543	81-0544	81-0545*	81-0546	Incidence
LUNGS (Con't.)		N	N	N	N	N	N	N	N	N	L	N	N	L	L	N	N	N	L	L	L	
Hemorrhage, multifocal																						
Hemorrhage, focal																			2		1	
Congestion, diffuse																						
Edema, multifocal																						
ESOPHAGUS		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
TRACHEA		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Hemorrhage, focal																						
THYROIDS		N	N	N	N	L	N	N	N	N	L	N	L	N	N	L	L	N	N	L	N	
Leukemia, myeloid																				P		
Follicular hyperplasia, focal											2											
Hyperplasia, C-cell, focal																						
Follicular cysts, multifocal											2		2									
Follicular cyst, solitary						2											2					
Follicular atrophy, multifocal																						
Follicular atrophy, focal																2						
Thyroiditis, chronic, active, focal																						
PARATHYROIDS		N	M	N	N	N	N	M	N	M	N	N	N	N	M	M	M	M	N	N	M	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0548*	81-0549	81-0550	81-0551*	81-0552	81-0553	81-0554	81-0555	81-0557	81-0558	81-0559*	81-0560*	81-0561	81-0562	81-0563	81-0564	81-0566	81-0567*	81-0568	81-0569	Incidence
LUNGS (Con't.)		L	L	L	L	N	L	L	N	L	N	L	L	N	N	N	L	N	L	N	N	
Hemorrhage, multifocal		2			4														2			
Hemorrhage, focal								1									2					
Congestion, diffuse																						
Edema, multifocal																						
ESOPHAGUS		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
TRACHEA		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Hemorrhage, focal																						
THYROIDS		N	L	N	N	N	N	N	N	L	L	N	N	N	L	N	L	N	N	L	L	
Leukemia, myeloid																						
Follicular hyperplasia, focal															2							
Hyperplasia, C-cell, focal										2	2											
Follicular cysts, multifocal																				2		
Follicular cyst, solitary			2														2				2	
Follicular atrophy, multifocal																						
Follicular atrophy, focal																						
Thyroiditis, chronic, active, focal																						
PARATHYROIDS		M	M	N	N	N	N	M	M	N	N	M	M	N	N	N	N	M	N	N	N	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I. .R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0570	81-0571*	81-0572*	81-0573	81-0574*	81-0575	81-0576	81-0578	81-0579*	81-0580*	81-0581	81-0582	81-0583	81-0584*	81-0586*	81-0587	81-0588*	81-0589	81-0590	81-0591	Incidence
LUNGS (Con't.)		N	L	L	L	L	N	N	N	N	L	L	N	L	L	L	L	L	L	N	L	
Hemorrhage, multifocal																						
Hemorrhage, focal																					2	
Congestion, diffuse						4								2		4			2			
Edema, multifocal																3						
ESOPHAGUS		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
TRACHEA		N	N	N	N	N	N	N	N	N	N	N	N	L	N	N	N	N	N	N	N	
Hemorrhage, focal														2								
THYROIDS		N	L	N	N	N	N	N	N	N	L	N	N	N	N	N	N	L	L	L	L	
Leukemia, myeloid																						
Follicular hyperplasia, focal																					2	
Hyperplasia, C-cell, focal																						
Follicular cysts, multifocal											2											
Follicular cyst, solitary																			2			
Follicular atrophy, multifocal			2								2							2		2		
Follicular atrophy, focal																						
Thyroiditis, chronic, active, focal																				2		
PARATHYROIDS		N	N	N	M	N	N	M	M	M	M	N	N	M	N	M	N	M	N	N	N	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0592*	81-0593	81-0594	81-0595	81-0596*															Incidence
LUNGS (Con't.)		N	N	N	L	L															(65)
Hemorrhage, multifocal																					3/65
Hemorrhage, focal																					5/65
Congestion, diffuse																					4/65
Edema, multifocal																					1/65
ESOPHAGUS		N	N	N	N	N															(65)
TRACHEA		N	N	N	N	N															(65)
Hemorrhage, focal																					1/65
THYROIDS		N	N	L	L	L															(65)
Leukemia, myeloid																					1/65
Follicular hyperplasia, focal																					3/65
Hyperplasia, C-cell, focal																					2/65
Follicular cysts, multifocal																					4/65
Follicular cyst, solitary					2	2															8/65
Follicular atrophy, multifocal																					4/65
Follicular atrophy, focal				1																	2/65
Thyroiditis, chronic, active, focal																					1/65
PARATHYROIDS		M	N	N	N	M															(40)

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I. R.I
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0523	81-0524	81-0525*	81-0527	81-0528	81-0529	81-0530	81-0531	81-0533	81-0534	81-0536	81-0537	81-0538	81-0539	81-0540	81-0542	81-0543	81-0544	81-0545*	81-0546	Incidence
HEART		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	L	N	
Malignant Lymphoma, lymphocytic type																						
Leukemia, myeloid																				P		
Myocarditis, chronic, multifocal																						
LIVER		N	N	N	N	N	N	N	L	N	N	N	N	N	N	L	L	N	N	L	L	
Malignant Lymphoma, mixed type																	P					
Malignant Lymphoma, lymphocytic type																						
Malignant Lymphoma, histiocytic type																						
Leukemia, myeloid																				P		
Hepatocellular adenoma, solitary																						
Focal cellular change									P							P						
Lipoma, solitary																P						
Hepatitis, chronic, active, focal																						
Fatty change, periacinar, diffuse																						
Fatty change, periacinar, multifocal																						
Hematopoiesis,extramedullary,multifocal																					2	
Necrosis, multifocal																						
Infarct, healed, solitary																						
Congestion, diffuse																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0548*	81-0549	81-0550	81-0551*	81-0552	81-0553	81-0554	81-0555	81-0557	81-0558	81-0559*	81-0560*	81-0561	81-0562	81-0563	81-0564	81-0566	81-0567*	81-0568	81-0569	Incidence
HEART		L	N	N	L	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, lymphocytic type		P																				
Leukemia, myeloid					P																	
Myocarditis, chronic, multifocal																						
LIVER		L	N	N	L	N	N	N	L	N	L	L	L	L	N	L	N	L	N	L	N	
Malignant Lymphoma, mixed type													P					P				
Malignant Lymphoma, lymphocytic type		P												P								
Malignant Lymphoma, histiocytic type												P										
Leukemia, myeloid					P																	
Hepatocellular adenoma, solitary																						
Focal cellular change																						
Lipoma, solitary																						
Hepatitis, chronic, active, focal																						
Fatty change, periacinar, diffuse																						
Fatty change, periacinar, multifocal														1								
Hematopoiesis,extramedullary,multifocal									1							2				2		
Necrosis, multifocal													2									
Infarct, healed, solitary											2											
Congestion, diffuse																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0570	81-0571*	81-0572*	81-0573	81-0574*	81-0575	81-0576	81-0578	81-0579*	81-0580*	81-0581	81-0582	81-0583	81-0584*	81-0586*	81-0587	81-0588*	81-0589	81-0590	81-0591	Incidence
HEART		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	L	N	N	
Malignant Lymphoma, lymphocytic type																						
Leukemia, myeloid																						
Myocarditis, chronic, multifocal																			2			
LIVER		N	L	L	L	N	L	L	N	N	N	N	N	N	L	N	L	L	L	N	L	
Malignant Lymphoma, mixed type			P		P										P							
Malignant Lymphoma, lymphocytic type																						
Malignant Lymphoma, histiocytic type																						
Leukemia, myeloid																						
Hepatocellular adenoma, solitary							P															
Focal cellular change																						
Lipoma, solitary																						
Hepatitis, chronic, active, focal																	3					
Fatty change, periacinar, diffuse																						
Fatty change, periacinar, multifocal																						
Hematopoiesis,extramedullary,multifocal				1				1											2		1	
Necrosis, multifocal																						
Infarct, healed, solitary																						
Congestion, diffuse																		3				

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0592*	81-0593	81-0594	81-0595	81-0596*															Incidence
HEART		N	N	N	N	N															(65)
Malignant Lymphoma, lymphocytic type																					1/65
Leukemia, myeloid																					2/65
Myocarditis, chronic, multifocal																					1/65
LIVER		L	N	L	L	L															(65)
Malignant Lymphoma, mixed type		P				P															8/65
Malignant Lymphoma, lymphocytic type																					2/65
Malignant Lymphoma, histiocytic type																					1/65
Leukemia, myeloid																					2/65
Hepatocellular adenoma, solitary																					1/65
Focal cellular change																					2/65
Lipoma, solitary																					1/65
Hepatitis, chronic, active, focal																					1/65
Fatty change, periacinar, diffuse						2															1/65
Fatty change, periacinar, multifocal																					1/65
Hematopoiesis,extramedullary,multifocal				1	1																10/65
Necrosis, multifocal																					1/65
Infarct, healed, solitary																					1/65
Congestion, diffuse																					1/65

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0523	81-0524	81-0525*	81-0527	81-0528	81-0529	81-0530	81-0531	81-0533	81-0534	81-0536	81-0537	81-0538	81-0539	81-0540	81-0542	81-0543	81-0544	81-0545*	81-0546	Incidence
KIDNEYS		N	N	N	N	N	L	N	L	L	L	L	L	L	L	L	L	L	L	L	N	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
Malignant Lymphoma, lymphocytic type, (Capsule)																						
Osteosarcoma, metastatic																						
Hyperplasia, tubular, multifocal						2		1		2		2	2				1		1			
Infarct, healed, solitary																						
Nephropathy, chronic, diffuse																						
Nephropathy, chronic, multifocal																			2			
Necrosis, tubular, multifocal						2							2									
Necrosis, tubular, focal														2		2						
Nephrocalcinosis, multifocal									1		1		1		1							
Congestion, diffuse																						
Cytoplasmic vacuolization, diffuse, (Tubules)																						
STOMACH		N	L	N	N	N	N	N	L	N	N	N	N	N	N	N	N	N	N	L	N	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, histiocytic(Serosa)																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

N.T.P.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0548*	81-0549	81-0550	81-0551*	81-0552	81-0553	81-0554	81-0555	81-0557	81-0558	81-0559*	81-0560*	81-0561	81-0562	81-0563	81-0564	81-0566	81-0567*	81-0568	81-0569	Incidence
KIDNEYS		L	L	L	L	L	L	N	L	L	L	N	L	L	L	N	L	L	L	N	L	
Malignant Lymphoma, mixed type													P									
Malignant Lymphoma, lymphocytic type		P					P			P				P								
Malignant Lymphoma, lymphocytic type, (Capsule)																						
Osteosarcoma, metastatic																						
Hyperplasia, tubular, multifocal						1	1		1					1			2				1	
Infarct, healed, solitary																			3			
Nephropathy, chronic, diffuse					3																	
Nephropathy, chronic, multifocal				2											2			2				
Necrosis, tubular, multifocal									1		1						3				2	
Necrosis, tubular, focal																						
Nephrocalcinosis, multifocal																			1			
Congestion, diffuse																			3			
Cytoplasmic vacuolization, diffuse, (Tubules)			1															1				
STOMACH		N	N	N	N	N	L	N	N	N	L	L	L	N	N	N	L	N	N	N	N	
Malignant Lymphoma, mixed type													P									
Malignant Lymphoma, histiocytic(Serosa)												P										

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.....R.I.
S[illegible]y No.: .L 06121 SN 7
C[illegible]pound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion / Accession Number	81-0570	81-0571*	81-0572*	81-0573	81-0574*	81-0575	81-0576	81-0578	81-0579*	81-0580*	81-0581	81-0582	81-0583	81-0584*	81-0586*	81-0587	81-0588*	81-0589	81-0590	81-0591	Incidence
KIDNEYS	L	L	L	L	N	L	L	L	L	L	L	L	L	N	N	L	L	L	L	L	
Malignant Lymphoma, mixed type		P		P							P	P						P			
Malignant Lymphoma, lymphocytic type			P																		
Malignant Lymphoma, lymphocytic type, (Capsule)																	P				
Osteosarcoma, metastatic										P											
Hyperplasia, tubular, multifocal	2					2	1	1		2	2					1			2	1	
Infarct, healed, solitary																					
Nephropathy, chronic, diffuse																					
Nephropathy, chronic, multifocal																					
Necrosis, tubular, multifocal																					
Necrosis, tubular, focal																					
Nephrocalcinosis, multifocal				1					3		2								2		
Congestion, diffuse																					
Cytoplasmic vacuolization, diffuse, (Tubules)				1				1	2				1					2			
STOMACH	N	L	N	L	N	N	L	N	L	N	L	N	N	N	N	N	N	N	L	N	
Malignant Lymphoma, mixed type		P		P																	
Malignant Lymphoma, histiocytic(Serosa)																					

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0592*	81-0593	81-0594	81-0595	81-0596*															Incidence
KIDNEYS		N	L	L	L	N															(65)
Malignant Lymphoma, mixed type																					6/65
Malignant Lymphoma, lymphocytic type																					5/65
Malignant Lymphoma, lymphocytic type, (Capsule)																					1/65
Osteosarcoma, metastatic																					1/65
Hyperplasia, tubular, multifocal				2																	23/65
Infarct, healed, solitary																					1/65
Nephropathy, chronic, diffuse																					1/65
Nephropathy, chronic, multifocal																					4/65
Necrosis, tubular, multifocal																					6/65
Necrosis, tubular, focal																					2/65
Nephrocalcinosis, multifocal																					9/65
Congestion, diffuse																					1/65
Cytoplasmic vacuolization, diffuse, (Tubules)			2		2																9/65
STOMACH		L	N	N	N	L															(65)
Malignant Lymphoma, mixed type		P				P															5/65
Malignant Lymphoma, histiocytic(Serosa)																					1/65

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0523	81-0524	81-0525*	81-0527	81-0528	81-0529	81-0530	81-0531	81-0533	81-0534	81-0536	81-0537	81-0538	81-0539	81-0540	81-0542	81-0543	81-0544	81-0545*	81-0546	Incidence
STOMACH (Con't.)		N	L	N	N	N	N	N	L	N	N	N	N	N	N	N	N	N	N	L	N	
Leukemia, myeloid																				P		
Ulcer, acute, focal, (Glandular)																						
Cyst, epithelial, solitary,(Glandular)			1						2													
Degeneration, cystic, multifocal, (Glandular)																						
DUODENUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	L	N	
Amyloidosis, diffuse																				3		
JEJUNUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
ILEUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
CECUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Nematodiasis																						
COLON		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
Nematodiasis																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I
FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0548*	81-0549	81-0550	81-0551*	81-0552	81-0553	81-0554	81-0555	81-0557	81-0558	81-0559*	81-0560*	81-0561	81-0562	81-0563	81-0564	81-0566	81-0567*	81-0568	81-0569	Incidence
STOMACH (Con't.)		N	N	N	N	N	L	N	N	N	L	L	L	N	N	N	L	N	N	N	N	
Leukemia, myeloid																						
Ulcer, acute, focal (Glandular)																						
Cyst, epithelial, solitary (Glandular)							2															
Degeneration, cystic, multifocal, (Glandular)											2						1					
DUODENUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Amyloidosis, diffuse																						
JEJUNUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
ILEUM		N	N	L	N	N	N	N	N	N	N	N	N	L	N	N	N	N	N	N	L	
Malignant Lymphoma, mixed type																					P	
Malignant Lymphoma, lymphocytic type				P										P								
CECUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	L	N	N	N	
Nematodiasis																		P				
COLON		N	N	N	N	N	N	N	N	N	N	N	N	N	L	N	N	N	N	N	N	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
Nematodiasis															P							

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0570	81-0571*	81-0572*	81-0573	81-0574*	81-0575	81-0576	81-0578	81-0579*	81-0580*	81-0581	81-0582	81-0583	81-0584*	81-0586*	81-0587	81-0588*	81-0589	81-0590	81-0591	Incidence
STOMACH (Con't.)		N	L	N	L	N	N	L	N	L	N	L	N	N	N	N	N	N	N	L	N	
Leukemia, myeloid																						
Ulcer, acute, focal (Glandular)										3												
Cyst, epithelial, solitary (Glandular)																						
Degeneration, cystic, multifocal, (Glandular)								2				2								2		
DUODENUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Amyloidosis, diffuse																						
JEJUNUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
ILEUM		N	N	N	N	N	N	N	N	N	N	N	L	N	N	N	N	N	N	N	N	
Malignant Lymphoma, mixed type													P									
Malignant Lymphoma, lymphocytic type																						
CECUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Nematodiasis																						
COLON		N	N	L	N	N	N	N	N	N	N	N	L	N	N	N	N	N	L	N	N	
Malignant Lymphoma, mixed type													P						P			
Malignant Lymphoma, lymphocytic type				P																		
Nematodiasis																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
S(/ No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0592*	81-0593	81-0594	81-0595	81-0596*	Incidence
STOMACH (Con't.)		L	N	N	N	L	(65)
Leukemia, myeloid							1/65
Ulcer, acute, focal (Glandular)							1/65
Cyst, epithelial, solitary (Glandular)							3/65
Degeneration, cystic, multifocal,							
(Glandular)							5/65
DUODENUM		N	N	N	N	N	(65)
Amyloidosis, diffuse							1/65
JEJUNUM		N	N	N	N	N	(65)
ILEUM		N	N	N	N	N	(65)
Malignant Lymphoma, mixed type							2/65
Malignant Lymphoma, lymphocytic type							2/65
CECUM		N	N	N	N	N	(65)
Nematodiasis							1/65
COLON		N	N	N	N	N	(65)
Malignant Lymphoma, mixed type							2/65
Malignant Lymphoma, lymphocytic type							1/65
Nematodiasis							1/65

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.[illegible]R.I.
S[illegible]dy No.: L 06121 SN 7
C[illegible]pound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion / Accession Number	81-0523	81-0524	81-0525*	81-0527	81-0528	81-0529	81-0530	81-0531	81-0533	81-0534	81-0536	81-0537	81-0538	81-0539	81-0540	81-0542	81-0543	81-0544	81-0545*	81-0546	Incidence
RECTUM	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, mixed type																					
Malignant Lymphoma, lymphocytic type																					
SKIN	N	N	L	L	L	L	L	N	N	N	L	L	L	L	L	L	L	L	L	N	
Dermatitis, chronic, active, diffuse																			2		
Dermatitis, chronic, diffuse			2	2		3	3					2	3	2	2	2	2	2			
Dermatitis, chronic, diffuse (Back)																					
Dermatitis, chronic, focal																					
Follicular atrophy, diffuse					2						3										
Epidermal inclusion cyst, solitary																					
MAMMARY GLAND	N	N	L	L	N	N	N	L	L	N	N	N	N	N	N	N	N	L	N	L	
Adenocarcinoma, multifocal																		P			
Adenocarcinoma, solitary																				P	
Malignant Lymphoma, mixed type																					
Malignant Lymphoma, lymphocytic type																					
Hyperplasia, cystic, diffuse			3	2				2	2									3			
STERNUM	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
BONE MARROW	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	N	L	
Malignant Lymphoma, mixed type																					

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
\- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0548*	81-0549	81-0550	81-0551*	81-0552	81-0553	81-0554	81-0555	81-0557	81-0558	81-0559*	81-0560*	81-0561	81-0562	81-0563	81-0564	81-0566	81-0567*	81-0568	81-0569	Incidence
RECTUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
SKIN		N	L	L	N	L	L	L	N	N	N	L	N	L	N	L	N	N	L	L	L	
Dermatitis, chronic, active, diffuse																						
Dermatitis, chronic, diffuse			2	1		3	3	2				2				2			2		2	
Dermatitis, chronic, diffuse (Back)																						
Dermatitis, chronic, focal														1						2		
Follicular atrophy, diffuse																						
Epidermal inclusion cyst, solitary																						
MAMMARY GLAND		L	N	N	N	N	N	N	N	N	N	N	L	N	N	N	N	N	M	N	N	
Adenocarcinoma, multifocal																						
Adenocarcinoma, solitary																						
Malignant Lymphoma, mixed type													P									
Malignant Lymphoma, lymphocytic type		P																				
Hyperplasia, cystic, diffuse																						
STERNUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
BONE MARROW		N	L	L	L	L	L	L	L	L	L	L	N	L	L	L	L	L	N	L	L	
Malignant Lymphoma, mixed type																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I....I.I.
S(y No.: L 06121 SN 7
Co...ound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0570	81-0571*	81-0572*	81-0573	81-0574*	81-0575	81-0576	81-0578	81-0579*	81-0580*	81-0581	81-0582	81-0583	81-0584*	81-0586*	81-0587	81-0588*	81-0589	81-0590	81-0591	Incidence
RECTUM		N	L	L	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, mixed type			P																			
Malignant Lymphoma, lymphocytic type				P																		
SKIN		N	L	N	L	N	L	L	N	N	N	N	L	N	L	N	L	L	L	L	L	
Dermatitis, chronic, active, diffuse																						
Dermatitis, chronic, diffuse			3		3		2	3							2		2	2	2	1	2	
Dermatitis, chronic, diffuse (Back)																					3	
Dermatitis, chronic, focal																						
Follicular atrophy, diffuse													3									
Epidermal inclusion cyst, solitary																			2			
MAMMARY GLAND		N	L	N	N	N	N	N	N	N	L	N	N	N	N	N	N	N	N	M	N	
Adenocarcinoma, multifocal																						
Adenocarcinoma, solitary																						
Malignant Lymphoma, mixed type			P																			
Malignant Lymphoma, lymphocytic type																						
Hyperplasia, cystic, diffuse											3											
STERNUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
BONE MARROW		L	L	N	L	L	L	L	L	L	L	L	L	L	N	L	L	L	L	L	L	
Malignant Lymphoma, mixed type																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0592*	81-0593	81-0594	81-0595	81-0596*															Incidence
RECTUM		N	N	N	N	N															(65)
Malignant Lymphoma, mixed type																					1/65
Malignant Lymphoma, lymphocytic type																					1/65
SKIN		N	N	N	N	L															(65)
Dermatitis, chronic, active, diffuse																					1/65
Dermatitis, chronic, diffuse						2															31/65
Dermatitis, chronic, diffuse, (Back)																					1/65
Dermatitis, chronic, focal																					2/65
Follicular atrophy, diffuse																					3/65
Epidermal inclusion cyst, solitary																					1/65
MAMMARY GLAND		N	N	N	N	N															(63)
Adenocarcinoma, multifocal																					1/63
Adenocarcinoma, solitary																					1/63
Malignant Lymphoma, mixed type																					2/63
Malignant Lymphoma, lymphocytic type																					1/63
Hyperplasia, cystic, diffuse																					6/63
STERNUM		N	N	N	N	N															(65)
BONE MARROW		L	L	L	L	L															(65)
Malignant Lymphoma, mixed type						P															1/65

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion / Accession Number	81-0523	81-0524	81-0525*	81-0527	81-0528	81-0529	81-0530	81-0531	81-0533	81-0534	81-0536	81-0537	81-0538	81-0539	81-0540	81-0542	81-0543	81-0544	81-0545*	81-0546	Incidence
BONE MARROW (Con't.)	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	N	L	
Malignant Lymphoma, histiocytic type																					
Leukemia, myeloid																					
Hyperplasia, myeloid, diffuse			2		2	2	2		2	2	2			2	2	2	2	2		2	
Myelofibrosis, diffuse					4									4							
Myelofibrosis, multifocal	3	4		3		2	4	3	3	3	3	3	4		3	3	3	3			
Myelofibrosis, focal			2																		
LESIONS (TISSUES NOT SPECIFICALLY																					
REQUIRED BY PROTOCOL)																					
AXILLARY LYMPH NODE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																					
GALL BLADDER	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
HARDERIAN GLAND	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Adenoma, solitary		P																			
HEPATIC LYMPH NODE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																					

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0548*	81-0549	81-0550	81-0551*	81-0552	81-0553	81-0554	81-0555	81-0557	81-0558	81-0559*	81-0560*	81-0561	81-0562	81-0563	81-0564	81-0566	81-0567*	81-0568	81-0569	Incidence
BONE MARROW (Con't.)		N	L	L	L	L	L	L	L	L	L	L	N	L	L	L	L	L	N	L	L	
Malignant Lymphoma, histiocytic type												P										
Leukemia, myeloid					P																	
Hyperplasia, myeloid, diffuse			2	2		2	2			2	2			2	2	2	2	2		2	2	
Myelofibrosis, diffuse																						
Myelofibrosis, multifocal			2	4		2	4	2	4	3	3			2	3	4	2	4		3	3	
Myelofibrosis, focal																						
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
AXILLARY LYMPH NODE		-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type						P																
GALL BLADDER		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
HARDERIAN GLAND		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Adenoma, solitary																						
HEPATIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0570	81-0571*	81-0572*	81-0573	81-0574*	81-0575	81-0576	81-0578	81-0579*	81-0580*	81-0581	81-0582	81-0583	81-0584*	81-0586*	81-0587	81-0588*	81-0589	81-0590	81-0591	Incidence
BONE MARROW (Con't.)		L	L	N	L	L	L	L	L	L	L	L	L	L	N	L	L	L	L	L	L	
Malignant Lymphoma, histiocytic type																						
Leukemia, myeloid																						
Hyperplasia, myeloid, diffuse		2	2		2		2	2	2			2	2	2		2	2	3	2	2	2	
Myelofibrosis, diffuse																						
Myelofibrosis, multifocal			3		3	3	2	2	4	3	3	4	3	3		3	3		2	3	3	
Myelofibrosis, focal		2																				
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
AXILLARY LYMPH NODE		-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type					P																	
GALL BLADDER		-	-	-	-	-	-	-	-	N	N	-	-	-	-	-	-	-	-	-	-	
HARDERIAN GLAND		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Adenoma, solitary																						
HEPATIC LYMPH NODE		-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type			P																			

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0592*	81-0593	81-0594	81-0595	81-0596*															Incidence
BONE MARROW (Con't.)		L	L	L	L	L															(65)
Malignant Lymphoma, histiocytic type																					1/65
Leukemia, myeloid																					1/65
Hyperplasia, myeloid, diffuse			2	2	2	3															45/65
Myelofibrosis, diffuse																					2/65
Myelofibrosis, multifocal		2	4	4	2	2															51/65
Myelofibrosis, focal																					2/65
LESIONS (TISSUES NOT SPECIFICALLY																					
REQUIRED BY PROTOCOL)																					
AXILLARY LYMPH NODE		L	-	-	-	-															(3)
Malignant Lymphoma, mixed type		P																			3/3
GALL BLADDER		-	-	-	-	-															(2)
HARDERIAN GLAND		-	-	-	-	-															(1)
Adenoma, solitary																					1/1
HEPATIC LYMPH NODE		-	-	-	-	-															(1)
Malignant Lymphoma, mixed type																					1/1

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

T. R.1
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0523	81-0524	81-0525*	81-0527	81-0528	81-0529	81-0530	81-0531	81-0533	81-0534	81-0536	81-0537	81-0538	81-0539	81-0540	81-0542	81-0543	81-0544	81-0545*	81-0546	Incidence
INGUINAL LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	
Malignant Lymphoma, mixed type																						
INTERCOSTAL MUSCLES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
Leukemia, myeloid																				P		
LUMBAR LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
Leukemia, myeloid																						
MANDIBULAR LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	L	-	
Malignant Lymphoma, mixed type															P							
Malignant Lymphoma, lymphocytic type																						
Leukemia, myeloid																				P		
MESENTERIC FAT		-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	
Steatitis, chronic, focal																						
Hemorrhage, focal									3													
MESENTERY		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0548*	81-0549	81-0550	81-0551*	81-0552	81-0553	81-0554	81-0555	81-0557	81-0558	81-0559*	81-0560*	81-0561	81-0562	81-0563	81-0564	81-0566	81-0567*	81-0568	81-0569	Incidence
INGUINAL LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
INTERCOSTAL MUSCLES		-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type													P									
Malignant Lymphoma, lymphocytic type																						
Leukemia, myeloid																						
LUMBAR LYMPH NODE		-	-	L	L	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type						P																
Malignant Lymphoma, lymphocytic type				P																		
Leukemia, myeloid					P																	
MANDIBULAR LYMPH NODE		-	-	L	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type						P																
Malignant Lymphoma, lymphocytic type				P																		
Leukemia, myeloid																						
MESENTERIC FAT		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Steatitis, chronic, focal																						
Hemorrhage, focal																						
MESENTERY		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	
Malignant Lymphoma, lymphocytic type																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0570	81-0571*	81-0572*	81-0573	81-0574*	81-0575	81-0576	81-0578	81-0579*	81-0580*	81-0581	81-0582	81-0583	81-0584*	81-0586*	81-0587	81-0588*	81-0589	81-0590	81-0591	Incidence
INGUINAL LYMPH NODE		-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type			P																			
INTERCOSTAL MUSCLES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																		P				
Leukemia, myeloid																						
LUMBAR LYMPH NODE		-	L	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type			P																			
Malignant Lymphoma, lymphocytic type				P																		
Leukemia, myeloid																						
MANDIBULAR LYMPH NODE		-	L	L	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type			P		P																	
Malignant Lymphoma, lymphocytic type				P																		
Leukemia, myeloid																						
MESENTERIC FAT		L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Steatitis, chronic, focal		3																				
Hemorrhage, focal																						
MESENTERY		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	
Malignant Lymphoma, lymphocytic type																		P				

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0592*	81-0593	81-0594	81-0595	81-0596*	Incidence
INGUINAL LYMPH NODE		L	-	-	-	-	(3)
Malignant Lymphoma, mixed type		P					2/3
INTERCOSTAL MUSCLES		-	-	-	-	L	(4)
Malignant Lymphoma, mixed type						P	2/4
Malignant Lymphoma, lymphocytic type							1/4
Leukemia, myeloid							1/4
LUMBAR LYMPH NODE		L	-	-	-	L	(7)
Malignant Lymphoma, mixed type		P				P	4/7
Malignant Lymphoma, lymphocytic type							2/7
Leukemia, myeloid							1/7
MANDIBULAR LYMPH NODE		L	-	-	-	-	(8)
Malignant Lymphoma, mixed type		P					5/8
Malignant Lymphoma, lymphocytic type							2/8
Leukemia, myeloid							1/8
MESENTERIC FAT		-	-	-	-	-	(2)
Steatitis, chronic, focal							1/2
Hemorrhage, focal							1/2
MESENTERY		-	L	-	-	-	(3)
Malignant Lymphoma, lymphocytic type							1/3

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0523	81-0524	81-0525*	81-0527	81-0528	81-0529	81-0530	81-0531	81-0533	81-0534	81-0536	81-0537	81-0538	81-0539	81-0540	81-0542	81-0543	81-0544	81-0545*	81-0546	Incidence
MESENTERY (Con't.)		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Lymphatic cysts, multiple																						
Hematoma, solitary																						
PAROVARIAN TISSUE		-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	L	-	-	
Malignant Lymphoma, mixed type														P					P			
Malignant Lymphoma, lymphocytic type																						
PITUITARY		-	-	L	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	
Adenoma, solitary (Anterior)				P					P													
RENAL LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
RESPIRATORY LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
SALIVARY GLAND		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
SKELETAL MUSCLE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Endometrial Stromal Sarcoma, invasive																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0548*	81-0549	81-0550	81-0551*	81-0552	81-0553	81-0554	81-0555	81-0557	81-0558	81-0559*	81-0560*	81-0561	81-0562	81-0563	81-0564	81-0566	81-0567*	81-0568	81-0569	Incidence
MESENTERY (Con't.)		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	
Lymphatic cysts, multiple																						
Hematoma, solitary																	3					
PAROVARIAN TISSUE		-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type							P															
PITUITARY		-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	N	-	-	-	L	
Adenoma, solitary (Anterior)								P													P	
RENAL LYMPH NODE		-	L	L	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type			P			P																
Malignant Lymphoma, lymphocytic type				P																		
RESPIRATORY LYMPH NODE		-	-	L	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type						P																
Malignant Lymphoma, lymphocytic type				P																		
SALIVARY GLAND		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
SKELETAL MUSCLE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Endometrial Stromal Sarcoma, invasive																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0570	81-0571*	81-0572*	81-0573	81-0574*	81-0575	81-0576	81-0578	81-0579*	81-0580*	81-0581	81-0582	81-0583	81-0584*	81-0586*	81-0587	81-0588*	81-0589	81-0590	81-0591	Incidence
MESENTERY (Con't.)		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	
Lymphatic cysts, multiple																						
Hematoma, solitary																						
PAROVARIAN TISSUE		-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type			P																			
Malignant Lymphoma, lymphocytic type																						
PITUITARY		-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	
Adenoma, solitary (Anterior)											P											
RENAL LYMPH NODE		-	L	L	L	N	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type			P		P								P									
Malignant Lymphoma, lymphocytic type				P																		
RESPIRATORY LYMPH NODE		-	L	L	L	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	
Malignant Lymphoma, mixed type			P		P										P							
Malignant Lymphoma, lymphocytic type				P																		
SALIVARY GLAND		-	-	N	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
SKELETAL MUSCLE		-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Endometrial Stromal Sarcoma, invasive						P																

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number: 81-0592*	81-0593	81-0594	81-0595	81-0596*	Incidence
MESENTERY (Con't.)	-	L	-	-	-	(3)
Lymphatic cysts, multiple		4				1/3
Hematoma, solitary						1/3
PAROVARIAN TISSUE	-	L	-	-	L	(6)
Malignant Lymphoma, mixed type		P			P	5/6
Malignant Lymphoma, lymphocytic type						1/6
PITUITARY	-	-	-	-	-	(6)
Adenoma, solitary (Anterior)						5/6
RENAL LYMPH NODE	L	-	-	-	L	(10)
Malignant Lymphoma, mixed type	P				P	7/10
Malignant Lymphoma, lymphocytic type						2/10
RESPIRATORY LYMPH NODE	L	-	-	-	-	(7)
Malignant Lymphoma, mixed type	P					5/7
Malignant Lymphoma, lymphocytic type						2/7
SALIVARY GLAND	L	-	-	-	-	(2)
Malignant Lymphoma, mixed type	P					1/2
SKELETAL MUSCLE	-	-	-	-	-	(1)
Endometrial Stromal Sarcoma, invasive						1/1

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

1. R.1
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0523	81-0524	81-0525*	81-0527	81-0528	81-0529	81-0530	81-0531	81-0533	81-0534	81-0536	81-0537	81-0538	81-0539	81-0540	81-0542	81-0543	81-0544	81-0545*	81-0546	Incidence
SUBCUTANEOUS LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
Hyperplasia, lymphoid, diffuse																						
SUBCUTIS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	
Leukemia, myeloid																				P		
THYMUS		-	-	-	-	-	N	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
VAGINA		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	-	N	-	N	
Malignant Lymphoma, lymphocytic type																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0548*	81-0549	81-0550	81-0551*	81-0552	81-0553	81-0554	81-0555	81-0557	81-0558	81-0559*	81-0560*	81-0561	81-0562	81-0563	81-0564	81-0566	81-0567*	81-0568	81-0569	Incidence
SUBCUTANEOUS LYMPH NODE		-	L	L	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type			P																			
Malignant Lymphoma, lymphocytic type				P			P															
Hyperplasia, lymphoid, diffuse																						
SUBCUTIS		-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Leukemia, myeloid					P																	
THYMUS		L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type		P																				
VAGINA		N	N	N	N	N	N	N	N	N	N	-	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, lymphocytic type																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0570	81-0571*	81-0572*	81-0573	81-0574*	81-0575	81-0576	81-0578	81-0579*	81-0580*	81-0581	81-0582	81-0583	81-0584*	81-0586*	81-0587	81-0588*	81-0589	81-0590	81-0591	Incidence
SUBCUTANEOUS LYMPH NODE		-	-	L	L	-	-	-	-	-	-	-	-	L	-	-	L	-	L	-	-	
Malignant Lymphoma, mixed type					P												P		P			
Malignant Lymphoma, lymphocytic type				P																		
Hyperplasia, lymphoid, diffuse														2								
SUBCUTIS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Leukemia, myeloid																						
THYMUS		-	L	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	
Malignant Lymphoma, mixed type			P																			
Malignant Lymphoma, lymphocytic type																						
VAGINA		N	N	L	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, lymphocytic type				P																		

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

T.I.I.M.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0592*	81-0593	81-0594	81-0595	81-0596*																Incidence
SUBCUTANEOUS LYMPH NODE		-	L	-	-	-																(9)
Malignant Lymphoma, mixed type																						4/9
Malignant Lymphoma, lymphocytic type																						3/9
Hyperplasia, lymphoid, diffuse			3																			2/9
SUBCUTIS		-	-	-	-	-																(2)
Leukemia, myeloid																						2/2
THYMUS		-	-	-	-	L																(5)
Malignant Lymphoma, mixed type						P																2/5
Malignant Lymphoma, lymphocytic type																						1/5
VAGINA		N	N	N	N	N																(62)
Malignant Lymphoma, lymphocytic type																						1/62

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN (
(pound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0674	81-0675	81-0676	81-0677	81-0678*	81-0679*	81-0680	81-0682*	81-0683	81-0684*	81-0686*	81-0688*	81-0689	81-0690	81-0691	81-0692*	81-0693	81-0694	81-0695	81-0696	Incidence
BRAIN		N	L	N	N	L	L	L	L	L	L	L	L	N	N	L	L	L	L	N	L	
Malignant Lymphoma, lymphocytic type							P															
Lymphocytosis, multifocal (Meninges)									2													
Compression, focal																						
Corpora amylacea, multifocal			2			1		2	2	2	2	2	2			2	2	2	2		2	
SPINAL CORD		N	N	N	N	N	L	N	N	N	N	N	N	N	N	N	N	N	N	N	L	
Hemangiosarcoma, solitary																						
Malignant Lymphoma, lymphocytic type							P															
Malignant Lymphoma, lymphocytic type, (Meninges)																						
Lymphocytosis, multifocal (Meninges)																					1	
Lymphocytosis, focal (Meninges)																						
SPLEEN		L	N	L	L	L	L	L	N	L	L	L	L	L	L	L	L	L	L	L	L	
Hemangiosarcoma, solitary																	P					
Malignant Lymphoma, mixed type										P	P	P	P		P				P	P		
Malignant Lymphoma, lymphocytic type							P															
Malignant Lymphoma, histiocytic type																						
Hyperplasia, lymphoid, diffuse		2		3	2			2						3		3	2	3			3	
Hematopoiesis, extramedullary, diffuse						3																

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0697*	81-0698	81-0699*	81-0700*	81-0702	81-0703	81-0704	81-0706	81-0707	81-0708*	81-0709	81-0710	81-0711	81-0712	81-0713	81-0714	81-0716	81-0718	81-0719	81-0720	Incidence
BRAIN		L	L	N	L	L	L	L	N	N	N	N	L	L	N	N	N	N	L	L	N	
Malignant Lymphoma, lymphocytic type																						
Lymphocytosis, multifocal (Meninges)																						
Compression, focal																						
Corpora amylacea, multifocal		2	2		1	1	2	2					2	2					2	2		
SPINAL CORD		N	N	N	N	N	N	L	N	N	L	N	N	N	N	N	N	N	N	N	N	
Hemangiosarcoma, solitary																						
Malignant Lymphoma, lymphocytic type																						
Malignant Lymphoma, lymphocytic type, (Meninges)																						
Lymphocytosis, multifocal (Meninges)								1			1											
Lymphocytosis, focal (Meninges)																						
SPLEEN		L	L	N	L	L	L	N	L	L	N	L	N	L	N	L	L	L	L	L	L	
Hemangiosarcoma, solitary																						
Malignant Lymphoma, mixed type		P																				
Malignant Lymphoma, lymphocytic type					P																	
Malignant Lymphoma, histiocytic type										P												
Hyperplasia, lymphoid, diffuse			2						3			2		2		2		2	2	3	2	
Hematopoiesis, extramedullary, diffuse						3	3															

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN /
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0722	81-0723	81-0724	81-0725	81-0726*	81-0727	81-0728*	81-0729	81-0730	81-0731*	81-0732	81-0733	81-0735	81-0736*	81-0737	81-0738	81-0739	81-0740*	81-0742*	81-0743	Incidence
BRAIN		L	L	N	N	L	N	N	L	L	L	L	L	L	L	L	L	N	L	L	N	
Malignant Lymphoma, lymphocytic type			P																			
Lymphocytosis, multifocal (Meninges)										2							2					
Compression, focal																				4		
Corpora amylacea, multifocal		2	2			1			2		2	2	2	2	1	2			2	2		
SPINAL CORD		N	L	N	N	N	N	N	N	L	L	N	N	N	N	N	L	N	N	N	N	
Hemangiosarcoma, solitary											P											
Malignant Lymphoma, lymphocytic type																						
Malignant Lymphoma, lymphocytic type, (Meninges)			P																			
Lymphocytosis, multifocal (Meninges)																	2					
Lymphocytosis, focal (Meninges)										1												
SPLEEN		L	L	N	L	L	L	L	L	L	N	L	L	L	L	L	L	L	L	N	L	
Hemangiosarcoma, solitary		P																				
Malignant Lymphoma, mixed type						P	P	P						P				P				
Malignant Lymphoma, lymphocytic type			P																			
Malignant Lymphoma, histiocytic type																						
Hyperplasia, lymphoid, diffuse					2				3	3		2	2		2	2	2				2	
Hematopoiesis, extramedullary, diffuse																			3			

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II
FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0745*	81-0746																				Incidence
BRAIN		N	N																				(62)
Malignant Lymphoma, lymphocytic type																							2/62
Lymphocytosis, multifocal (Meninges)																							3/62
Compression, focal																							1/62
Corpora amylacea, multifocal																							35/62
SPINAL CORD		N	N																				(62)
Hemangiosarcoma, solitary																							1/62
Malignant Lymphoma, lymphocytic type																							1/62
Malignant Lymphoma, lymphocytic type, (Meninges)																							1/62
Lymphocytosis, multifocal (Meninges)																							4/62
Lymphocytosis, focal (Meninges)																							1/62
SPLEEN		L	L																				(62)
Hemangiosarcoma, solitary																							2/62
Malignant Lymphoma, mixed type																							13/62
Malignant Lymphoma, lymphocytic type																							3/62
Malignant Lymphoma, histiocytic type																							1/62
Hyperplasia, lymphoid, diffuse			2																				29/62
Hematopoiesis, extramedullary, diffuse		3																					5/62

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.. L 0[illegible] SN ,
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0674	81-0675	81-0676	81-0677	81-0678*	81-0679*	81-0680	81-0682*	81-0683	81-0684*	81-0686*	81-0688*	81-0689	81-0690	81-0691	81-0692*	81-0693	81-0694	81-0695	81-0696	Incidence
HEART		N	N	N	N	N	L	N	N	N	L	L	N	N	N	N	L	N	L	N	N	
Malignant Lymphoma, mixed type											P	P										
Malignant Lymphoma, plasmacytic type																						
Myocarditis, acute, multifocal							2															
Myocarditis, chronic, multifocal																2		1				
LIVER		N	L	N	N	N	L	N	N	N	L	L	L	N	N	N	L	N	L	N	N	
Undifferentiated Sarcoma, multifocal																						
Undifferentiated Sarcoma, primary site unknown																						
Hemangiosarcoma, solitary																						
Hepatocellular carcinoma, solitary																						
Malignant Lymphoma, mixed type											P	P	P						P			
Malignant Lymphoma, lymphocytic type							P															
Malignant Lymphoma, plasmacytic type																						
Hemangiosarcoma, metastatic																P						
Hepatocellular adenoma, solitary																						
Angiectasis, focal																						
Hematopoiesis, extramedullary, multifocal			2																			

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0697*	81-0698	81-0699*	81-0700*	81-0702	81-0703	81-0704	81-0706	81-0707	81-0708*	81-0709	81-0710	81-0711	81-0712	81-0713	81-0714	81-0716	81-0718	81-0719	81-0720	Incidence
HEART		N	N	L	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, plasmacytic type				P																		
Myocarditis, acute, multifocal																						
Myocarditis, chronic, multifocal																						
LIVER		L	N	L	L	N	L	L	L	N	N	N	N	L	N	N	N	N	L	L	N	
Undifferentiated Sarcoma, multifocal							P															
Undifferentiated Sarcoma, primary site unknown																						
Hemangiosarcoma, solitary								P														
Hepatocellular carcinoma, solitary									P										P	P		
Malignant Lymphoma, mixed type		P																				
Malignant Lymphoma, lymphocytic type					P																	
Malignant Lymphoma, plasmacytic type				P																		
Hemangiosarcoma, metastatic																						
Hepatocellular adenoma, solitary														P								
Angiectasis, focal																						
Hematopoiesis, extramedullary, multifocal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0722	81-0723	81-0724	81-0725	81-0726*	81-0727	81-0728*	81-0729	81-0730	81-0731*	81-0732	81-0733	81-0735	81-0736*	81-0737	81-0738	81-0739	81-0740*	81-0742*	81-0743	Incidence
HEART		N	N	N	N	N	N	L	N	N	N	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, mixed type								P														
Malignant Lymphoma, plasmacytic type																						
Myocarditis, acute, multifocal																						
Myocarditis, chronic, multifocal																						
LIVER		N	L	N	N	L	N	L	N	N	N	N	L	L	L	L	L	L	L	N	N	
Undifferentiated Sarcoma, multifocal																						
Undifferentiated Sarcoma, primary site unknown																			P			
Hemangiosarcoma, solitary																						
Hepatocellular carcinoma, solitary																P						
Malignant Lymphoma, mixed type					P		P							P				P				
Malignant Lymphoma, lymphocytic type			P																			
Malignant Lymphoma, plasmacytic type																						
Hemangiosarcoma, metastatic																						
Hepatocellular adenoma, solitary																						
Angiectasis, focal																	1					
Hematopoiesis,extramedullary,multifocal													1	2	1							

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0745*	81-0746																			Incidence
HEART		N	N																			(62)
Malignant Lymphoma, mixed type																						3/62
Malignant Lymphoma, plasmacytic type																						1/62
Myocarditis, acute, multifocal																						1/62
Myocarditis, chronic, multifocal																						2/62
LIVER		L	N																			(62)
Undifferentiated Sarcoma, multifocal																						1/62
Undifferentiated Sarcoma, primary site unknown																						1/62
Hemangiosarcoma, solitary																						1/62
Hepatocellular carcinoma, solitary																						4/62
Malignant Lymphoma, mixed type																						9/62
Malignant Lymphoma, lymphocytic type																						3/62
Malignant Lymphoma, plasmacytic type		P																				2/62
Hemangiosarcoma, metastatic																						1/62
Hepatocellular adenoma, solitary																						1/62
Angiectasis, focal																						1/62
Hematopoiesis, extramedullary, multifocal																						4/62

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN / Lesion	Accession Number	81-0674	81-0675	81-0676	81-0677	81-0678*	81-0679*	81-0680	81-0682*	81-0683	81-0684*	81-0686*	81-0688*	81-0689	81-0690	81-0691	81-0692*	81-0693	81-0694	81-0695	81-0696	Incidence
KIDNEYS		L	N	N	L	N	L	L	L	L	L	L	N	N	N	N	L	L	L	N	N	
Undifferentiated Sarcoma, primary site unknown																						
Malignant Lymphoma, mixed type											P	P							P			
Malignant Lymphoma, lymphocytic type							P															
Malignant Lymphoma, plasmacytic type																						
Hyperplasia, tubular, multifocal								1		1												
Infarct, healed, focal (Cortex)																						
Nephrocalcinosis, multifocal								1														
Necrosis, tubular, multifocal																						
Necrosis, tubular, multifocal, unilateral									1													
Dilatation, multifocal (Tubules)																	2					
Cytoplasmic vacuolization, diffuse, (Tubules)		1			2													2				
OVARIES		L	N	L	L	N	N	N	N	L	L	L	L	N	N	N	L	N	L	L	L	
Undifferentiated Sarcoma, primary site unknown																						
Malignant Lymphoma, mixed type											P		P									
Malignant Lymphoma, plasmacytic type																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0697*	81-0698	81-0699*	81-0700*	81-0702	81-0703	81-0704	81-0706	81-0707	81-0708*	81-0709	81-0710	81-0711	81-0712	81-0713	81-0714	81-0716	81-0718	81-0719	81-0720	Incidence
KIDNEYS		N	L	N	L	L	L	N	L	N	L	L	N	N	L	L	L	L	N	N	L	
Undifferentiated Sarcoma, primary site unknown																						
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type					P																	
Malignant Lymphoma, plasmacytic type																						
Hyperplasia, tubular, multifocal			1			2	2		1			1			2	1		1			1	
Infarct, healed, focal (Cortex)																						
Nephrocalcinosis, multifocal																						
Necrosis, tubular, multifocal																						
Necrosis, tubular, multifocal, unilateral																	2					
Dilatation, multifocal (Tubules)																						
Cytoplasmic vacuolization, diffuse, (Tubules)							2				1											
OVARIES		N	L	N	L	L	N	L	N	N	N	N	L	L	L	N	N	N	L	L	L	
Undifferentiated Sarcoma, primary site unknown																						
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, plasmacytic type																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN (
(pound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY (..CIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0722	81-0723	81-0724	81-0725	81-0726*	81-0727	81-0728*	81-0729	81-0730	81-0731*	81-0732	81-0733	81-0735	81-0736*	81-0737	81-0738	81-0739	81-0740*	81-0742*	81-0743	Incidence
KIDNEYS		L	L	N	L	L	L	L	N	N	N	N	L	L	L	L	L	L	L	N	N	
Undifferentiated Sarcoma, primary site																						
unknown																			P			
Malignant Lymphoma, mixed type						P		P						P				P				
Malignant Lymphoma, lymphocytic type			P																			
Malignant Lymphoma, plasmacytic type																						
Hyperplasia, tubular, multifocal		1			1		2							1	1		1	1				
Infarct, healed, focal (Cortex)																2						
Nephrocalcinosis, multifocal													1									
Necrosis, tubular, multifocal																	2					
Necrosis,tubular,multifocal,unilateral																						
Dilatation, multifocal (Tubules)			3																			
Cytoplasmic vacuolization, diffuse,																						
(Tubules)																						
OVARIES		N	N	L	N	L	L	L	N	M	L	N	N	L	N	N	N	L	L	N	L	
Undifferentiated Sarcoma, primary site																						
unknown																			P			
Malignant Lymphoma, mixed type								P														
Malignant Lymphoma, plasmacytic type																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0745*	81-0746																				Incidence
KIDNEYS		L	L																				(62)
Undifferentiated Sarcoma, primary site unknown																							1/62
Malignant Lymphoma, mixed type																							7/62
Malignant Lymphoma, lymphocytic type																							3/62
Malignant Lymphoma, plasmacytic type		P																					1/62
Hyperplasia, tubular, multifocal		2	1																				20/62
Infarct, healed, focal (Cortex)																							1/62
Nephrocalcinosis, multifocal																							2/62
Necrosis, tubular, multifocal																							1/62
Necrosis, tubular, multifocal, unilateral																							2/62
Dilatation, multifocal (Tubules)																							2/62
Cytoplasmic vacuolization, diffuse, (Tubules)																							5/62
OVARIES		L	N																				(61)
Undifferentiated Sarcoma, primary site unknown																							1/61
Malignant Lymphoma, mixed type																							3/61
Malignant Lymphoma, plasmacytic type		P																					1/61

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0674	81-0675	81-0676	81-0677	81-0678*	81-0679*	81-0680	81-0682*	81-0683	81-0684*	81-0686*	81-0688*	81-0689	81-0690	81-0691	81-0692*	81-0693	81-0694	81-0695	81-0696	Incidence
OVARIES (Con't.)		L	N	L	L	N	N	N	N	L	L	L	L	N	N	N	L	N	L	L	L	
Hemangiosarcoma, metastatic																						
Granulosa-cell tumor, solitary																						
Necrosis, diffuse																						
Parovarian cysts, bilateral					4							3										
Parovarian cyst, solitary		3		2						4			3				4		4	3		
Follicular cyst, solitary																					3	
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
ADRENALS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Pheochromocytoma, solitary																						
Malignant Lymphoma, lymphocytic type																						
AXILLARY LYMPH NODE		-	-	-	-	-	L	-	-	-	-	-	L	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type													P									
Malignant Lymphoma, lymphocytic type							P															
CECUM		-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type											P											

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II
FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0697*	81-0698	81-0699*	81-0700*	81-0702	81-0703	81-0704	81-0706	81-0707	81-0708*	81-0709	81-0710	81-0711	81-0712	81-0713	81-0714	81-0716	81-0718	81-0719	81-0720	Incidence
OVARIES (Con't.)		N	L	N	L	L	N	L	N	N	N	N	L	L	L	N	N	N	L	L	L	
Hemangiosarcoma, metastatic																						
Granulosa-cell tumor, solitary					P																	
Necrosis, diffuse															4							
Parovarian cysts, bilateral								4												4		
Parovarian cyst, solitary			3										2	4					2		3	
Follicular cyst, solitary						3									4							
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
ADRENALS		-	-	-	L	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	
Pheochromocytoma, solitary											P											
Malignant Lymphoma, lymphocytic type					P																	
AXILLARY LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
CECUM		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

St..., No.. L O... SN .
...pound: RDX
...minal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0722	81-0723	81-0724	81-0725	81-0726*	81-0727	81-0728*	81-0729	81-0730	81-0731*	81-0732	81-0733	81-0735	81-0736*	81-0737	81-0738	81-0739	81-0740*	81-0742*	81-0743	Incidence
OVARIES (Con't.)		N	N	L	N	L	L	L	N	M	L	N	N	L	N	N	N	L	L	N	L	
Hemangiosarcoma, metastatic											P											
Granulosa-cell tumor, solitary																						
Necrosis, diffuse																						
Parovarian cysts, bilateral																						
Parovarian cyst, solitary				4										3				3			3	
Follicular cyst, solitary						4	3															
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
ADRENALS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Pheochromocytoma, solitary																						
Malignant Lymphoma, lymphocytic type																						
AXILLARY LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
CECUM		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0745*	81-0746																				Incidence
OVARIES (Con't.)		L	N																				(61)
Hemangiosarcoma, metastatic																							1/61
Granulosa-cell tumor, solitary																							1/61
Necrosis, diffuse																							1/61
Parovarian cysts, bilateral																							4/61
Parovarian cyst, solitary																							16/61
Follicular cyst, solitary																							5/61
LESIONS (TISSUES NOT SPECIFICALLY																							
REQUIRED BY PROTOCOL)																							
ADRENALS		-	-																				(2)
Pheochromocytoma, solitary																							1/2
Malignant Lymphoma, lymphocytic type																							1/2
AXILLARY LYMPH NODE		-	-																				(2)
Malignant Lymphoma, mixed type																							1/2
Malignant Lymphoma, lymphocytic type																							1/2
CECUM		-	-																				(1)
Malignant Lymphoma, mixed type																							1/1

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: [illegible] 3N 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0674	81-0675	81-0676	81-0677	81-0678*	81-0679*	81-0680	81-0682*	81-0683	81-0684*	81-0686*	81-0688*	81-0689	81-0690	81-0691	81-0692*	81-0693	81-0694	81-0695	81-0696	Incidence
COLON		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
EYES		L	-	-	-	-	L	-	-	-	-	L	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type												P										
Phthisis bulbi, unilateral		4					4															
GALL BLADDER		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
HARDERIAN GLAND		-	-	-	-	-	L	-	-	-	-	-	L	-	-	-	-	-	-	-	-	
Adenoma, solitary							P						P									
HEPATIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type												P										
Hemorrhage, focal																						
INGUINAL LYMPH NODE		-	-	-	-	-	L	-	-	-	-	-	L	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type													P									
Malignant Lymphoma, lymphocytic type							P															
JEJUNUM		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
LUMBAR LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	L	-	-	
Malignant Lymphoma, mixed type													P						P			
Malignant Lymphoma, lymphocytic type																						
Malignant Lymphoma, plasmacytic type																						
Congestion, diffuse																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
C/ ound: RDX
T. inal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY (IDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0697*	81-0698	81-0699*	81-0700*	81-0702	81-0703	81-0704	81-0706	81-0707	81-0708*	81-0709	81-0710	81-0711	81-0712	81-0713	81-0714	81-0716	81-0718	81-0719	81-0720	Incidence
COLON		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
EYES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Phthisis bulbi, unilateral																						
GALL BLADDER		-	-	-	-	-	N	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
HARDERIAN GLAND		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Adenoma, solitary																						
HEPATIC LYMPH NODE		L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type		P																				
Hemorrhage, focal		3																				
INGUINAL LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
JEJUNUM		-	-	N	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
LUMBAR LYMPH NODE		L	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type		P																				
Malignant Lymphoma, lymphocytic type					P																	
Malignant Lymphoma, plasmacytic type																						
Congestion, diffuse																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0722	81-0723	81-0724	81-0725	81-0726*	81-0727	81-0728*	81-0729	81-0730	81-0731*	81-0732	81-0733	81-0735	81-0736*	81-0737	81-0738	81-0739	81-0740*	81-0742*	81-0743	Incidence
COLON		-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	
EYES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Phthisis bulbi, unilateral																						
GALL BLADDER		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
HARDERIAN GLAND		-	-	-	-	-	L	N	-	-	-	-	-	-	-	-	-	-	-	-	-	
Adenoma, solitary							P															
HEPATIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Hemorrhage, focal																						
INGUINAL LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
JEJUNUM		-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	
LUMBAR LYMPH NODE		-	-	-	-	L	-	L	-	-	-	-	-	L	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type						P		P						P								
Malignant Lymphoma, lymphocytic type																						
Malignant Lymphoma, plasmacytic type																						
Congestion, diffuse																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II
FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number 81-0745*	81-0746	Incidence
COLON	-	-	(1)
EYES	-	-	(3)
Malignant Lymphoma, mixed type			1/3
Phthisis bulbi, unilateral			2/3
GALL BLADDER	-	-	(1)
HARDERIAN GLAND	-	L	(5)
Adenoma, solitary		P	4/5
HEPATIC LYMPH NODE	-	-	(2)
Malignant Lymphoma, mixed type			2/2
Hemorrhage, focal			1/2
INGUINAL LYMPH NODE	-	-	(2)
Malignant Lymphoma, mixed type			1/2
Malignant Lymphoma, lymphocytic type.			1/2
JEJUNUM	-	-	(2)
LUMBAR LYMPH NODE	L	-	(8)
Malignant Lymphoma, mixed type			6/8
Malignant Lymphoma, lymphocytic type			1/8
Malignant Lymphoma, plasmacytic type	P		1/8
Congestion, diffuse	2		1/8

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN
(pound: RDX
minal Sacrifice
Dose (m/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY (CIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0674	81-0675	81-0676	81-0677	81-0678*	81-0679*	81-0680	81-0682*	81-0683	81-0684*	81-0686*	81-0688*	81-0689	81-0690	81-0691	81-0692*	81-0693	81-0694	81-0695	81-0696	Incidence
LUNGS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
Hemorrhage, multifocal																2						
Congestion, multifocal																						
MAMMARY GLAND		-	N	-	-	-	-	-	-	-	-	L	L	-	N	-	L	-	N	N	-	
Adenocarcinoma, solitary																						
Malignant Lymphoma, mixed type												P										
Fibroadenoma, multifocal																						
Fibroadenoma, solitary													P									
Adenoacanthoma, solitary																						
Adenoma, solitary																						
Hyperplasia, cystic, multifocal																4						
MANDIBULAR LYMPH NODE		-	-	-	-	-	-	-	-	-	L	L	L	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type											P	P	P									
Malignant Lymphoma, lymphocytic type																						
MESENTERIC FAT		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Steatitis, chronic, focal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
C(ound: RDX
T. .inal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY (.IDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0697*	81-0698	81-0699*	81-0700*	81-0702	81-0703	81-0704	81-0706	81-0707	81-0708*	81-0709	81-0710	81-0711	81-0712	81-0713	81-0714	81-0716	81-0718	81-0719	81-0720	Incidence
LUNGS		L	-	-	L	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type					P																	
Hemorrhage, multifocal		1									1											
Congestion, multifocal																						
MAMMARY GLAND		L	-	N	-	-	L	N	N	-	-	-	-	-	-	-	-	-	-	N	N	
Adenocarcinoma, solitary		P																				
Malignant Lymphoma, mixed type																						
Fibroadenoma, multifocal																						
Fibroadenoma, solitary																						
Adenoacanthoma, solitary							P															
Adenoma, solitary																						
Hyperplasia, cystic, multifocal																						
MANDIBULAR LYMPH NODE		L	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type		P																				
Malignant Lymphoma, lymphocytic type					P																	
MESENTERIC FAT		-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	
Steatitis, chronic, focal														2								

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 00121 SN (
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0722	81-0723	81-0724	81-0725	81-0726*	81-0727	81-0728*	81-0729	81-0730	81-0731*	81-0732	81-0733	81-0735	81-0736*	81-0737	81-0738	81-0739	81-0740*	81-0742*	81-0743	Incidence
LUNGS		-	-	-	-	L	-	L	-	-	-	-	-	-	-	-	-	-	L	-	-	
Malignant Lymphoma, mixed type						P		P														
Malignant Lymphoma, lymphocytic type																						
Hemorrhage, multifocal																						
Congestion, multifocal																			2			
MAMMARY GLAND		-	-	-	-	-	-	L	N	-	-	-	-	-	L	-	-	-	L	-	-	
Adenocarcinoma, solitary																						
Malignant Lymphoma, mixed type								P														
Fibroadenoma, multifocal																			P			
Fibroadenoma, solitary																						
Adenoacanthoma, solitary																						
Adenoma, solitary															P							
Hyperplasia, cystic, multifocal																						
MANDIBULAR LYMPH NODE		-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type						P																
Malignant Lymphoma, lymphocytic type																						
MESENTERIC FAT		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Steatitis, chronic, focal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0745*	81-0746																			Incidence
LUNGS		-	-																			(7)
Malignant Lymphoma, mixed type																						2/7
Malignant Lymphoma, lymphocytic type																						1/7
Hemorrhage, multifocal																						3/7
Congestion, multifocal																						1/7
MAMMARY GLAND		-	-																			(18)
Adenocarcinoma, solitary																						1/18
Malignant Lymphoma, mixed type																						2/18
Fibroadenoma, multifocal																						1/18
Fibroadenoma, solitary																						1/18
Adenoacanthoma, solitary																						1/18
Adenoma, solitary																						1/18
Hyperplasia, cystic, multifocal																						1/18
MANDIBULAR LYMPH NODE		-	-																			(6)
Malignant Lymphoma, mixed type																						5/6
Malignant Lymphoma, lymphocytic type																						1/6
MESENTERIC FAT		-	-																			(1)
Steatitis, chronic, focal																						1/1

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0674	81-0675	81-0676	81-0677	81-0678*	81-0679*	81-0680	81-0682*	81-0683	81-0684*	81-0686*	81-0688*	81-0689	81-0690	81-0691	81-0692*	81-0693	81-0694	81-0695	81-0696	Incidence
MESENTERIC LYMPH NODE		-	L	-	-	-	-	-	-	-	L	L	L	-	-	-	-	-	L	-	-	
Undifferentiated Sarcoma, primary site																						
unknown																						
Malignant Lymphoma, mixed type											P	P	P						P			
Malignant Lymphoma, lymphocytic type																						
Malignant Lymphoma, histiocytic type																						
Malignant Lymphoma, plasmacytic type																						
Hyperplasia, lymphoid, diffuse			2																			
MESENTERY		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Undifferentiated Sarcoma, primary site																						
unknown																						
Malignant Lymphoma, plasmacytic type																						
Undifferentiated Sarcoma, metastatic																						
PANCREAS		-	-	-	-	-	-	-	-	-	L	-	-	N	-	-	-	-	L	-	-	
Undifferentiated Sarcoma, primary site																						
unknown																						
Malignant Lymphoma, mixed type											P								P			
Malignant Lymphoma, plasmacytic type																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0697*	81-0698	81-0699*	81-0700*	81-0702	81-0703	81-0704	81-0706	81-0707	81-0708*	81-0709	81-0710	81-0711	81-0712	81-0713	81-0714	81-0716	81-0718	81-0719	81-0720	Incidence
MESENTERIC LYMPH NODE		L	L	-	L	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	
Undifferentiated Sarcoma, primary site unknown																						
Malignant Lymphoma, mixed type		P																				
Malignant Lymphoma, lymphocytic type					P																	
Malignant Lymphoma, histiocytic type										P												
Malignant Lymphoma, plasmacytic type																						
Hyperplasia, lymphoid, diffuse			3																			
MESENTERY		-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Undifferentiated Sarcoma, primary site unknown																						
Malignant Lymphoma, plasmacytic type																						
Undifferentiated Sarcoma, metastatic							P															
PANCREAS		L	N	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Undifferentiated Sarcoma, primary site unknown																						
Malignant Lymphoma, mixed type		P																				
Malignant Lymphoma, plasmacytic type																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
(pound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY (ICIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0722	81-0723	81-0724	81-0725	81-0726*	81-0727	81-0728*	81-0729	81-0730	81-0731*	81-0732	81-0733	81-0735	81-0736*	81-0737	81-0738	81-0739	81-0740*	81-0742*	81-0743	Incidence
MESENTERIC LYMPH NODE		-	L	-	-	L	-	L	-	L	-	-	-	L	L	-	-	-	L	-	-	
Undifferentiated Sarcoma, primary site																						
unknown																			P			
Malignant Lymphoma, mixed type						P		P						P								
Malignant Lymphoma, lymphocytic type			P																			
Malignant Lymphoma, histiocytic type																						
Malignant Lymphoma, plasmacytic type																						
Hyperplasia, lymphoid, diffuse										3					3							
MESENTERY		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	
Undifferentiated Sarcoma, primary site																						
unknown																			P			
Malignant Lymphoma, plasmacytic type																						
Undifferentiated Sarcoma, metastatic																						
PANCREAS		-	-	-	-	L	-	L	-	N	-	-	-	-	-	-	-	-	L	-	-	
Undifferentiated Sarcoma, primary site																						
unknown																			P			
Malignant Lymphoma, mixed type						P		P														
Malignant Lymphoma, plasmacytic type																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0745*	81-0746																			Incidence
MESENTERIC LYMPH NODE		L	-																			(17)
Undifferentiated Sarcoma, primary site																						
unknown																						1/17
Malignant Lymphoma, mixed type																						8/17
Malignant Lymphoma, lymphocytic type																						2/17
Malignant Lymphoma, histiocytic type																						1/17
Malignant Lymphoma, plasmacytic type		P																				1/17
Hyperplasia, lymphoid, diffuse																						4/17
MESENTERY		L	-																			(3)
Undifferentiated Sarcoma, primary site																						
unknown																						1/3
Malignant Lymphoma, plasmacytic type		P																				1/3
Undifferentiated Sarcoma, metastatic																						1/3
PANCREAS		L	-																			(10)
Undifferentiated Sarcoma, primary site																						
unknown																						1/10
Malignant Lymphoma, mixed type																						5/10
Malignant Lymphoma, plasmacytic type		P																				1/10

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

T.R.

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0674	81-0675	81-0676	81-0677	81-0678*	81-0679*	81-0680	81-0682*	81-0683	81-0684*	81-0686*	81-0688*	81-0689	81-0690	81-0691	81-0692*	81-0693	81-0694	81-0695	81-0696	Incidence
PANCREATIC LYMPH NODE		-	-	-	-	-	-	-	-	-	L	L	L	L	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type											P	P	P									
Hyperplasia, lymphoid, diffuse														2								
PARATHYROIDS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Adenoma, solitary																						
PAROVARIAN TISSUE		-	-	-	-	-	L	-	-	L	-	L	-	-	-	-	-	-	L	-	-	
Malignant Lymphoma, mixed type										P		P							P			
Malignant Lymphoma, lymphocytic type							P															
Malignant Lymphoma, histiocytic type																						
PELVIC LYMPH NODE		-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type							P															
PITUITARY		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	
Adenoma, solitary (Anterior)																	P					
RENAL LYMPH NODE		-	-	-	-	-	-	-	-	-	L	L	L	-	-	-	-	-	L	-	-	
Malignant Lymphoma, mixed type											P	P	P						P			
Malignant Lymphoma, plasmacytic type																						
Congestion, diffuse																						

Symbols:
N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity:
1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0697*	81-0698	81-0699*	81-0700*	81-0702	81-0703	81-0704	81-0706	81-0707	81-0708*	81-0709	81-0710	81-0711	81-0712	81-0713	81-0714	81-0716	81-0718	81-0719	81-0720	Incidence
PANCREATIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Hyperplasia, lymphoid, diffuse																						
PARATHYROIDS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Adenoma, solitary																						
PAROVARIAN TISSUE		L	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type		P																				
Malignant Lymphoma, lymphocytic type																						
Malignant Lymphoma, histiocytic type										P												
PELVIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type																						
PITUITARY		-	L	-	-	-	L	-	-	-	-	L	-	-	-	-	-	L	-	-	-	
Adenoma, solitary (Anterior)			P				P					P						P				
RENAL LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, plasmacytic type																						
Congestion, diffuse																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion / Accession Number	81-0722	81-0723	81-0724	81-0725	81-0726*	81-0727	81-0728*	81-0729	81-0730	81-0731*	81-0732	81-0733	81-0735	81-0736*	81-0737	81-0738	81-0739	81-0740*	81-0742*	81-0743	Incidence
PANCREATIC LYMPH NODE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																					
Hyperplasia, lymphoid, diffuse																					
PARATHYROIDS	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Adenoma, solitary		P																			
PAROVARIAN TISSUE	-	L	-	-	L	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	
Malignant Lymphoma, mixed type					P												P				
Malignant Lymphoma, lymphocytic type		P																			
Malignant Lymphoma, histiocytic type																					
PELVIC LYMPH NODE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type																					
PITUITARY	L	L										L		L					L	L	
Adenoma, solitary (Anterior)	P	P										P		P					P	P	
RENAL LYMPH NODE	-	-	-	-	-	-	L	-	-	-	-	-	L	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type							P						P								
Malignant Lymphoma, plasmacytic type																					
Congestion, diffuse																					

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0745*	81-0746																			Incidence
PANCREATIC LYMPH NODE		-	-																			(4)
Malignant Lymphoma, mixed type																						3/4
Hyperplasia, lymphoid, diffuse																						1/4
PARATHYROIDS		-	-																			(1)
Adenoma, solitary																						1/1
PAROVARIAN TISSUE		-	-																			(9)
Malignant Lymphoma, mixed type																						6/9
Malignant Lymphoma, lymphocytic type																						2/9
Malignant Lymphoma, histiocytic type																						1/9
PELVIC LYMPH NODE		-	-																			(1)
Malignant Lymphoma, lymphocytic type																						1/1
PITUITARY		-	-																			(11)
Adenoma, solitary (Anterior)																						11/11
RENAL LYMPH NODE		L	-																			(7)
Malignant Lymphoma, mixed type																						6/7
Malignant Lymphoma, plasmacytic type		P																				1/7
Congestion, diffuse		3																				1/7

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0674	81-0675	81-0676	81-0677	81-0678*	81-0679*	81-0680	81-0682*	81-0683	81-0684*	81-0686*	81-0688*	81-0689	81-0690	81-0691	81-0692*	81-0693	81-0694	81-0695	81-0696	Incidence
RESPIRATORY LYMPH NODE		-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type											P											
Malignant Lymphoma, histiocytic type																						
SALIVARY GLAND		-	-	-	-	-	-	-	-	-	L	L	N	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type											P	P										
SKELETAL MUSCLE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Myositis, chronic, active, multifocal																						
SKIN		-	L	-	L	L	-	L	-	-	-	N	L	-	L	L	L	-	L	L	-	
Squamous papilloma, solitary																						
Dermatitis, chronic, diffuse						2		2					1		3	2			2	2		
Dermatitis, chronic, multifocal																	2					
Dermatitis, chronic, focal			3																			
Follicular atrophy, diffuse					2																	
STOMACH		-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	
Undifferentiated Sarcoma, primary site unknown																						
Malignant Lymphoma, mixed type											P											
Cysts, epithelial, multifocal(Glandular)											2											

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0697*	81-0698	81-0699*	81-0700*	81-0702	81-0703	81-0704	81-0706	81-0707	81-0708*	81-0709	81-0710	81-0711	81-0712	81-0713	81-0714	81-0716	81-0718	81-0719	81-0720	Incidence
RESPIRATORY LYMPH NODE		L	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type		P																				
Malignant Lymphoma, histiocytic type										P												
SALIVARY GLAND		L	-	-	N	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type		P																				
SKELETAL MUSCLE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Myositis, chronic, active, multifocal																						
SKIN		N	N	N	L	-	N	L	L	L	-	L	-	L	-	-	-	-	L	L	L	
Squamous papilloma, solitary												P										
Dermatitis, chronic, diffuse					1			2	3	2				2						2	2	
Dermatitis, chronic, multifocal																			2			
Dermatitis, chronic, focal																						
Follicular atrophy, diffuse																						
STOMACH		-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-	-	
Undifferentiated Sarcoma, primary site unknown																						
Malignant Lymphoma, mixed type																						
Cysts, epithelial, multifocal(Glandular)																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0722	81-0723	81-0724	81-0725	81-0726*	81-0727	81-0728*	81-0729	81-0730	81-0731*	81-0732	81-0733	81-0735	81-0736*	81-0737	81-0738	81-0739	81-0740*	81-0742*	81-0743	Incidence
RESPIRATORY LYMPH NODE		-	-	-	-	L	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type						P		P														
Malignant Lymphoma, histiocytic type																						
SALIVARY GLAND		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
SKELETAL MUSCLE		-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	
Myositis, chronic, active, multifocal											3											
SKIN		-	-	L	-	-	L	-	L	L	L	-	-	-	-	-	-	-	-	-	-	
Squamous papilloma, solitary																						
Dermatitis, chronic, diffuse				2					2	2	1											
Dermatitis, chronic, multifocal							2															
Dermatitis, chronic, focal																						
Follicular atrophy, diffuse																						
STOMACH		-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-	-	L	-	-	
Undifferentiated Sarcoma, primary site unknown																			P			
Malignant Lymphoma, mixed type																						
Cysts, epithelial, multifocal (Glandular)																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

N.I.H.:
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0745*	81-0746																			Incidence
RESPIRATORY LYMPH NODE		-	-																			(5)
Malignant Lymphoma, mixed type																						4/5
Malignant Lymphoma, histiocytic type																						1/5
SALIVARY GLAND		-	-																			(5)
Malignant Lymphoma, mixed type																						3/5
SKELETAL MUSCLE		-	-																			(1)
Myositis, chronic, active, multifocal																						1/1
SKIN		-	-																			(29)
Squamous papilloma, solitary																						1/29
Dermatitis, chronic, diffuse																						18/29
Dermatitis, chronic, multifocal																						3/29
Dermatitis, chronic, focal																						1/29
Follicular atrophy, diffuse																						1/29
STOMACH		-	-																			(4)
Undifferentiated Sarcoma, primary site unknown																						1/4
Malignant Lymphoma, mixed type																						1/4
Cysts, epithelial, multifocal (Glandular)																						1/4

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I ..R.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0674	81-0675	81-0676	81-0677	81-0678*	81-0679*	81-0680	81-0682*	81-0683	81-0684*	81-0686*	81-0688*	81-0689	81-0690	81-0691	81-0692*	81-0693	81-0694	81-0695	81-0696	Incidence
SUBCUTANEOUS LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
SUBCUTIS		-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Fibrosarcoma, solitary						P																
THYMUS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
THYROIDS		-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	
Follicular carcinoma, solitary																						
Malignant Lymphoma, mixed type											P											
Malignant Lymphoma, lymphocytic type																						
TRACHEA		-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-	-	
URINARY BLADDER		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
UTERUS		L	L	L	L	L	-	L	L	L	L	L	-	L	L	L	L	L	L	L	L	
Endometrial Stromal Sarcoma, solitary																						
Malignant Lymphoma, plasmacytic type																						
Hemangioma, solitary																						
Metaplasia, squamous, multifocal																				1		
Hyperplasia, cystic, glandular, diffuse		3	4	4	4	3		4	3	4	3	3		4	3	2	3	4	4	4	4	
Endometritis, acute, diffuse																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0697*	81-0698	81-0699*	81-0700*	81-0702	81-0703	81-0704	81-0706	81-0707	81-0708*	81-0709	81-0710	81-0711	81-0712	81-0713	81-0714	81-0716	81-0718	81-0719	81-0720	Incidence
SUBCUTANEOUS LYMPH NODE		L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type		P																				
SUBCUTIS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	
Fibrosarcoma, solitary																				P		
THYMUS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
THYROIDS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Follicular carcinoma, solitary																						
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
TRACHEA		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
URINARY BLADDER		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
UTERUS		-	L	L	-	L	L	N	-	L	L	L	L	L	L	L	L	L	L	L	L	
Endometrial Stromal Sarcoma, solitary																						
Malignant Lymphoma, plasmacytic type				P																		
Hemangioma, solitary															P							
Metaplasia, squamous, multifocal																						
Hyperplasia, cystic, glandular, diffuse			3			3	3			4	3	4	4	2	4		4	4	3	3	4	
Endometritis, acute, diffuse																					3	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0722	81-0723	81-0724	81-0725	81-0726*	81-0727	81-0728*	81-0729	81-0730	81-0731*	81-0732	81-0733	81-0735	81-0736*	81-0737	81-0738	81-0739	81-0740*	81-0742*	81-0743	Incidence
SUBCUTANEOUS LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
SUBCUTIS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Fibrosarcoma, solitary																						
THYMUS		-	-	-	-	-	-	L	-	N	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type								P														
THYROIDS		-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Follicular carcinoma, solitary			P																			
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type			P																			
TRACHEA		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
URINARY BLADDER		-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-	-	
UTERUS		-	-	L	-	L	L	-	L	L	-	-	L	L	L	L	L	-	-	-	L	
Endometrial Stromal Sarcoma, solitary							P															
Malignant Lymphoma, plasmacytic type																						
Hemangioma, solitary																						
Metaplasia, squamous, multifocal																						
Hyperplasia, cystic, glandular, diffuse				4		2	4		4	3			4	3	2	2	4				4	
Endometritis, acute, diffuse																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number 81-0745*	81-0746	Incidence
SUBCUTANEOUS LYMPH NODE	-	-	(1)
Malignant Lymphoma, mixed type			1/1
SUBCUTIS	-	-	(2)
Fibrosarcoma, solitary			2/2
THYMUS	-	-	(2)
Malignant Lymphoma, mixed type			1/2
THYROIDS	-	-	(2)
Follicular carcinoma, solitary			1/2
Malignant Lymphoma, mixed type			1/2
Malignant Lymphoma, lymphocytic type			1/2
TRACHEA	-	-	(1)
URINARY BLADDER	-	-	(1)
UTERUS	L	L	(48)
Endometrial Stromal Sarcoma, solitary			1/48
Malignant Lymphoma, plasmacytic type	P		2/48
Hemangioma, solitary			1/48
Metaplasia, squamous, multifocal			1/48
Hyperplasia, cystic, glandular, diffuse		4	44/48
Endometritis, acute, diffuse			1/48

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0674	81-0675	81-0676	81-0677	81-0678*	81-0679*	81-0680	81-0682*	81-0683	81-0684*	81-0686*	81-0688*	81-0689	81-0690	81-0691	81-0692*	81-0693	81-0694	81-0695	81-0696	Incidence
UTERUS (Con't.)		L	L	L	L	L	-	L	L	L	L	L	-	L	L	L	L	L	L	L	L	
Endometritis, acute, focal																						
Hematoma, organized, solitary																						
Hematoma, solitary																						
Hydrometra, diffuse																						
Hydrometra, focal																						
VAGINA		N	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	N	
VERTEBRAE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Hemangiosarcoma, invasive																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0697*	81-0698	81-0699*	81-0700*	81-0702	81-0703	81-0704	81-0706	81-0707	81-0708*	81-0709	81-0710	81-0711	81-0712	81-0713	81-0714	81-0716	81-0718	81-0719	81-0720	Incidence
UTERUS (Con't.)		-	L	L	-	L	L	N	-	L	L	L	L	L	L	L	L	L	L	L	L	
Endometritis, acute, focal																						
Hematoma, organized, solitary																						
Hematoma, solitary																	3					
Hydrometra, diffuse																4						
Hydrometra, focal																						
VAGINA		-	N	-	-	N	-	N	-	-	-	-	N	N	-	-	N	-	N	N	-	
VERTEBRAE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Hemangiosarcoma, invasive																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I...F.R...
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0722	81-0723	81-0724	81-0725	81-0726*	81-0727	81-0728*	81-0729	81-0730	81-0731*	81-0732	81-0733	81-0735	81-0736*	81-0737	81-0738	81-0739	81-0740*	81-0742*	81-0743	Incidence
UTERUS (Con't.)		-	-	L	-	L	L	-	L	L	-	-	L	L	L	L	L	-	-	-	L	
Endometritis, acute, focal																						
Hematoma, organized, solitary															3							
Hematoma, solitary																						
Hydrometra, diffuse																						
Hydrometra, focal															4							
VAGINA		-	-	-	-	-	-	-	-	-	-	-	-	N	-	N	-	-	-	-	N	
VERTEBRAE		-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	
Hemangiosarcoma, invasive											P											

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.I.M.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II
FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number 81-0745*	81-0746																			Incidence
UTERUS (Con't.)	L	L																			(48)
Endometritis, acute, focal		3																			1/48
Hematoma, organized, solitary																					1/48
Hematoma, solitary																					1/48
Hydrometra, diffuse																					1/48
Hydrometra, focal																					1/48
VAGINA	-	-																			(14)
VERTEBRAE	-	-																			(1)
Hemangiosarcoma, invasive																					1/1

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 00121 SN /
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0822*	81-0823	81-0824	81-0825	81-0826*	81-0827*	81-0828	81-0829	81-0830	81-0831	81-0832*	81-0833	81-0834	81-0836	81-0837	81-0838*	81-0839*	81-0840	81-0841	81-0843	Incidence
BRAIN		L	L	L	L	L	L	N	N	N	N	N	N	L	N	N	N	N	N	N	L	
Malignant Lymphoma, mixed type							P															
Lymphocytosis, multifocal																						
Lymphocytosis, multifocal (Meninges)														2								
Lymphocytosis, focal (Meninges)																						
Compression, focal																						
Corpora amylacea, multifocal		2	2	1	2	2															2	
SPINAL CORD		N	N	N	N	N	N	N	N	N	N	N	N	L	N	N	N	N	N	N	N	
Lymphocytosis, multifocal																						
Lymphocytosis, multifocal (Meninges)														2								
Lymphocytosis, focal (Meninges)																						
SPLEEN		L	L	L	L	N	L	N	N	L	N	L	L	L	N	L	L	L	L	L	L	
Malignant Lymphoma, mixed type							P									P		P				
Malignant Lymphoma, lymphocytic type												P										
Granulosa-cell Carcinoma, metastatic																						
Hyperplasia, lymphoid, diffuse			2	2	2					2				3						2		
Splenitis, acute, diffuse							4															
Hematopoiesis, extramedullary, diffuse		4											3				3		3		3	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0844	81-0846*	81-0847	81-0848	81-0849*	81-0850	81-0851	81-0852	81-0853	81-0855*	81-0856	81-0857*	81-0858*	81-0859*	81-0860	81-0861	81-0862	81-0863*	81-0864	81-0866	Incidence
BRAIN		L	N	N	N	N	N	L	L	L	L	L	N	N	N	N	N	N	N	L	N	
Malignant Lymphoma, mixed type																						
Lymphocytosis, multifocal										1												
Lymphocytosis, multifocal (Meninges)								2												2		
Lymphocytosis, focal (Meninges)																						
Compression, focal																						
Corpora amylacea, multifocal		2						2	2		2	2										
SPINAL CORD		N	N	N	N	N	N	L	N	L	N	L	N	N	N	N	N	L	N	L	N	
Lymphocytosis, multifocal										1												
Lymphocytosis, multifocal (Meninges)								2				2						1		2		
Lymphocytosis, focal, (Meninges)																						
SPLEEN		L	L	N	L	L	L	L	L	L	N	L	L	L	L	L	L	L	L	L	L	
Malignant Lymphoma, mixed type		P			P			P	P				P	P		P	P				P	
Malignant Lymphoma, lymphocytic type																						
Granulosa-cell Carcinoma, metastatic						P																
Hyperplasia, lymphoid, diffuse			2				2			2		2			2			3		2		
Splenitis, acute, diffuse																						
Hematopoiesis, extramedullary, diffuse							3		3										3			

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: [illegible] SN /
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0867	81-0868	81-0869	81-0871	81-0872	81-0873	81-0874	81-0875	81-0876*	81-0877	81-0878	81-0879	81-0880	81-0881	81-0882	81-0885	81-0888	81-0889*	81-0890	81-0892	Incidence
BRAIN		L	N	L	L	L	N	N	L	L	L	N	N	N	N	L	N	N	N	L	N	
Malignant Lymphoma, mixed type																						
Lymphocytosis, multifocal																						
Lymphocytosis, multifocal (Meninges)		1			2																	
Lymphocytosis, focal (Meninges)											1											
Compression, focal										3												
Corpora amylacea, multifocal		2		1		2			2							2				2		
SPINAL CORD		L	N	L	L	N	L	N	N	N	N	N	L	N	N	N	N	N	N	N	N	
Lymphocytosis, multifocal																						
Lymphocytosis, multifocal (Meninges)		1			1		1						1									
Lymphocytosis, focal (Meninges)				2																		
SPLEEN		L	L	L	L	L	N	L	L	L	L	N	L	L	L	L	L	L	L	L	L	
Malignant Lymphoma, mixed type														P								
Malignant Lymphoma, lymphocytic type																						
Granulosa-cell carcinoma, metastatic																						
Hyperplasia, lymphoid, diffuse		2	2	2	3	2		1	3	2	1		2		2	2	2	3		2	2	
Splenitis, acute, diffuse																						
Hematopoiesis, extramedullary, diffuse																			3			

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number 81-0893	81-0894	81-0895	81-0896																	Incidence
BRAIN	L	N	N	N																	(64)
Malignant Lymphoma, mixed type																					1/64
Lymphocytosis, multifocal																					1/64
Lymphocytosis, multifocal (Meninges)																					5/64
Lymphocytosis, focal (Meninges)																					1/64
Compression, focal																					1/64
Corpora amylacea, multifocal	2																				18/64
SPINAL CORD	N	N	N	N																	(64)
Lymphocytosis, multifocal																					1/64
Lymphocytosis, multifocal (Meninges)																					9/64
Lymphocytosis, focal, (Meninges)																					1/64
SPLEEN	L	N	L	L																	(64)
Malignant Lymphoma, mixed type				P																	14/64
Malignant Lymphoma, lymphocytic type																					1/64
Granulosa-cell Carcinoma, metastatic																					1/64
Hyperplasia, lymphoid, diffuse	3																				30/64
Splenitis, acute, diffuse																					1/64
Hematopoiesis, extramedullary, diffuse	3		3																		11/64

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
\- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0822*	81-0823	81-0824	81-0825	81-0826*	81-0827*	81-0828	81-0829	81-0830	81-0831	81-0832*	81-0833	81-0834	81-0836	81-0837	81-0838*	81-0839*	81-0840	81-0841	81-0843	Incidence
HEART		N	N	N	N	N	L	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, mixed type							P															
Myocarditis, chronic, multifocal																						
LIVER		L	N	N	N	N	L	L	L	N	L	L	N	L	L	N	N	L	L	N	N	
Hepatocellular carcinoma, solitary															P				P			
Malignant Lymphoma, mixed type							P											P				
Malignant Lymphoma, lymphocytic type												P										
Hepatocellular adenoma, solitary									P					P								
Focal cellular change								P			P											
Hemangioma, solitary																						
Infarct, acute, solitary																						
Hematopoiesis,extramedullary,multifocal		2																				
KIDNEYS		L	L	L	L	N	L	N	N	N	N	L	N	N	L	L	N	L	L	N	N	
Renal cell Carcinoma, solitary							P															
Malignant Lymphoma, mixed type							P											P	P			
Malignant Lymphoma, lymphocytic type												P										
Fibrosarcoma, metastatic, unilateral		P																				
Metaplasia, osseous, focal (Cortex)																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0844	81-0846*	81-0847	81-0848	81-0849*	81-0850	81-0851	81-0852	81-0853	81-0855*	81-0856	81-0857*	81-0858*	81-0859*	81-0860	81-0861	81-0862	81-0863*	81-0864	81-0866	Incidence
HEART		N	N	N	N	N	N	N	L	L	L	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, mixed type																						
Myocarditis, chronic, multifocal									2	2	2											
LIVER		L	N	L	L	N	L	L	L	L	N	L	L	L	N	L	L	N	L	N	N	
Hepatocellular carcinoma, solitary																			P			
Malignant Lymphoma, mixed type		P						P	P				P	P		P	P					
Malignant Lymphoma, lymphocytic type																						
Hepatocellular adenoma, solitary				P	P		P															
Focal cellular change										P												
Hemangioma, solitary												P										
Infarct, acute, solitary																			4			
Hematopoiesis,extramedullary,multifocal																						
KIDNEYS		L	N	L	L	L	N	L	L	L	N	N	L	L	N	L	L	N	N	L	N	
Renal cell Carcinoma, solitary																				P		
Malignant Lymphoma, mixed type		P														P	P					
Malignant Lymphoma, lymphocytic type																						
Fibrosarcoma, metastatic, unilateral																						
Metaplasia, osseous, focal (Cortex)																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

1 F.H.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0867	81-0868	81-0869	81-0871	81-0872	81-0873	81-0874	81-0875	81-0876*	81-0877	81-0878	81-0879	81-0880	81-0881	81-0882	81-0885	81-0888	81-0889*	81-0890	81-0892	Incidence
HEART		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, mixed type																						
Myocarditis, chronic, multifocal																						
LIVER		N	L	N	N	N	N	N	N	N	L	N	L	N	L	N	N	N	L	L	N	
Hepatocellular carcinoma, solitary																						
Malignant Lymphoma, mixed type													P									
Malignant Lymphoma, lymphocytic type																						
Hepatocellular adenoma, solitary																			P			
Focal cellular change																						
Hemangioma, solitary											P											
Infarct, acute, solitary																						
Hematopoiesis,extramedullary,multifocal			2												2					1		
KIDNEYS		L	N	L	L	N	N	N	N	N	N	L	N	L	L	N	L	L	L	L	N	
Renal cell Carcinoma, solitary																						
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
Fibrosarcoma, metastatic, unilateral																						
Metaplasia, osseous, focal (Cortex)																		2				

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0893	81-0894	81-0895	81-0896																	Incidence
HEART		N	N	N	N																	(64)
Malignant Lymphoma, mixed type																						1/64
Myocarditis, chronic, multifocal																						3/64
LIVER		L	N	N	N																	(64)
Hepatocellular carcinoma, solitary																						3/64
Malignant Lymphoma, mixed type																						10/64
Malignant Lymphoma, lymphocytic type																						1/64
Hepatocellular adenoma, solitary																						6/64
Focal cellular change																						3/64
Hemangioma, solitary																						2/64
Infarct, acute, solitary																						1/64
Hematopoiesis,extramedullary,multifocal		3																				5/64
KIDNEYS		L	L	L	L																	(64)
Renal cell Carcinoma, solitary																						2/64
Malignant Lymphoma, mixed type																						6/64
Malignant Lymphoma, lymphocytic type				P																		2/64
Fibrosarcoma, metastatic, unilateral																						1/64
Metaplasia, osseous, focal (Cortex)																						1/64

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Std No. 7 UC SN
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGICAL INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0822*	81-0823	81-0824	81-0825	81-0826*	81-0827*	81-0828	81-0829	81-0830	81-0831	81-0832*	81-0833	81-0834	81-0836	81-0837	81-0838*	81-0839*	81-0840	81-0841	81-0843	Incidence
KIDNEYS (Con't.)		L	L	L	L	N	L	N	N	N	N	L	N	N	L	L	N	L	L	N	N	
Hyperplasia, tubular, multifocal					2										2				1			
Hyperplasia,tubular,multifocal,unilateral																						
Nephropathy, chronic, diffuse							2															
Necrosis, tubular, multifocal																						
Necrosis,tubular,multifocal,unilateral																						
Nephrocalcinosis, multifocal																						
Infarct, acute, focal																						
Cysts, multiple, unilateral (Cortex)																						
Congestion, multifocal																						
Cytoplasmic vacuolization, diffuse,																						
(Tubules)		1	1	1												2						
OVARIES		N	N	N	L	M	L	L	L	N	L	L	N	N	N	L	N	L	N	N	N	
Granulosa-cell Carcinoma, bilateral																						
Malignant Lymphoma, mixed type																		P				
Malignant Lymphoma, lymphocytic type												P										
Renal cell Carcinoma, metastatic							P															
Granulosa-thecal tumor, solitary																						
Cystadenoma, solitary																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
\- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0844	81-0846*	81-0847	81-0848	81-0849*	81-0850	81-0851	81-0852	81-0853	81-0855*	81-0856	81-0857*	81-0858*	81-0859*	81-0860	81-0861	81-0862	81-0863*	81-0864	81-0866	Incidence
KIDNEYS (Con't.)		L	N	L	L	L	N	L	L	L	N	N	L	L	N	L	L	N	N	L	N	
Hyperplasia, tubular, multifocal		2			1				1	1							1					
Hyperplasia,tubular,multifocal,unilateral														1								
Nephropathy, chronic, diffuse																						
Necrosis, tubular, multifocal		2																				
Necrosis,tubular,multifocal,unilateral														1								
Nephrocalcinosis, multifocal				1					1	1												
Infarct, acute, focal						2																
Cysts, multiple, unilateral (Cortex)																						
Congestion, multifocal													2									
Cytoplasmic vacuolization, diffuse, (Tubules)								1														
OVARIES		L	N	N	N	L	N	N	L	N	N	N	L	L	N	N	L	N	L	L	L	
Granulosa-cell Carcinoma, bilateral						P																
Malignant Lymphoma, mixed type		P							P				P	P								
Malignant Lymphoma, lymphocytic type																						
Renal cell Carcinoma, metastatic																						
Granulosa-thecal tumor, solitary																						
Cystadenoma, solitary																				P		

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Stu[illegible] No.: [illegible] SN .
[illegible]pound: RDX
[illegible]minal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY [illegible]NCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion / Accession Number	81-0867	81-0868	81-0869	81-0871	81-0872	81-0873	81-0874	81-0875	81-0876*	81-0877	81-0878	81-0879	81-0880	81-0881	81-0882	81-0885	81-0888	81-0889*	81-0890	81-0892	Incidence
KIDNEYS (Con't.)	L	N	L	L	N	N	N	N	N	N	L	N	L	L	N	L	L	L	L	N	
Hyperplasia, tubular, multifocal				1									2			2					
Hyperplasia,tubular,multifocal,unilateral																					
Nephropathy, chronic, diffuse																		4			
Necrosis, tubular, multifocal																2					
Necrosis,tubular,multifocal,unilateral	2		1																		
Nephrocalcinosis, multifocal											1		1						1		
Infarct, acute, focal																					
Cysts, multiple, unilateral (Cortex)			2																		
Congestion, multifocal																					
Cytoplasmic vacuolization, diffuse,																					
(Tubules)													1	1			2				
OVARIES	N	L	N	N	N	N	N	N	L	N	L	L	L	N	N	N	L	L	N	N	
Granulosa-cell Carcinoma, bilateral																					
Malignant Lymphoma, mixed type																					
Malignant Lymphoma, lymphocytic type																					
Renal cell Carcinoma, metastatic																					
Granulosa-thecal tumor, solitary																	P				
Cystadenoma, solitary																					

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
\- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

N.I.H.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0893	81-0894	81-0895	81-0896																Incidence
KIDNEYS (Con't.)		L	L	L	L																(64)
Hyperplasia, tubular, multifocal		2	2		1																14/64
Hyperplasia,tubular,multifocal,unilateral																					1/64
Nephropathy, chronic, diffuse																					2/64
Necrosis, tubular, multifocal																					2/64
Necrosis,tubular,multifocal,unilateral																					3/64
Nephrocalcinosis, multifocal																					6/64
Infarct, acute, focal																					1/64
Cysts, multiple, unilateral (Cortex)																					1/64
Congestion, multifocal																					1/64
Cytoplasmic vacuolization, diffuse,																					
(Tubules)			1	1																	10/64
OVARIES		N	N	N	N																(63)
Granulosa-cell Carcinoma, bilateral																					1/63
Malignant Lymphoma, mixed type																					5/63
Malignant Lymphoma, lymphocytic type																					1/63
Renal cell Carcinoma, metastatic																					1/63
Granulosa-thecal tumor, solitary																					1/63
Cystadenoma, solitary																					1/63

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
\- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Compound: RDX
minal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0822*	81-0823	81-0824	81-0825	81-0826*	81-0827*	81-0828	81-0829	81-0830	81-0831	81-0832*	81-0833	81-0834	81-0836	81-0837	81-0838*	81-0839*	81-0840	81-0841	81-0843	Incidence
OVARIES (Con't.)		N	N	N	L	M	L	L	L	N	L	L	N	N	N	L	N	L	N	N	N	
Keratinized cyst, solitary																						
Parovarian cysts, bilateral																						
Parovarian cyst, solitary					3			2	2		2											
Follicular cyst, solitary							3															
Abscesses, multiple, bilateral																						
Abscess, solitary																4						
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
ADRENALS		-	-	-	-	-	N	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Pheochromocytoma, solitary																						
Fibroma, solitary (Capsule)																						
AXILLARY LYMPH NODE		-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	L	-	-	-	
Malignant Lymphoma, mixed type																		P				
Malignant Lymphoma, lymphocytic type												P										
CECUM		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Leiomyoma, solitary																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0844	81-0846*	81-0847	81-0848	81-0849*	81-0850	81-0851	81-0852	81-0853	81-0855*	81-0856	81-0857*	81-0858*	81-0859*	81-0860	81-0861	81-0862	81-0863*	81-0864	81-0866	Incidence
OVARIES (Con't.)		L	N	N	N	L	N	N	L	N	N	N	L	L	N	N	L	N	L	L	L	
Keratinized cyst, solitary																						
Parovarian cysts, bilateral		3																				
Parovarian cyst, solitary													4							3	2	
Follicular cyst, solitary																	4		4			
Abscesses, multiple, bilateral																						
Abscess, solitary																						
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
ADRENALS		-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	L	-	-	-	-	
Pheochromocytoma, solitary														P								
Fibroma, solitary (Capsule)																	P					
AXILLARY LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
CECUM		-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	
Leiomyoma, solitary											P											

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: [illegible] 061[illegible] SN
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0867	81-0868	81-0869	81-0871	81-0872	81-0873	81-0874	81-0875	81-0876*	81-0877	81-0878	81-0879	81-0880	81-0881	81-0882	81-0885	81-0888	81-0889*	81-0890	81-0892	Incidence
OVARIES (Con't.)		N	L	N	N	N	N	N	N	L	N	L	L	L	N	N	N	L	L	N	N	
Keratinized cyst, solitary										4												
Parovarian cysts, bilateral															.							
Parovarian cyst, solitary			4									4	3					3				
Follicular cyst, solitary														3								
Abscesses, multiple, bilateral																			4			
Abscess, solitary																						
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
ADRENALS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Pheochromocytoma, solitary																						
Fibroma, solitary (Capsule)																						
AXILLARY LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
CECUM		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Leiomyoma, solitary																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0893	81-0894	81-0895	81-0896																	Incidence
OVARIES (Con't.)		N	N	N	N																	(63)
Keratinized cyst, solitary																						1/63
Parovarian cysts, bilateral																						1/63
Parovarian cyst, solitary																						11/63
Follicular cyst, solitary																						4/63
Abscesses, multiple, bilateral																						1/63
Abscess, solitary																						1/63
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
ADRENALS		-	-	-	-																	(3)
Pheochromocytoma, solitary																						1/3
Fibroma, solitary (Capsule)																						1/3
AXILLARY LYMPH NODE		-	-	-	-																	(2)
Malignant Lymphoma, mixed type																						1/2
Malignant Lymphoma, lymphocytic type																						1/2
CECUM		-	-	-	-																	(1)
Leiomyoma, solitary																						1/1

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Stu[illegible] No.[illegible] SN .
C[illegible]ound: RDX
T[illegible]inal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0822*	81-0823	81-0824	81-0825	81-0826*	81-0827*	81-0828	81-0829	81-0830	81-0831	81-0832*	81-0833	81-0834	81-0836	81-0837	81-0838*	81-0839*	81-0840	81-0841	81-0843	Incidence
COLON		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
DUODENUM		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	
EYES		-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	
Phthisis bulbi, unilateral																					3	
Keratitis, chronic, focal, unilateral					4																	
HARDERIAN GLAND		-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	
Adenocarcinoma, solitary													P									
Adenoma, solitary																						
HEPATIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	L	-	-	-	
Malignant Lymphoma, mixed type																		P				
Malignant Lymphoma, lymphocytic type												P										
ILEUM		-	-	-	L	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	
Malignant Lymphoma, mixed type					P											P						
INGUINAL LYMPH NODE		-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	L	-	-	-	
Malignant Lymphoma, mixed type																		P				
Malignant Lymphoma, lymphocytic type												P										
INTERCOSTAL MUSCLES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Granulosa-cell Carcinoma, metastatic																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0844	81-0846*	81-0847	81-0848	81-0849*	81-0850	81-0851	81-0852	81-0853	81-0855*	81-0856	81-0857*	81-0858*	81-0859*	81-0860	81-0861	81-0862	81-0863*	81-0864	81-0866	Incidence
COLON		-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type			P																			
DUODENUM		-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-	-	
EYES		-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Phthisis bulbi, unilateral						4																
Keratitis, chronic, focal, unilateral																						
HARDERIAN GLAND		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	
Adenocarcinoma, solitary																						
Adenoma, solitary																			P			
HEPATIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	L	L	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type													P	P								
Malignant Lymphoma, lymphocytic type																						
ILEUM		-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type									P													
INGUINAL LYMPH NODE		-	-	-	N	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
INTERCOSTAL MUSCLES		-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Granulosa-cell Carcinoma, metastatic						P																

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

* Died on Study
or
Moribund Sacrifice

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

ORGAN Lesion	Accession Number	81-0867	81-0868	81-0869	81-0871	81-0872	81-0873	81-0874	81-0875	81-0876*	81-0877	81-0878	81-0879	81-0880	81-0881	81-0882	81-0885	81-0888	81-0889*	81-0890	81-0892	Incidence
COLON		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
DUODENUM		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
EYES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Phthisis bulbi, unilateral																						
Keratitis, chronic, focal, unilateral																						
HARDERIAN GLAND		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Adenocarcinoma, solitary																						
Adenoma, solitary																						
HEPATIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
ILEUM		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
INGUINAL LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
INTERCOSTAL MUSCLES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Granulosa-cell Carcinoma, metastatic																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number 81-0893	81-0894	81-0895	81-0896	Incidence
COLON	-	-	-	-	(1)
Malignant Lymphoma, mixed type					1/1
DUODENUM	-	-	-	-	(2)
EYES	-	-	-	-	(3)
Phthisis bulbi, unilateral					2/3
Keratitis, chronic, focal, unilateral					1/3
HARDERIAN GLAND	-	-	-	-	(2)
Adenocarcinoma, solitary					1/2
Adenoma, solitary					1/2
HEPATIC LYMPH NODE	-	-	-	-	(4)
Malignant Lymphoma, mixed type					3/4
Malignant Lymphoma, lymphocytic type					1/4
ILEUM	-	-	-	-	(3)
Malignant Lymphoma, mixed type					3/3
INGUINAL LYMPH NODE	-	-	-	-	(3)
Malignant Lymphoma, mixed type					1/3
Malignant Lymphoma, lymphocytic type					1/3
INTERCOSTAL MUSCLES	-	-	-	-	(1)
Granulosa-cell Carcinoma, metastatic					1/1

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0822*	81-0823	81-0824	81-0825	81-0826*	81-0827*	81-0828	81-0829	81-0830	81-0831	81-0832*	81-0833	81-0834	81-0836	81-0837	81-0838*	81-0839*	81-0840	81-0841	81-0843	Incidence
JEJUNUM		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
LUMBAR LYMPH NODE		L	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	L	-	-	-	
Malignant Lymphoma, mixed type																		P				
Malignant Lymphoma, lymphocytic type												P										
Hyperplasia, lymphoid, diffuse		3																				
Hemorrhage, multifocal		4																				
Hemorrhage, focal																						
Edema, diffuse																						
Congestion, diffuse																						
LUNGS		L	-	-	-	-	L	-	-	-	-	L	-	-	-	L	-	-	-	-	-	
Alveolar/bronchiolar Carcinoma,solitary																						
Malignant Lymphoma, lymphocytic type												P										
Fibrosarcoma, metastatic		P																				
Granulosa-cell Carcinoma, metastatic																						
Renal-cell Carcinoma, metastatic							P															
Alveolar/bronchiolar adenoma, solitary																P						
Hemorrhage, multifocal																						
Edema, multifocal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0844	81-0846*	81-0847	81-0848	81-0849*	81-0850	81-0851	81-0852	81-0853	81-0855*	81-0856	81-0857*	81-0858*	81-0859*	81-0860	81-0861	81-0862	81-0863*	81-0864	81-0866	Incidence
JEJUNUM		-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-	-	
LUMBAR LYMPH NODE		L	-	L	L	-	L	-	-	-	-	-	-	L	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type		P												P								
Malignant Lymphoma, lymphocytic type																						
Hyperplasia, lymphoid, diffuse																						
Hemorrhage, multifocal																						
Hemorrhage, focal				3																		
Edema, diffuse							3															
Congestion, diffuse					3																	
LUNGS		-	-	-	-	L	-	-	N	-	-	-	-	-	-	-	-	L	-	-	-	
Alveolar/bronchiolar Carcinoma, solitary																		P				
Malignant Lymphoma, lymphocytic type																						
Fibrosarcoma, metastatic																						
Granulosa-cell Carcinoma, metastatic						P																
Renal-cell Carcinoma, metastatic																						
Alveolar/bronchiolar adenoma, solitary																						
Hemorrhage, multifocal																						
Edema, multifocal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Stu . lo.: 06 SN .
C(ound: RDX
Te..inal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY (CIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0867	81-0868	81-0869	81-0871	81-0872	81-0873	81-0874	81-0875	81-0876*	81-0877	81-0878	81-0879	81-0880	81-0881	81-0882	81-0885	81-0888	81-0889*	81-0890	81-0892	Incidence
JEJUNUM		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
LUMBAR LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
Hyperplasia, lymphoid, diffuse																						
Hemorrhage, multifocal																						
Hemorrhage, focal																						
Edema, diffuse																						
Congestion, diffuse																						
LUNGS		-	L	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	L	-	-	
Alveolar/bronchiolar Carcinoma, solitary																						
Malignant Lymphoma, lymphocytic type																						
Fibrosarcoma, metastatic																						
Granulosa-cell Carcinoma, metastatic																						
Renal-cell Carcinoma, metastatic																						
Alveolar/bronchiolar adenoma, solitary			P																			
Hemorrhage, multifocal																			4			
Edema, multifocal																			3			

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number 81-0893	81-0894	81-0895	81-0896																Incidence
JEJUNUM	-	-	-	-																(1)
LUMBAR LYMPH NODE	-	-	L	-																(9)
Malignant Lymphoma, mixed type																				3/9
Malignant Lymphoma, lymphocytic type			P																	2/9
Hyperplasia, lymphoid, diffuse																				1/9
Hemorrhage, multifocal																				1/9
Hemorrhage, focal																				1/9
Edema, diffuse																				1/9
Congestion, diffuse																				1/9
LUNGS	-	-	-	-																(10)
Alveolar/bronchiolar Carcinoma, solitary																				1/10
Malignant Lymphoma, lymphocytic type																				1/10
Fibrosarcoma, metastatic																				1/10
Granulosa-cell Carcinoma, metastatic																				1/10
Renal-cell Carcinoma, metastatic																				1/10
Alveolar/bronchiolar adenoma, solitary																				2/10
Hemorrhage, multifocal																				1/10
Edema, multifocal																				1/10

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0822*	81-0823	81-0824	81-0825	81-0826*	81-0827*	81-0828	81-0829	81-0830	81-0831	81-0832*	81-0833	81-0834	81-0836	81-0837	81-0838*	81-0839*	81-0840	81-0841	81-0843	Incidence
MAMMARY GLAND		L	-	-	-	-	-	-	N	-	-	-	N	-	N	-	-	N	-	-	-	
Adenocarcinoma, solitary																						
Fibrosarcoma, metastatic		P																				
Hyperplasia, cystic, multifocal		4																				
MANDIBULAR LYMPH NODE		-	-	-	-	-	L	-	-	-	-	L	-	-	-	-	-	L	-	-	-	
Malignant Lymphoma, mixed type							P											P				
Malignant Lymphoma, lymphocytic type												P										
Hyperplasia, lymphoid, diffuse																						
Congestion, diffuse																						
MESENTERIC FAT		-	-	-	-	-	-	-	-	L	-	-	-	L	-	-	-	-	L	-	-	
Steatitis, chronic, focal										3				3					3			
MESENTERIC LYMPH NODE		L	-	-	-	N	L	-	-	-	-	-	-	-	L	L	-	L	-	-	-	
Malignant Lymphoma, mixed type																P		P				
Renal-cell Carcinoma, metastatic							P															
Hyperplasia, lymphoid, diffuse		4													3							
Edema, diffuse																						
Congestion, diffuse		4																				
ORBITAL CAVITY		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Granulosa-cell Carcinoma, metastatic																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0844	81-0846*	81-0847	81-0848	81-0849*	81-0850	81-0851	81-0852	81-0853	81-0855*	81-0856	81-0857*	81-0858*	81-0859*	81-0860	81-0861	81-0862	81-0863*	81-0864	81-0866	Incidence
MAMMARY GLAND		-	-	-	L	-	-	-	-	-	L	-	-	N	N	-	-	-	-	N	-	
Adenocarcinoma, solitary					P						P											
Fibrosarcoma, metastatic																						
Hyperplasia, cystic, multifocal																						
MANDIBULAR LYMPH NODE		-	-	-	L	-	-	-	-	-	-	-	-	L	L	-	-	-	-	-	-	
Malignant Lymphoma, mixed type														P								
Malignant Lymphoma, lymphocytic type																						
Hyperplasia, lymphoid, diffuse					2																	
Congestion, diffuse															2							
MESENTERIC FAT		-	-	-	-	L	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	
Steatitis, chronic, focal						3		3														
MESENTERIC LYMPH NODE		L	L	-	L	L	-	-	-	-	-	-	L	L	-	-	-	-	-	-	L	
Malignant Lymphoma, mixed type		P	P										P	P							P	
Renal-cell Carcinoma, metastatic																						
Hyperplasia, lymphoid, diffuse					2																	
Edema, diffuse						3																
Congestion, diffuse																						
ORBITAL CAVITY		-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Granulosa-cell Carcinoma, metastatic						P																

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: [illegible] SN ,
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0867	81-0868	81-0869	81-0871	81-0872	81-0873	81-0874	81-0875	81-0876*	81-0877	81-0878	81-0879	81-0880	81-0881	81-0882	81-0885	81-0888	81-0889*	81-0890	81-0892	Incidence
MAMMARY GLAND		-	-	-	N	N	-	N	-	L	N	L	-	-	-	-	-	-	-	-	-	
Adenocarcinoma, solitary												P										
Fibrosarcoma, metastatic																						
Hyperplasia, cystic, multifocal										3												
MANDIBULAR LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
Hyperplasia, lymphoid, diffuse																						
Congestion, diffuse																						
MESENTERIC FAT		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Steatitis, chronic, focal																						
MESENTERIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Renal-cell Carcinoma, metastatic																						
Hyperplasia, lymphoid, diffuse																						
Edema, diffuse																						
Congestion, diffuse																						
ORBITAL CAVITY		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Granulosa-cell Carcinoma, metastatic																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0893	81-0894	81-0895	81-0896																Incidence
MAMMARY GLAND		-	N	L	-																(18)
Adenocarcinoma, solitary																					3/18
Fibrosarcoma, metastatic																					1/18
Hyperplasia, cystic, multifocal				2																	3/18
MANDIBULAR LYMPH NODE		-	-	-	-																(6)
Malignant Lymphoma, mixed type																					3/6
Malignant Lymphoma, lymphocytic type																					1/6
Hyperplasia, lymphoid, diffuse																					1/6
Congestion, diffuse																					1/6
MESENTERIC FAT		-	-	-	-																(5)
Steatitis, chronic, focal																					5/5
MESENTERIC LYMPH NODE		-	-	-	-																(13)
Malignant Lymphoma, mixed type																					7/13
Renal-cell Carcinoma, metastatic																					1/13
Hyperplasia, lymphoid, diffuse																					3/13
Edema, diffuse																					1/13
Congestion, diffuse																					1/13
ORBITAL CAVITY		-	-	-	-																(1)
Granulosa-cell Carcinoma, metastatic																					1/1

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN /
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0822*	81-0823	81-0824	81-0825	81-0826*	81-0827*	81-0828	81-0829	81-0830	81-0831	81-0832*	81-0833	81-0834	81-0836	81-0837	81-0838*	81-0839*	81-0840	81-0841	81-0843	Incidence
PANCREAS		-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type												P										
Granulosa-cell Carcinoma, metastatic																						
Necrosis, diffuse																						
Abscesses, multiple																						
Cystic ducts, multifocal																						
PANCREATIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type												P										
PAROVARIAN TISSUE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	
Malignant Lymphoma, mixed type																P						
Malignant Lymphoma, lymphocytic type																						
PERITONEUM		-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Renal-cell Carcinoma, metastatic							P															
PITUITARY		L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Adenocarcinoma, solitary (Anterior)																						
Adenoma, solitary (Anterior)		P																				
Congestion, diffuse																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0844	81-0846*	81-0847	81-0848	81-0849*	81-0850	81-0851	81-0852	81-0853	81-0855*	81-0856	81-0857*	81-0858*	81-0859*	81-0860	81-0861	81-0862	81-0863*	81-0864	81-0866	Incidence
PANCREAS		-	-	-	-	L	-	-	-	-	-	-	-	L	-	L	-	-	-	-	L	
Malignant Lymphoma, mixed type														P		P					P	
Malignant Lymphoma, lymphocytic type																						
Granulosa-cell Carcinoma, metastatic						P																
Necrosis, diffuse																						
Abscesses, multiple																						
Cystic ducts, multifocal																						
PANCREATIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	
Malignant Lymphoma, mixed type																P						
Malignant Lymphoma, lymphocytic type																						
PAROVARIAN TISSUE		-	-	-	-	-	-	L	-	-	-	-	-	-	-	L	-	-	-	-	-	
Malignant Lymphoma, mixed type								P								P						
Malignant Lymphoma, lymphocytic type																						
PERITONEUM		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Renal-cell Carcinoma, metastatic																						
PITUITARY		-	-	-	L	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	
Adenocarcinoma, solitary (Anterior)																						
Adenoma, solitary (Anterior)					P																	
Congestion, diffuse														2								

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion / Accession Number	81-0867	81-0868	81-0869	81-0871	81-0872	81-0873	81-0874	81-0875	81-0876*	81-0877	81-0878	81-0879	81-0880	81-0881	81-0882	81-0885	81-0888	81-0889*	81-0890	81-0892	Incidence
PANCREAS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	
Malignant Lymphoma, mixed type																					
Malignant Lymphoma, lymphocytic type																					
Granulosa-cell Carcinoma, metastatic																					
Necrosis, diffuse																		4			
Abscesses, multiple																		4			
Cystic ducts, multifocal																		4			
PANCREATIC LYMPH NODE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																					
Malignant Lymphoma, lymphocytic type																					
PAROVARIAN TISSUE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																					
Malignant Lymphoma, lymphocytic type																					
PERITONEUM	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Renal-cell Carcinoma, metastatic																					
PITUITARY	L	-	-	-	-	-	-	-	L	-	-	-	-	-	L	-	-	-	-	-	
Adenocarcinoma, solitary (Anterior)									P												
Adenoma, solitary (Anterior)	P														P						
Congestion, diffuse																					

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number 81-0893	81-0894	81-0895	81-0896																	Incidence
PANCREAS	-	-	-	-																	(6)
Malignant Lymphoma, mixed type																					3/6
Malignant Lymphoma, lymphocytic type																					1/6
Granulosa-cell Carcinoma, metastatic																					1/6
Necrosis, diffuse																					1/6
Abscesses, multiple																					1/6
Cystic ducts, multifocal																					1/6
PANCREATIC LYMPH NODE	-	-	-	-																	(2)
Malignant Lymphoma, mixed type																					1/2
Malignant Lymphoma, lymphocytic type																					1/2
PAROVARIAN TISSUE	-	-	L	-																	(4)
Malignant Lymphoma, mixed type																					3/4
Malignant Lymphoma, lymphocytic type			P																		1/4
PERITONEUM	-	-	-	-																	(1)
Renal-cell Carcinoma, metastatic																					1/1
PITUITARY	-	-	-	-																	(6)
Adenocarcinoma, solitary (Anterior)																					1/6
Adenoma, solitary (Anterior)																					4/6
Congestion, diffuse																					1/6

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I....R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0822*	81-0823	81-0824	81-0825	81-0826*	81-0827*	81-0828	81-0829	81-0830	81-0831	81-0832*	81-0833	81-0834	81-0836	81-0837	81-0838*	81-0839*	81-0840	81-0841	81-0843	Incidence
PLEURA		L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Fibrosarcoma, metastatic		P																				
RENAL LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	
Malignant Lymphoma, mixed type																		P				
Malignant Lymphoma, lymphocytic type																						
RESPIRATORY LYMPH NODE		-	-	-	-	-	L	-	-	-	-	L	-	-	-	-	-	L	-	-	-	
Malignant Lymphoma, mixed type							P											P				
Malignant Lymphoma, lymphocytic type												P										
Edema, diffuse																						
SALIVARY GLAND		-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type												P										
SKIN		L	-	-	L	-	L	L	L	L	L	-	L	L	L	L	L	L	L	L	-	
Squamous cell Carcinoma, solitary																						
Dermatitis, chronic, active, focal																4						
Dermatitis, chronic, diffuse		3			2			2	1	1	1		3	2	1		2	3	2	2		
Dermatitis, chronic, multifocal							2															
Dermatitis, chronic, focal																						
Ulcers, acute, multifocal																4						
Follicular atrophy, diffuse																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0844	81-0846*	81-0847	81-0848	81-0849*	81-0850	81-0851	81-0852	81-0853	81-0855*	81-0856	81-0857*	81-0858*	81-0859*	81-0860	81-0861	81-0862	81-0863*	81-0864	81-0866	Incidence
PLEURA		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Fibrosarcoma, metastatic																						
RENAL LYMPH NODE		L	L	-	-	-	-	L	L	-	-	-	-	L	-	L	-	-	-	-	L	
Malignant Lymphoma, mixed type		P	P					P	P					P		P					P	
Malignant Lymphoma, lymphocytic type																						
RESPIRATORY LYMPH NODE		L	L	-	-	-	-	-	L	-	-	-	-	L	-	-	-	-	-	-	L	
Malignant Lymphoma, mixed type		P	P						P					P							P	
Malignant Lymphoma, lymphocytic type																						
Edema, diffuse																						
SALIVARY GLAND		-	-	-	N	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type																						
SKIN		-	-	-	N	-	-	-	-	-	N	-	L	N	L	-	L	-	L	L	L	
Squamous cell Carcinoma, solitary																						
Dermatitis, chronic, active, focal																						
Dermatitis, chronic, diffuse													1		1		2			2	2	
Dermatitis, chronic, multifocal																						
Dermatitis, chronic, focal																						
Ulcers, acute, multifocal																						
Follicular atrophy, diffuse																			3			

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

1....R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7,0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0867	81-0868	81-0869	81-0871	81-0872	81-0873	81-0874	81-0875	81-0876*	81-0877	81-0878	81-0879	81-0880	81-0881	81-0882	81-0885	81-0888	81-0889*	81-0890	81-0892	Incidence
PLEURA		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Fibrosarcoma, metastatic																						
RENAL LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
RESPIRATORY LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
Edema, diffuse																			3			
SALIVARY GLAND		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type																						
SKIN		-	L	N	L	L	-	L	L	N	N	L	L	N	L	L	-	-	-	-	L	
Squamous cell Carcinoma, solitary																						
Dermatitis, chronic, active, focal																						
Dermatitis, chronic, diffuse			2		3	2		3	1			2	2		2	3					2	
Dermatitis, chronic, multifocal																						
Dermatitis, chronic, focal																						
Ulcers, acute, multifocal																						
Follicular atrophy, diffuse																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number 81-0893	81-0894	81-0895	81-0896	Incidence
PLEURA	-	-	-	-	(1)
Fibrosarcoma, metastatic					1/1
RENAL LYMPH NODE	-	-	L	-	(9)
Malignant Lymphoma, mixed type					8/9
Malignant Lymphoma, lymphocytic type			P		1/9
RESPIRATORY LYMPH NODE	-	-	-	L	(10)
Malignant Lymphoma, mixed type				P	8/10
Malignant Lymphoma, lymphocytic type					1/10
Edema, diffuse					1/10
SALIVARY GLAND	-	-	-	-	(3)
Malignant Lymphoma, lymphocytic type					1/3
SKIN	L	L	L	L	(42)
Squamous cell Carcinoma, solitary			P		1/42
Dermatitis, chronic, active, focal					1/42
Dermatitis, chronic, diffuse	3		2	2	31/42
Dermatitis, chronic, multifocal					1/42
Dermatitis, chronic, focal		2			1/42
Ulcers, acute, multifocal					1/42
Follicular atrophy, diffuse			3		2/42

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

1. . R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0822*	81-0823	81-0824	81-0825	81-0826*	81-0827*	81-0828	81-0829	81-0830	81-0831	81-0832*	81-0833	81-0834	81-0836	81-0837	81-0838*	81-0839*	81-0840	81-0841	81-0843	Incidence
STOMACH		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
SUBCUTANEOUS LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	
Malignant Lymphoma, mixed type																		P				
SUBCUTIS		L	-	-	-	-	L	-	-	-	-	-	-	-	-	-	L	-	-	-	-	
Fibrosarcoma, multifocal		P																				
Fibrosarcoma, solitary																						
Fibroma, solitary																						
Hemangioma, solitary (Vulva)																	P					
Granulomata, foreign body, multifocal							2															
Abscess, solitary (Head)																						
THYMUS		-	-	-	-	-	L	-	-	-	-	-	-	N	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Granulosa-cell Carcinoma, metastatic																						
Renal-cell Carcinoma, metastatic							P															
THYROIDS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
TRACHEA		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
URINARY BLADDER		-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Renal-cell Carcinoma, metastatic							P															

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0844	81-0846*	81-0847	81-0848	81-0849*	81-0850	81-0851	81-0852	81-0853	81-0855*	81-0856	81-0857*	81-0858*	81-0859*	81-0860	81-0861	81-0862	81-0863*	81-0864	81-0866	Incidence
STOMACH		-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-	-	
SUBCUTANEOUS LYMPH NODE		-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
SUBCUTIS		-	-	-	-	-	L	-	-	-	-	-	-	L	L	-	-	-	-	-	-	
Fibrosarcoma, multifocal																						
Fibrosarcoma, solitary							P								P							
Fibroma, solitary														P								
Hemangioma, solitary (Vulva)																						
Granulomata, foreign body, multifocal																						
Abscess, solitary (Head)														4								
THYMUS		L	-	-	N	L	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	
Malignant Lymphoma, mixed type		P																				
Granulosa-cell Carcinoma, metastatic						P																
Renal-cell Carcinoma, metastatic																						
THYROIDS		-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	
TRACHEA		-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	
URINARY BLADDER		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Renal-cell Carcinoma, metastatic																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I....R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0867	81-0868	81-0869	81-0871	81-0872	81-0873	81-0874	81-0875	81-0876*	81-0877	81-0878	81-0879	81-0880	81-0881	81-0882	81-0885	81-0888	81-0889*	81-0890	81-0892	Incidence
STOMACH		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
SUBCUTANEOUS LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
SUBCUTIS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Fibrosarcoma, multifocal																						
Fibrosarcoma, solitary																						
Fibroma, solitary																						
Hemangioma, solitary (Vulva)																						
Granulomata, foreign body, multifocal																						
Abscess, solitary (Head)																						
THYMUS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Granulosa-cell Carcinoma, metastatic																						
Renal-cell Carcinoma, metastatic																						
THYROIDS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
TRACHEA		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
URINARY BLADDER		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Renal-cell Carcinoma, metastatic																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number 81-0893	81-0894	81-0895	81-0896																	Incidence
STOMACH	-	-	-	-																	(1)
SUBCUTANEOUS LYMPH NODE	-	-	-	-																	(2)
Malignant Lymphoma, mixed type																					1/2
SUBCUTIS	-	-	-	-																	(6)
Fibrosarcoma, multifocal																					1/6
Fibrosarcoma, solitary																					2/6
Fibroma, solitary																					1/6
Hemangioma, solitary (Vulva)																					1/6
Granulomata, foreign body, multifocal																					1/6
Abscess, solitary (Head)																					1/6
THYMUS	-	-	-	-																	(6)
Malignant Lymphoma, mixed type																					1/6
Granulosa-cell Carcinoma, metastatic																					1/6
Renal-cell Carcinoma, metastatic																					1/6
THYROIDS	-	-	-	-																	(1)
TRACHEA	-	-	-	-																	(1)
URINARY BLADDER	-	-	-	-																	(1)
Renal-cell Carcinoma, metastatic																					1/1

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0822*	81-0823	81-0824	81-0825	81-0826*	81-0827*	81-0828	81-0829	81-0830	81-0831	81-0832*	81-0833	81-0834	81-0836	81-0837	81-0838*	81-0839*	81-0840	81-0841	81-0843	Incidence
UTERUS		L	L	L	L	L	L	L	L	L	L	L	L	L	L	-	L	L	L	L	L	
Hemangiosarcoma, solitary																			P			
Malignant Lymphoma, mixed type																		P				
Malignant Lymphoma, lymphocytic type												P										
Fibrosarcoma, metastatic		P																				
Renal-cell Carcinoma, metastatic							P															
Endometrial stromal polyp, solitary																						
Hemangioma, solitary																						
Hyperplasia, cystic, glandular, diffuse			4	2	3			3	4	4	3		4	4	2		2			4	4	
Endometritis, acute, hemorrhagic, diffuse																						
Metritis, acute, diffuse						4																
Hydrometra, diffuse		4																				
VAGINA		-	-	-	N	-	-	-	-	-	-	-	N	-	-	-	N	-	-	-	-	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0844	81-0846*	81-0847	81-0848	81-0849*	81-0850	81-0851	81-0852	81-0853	81-0855*	81-0856	81-0857*	81-0858*	81-0859*	81-0860	81-0861	81-0862	81-0863*	81-0864	81-0866	Incidence
UTERUS		-	L	L	L	-	L	L	L	L	-	L	-	-	N	L	L	-	-	-	L	
Hemangiosarcoma, solitary																						
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
Fibrosarcoma, metastatic																						
Renal-cell Carcinoma, metastatic																						
Endometrial stromal polyp, solitary								P														
Hemangioma, solitary							P															
Hyperplasia, cystic, glandular, diffuse			4	3	2		3	4	4	4		2				3	4				3	
Endometritis, acute, hemorrhagic, diffuse																						
Metritis, acute, diffuse																						
Hydrometra, diffuse																						
VAGINA		-	-	-	-	-	-	N	-	-	-	-	-	-	N	-	-	-	-	-	-	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0867	81-0868	81-0869	81-0871	81-0872	81-0873	81-0874	81-0875	81-0876*	81-0877	81-0878	81-0879	81-0880	81-0881	81-0882	81-0885	81-0888	81-0889*	81-0890	81-0892	Incidence
UTERUS		L	L	L	L	L	L	L	L	L	L	-	L	L	L	L	L	L	L	L	L	
Hemangiosarcoma, solitary								P														
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
Fibrosarcoma, metastatic																						
Renal-cell Carcinoma, metastatic																						
Endometrial stromal polyp, solitary																						
Hemangioma, solitary									P	P												
Hyperplasia, cystic, glandular, diffuse		4	4	3	4	4	3	4			4		4	3	4	3	4	2		3	3	
Endometritis, acute, hemorrhagic, diffuse																			4			
Metritis, acute, diffuse																						
Hydrometra, diffuse																						
VAGINA		-	-	-	N	-	-	-	N	-	-	-	-	-	-	-	-	N	-	-	N	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number 81-0893	81-0894	81-0895	81-0896																	Incidence
UTERUS	L	-	-	L																	(52)
Hemangiosarcoma, solitary																					2/52
Malignant Lymphoma, mixed type																					1/52
Malignant Lymphoma, lymphocytic type																					1/52
Fibrosarcoma, metastatic																					1/52
Renal-cell Carcinoma, metastatic																					1/52
Endometrial stromal polyp, solitary																					1/52
Hemangioma, solitary																					3/52
Hyperplasia, cystic, glandular, diffuse	4			3																	42/5
Endometritis, acute, hemorrhagic,diffuse																					1/52
Metritis, acute, diffuse																					1/52
Hydrometra, diffuse																					1/52
VAGINA	-	-	-	N																	(10)

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0972*	81-0973	81-0974	81-0975	81-0976	81-0977	81-0978	81-0980	81-0981*	81-0982*	81-0983	81-0985	81-0986	81-0987	81-0988*	81-0989	81-0990	81-0991*	81-0992*	81-0993*	Incidence
BRAIN		L	N	N	L	L	L	L	N	N	N	L	L	L	L	N	L	L	L	L	N	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
Lymphocytosis, multifocal (Meninges)																	2					
Hemorrhage, multifocal																						
Corpora amylacea, multifocal		2			2	2	2	2				2	2	2	2		2	2	2	2		
SPINAL CORD		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	L	N	N	N	N	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
Lymphocytosis, multifocal (Meninges)																	2					
Hemorrhage, multifocal																						
SPLEEN		L	L	L	L	L	L	L	N	L	L	L	L	L	N	N	L	N	L	L	L	
Hemangiosarcoma, multifocal																						
Hemangiosarcoma, solitary																						
Malignant Lymphoma, mixed type																	P		P			
Malignant Lymphoma, lymphocytic type														P								
Malignant Lymphoma, histiocytic type					P					P											P	
Leukemia, myeloid																						
Hyperplasia, lymphoid, diffuse			2	2		2	3	2				3	2									

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0994	81-0995	81-0996*	81-0998*	81-0999	81-1000	81-1001*	81-1003	81-1004	81-1005*	81-1006	81-1007*	81-1008	81-1010	81-1012*	81-1013	81-1014	81-1015	81-1016	81-1017*	Incidence
BRAIN		L	L	L	L	L	N	N	L	L	N	N	N	L	L	L	L	L	L	L	N	
Malignant Lymphoma, mixed type				P																		
Malignant Lymphoma, lymphocytic type																						
Lymphocytosis, multifocal (Meninges)																						
Hemorrhage, multifocal																3						
Corpora amylacea, multifocal		2	2		2	1			2	2				2	2		2	2	2	2		
SPINAL CORD		N	N	L	N	N	N	N	N	N	N	N	N	N	N	L	N	N	N	N	N	
Malignant Lymphoma, mixed type				P																		
Malignant Lymphoma, lymphocytic type																						
Lymphocytosis, multifocal (Meninges)																						
Hemorrhage, multifocal																3						
SPLEEN		L	L	L	N	L	L	N	L	L	L	L	L	L	L	N	L	N	L	L	L	
Hemangiosarcoma, multifocal													P									
Hemangiosarcoma, solitary																			P		P	
Malignant Lymphoma, mixed type				P							P			P								
Malignant Lymphoma, lymphocytic type		P					P															
Malignant Lymphoma, histiocytic type																						
Leukemia, myeloid																						
Hyperplasia, lymphoid, diffuse			3			2			2	3		2			2		3					

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1018	81-1019*	81-1020	81-1021	81-1022*	81-1023*	81-1024	81-1025	81-1026	81-1027	81-1028	81-1029*	81-1031	81-1032	81-1035*	81-1036	81-1037	81-1039*	81-1040	81-1041	Incidence
BRAIN		L	N	L	L	L	N	L	L	L	N	L	L	N	L	L	N	N	L	N	N	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type						P																
Lymphocytosis, multifocal (Meninges)																						
Hemorrhage, multifocal																						
Corpora amylacea, multifocal		2		2	2			2	2	2		2	2		2	2			1			
SPINAL CORD		N	N	N	N	L	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type						P																
Lymphocytosis, multifocal (Meninges)																						
Hemorrhage, multifocal																						
SPLEEN		L	L	L	L	L	N	L	L	L	L	N	L	L	L	N	L	L	L	N	L	
Hemangiosarcoma, multifocal																						
Hemangiosarcoma, solitary																						
Malignant Lymphoma, mixed type					P			P			P											
Malignant Lymphoma, lymphocytic type			P			P							P				P					
Malignant Lymphoma, histiocytic type																						
Leukemia, myeloid																			P			
Hyperplasia, lymphoid, diffuse		2							3	2				2	2			3			2	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number 81-1042	81-1043	81-1044	81-1045*																	Incidence
BRAIN	N	N	L	L																	(64)
Malignant Lymphoma, mixed type																					1/64
Malignant Lymphoma, lymphocytic type																					1/64
Lymphocytosis, multifocal (Meninges)																					1/64
Hemorrhage, multifocal																					1/64
Corpora amylacea, multifocal			2	2																	38/64
SPINAL CORD	N	N	N	N																	(64)
Malignant Lymphoma, mixed type																					1/64
Malignant Lymphoma, lymphocytic type																					1/64
Lymphocytosis, multifocal (Meninges)																					1/64
Hemorrhage, multifocal																					1/64
SPLEEN	L	L	L	L																	(64)
Hemangiosarcoma, multifocal																					1/64
Hemangiosarcoma, solitary																					2/64
Malignant Lymphoma, mixed type				P																	9/64
Malignant Lymphoma, lymphocytic type																					7/64
Malignant Lymphoma, histiocytic type																					3/64
Leukemia, myeloid																					1/64
Hyperplasia, lymphoid, diffuse	3	2	3																		24/64

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0972*	81-0973	81-0974	81-0975	81-0976	81-0977	81-0978	81-0980	81-0981*	81-0982*	81-0983	81-0985	81-0986	81-0987	81-0988*	81-0989	81-0990	81-0991*	81-0992*	81-0993*	Incidence
SPLEEN (Con't.)		L	L	L	L	L	L	L	N	L	L	L	L	L	N	N	L	N	L	L	L	
Hematopoiesis, extramedullary, diffuse		4									3									3		
HEART		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	L	N	N	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
Leukemia, myeloid																						
Myocarditis, acute, multifocal																			2			
Myocarditis, chronic, multifocal																						
LIVER		N	L	N	L	L	N	L	L	L	L	L	L	L	N	L	N	L	L	N	L	
Hepatocellular carcinoma, multifocal																						
Hepatocellular carcinoma, solitary			P						P			P										
Malignant Lymphoma, mixed type															P				P			
Malignant Lymphoma, lymphocytic type																						
Malignant Lymphoma, histiocytic type					P					P												
Leukemia, myeloid																						
Hemangiosarcoma, metastatic																						
Hepatocellular adenoma, solitary											P										P	
Focal cellular change										P												
Abscesses, multifocal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0994	81-0995	81-0996*	81-0998*	81-0999	81-1000	81-1001*	81-1003	81-1004	81-1005*	81-1006	81-1007*	81-1008	81-1010	81-1012*	81-1013	81-1014	81-1015	81-1016	81-1017*	Incidence
SPLEEN (Con't.)		L	L	L	N	L	L	N	L	L	L	L	L	L	L	N	L	N	L	L	L	
Hematopoiesis, extramedullary, diffuse																				3		
HEART		N	N	L	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, mixed type				P																		
Malignant Lymphoma, lymphocytic type																						
Leukemia, myeloid																						
Myocarditis, acute, multifocal																						
Myocarditis, chronic, multifocal																						
LIVER		N	L	L	L	L	N	N	L	N	L	N	N	N	L	N	L	N	L	L	L	
Hepatocellular carcinoma, multifocal									P													
Hepatocellular carcinoma, solitary																						
Malignant Lymphoma, mixed type				P							P											
Malignant Lymphoma, lymphocytic type																						
Malignant Lymphoma, histiocytic type																						
Leukemia, myeloid																						
Hemangiosarcoma, metastatic																					P	
Hepatocellular adenoma, solitary																	P		P			
Focal cellular change			P																			
Abscesses, multifocal					2																	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1018	81-1019*	81-1020	81-1021	81-1022*	81-1023*	81-1024	81-1025	81-1026	81-1027	81-1028	81-1029*	81-1031	81-1032	81-1035*	81-1036	81-1037	81-1039*	81-1040	81-1041	Incidence
SPLEEN (Con't.)		L	L	L	L	L	N	L	L	L	L	N	L	L	L	N	L	L	L	N	L	
Hematopoiesis, extramedullary, diffuse				4																		
HEART		N	L	N	N	N	N	N	N	L	N	N	N	N	N	N	N	N	L	N	N	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type			P																			
Leukemia, myeloid																			P			
Myocarditis, acute, multifocal																						
Myocarditis, chronic, multifocal										1												
LIVER		L	L	N	L	N	N	N	N	N	N	N	L	N	L	N	L	L	L	L	L	
Hepatocellular carcinoma, multifocal																						
Hepatocellular carcinoma, solitary																		P				
Malignant Lymphoma, mixed type					P																	
Malignant Lymphoma, lymphocytic type			P										P				P					
Malignant Lymphoma, histiocytic type																						
Leukemia, myeloid																			P			
Hemangiosarcoma, metastatic																						
Hepatocellular adenoma, solitary		P																			P	
Focal cellular change																						
Abscesses, multifocal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number 81-1042	81-1043	81-1044	81-1045*	Incidence
SPLEEN (Con't.)	L	L	L	L	(64)
Hematopoiesis, extramedullary, diffuse					5/64
HEART	N	L	N	N	(64)
Malignant Lymphoma, mixed type					1/64
Malignant Lymphoma, lymphocytic type					1/64
Leukemia, myeloid					1/64
Myocarditis, acute, multifocal					1/64
Myocarditis, chronic, multifocal		2			2/64
LIVER	L	L	N	L	(64)
Hepatocellular carcinoma, multifocal					1/64
Hepatocellular carcinoma, solitary	P				5/64
Malignant Lymphoma, mixed type				P	6/64
Malignant Lymphoma, lymphocytic type					3/64
Malignant Lymphoma, histiocytic type					2/64
Leukemia, myeloid					1/64
Hemangiosarcoma, metastatic					1/64
Hepatocellular adenoma, solitary					6/64
Focal cellular change					2/64
Abscesses, multifocal					1/64

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion / Accession Number	81-0972*	81-0973	81-0974	81-0975	81-0976	81-0977	81-0978	81-0980	81-0981*	81-0982*	81-0983	81-0985	81-0986	81-0987	81-0988*	81-0989	81-0990	81-0991*	81-0992*	81-0993*	Incidence
LIVER (Con't.)	N	L	N	L	L	N	L	L	L	L	L	L	L	N	L	N	L	L	N	L	
Hematopoiesis, extramedullary, diffuse																					
Hematopoiesis,extramedullary,multifocal					2		2					2	1				1				
KIDNEYS	N	L	L	L	N	L	N	L	L	N	L	L	L	N	N	L	L	L	N	L	
Malignant Lymphoma, mixed type																		P			
Malignant Lymphoma, lymphocytic type													P								
Malignant Lymphoma, histiocytic type				P																P	
Leukemia, myeloid																					
Hepatocellular carcinoma, metastatic											(P)										
Metaplasia, osseous, focal																					
Hyperplasia, tubular, diffuse																					
Hyperplasia, tubular, multifocal		2		2		2		2			2		2				1				
Granuloma, solitary																1					
Pyelonephritis, chronic, active, multifocal																		2			
Nephropathy, chronic, multifocal																					
Infarcts, healed, multifocal (Cortex)																					
Nephrocalcinosis, multifocal																					
Necrosis, multifocal (Tubules)												2						2			

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion / Accession Number	81-0994	81-0995	81-0996*	81-0998*	81-0999	81-1000	81-1001*	81-1003	81-1004	81-1005*	81-1006	81-1007*	81-1008	81-1010	81-1012*	81-1013	81-1014	81-1015	81-1016	81-1017*	Incidence
LIVER (Con't.)	N	L	L	L	L	N	N	L	N	L	N	N	N	L	N	L	N	L	L	L	
Hematopoiesis, extramedullary, diffuse																					
Hematopoiesis, extramedullary, multifocal					1									1					1		
KIDNEYS	L	L	L	N	N	N	N	N	N	N	N	N	L	L	L	L	L	L	L	L	
Malignant Lymphoma, mixed type			P																		
Malignant Lymphoma, lymphocytic type	P																				
Malignant Lymphoma, histiocytic type																					
Leukemia, myeloid																					
Hepatocellular carcinoma, metastatic																					
Metaplasia, osseous, focal																				2	
Hyperplasia, tubular, diffuse																					
Hyperplasia, tubular, multifocal		1											2	2	2	2	1	2	1		
Granuloma, solitary																					
Pyelonephritis, chronic, active, multifocal																					
Nephropathy, chronic, multifocal																					
Infarcts, healed, multifocal (Cortex)																					
Nephrocalcinosis, multifocal																	1				
Necrosis, multifocal (Tubules)																					

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1018	81-1019*	81-1020	81-1021	81-1022*	81-1023*	81-1024	81-1025	81-1026	81-1027	81-1028	81-1029*	81-1031	81-1032	81-1035*	81-1036	81-1037	81-1039*	81-1040	81-1041	Incidence
LIVER (Con't.)		L	L	N	L	N	N	N	N	N	N	N	L	N	L	N	L	L	L	L	L	
Hematopoiesis,extramedullary,diffuse															2							
Hematopoiesis,extramedullary,multifocal		1															1			1		
KIDNEYS		L	L	N	L	N	N	L	N	L	L	L	L	L	L	N	N	N	L	L	L	
Malignant Lymphoma, mixed type												P										
Malignant Lymphoma, lymphocytic type			P										P									
Malignant Lymphoma, histiocytic type																						
Leukemia, myeloid																			P			
Hepatocellular carcinoma, metastatic																						
Metaplasia, osseous, focal																						
Hyperplasia, tubular, diffuse					2																	
Hyperplasia, tubular, multifocal								2			1	2	2	2	2					1	2	
Granuloma, solitary																						
Pyelonephritis, chronic, active, multifocal																						
Nephropathy, chronic, multifocal										3												
Infarcts, healed, multifocal (Cortex)		3																				
Nephrocalcinosis, multifocal																						
Necrosis, multifocal (Tubules)																				1		

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number 81-1042	81-1043	81-1044	81-1045*																	Incidence
LIVER (Con't.)	L	L	N	L																	(64)
Hematopoiesis, extramedullary, diffuse		1																			2/64
Hematopoiesis,extramedullary,multifocal																					11/64
KIDNEYS	L	L	L	N																	(64)
Malignant Lymphoma, mixed type																					3/64
Malignant Lymphoma, lymphocytic type																					4/64
Malignant Lymphoma, histiocytic type																					2/64
Leukemia, myeloid																					1/64
Hepatocellular carcinoma, metastatic																					1/64
Metaplasia, osseous, focal																					1/64
Hyperplasia, tubular, diffuse																					1/64
Hyperplasia, tubular, multifocal	1	1	2																		26/64
Granuloma, solitary																					1/64
Pyelonephritis, chronic, active, multifocal																					1/64
Nephropathy, chronic, multifocal																					1/64
Infarcts, healed, multifocal (Cortex)																					1/64
Nephrocalcinosis, multifocal																					1/64
Necrosis, multifocal (Tubules)																					3/64

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0972*	81-0973	81-0974	81-0975	81-0976	81-0977	81-0978	81-0980	81-0981*	81-0982*	81-0983	81-0985	81-0986	81-0987	81-0988*	81-0989	81-0990	81-0991*	81-0992*	81-0993*	Incidence
KIDNEYS (Con't.)		N	L	L	L	N	L	N	L	L	N	L	L	L	N	N	L	L	L	N	L	
Dilatation, multifocal (Tubules)										2				1								
Pigmentation, diffuse																						
Congestion, diffuse																						
Cytoplasmic vacuolization, diffuse, (Tubules)				1					1													
OVARIES		L	N	L	N	N	N	N	L	L	N	N	L	L	N	N	N	N	L	L	N	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
Malignant Lymphoma, histiocytic type										P												
Luteoma, solitary		P																				
Hematoma, solitary																						
Abscesses, multifocal, unilateral																			4			
Parovarian cysts, bilateral																						
Parovarian cyst, solitary		4		4					3				3	3						3		
Hemorrhage, focal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0994	81-0995	81-0996*	81-0998*	81-0999	81-1000	81-1001*	81-1003	81-1004	81-1005*	81-1006	81-1007*	81-1008	81-1010	81-1012*	81-1013	81-1014	81-1015	81-1016	81-1017*	Incidence
KIDNEYS (Con't.)		L	L	L	N	N	N	N	N	N	N	N	N	L	L	L	L	L	L	L	L	
Dilatation, multifocal (Tubules)																						
Pigmentation, diffuse																				2		
Congestion, diffuse																3						
Cytoplasmic vacuolization, diffuse, (Tubules)			1															1				
OVARIES		L	N	L	N	L	N	L	N	N	N	N	N	N	L	N	N	N	N	L	N	
Malignant Lymphoma, mixed type				P																		
Malignant Lymphoma, lymphocytic type																						
Malignant Lymphoma, histiocytic type																						
Luteoma, solitary																						
Hematoma, solitary																				4		
Abscesses, multifocal, unilateral																						
Parovarian cysts, bilateral															2							
Parovarian cyst, solitary		3		4				3														
Hemorrhage, focal						3																

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1018	81-1019*	81-1020	81-1021	81-1022*	81-1023*	81-1024	81-1025	81-1026	81-1027	81-1028	81-1029*	81-1031	81-1032	81-1035*	81-1036	81-1037	81-1039*	81-1040	81-1041	Incidence
KIDNEYS (Con't.)		L	L	N	L	N	N	L	N	L	L	L	L	L	L	N	N	N	L	L	L	
Dilatation, multifocal (Tubules)													2									
Pigmentation, diffuse																						
Congestion, diffuse																						
Cytoplasmic vacuolization, diffuse, (Tubules)					1			1														
OVARIES		L	L	L	N	N	N	N	N	L	N	N	L	N	N	N	N	N	N	L	L	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type			P										P									
Malignant Lymphoma, histiocytic type																						
Luteoma, solitary																						
Hematoma, solitary																						
Abscesses, multifocal, unilateral																						
Parovarian cysts, bilateral																						
Parovarian cyst, solitary		3		4						2										3	4	
Hemorrhage, focal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number 81-1042	81-1043	81-1044	81-1045*																	Incidence
KIDNEYS (Con't.)	L	L	L	N																	(64)
Dilatation, multifocal (Tubules)																					3/64
Pigmentation, diffuse																					1/64
Congestion, diffuse																					1/64
Cytoplasmic vacuolization, diffuse, (Tubules)		1																			7/64
OVARIES	N	N	L	L																	(64)
Malignant Lymphoma, mixed type				P																	2/64
Malignant Lymphoma, lymphocytic type																					2/64
Malignant Lymphoma, histiocytic type																					1/64
Luteoma, solitary																					1/64
Hematoma, solitary																					1/64
Abscesses, multifocal, unilateral																					1/64
Parovarian cysts, bilateral																					1/64
Parovarian cyst, solitary			3																		15/64
Hemorrhage, focal																					1/64

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion / Accession Number	81-0972*	81-0973	81-0974	81-0975	81-0976	81-0977	81-0978	81-0980	81-0981*	81-0982*	81-0983	81-0985	81-0986	81-0987	81-0988*	81-0989	81-0990	81-0991*	81-0992*	81-0993*	Incidence
LESIONS (TISSUES NOT SPECIFICALLY																					
REQUIRED BY PROTOCOL)																					
ADRENALS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	
Pheochromocytoma, solitary																P					
AXILLARY LYMPH NODE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																					
Malignant Lymphoma, lymphocytic type																					
CECUM	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
COCCYGEAL VERTEBRAE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																					
COLON	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	
Colitis, acute, focal										4											
DUODENUM	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Hemorrhage, multifocal																					
EYES	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
GALL BLADDER	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
HARDERIAN GLAND	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Adenoma, solitary																					

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0994	81-0995	81-0996*	81-0998*	81-0999	81-1000	81-1001*	81-1003	81-1004	81-1005*	81-1006	81-1007*	81-1008	81-1010	81-1012*	81-1013	81-1014	81-1015	81-1016	81-1017*	Incidence
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
ADRENALS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Pheochromocytoma, solitary																						
AXILLARY LYMPH NODE		-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type				P																		
Malignant Lymphoma, lymphocytic type																						
CECUM		-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	
COCCYGEAL VERTEBRAE		-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type				P																		
COLON		-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	
Colitis, acute, focal																						
DUODENUM		-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	
Hemorrhage, multifocal																3						
EYES		-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	
GALL BLADDER		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	
HARDERIAN GLAND		-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	
Adenoma, solitary															P							

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1018	81-1019*	81-1020	81-1021	81-1022*	81-1023*	81-1024	81-1025	81-1026	81-1027	81-1028	81-1029*	81-1031	81-1032	81-1035*	81-1036	81-1037	81-1039*	81-1040	81-1041	Incidence
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
ADRENALS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	
Pheochromocytoma, solitary																P						
AXILLARY LYMPH NODE		-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type			P																			
CECUM		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
COCCYGEAL VERTEBRAE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
COLON		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Colitis, acute, focal																						
DUODENUM		-	-	N	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Hemorrhage, multifocal																						
EYES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
GALL BLADDER		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
HARDERIAN GLAND		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Adenoma, solitary																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1042	81-1043	81-1044	81-1045*																	Incidence
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
ADRENALS		-	-	-	-																	(2)
Pheochromocytoma, solitary																						2/2
AXILLARY LYMPH NODE		-	-	-	-																	(2)
Malignant Lymphoma, mixed type																						1/2
Malignant Lymphoma, lymphocytic type																						1/2
CECUM		-	-	-	-																	(1)
COCCYGEAL VERTEBRAE		-	-	-	-																	(1)
Malignant Lymphoma, mixed type																						1/1
COLON		-	-	-	-																	(2)
Colitis, acute, focal																						1/2
DUODENUM		-	-	-	-																	(2)
Hemorrhage, multifocal																						1/2
EYES		-	-	-	-																	(1)
GALL BLADDER		-	-	-	N																	(2)
HARDERIAN GLAND		-	-	-	-																	(1)
Adenoma, solitary																						1/1

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0972*	81-0973	81-0974	81-0975	81-0976	81-0977	81-0978	81-0980	81-0981*	81-0982*	81-0983	81-0985	81-0986	81-0987	81-0988*	81-0989	81-0990	81-0991*	81-0992*	81-0993*	Incidence
ILEUM		-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, histiocytic type										P												
Congestion, diffuse																						
INTERCOSTAL MUSCLES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
JEJUNUM		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Congestion, diffuse																						
LUMBAR LYMPH NODE		L	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	L	-	-	
Malignant Lymphoma, mixed type																P			P			
Malignant Lymphoma, lymphocytic type																						
Leukemia, myeloid																						
Hyperplasia, lymphoid, diffuse		3																				
LUNGS		N	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	L	N	
Alveolar/bronchiolar carcinoma, multifocal																						
Alveolar/bronchiolar carcinoma,solitary																						
Malignant Lymphoma, mixed type																P						
Malignant Lymphoma, lymphocytic type																						
Hemangiosarcoma, metastatic																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0994	81-0995	81-0996*	81-0998*	81-0999	81-1000	81-1001*	81-1003	81-1004	81-1005*	81-1006	81-1007*	81-1008	81-1010	81-1012*	81-1013	81-1014	81-1015	81-1016	81-1017*	Incidence
ILEUM		-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	
Malignant Lymphoma, histiocytic type																						
Congestion, diffuse																2						
INTERCOSTAL MUSCLES		-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type				P																		
JEJUNUM		-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	
Congestion, diffuse																2						
LUMBAR LYMPH NODE		-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type				P																		
Malignant Lymphoma, lymphocytic type																						
Leukemia, myeloid																						
Hyperplasia, lymphoid, diffuse																						
LUNGS		-	-	L	L	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	L	
Alveolar/bronchiolar carcinoma,																						
multifocal					P																	
Alveolar/bronchiolar carcinoma,solitary																						
Malignant Lymphoma, mixed type				P																		
Malignant Lymphoma, lymphocytic type																P						
Hemangiosarcoma, metastatic																					P	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1018	81-1019	81-1020	81-1021	81-1022*	81-1023*	81-1024	81-1025	81-1026	81-1027	81-1028	81-1029*	81-1031	81-1032	81-1035*	81-1036	81-1037	81-1039*	81-1040	81-1041	Incidence
ILEUM		-	-	N	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, histiocytic type																						
Congestion, diffuse																						
INTERCOSTAL MUSCLES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
JEJUNUM		-	-	N	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Congestion, diffuse																						
LUMBAR LYMPH NODE		-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type			P																			
Leukemia, myeloid																			P			
Hyperplasia, lymphoid, diffuse																						
LUNGS		-	L	-	-	-	L	-	-	-	-	-	L	-	-	-	-	-	-	-	-	
Alveolar/bronchiolar carcinoma, multifocal																						
Alveolar/bronchiolar carcinoma,solitary							P															
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type			P										P									
Hemangiosarcoma, metastatic																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1042	81-1043	81-1044	81-1045*																	Incidence
ILEUM		-	-	-	-																	(3)
Malignant Lymphoma, histiocytic type																						1/3
Congestion, diffuse																						1/3
INTERCOSTAL MUSCLES		-	-	-	-																	(1)
Malignant Lymphoma, mixed type																						1/1
JEJUNUM		-	-	-	-																	(2)
Congestion, diffuse																						1/2
LUMBAR LYMPH NODE		-	-	-	-																	(6)
Malignant Lymphoma, mixed type																						3/6
Malignant Lymphoma, lymphocytic type																						1/6
Leukemia, myeloid																						1/6
Hyperplasia, lymphoid, diffuse																						1/6
LUNGS		-	-	-	-																	(11)
Alveolar/bronchiolar carcinoma, multifocal																						1/11
Alveolar/bronchiolar carcinoma,solitary																						1/11
Malignant Lymphoma, mixed type																						2/11
Malignant Lymphoma, lymphocytic type																						3/11
Hemangiosarcoma, metastatic																						1/11

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0972*	81-0973	81-0974	81-0975	81-0976	81-0977	81-0978	81-0980	81-0981*	81-0982*	81-0983	81-0985	81-0986	81-0987	81-0988*	81-0989	81-0990	81-0991*	81-0992*	81-0993*	Incidence
LUNGS (Con't.)		N	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	L	N	
Fibrosarcoma, metastatic																				P		
Histiocytosis, diffuse																						
Congestion, diffuse																						
MAMMARY GLAND		-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-	
Adenocarcinoma, solitary																						
MANDIBULAR LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
MESENTERIC FAT		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	
Steatitis, chronic, focal																						
Hematoma, solitary																	2					
MESENTERIC LYMPH NODE		-	-	-	-	-	-	N	-	L	M	-	-	-	-	L	-	-	-	-	L	
Malignant Lymphoma, mixed type																P						
Malignant Lymphoma, lymphocytic type																						
Malignant Lymphoma, histiocytic type										P											P	
Hyperplasia, reticulum-cell, diffuse																						
MESENTERY		-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	FEMALE MICE																		Incidence
		81-0994	81-0995	81-0996*	81-0998*	81-0999	81-1000	81-1001*	81-1003	81-1004	81-1005*	81-1006	81-1007*	81-1008	81-1010	81-1012*	81-1013	81-1014	81-1015	81-1016	81-1017*	
LUNGS (Con't.)		-	-	L	L	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	L	
Fibrosarcoma, metastatic																						
Histiocytosis, diffuse																						
Congestion, diffuse																4						
MAMMARY GLAND		-	N	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	
Adenocarcinoma, solitary																						
MANDIBULAR LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																P						
MESENTERIC FAT		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Steatitis, chronic, focal																						
Hematoma, solitary																						
MESENTERIC LYMPH NODE		-	-	-	-	-	L	-	-	-	L	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type											P											
Malignant Lymphoma, lymphocytic type							P															
Malignant Lymphoma, histiocytic type																						
Hyperplasia, reticulum-cell, diffuse																						
MESENTERY		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1018	81-1019*	81-1020	81-1021	81-1022*	81-1023*	81-1024	81-1025	81-1026	81-1027	81-1028	81-1029*	81-1031	81-1032	81-1035*	81-1036	81-1037	81-1039*	81-1040	81-1041	Incidence
LUNGS (Con't.)		-	L	-	-	-	L	-	-	-	-	-	L	-	-	-	-	-	-	-	-	
Fibrosarcoma, metastatic																						
Histiocytosis, diffuse							3															
Congestion, diffuse																						
MAMMARY GLAND		L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	
Adenocarcinoma, solitary		P																	P			
MANDIBULAR LYMPH NODE		-	L	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type								P														
Malignant Lymphoma, lymphocytic type			P																			
MESENTERIC FAT		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	
Steatitis, chronic, focal																				3		
Hematoma, solitary																						
MESENTERIC LYMPH NODE		-	L	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type			P																			
Malignant Lymphoma, histiocytic type																						
Hyperplasia, reticulum-cell, diffuse				3																		
MESENTERY		-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type		.											P									

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice

HISTOPATHOLOGY INCIDENCE TABLE

Dose (mg/kg/day): 35.0 mg/kg/day GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1042	81-1043	81-1044	81-1045*																Incidence
LUNGS (Con't.)		-	-	-	-																(11)
Fibrosarcoma, metastatic																					1/11
Histiocytosis, diffuse																					1/11
Congestion, diffuse																					1/11
MAMMARY GLAND		-	-	-	N																(6)
Adenocarcinoma, solitary																					2/6
MANDIBULAR LYMPH NODE		-	-	-	-																(3)
Malignant Lymphoma, mixed type																					1/3
Malignant Lymphoma, lymphocytic type																					2/3
MESENTERIC FAT		-	-	-	-																(2)
Steatitis, chronic, focal																					1/2
Hematoma, solitary																					1/2
MESENTERIC LYMPH NODE		-	-	-	-																(8)
Malignant Lymphoma, mixed type																					2/8
Malignant Lymphoma, lymphocytic type																					2/8
Malignant Lymphoma, histiocytic type																					2/8
Hyperplasia, reticulum-cell, diffuse																					1/8
MESENTERY		-	-	-	-																(2)
Malignant Lymphoma, lymphocytic type																					1/2

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0972*	81-0973	81-0974	81-0975	81-0976	81-0977	81-0978	81-0980	81-0981*	81-0982*	81-0983	81-0985	81-0986	81-0987	81-0988*	81-0989	81-0990	81-0991*	81-0992*	81-0993*	Incidence
MESENTERY (Con't.)		-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, histiocytic type										P												
PANCREAS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type																						
Acinar atrophy, diffuse																						
Dilated ducts, multifocal																						
PANCREATIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type																						
PARIETAL PLEURA		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	
Fibrosarcoma, metastatic																				P		
PAROVARIAN TISSUE		-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type							P															
PITUITARY		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Adenoma, solitary (Anterior)																						
Hyperplasia, focal (Anterior)																						
RENAL LYMPH NODE		-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type																						
Malignant Lymphoma, histiocytic type										P												

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0994	81-0995	81-0996*	81-0998*	81-0999	81-1000	81-1001*	81-1003	81-1004	81-1005*	81-1006	81-1007*	81-1008	81-1010	81-1012*	81-1013	81-1014	81-1015	81-1016	81-1017*	Incidence
MESENTERY (Con't.)		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, histiocytic type																						
PANCREAS		-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type																						
Acinar atrophy, diffuse			4																			
Dilated ducts, multifocal			4																			
PANCREATIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type																						
PARIETAL PLEURA		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Fibrosarcoma, metastatic																						
PAROVARIAN TISSUE		L	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type														P								
Malignant Lymphoma, lymphocytic type		P																				
PITUITARY		-	-	-	-	-	-	N	-	-	-	-	-	L	-	-	-	L	L	-	-	
Adenoma, solitary (Anterior)														P				P				
Hyperplasia, focal (Anterior)																			3			
RENAL LYMPH NODE		-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type							P															
Malignant Lymphoma, histiocytic type																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1018	81-1019*	81-1020	81-1021	81-1022*	81-1023*	81-1024	81-1025	81-1026	81-1027	81-1028	81-1029*	81-1031	81-1032	81-1035*	81-1036	81-1037	81-1039*	81-1040	81-1041	Incidence
MESENTERY (Con't.)		-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	
Malignant Lymphoma, histiocytic type																						
PANCREAS		-	N	N	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type													P									
Acinar atrophy, diffuse																						
Dilated ducts, multifocal																						
PANCREATIC LYMPH NODE		-	L	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type			P										P									
PARIETAL PLEURA		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Fibrosarcoma, metastatic																						
PAROVARIAN TISSUE		-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type						P																
PITUITARY		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Adenoma, solitary (Anterior)																						
Hyperplasia, focal (Anterior)																						
RENAL LYMPH NODE		-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type			P																			
Malignant Lymphoma, histiocytic type																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number 81-1042	81-1043	81-1044	81-1045*																	Incidence
MESENTERY (Con't.)	-	-	-	-																	(2)
Malignant Lymphoma, histiocytic type																					1/2
PANCREAS	-	-	-	-																	(4)
Malignant Lymphoma, lymphocytic type																					1/4
Acinar atrophy, diffuse																					1/4
Dilated ducts, multifocal																					1/4
PANCREATIC LYMPH NODE	-	-	-	-																	(2)
Malignant Lymphoma, lymphocytic type																					2/2
PARIETAL PLEURA	-	-	-	-																	(1)
Fibrosarcoma, metastatic																					1/1
PAROVARIAN TISSUE	-	-	-	-																	(4)
Malignant Lymphoma, mixed type																					1/4
Malignant Lymphoma, lymphocytic type																					3/4
PITUITARY	-	-	-	-																	(4)
Adenoma, solitary (Anterior)																					2/4
Hyperplasia, focal (Anterior)																					1/4
RENAL LYMPH NODE	-	-	-	-																	(3)
Malignant Lymphoma, lymphocytic type																					2/3
Malignant Lymphoma, histiocytic type																					1/3

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice

HISTOPATHOLOGY INCIDENCE TABLE

Dose (mg/kg/day): 35.0 mg/kg/day GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0972*	81-0973	81-0974	81-0975	81-0976	81-0977	81-0978	81-0980	81-0981*	81-0982*	81-0983	81-0985	81-0986	81-0987	81-0988*	81-0989	81-0990	81-0991*	81-0992*	81-0993*	Incidence
RESPIRATORY LYMPH NODE		-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
Malignant Lymphoma, histiocytic type										P												
SALIVARY GLAND		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type																						
SKELETAL MUSCLE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type																						
SKIN		-	-	-	-	L	L	-	-	L	-	L	L	L	L	-	-	-	-	-	-	
Dermatitis, chronic, diffuse						3	3			2		3		2	2							
Dermatitis, chronic, focal													3									
Follicular atrophy, diffuse																						
Follicular atrophy, focal																						
STOMACH		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
SUBCUTIS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	
Fibrosarcoma, multifocal																				P		
THORACIC CAVITY		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Alveolar/bronchiolar carcinoma, metastatic																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0994	81-0995	81-0996*	81-0998*	81-0999	81-1000	81-1001*	81-1003	81-1004	81-1005*	81-1006	81-1007*	81-1008	81-1010	81-1012*	81-1013	81-1014	81-1015	81-1016	81-1017*	Incidence
RESPIRATORY LYMPH NODE		-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type				P																		
Malignant Lymphoma, lymphocytic type																						
Malignant Lymphoma, histiocytic type																						
SALIVARY GLAND		-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type																P						
SKELETAL MUSCLE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type																						
SKIN		N	L	-	-	-	-	-	L	L	-	-	L	-	L	-	-	-	L	-	-	
Dermatitis, chronic, diffuse									2	3			3		2				2			
Dermatitis, chronic, focal																						
Follicular atrophy, diffuse																						
Follicular atrophy, focal			2																			
STOMACH		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
SUBCUTIS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Fibrosarcoma, multifocal																						
THORACIC CAVITY		-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Alveolar/bronchiolar carcinoma, metastatic					P																	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1018	81-1019*	81-1020	81-1021	81-1022*	81-1023*	81-1024	81-1025	81-1026	81-1027	81-1028	81-1029*	81-1031	81-1032	81-1035*	81-1036	81-1037	81-1039*	81-1040	81-1041	Incidence
RESPIRATORY LYMPH NODE		-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type			P																			
Malignant Lymphoma, histiocytic type																						
SALIVARY GLAND		-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type			P																			
SKELETAL MUSCLE		-	-	-	-	N	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type													P									
SKIN		-	-	-	-	-	-	-	-	-	L	-	L	-	-	-	-	L	L	-	L	
Dermatitis, chronic, diffuse											2		2						3		2	
Dermatitis, chronic, focal																						
Follicular atrophy, diffuse																		2				
Follicular atrophy, focal																						
STOMACH		-	-	-	-	-	N	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
SUBCUTIS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Fibrosarcoma, multifocal																						
THORACIC CAVITY		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Alveolar/bronchiolar carcinoma, metastatic																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice

HISTOPATHOLOGY INCIDENCE TABLE

Dose (mg/kg/day): 35.0 mg/kg/day GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1042	81-1043	81-1044	81-1045*	Incidence
RESPIRATORY LYMPH NODE		-	-	-	-	(3)
Malignant Lymphoma, mixed type						1/3
Malignant Lymphoma, lymphocytic type						1/3
Malignant Lymphoma, histiocytic type						1/3
SALIVARY GLAND		-	-	-	-	(2)
Malignant Lymphoma, lymphocytic type						2/2
SKELETAL MUSCLE		-	-	-	-	(2)
Malignant Lymphoma, lymphocytic type						1/2
SKIN		-	L	L	L	(22)
Dermatitis, chronic, diffuse			3	2	3	18/22
Dermatitis, chronic, focal						1/22
Follicular atrophy, diffuse						1/22
Follicular atrophy, focal						1/22
STOMACH		-	-	-	-	(1)
SUBCUTIS		-	-	-	-	(1)
Fibrosarcoma, multifocal						1/1
THORACIC CAVITY		-	-	-	-	(1)
Alveolar/bronchiolar carcinoma, metastatic						1/1

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0972*	81-0973	81-0974	81-0975	81-0976	81-0977	81-0978	81-0980	81-0981*	81-0982*	81-0983	81-0985	81-0986	81-0987	81-0988*	81-0989	81-0990	81-0991*	81-0992*	81-0993*	Incidence
THORACIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
THYMUS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	L	L	
Malignant Lymphoma, mixed type																P						
Malignant Lymphoma, lymphocytic type																						
Malignant Lymphoma, histiocytic type																					P	
Fibrosarcoma, metastatic																				P		
UTERUS		L	L	-	L	L	L	L	L	L	-	L	L	L	L	-	L	L	L	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
Hemangioma, solitary																						
Hematoma, solitary																						
Hyperplasia, cystic, glandular, diffuse		4	4		4	4	2	4	2	2		4	3	3	4		4	4	3			
Endometritis, acute, diffuse														3								
Mineralization, multifocal																						
VAGINA		N	-	-	-	-	N	-	-	L	-	-	N	-	-	-	-	N	N	-	-	
Malignant Lymphoma, histiocytic type										P												

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion / Accession Number	81-0994	81-0995	81-0996*	81-0998*	81-0999	81-1000	81-1001*	81-1003	81-1004	81-1005*	81-1006	81-1007*	81-1008	81-1010	81-1012*	81-1013	81-1014	81-1015	81-1016	81-1017*	Incidence
THORACIC LYMPH NODE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	
THYMUS	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type			P																		
Malignant Lymphoma, lymphocytic type																					
Malignant Lymphoma, histiocytic type																					
Fibrosarcoma, metastatic																					
UTERUS	L	L	L	L	L	-	L	L	L	L	L	L	L	L	L	L	L	L	-	-	
Malignant Lymphoma, mixed type			P							P											
Malignant Lymphoma, lymphocytic type															P						
Hemangioma, solitary																					
Hematoma, solitary					4																
Hyperplasia, cystic, glandular, diffuse	2	3	3	3	4		2	2	4		4	2	3	3		4	3	4			
Endometritis, acute, diffuse																					
Mineralization, multifocal	3																				
VAGINA	N	N	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, histiocytic type																					

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1018	81-1019*	81-1020	81-1021	81-1022*	81-1023*	81-1024	81-1025	81-1026	81-1027	81-1028	81-1029*	81-1031	81-1032	81-1035*	81-1036	81-1037	81-1039*	81-1040	81-1041	Incidence
THORACIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
THYMUS		-	L	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type			P			P																
Malignant Lymphoma, histiocytic type																						
Fibrosarcoma, metastatic																						
UTERUS		L	-	-	-	L	-	-	L	L	L	L	L	L	L	-	L	L	L	L	L	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
Hemangioma, solitary										P												
Hematoma, solitary																						
Hyperplasia, cystic, glandular, diffuse		4				3			4	4	4	3	4	3	4		4	4	3	4	4	
Endometritis, acute, diffuse																						
Mineralization, multifocal																						
VAGINA		-	-	-	-	N	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, histiocytic type																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1042	81-1043	81-1044	81-1045*																Incidence
THORACIC LYMPH NODE		-	-	-	-																(1)
THYMUS		-	-	-	-																(6)
Malignant Lymphoma, mixed type																					2/6
Malignant Lymphoma, lymphocytic type																					2/6
Malignant Lymphoma, histiocytic type																					1/6
Fibrosarcoma, metastatic																					1/6
UTERUS		L	L	L	L																(50)
Malignant Lymphoma, mixed type																					2/50
Malignant Lymphoma, lymphocytic type																					1/50
Hemangioma, solitary																					1/50
Hematoma, solitary																					1/50
Hyperplasia, cystic, glandular, diffuse		3	3	4	2																48/50
Endometritis, acute, diffuse																					1/50
Mineralization, multifocal																					1/50
VAGINA		N	N	-	-																(12)
Malignant Lymphoma, histiocytic type																					1/12

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1122	81-1124	81-1127*	81-1128	81-1129	81-1130	81-1135	81-1136*	81-1137	81-1138	81-1139	81-1140	81-1145	81-1146	81-1147*	81-1151	81-1152	81-1169	81-1171	81-1172*	Incidence
BRAIN		N	L	N	N	N	L	L	L	N	N	N	N	L	N	N	N	N	N	N	N	
Malignant Lymphoma, mixed type														P								
Meningoencephalitis, acute, multifocal									3													
Corpora amylacea, multifocal			2				1	1														
SPINAL CORD		N	N	N	N	N	N	N	L	N	N	N	N	L	N	N	N	N	N	N	N	
Malignant Lymphoma, mixed type(Meninges)														P								
Meningitis, acute, multifocal									3													
EYES		N	N	N	L	L	N	N	N	N	N	N	N	N	L	N	N	L	N	N	L	
Phthisis bulbi, unilateral						4												4				
Keratitis, chronic, active, diffuse, unilateral																					4	
Cataract, subcapsular, bilateral																						
Cataract, subcapsular, unilateral					2	2									3							
OPTIC NERVES		N	N	N	N	N	N	N	L	N	N	N	N	N	N	N	N	M	N	N	N	
Perineuritis, acute, diffuse, bilateral									3													
ADRENALS		N	N	N	N	N	N	N	L	N	N	N	N	N	N	N	N	L	N	N	N	
Pheochromocytoma, solitary									P									P				
Hyperplasia, cortical, focal																						
Hyperplasia, medullary, focal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number 81-1176	81-1177	81-1178	81-1179	81-1180	81-1183*	81-1185	81-1186	81-1189	81-1193*	81-1194	Incidence
BRAIN	N	N	N	L	L	L	L	L	N	N	L	(31)
Malignant Lymphoma, mixed type												1/31
Meningoencephalitis, acute, multifocal												1/31
Corpora amylacea, multifocal				2	1	2	2	2			2	9/31
SPINAL CORD	N	N	N	N	N	N	N	N	N	N	N	(31)
Malignant Lymphoma, mixed type(Meninges)												1/31
Meningitis, acute, multifocal												1/31
EYES	N	N	N	N	N	N	L	N	N	N	L	(31)
Phthisis bulbi, unilateral												2/31
Keratitis, chronic, active, diffuse, unilateral												1/31
Cataract, subcapsular, bilateral							1					1/31
Cataract, subcapsular, unilateral											2	4/31
OPTIC NERVES	N	N	N	M	N	N	N	N	N	N	M	(28)
Perineuritis, acute, diffuse, bilateral												1/28
ADRENALS	L	N	N	N	N	N	N	N	L	N	N	(31)
Pheochromocytoma, solitary												2/31
Hyperplasia, cortical, focal	2											1/31
Hyperplasia, medullary, focal									2			1/31

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1122	81-1124	81-1127*	81-1128	81-1129	81-1130	81-1135	81-1136*	81-1137	81-1138	81-1139	81-1140	81-1145	81-1146	81-1147*	81-1151	81-1152	81-1169	81-1171	81-1172*	Incidence
SPLEEN		L	L	L	L	L	L	N	N	L	L	L	L	L	N	L	L	L	L	L	N	
Hemangiosarcoma, multifocal				P																		
Hemangiosarcoma, solitary																						
Malignant Lymphoma, mixed type		P			P		P							P		P				P		
Malignant Lymphoma, lymphocytic type			P																			
Hyperplasia, lymphoid, diffuse										2	2	2					2	2	2			
Hematopoiesis, extramedullary, diffuse						2							2									
PANCREAS		N	N	N	N	N	L	N	N	N	N	N	N	L	N	L	N	N	L	N	N	
Malignant Lymphoma, mixed type														P		P						
Cystic duct																			3			
Acinar atrophy, diffuse							3															
MESENTERIC LYMPH NODE		M	N	N	L	L	M	L	N	L	L	N	L	L	N	L	N	L	L	L	M	
Hemangiosarcoma, solitary																						
Malignant Lymphoma, mixed type					P						P			P		P				P		
Hyperplasia, lymphoid, diffuse						2		2		2			2					2	2			
OVARIES		N	N	L	N	N	N	N	N	L	N	N	N	L	N	L	L	N	N	L	N	
Malignant Lymphoma, mixed type														P		P						
Cystadenoma, solitary																						
Hemorrhagic cyst, solitary																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1176	81-1177	81-1178	81-1179	81-1180	81-1183*	81-1185	81-1186	81-1189	81-1193*	81-1194									Incidence
SPLEEN		N	L	L	L	L	N	N	N	N	L	L									(31)
Hemangiosarcoma, multifocal																					1/31
Hemangiosarcoma, solitary						P															1/31
Malignant Lymphoma, mixed type				P	P						P										9/31
Malignant Lymphoma, lymphocytic type												P									2/31
Hyperplasia, lymphoid, diffuse			2																		7/31
Hematopoiesis, extramedullary, diffuse																					2/31
PANCREAS		N	N	N	L	N	N	N	N	N	N	N									(31)
Malignant Lymphoma, mixed type					P																3/31
Cystic duct																					1/31
Acinar atrophy, diffuse																					1/31
MESENTERIC LYMPH NODE		N	L	L	L	N	M	N	N	N	L	M									(26)
Hemangiosarcoma, solitary											P										1/26
Malignant Lymphoma, mixed type				P	P						P										8/26
Hyperplasia, lymphoid, diffuse			2																		7/26
OVARIES		L	N	L	N	N	N	N	N	L	N	N									(31)
Malignant Lymphoma, mixed type																					2/31
Cystadenoma, solitary										P											1/31
Hemorrhagic cyst, solitary				4																	1/31

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1122	81-1124	81-1127*	81-1128	81-1129	81-1130	81-1135	81-1136*	81-1137	81-1138	81-1139	81-1140	81-1145	81-1146	81-1147*	81-1151	81-1152	81-1169	81-1171	81-1172*	Incidence
OVARIES (Con't.)		N	N	L	N	N	N	N	N	L	N	N	N	L	N	L	L	N	N	L	N	
Parovarian cysts, multiple, bilateral																						
Parovarian cysts, multiple, unilateral																				2		
Parovarian cyst, solitary																						
Follicular cyst, solitary				3						2							2					
UTERUS		L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	
Endometrial Stromal Sarcoma, solitary									P													
Malignant Lymphoma, mixed type														P								
Squamous metaplasia, multifocal																		4				
Endometrial Stromal Polyp, multifocal																						
Granulomata, multiple (Serosa)																				4		
Hyperplasia, cystic, glandular, diffuse		4	3	3	4	4	3	2		3	4	4	4	4	4	4	3	3	4	4		
Endometritis, acute, diffuse																					2	
Endometritis, acute, multifocal																1						
Hemorrhage, focal																		4				
Hydrometra, diffuse																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1176	81-1177	81-1178	81-1179	81-1180	81-1183*	81-1185	81-1186	81-1189	81-1193*	81-1194	Incidence
OVARIES (Con't.)		L	N	L	N	N	N	N	N	L	N	N	(31)
Parovarian cysts, multiple, bilateral										3			1/31
Parovarian cysts, multiple, unilateral													1/31
Parovarian cyst, solitary		2											1/31
Follicular cyst, solitary													3/31
UTERUS		L	L	L	L	L	L	L	L	L	L	L	(31)
Endometrial Stromal Sarcoma, solitary													1/31
Malignant Lymphoma, mixed type													1/31
Squamous metaplasia, multifocal									3				2/31
Endometrial Stromal Polyp, multifocal									P				1/31
Granulomata, multiple (Serosa)													1/31
Hyperplasia, cystic, glandular, diffuse		3	4	4	4	4	3	4		3	1	4	28/31
Endometritis, acute, diffuse									4				2/31
Endometritis, acute, multifocal						1		2					3/31
Hemorrhage, focal													1/31
Hydrometra, diffuse								2					1/31

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion / Accession Number	81-1122	81-1124	81-1127*	81-1128	81-1129	81-1130	81-1135	81-1136*	81-1137	81-1138	81-1139	81-1140	81-1145	81-1146	81-1147*	81-1151	81-1152	81-1169	81-1171	81-1172*	Incidence
URINARY BLADDER	L	L	N	N	N	N	N	N	N	N	N	N	L	N	L	N	N	N	L	L	
Malignant Lymphoma, mixed type	P												P		P				P		
Malignant Lymphoma, lymphocytic type		P																			
Cystitis, chronic, active, diffuse																				4	
LUNGS	L	L	L	N	N	N	L	L	N	L	N	L	L	N	L	N	N	N	L	L	
Alveolar/bronchiolar carcinoma, multifocal																					
Alveolar/bronchiolar carcinoma, solitary										P		P									
Malignant Lymphoma, mixed type	P												P		P				P		
Malignant Lymphoma, lymphocytic type		P																			
Leukemia, myeloid							P														
Alveolar/bronchiolar adenoma, solitary			P												P						
Histiocytosis, multifocal	2		2					2		2									1		
Hemorrhage, multifocal								2													
Congestion, multifocal																				3	
ESOPHAGUS	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
TRACHEA	N	N	N	N	N	L	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Hemorrhage, focal						2															

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1176	81-1177	81-1178	81-1179	81-1180	81-1183*	81-1185	81-1186	81-1189	81-1193*	81-1194	Incidence
URINARY BLADDER		N	N	L	N	N	N	N	N	N	N	L	(31)
Malignant Lymphoma, mixed type				P									5/31
Malignant Lymphoma, lymphocytic type												P	2/31
Cystitis, chronic, active, diffuse													1/31
LUNGS		L	L	L	L	L	N	N	L	N	L	N	(31)
Alveolar/bronchiolar carcinoma,													
multifocal						P							1/31
Alveolar/bronchiolar carcinoma,													
solitary									P				3/31
Malignant Lymphoma, mixed type				P	P						P		7/31
Malignant Lymphoma, lymphocytic type													1/31
Leukemia, myeloid													1/31
Alveolar/bronchiolar adenoma, solitary			P										3/31
Histiocytosis, multifocal		1				2			2		1		9/31
Hemorrhage, multifocal													1/31
Congestion, multifocal													1/31
ESOPHAGUS		N	N	N	N	N	N	N	N	N	N	N	(31)
TRACHEA		N	N	N	N	N	N	N	N	N	N	N	(31)
Hemorrhage, focal													1/31

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1122	81-1124	81-1127*	81-1128	81-1129	81-1130	81-1135	81-1136*	81-1137	81-1138	81-1139	81-1140	81-1145	81-1146	81-1147*	81-1151	81-1152	81-1169	81-1171	81-1172*	Incidence
THYROIDS		N	N	N	N	N	N	N	N	N	N	N	N	L	N	N	L	N	N	N	N	
Follicular carcinoma, multifocal																	P					
Malignant Lymphoma, mixed type														P								
Follicular hyperplasia, focal																						
Abscess, solitary																						
PARATHYROIDS		N	N	M	M	M	N	N	M	M	N	M	N	N	M	N	N	N	N	N	M	
HEART		N	N	N	N	N	N	L	N	N	N	N	N	L	N	N	N	N	N	N	N	
Malignant Lymphoma, mixed type														P								
Leukemia, myeloid								P														
Myocarditis, chronic, multifocal																						
Mineralization, multifocal																						
LIVER		L	N	L	N	N	N	L	N	L	N	L	N	L	N	L	L	L	N	L	L	
Hepatocellular carcinoma, solitary														P			P					
Malignant Lymphoma, mixed type														P		P						
Leukemia, myeloid								P														
Hemangiosarcoma, metastatic				P																		
Hepatocellular adenoma, solitary		P																P				
Hemangioma, solitary																				P		

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1176	81-1177	81-1178	81-1179	81-1180	81-1183*	81-1185	81-1186	81-1189	81-1193*	81-1194	Incidence
THYROIDS		N	N	L	N	N	N	N	N	N	L	N	(31)
Follicular carcinoma, multifocal													1/31
Malignant Lymphoma, mixed type													1/31
Follicular hyperplasia, focal											2		1/31
Abscess, solitary				2									1/31
PARATHYROIDS		N	M	N	N	M	N	N	N	N	N	M	(20)
HEART		N	N	N	L	N	L	N	N	N	N	N	(31)
Malignant Lymphoma, mixed type													1/31
Leukemia, myeloid							P						2/31
Myocarditis, chronic, multifocal					2								1/31
Mineralization, multifocal					2								1/31
LIVER		N	N	L	L	L	L	N	N	L	N	N	(31)
Hepatocellular carcinoma, solitary						P							3/31
Malignant Lymphoma, mixed type				P	P								4/31
Leukemia, myeloid							P						2/31
Hemangiosarcoma, metastatic													1/31
Hepatocellular adenoma, solitary										P			3/31
Hemangioma, solitary													1/31

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice

HISTOPATHOLOGY INCIDENCE TABLE

Dose (mg/kg/day): 175/100 mg/kg/day GROUP V

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1122	81-1124	81-1127*	81-1128	81-1129	81-1130	81-1135	81-1136*	81-1137	81-1138	81-1139	81-1140	81-1145	81-1146	81-1147*	81-1151	81-1152	81-1169	81-1171	81-1172*	Incidence
LIVER (Con't.)		L	N	L	N	N	N	L	N	L	N	L	N	L	N	L	L	L	N	L	L	
Hepatitis, periportal, chronic, active,																						
multifocal				3																		
Fatty change, diffuse																					1	
Hematopoiesis,extramedullary,multifocal										1		1						1				
Necrosis, focal				2																		
KIDNEYS		N	L	N	L	N	L	L	L	L	L	L	L	L	L	L	N	L	N	L	L	
Malignant Lymphoma, mixed type					P		P				P			P								
Malignant Lymphoma, lymphocytic type			P																			
Leukemia, myeloid								P														
Hyperplasia, tubular, multifocal			2							1	2		2		2	2		2		2		
Pyelonephritis, acute, diffuse																					4	
Infarct, healed, solitary											2											
Nephropathy, chronic, multifocal							2															
Necrosis, tubular, multifocal															2					2		
Nephrocalcinosis, multifocal												1										
Hydronephrosis, bilateral																					4	
Hydronephrosis, focal									4													

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1176	81-1177	81-1178	81-1179	81-1180	81-1183*	81-1185	81-1186	81-1189	81-1193*	81-1194	Incidence
LIVER (Con't.)		N	N	L	L	L	L	N	N	L	N	N	(31)
Hepatitis, periportal, chronic, active,													
multifocal													1/31
Fatty change, diffuse													1/31
Hematopoiesis, extramedullary, multifocal													3/31
Necrosis, focal													1/31
KIDNEYS		L	L	L	L	L	N	L	L	L	L	L	(31)
Malignant Lymphoma, mixed type				P	P						P		7/31
Malignant Lymphoma, lymphocytic type													1/31
Leukemia, myeloid													1/31
Hyperplasia, tubular, multifocal		1			2	2			1	2		2	14/31
Pyelonephritis, acute, diffuse													1/31
Infarct, healed, solitary													1/31
Nephropathy, chronic, multifocal			2	2				1					4/31
Necrosis, tubular, multifocal													2/31
Nephrocalcinosis, multifocal					2	2				1		1	5/31
Hydronephrosis, bilateral													1/31
Hydronephrosis, focal													1/31

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion / Accession Number	81-1122	81-1124	81-1127*	81-1128	81-1129	81-1130	81-1135	81-1136*	81-1137	81-1138	81-1139	81-1140	81-1145	81-1146	81-1147*	81-1151	81-1152	81-1169	81-1171	81-1172*	Incidence
KIDNEYS (Con't.)	N	L	N	L	N	L	L	L	L	L	L	L	L	L	L	N	L	N	L	L	
Cytoplasmic vacuolization, diffuse,																					
(Tubules)		1																			
Dilatation, diffuse (Tubules)															3						
Amyloidosis, diffuse (Glomerular)															3						
STOMACH	L	N	N	N	N	L	N	L	N	N	L	N	N	N	N	N	L	N	N	N	
Malignant Lymphoma, mixed type						P															
Gastritis, acute, focal																					
Gastritis, chronic, active, focal,																					
(Forestomach)											3										
Lymphocytosis, multifocal (Glandular)								2													
Mineralization, focal (Glandular)	2																2				
DUODENUM	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
JEJUNUM	N	N	N	N	L	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, mixed type					P																
ILEUM	N	L	N	N	L	N	N	N	N	N	N	N	N	N	N	N	N	N	L	N	
Malignant Lymphoma, mixed type					P														P		
Malignant Lymphoma, lymphocytic type		P																			

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1176	81-1177	81-1178	81-1179	81-1180	81-1183*	81-1185	81-1186	81-1189	81-1193*	81-1194	Incidence
KIDNEYS (Con't.)		L	L	L	L	L	N	L	L	L	L	L	(31)
Cytoplasmic vacuolization, diffuse,													
(Tubules)				2						2	2		4/31
Dilatation, diffuse (Tubules)													1/31
Amyloidosis, diffuse (Glomerular)													1/31
STOMACH		N	N	L	L	N	N	N	N	N	N	L	(31)
Malignant Lymphoma, mixed type				P	P								3/31
Gastritis, acute, focal												2	1/31
Gastritis, chronic, active, focal,													
(Forestomach)													1/31
Lymphocytosis, multifocal (Glandular)													1/31
Mineralization, focal (Glandular)													2/31
DUODENUM		N	N	N	N	N	N	N	N	N	N	N	(31)
JEJUNUM		N	N	N	N	N	N	N	N	N	N	N	(31)
Malignant Lymphoma, mixed type													1/31
ILEUM		N	N	N	N	N	N	N	N	N	N	N	(31)
Malignant Lymphoma, mixed type													2/31
Malignant Lymphoma, lymphocytic type													1/31

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice

HISTOPATHOLOGY INCIDENCE TABLE

Dose (mg/kg/day): 175/100 mg/kg/day GROUP V

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1122	81-1124	81-1127*	81-1128	81-1129	81-1130	81-1135	81-1136*	81-1137	81-1138	81-1139	81-1140	81-1145	81-1146	81-1147*	81-1151	81-1152	81-1169	81-1171	81-1172*	Incidence
CECUM		N	N	N	N	L	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, mixed type						P																
COLON		L	L	N	L	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Leiomyosarcoma, solitary		P																				
Malignant Lymphoma, mixed type					P																	
Malignant Lymphoma, lymphocytic type			P																			
RECTUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	L	N	N	N	N	N	
Malignant Lymphoma, mixed type																P						
SKIN		L	N	N	L	L	N	N	L	N	N	N	L	L	N	N	N	N	N	N	N	
Melanoma, solitary													P									
Keratoacanthoma, solitary						P																
Dermatitis, chronic, diffuse					2				3				2	3								
Dermatitis, chronic, multifocal																						
Dermatitis, chronic, focal		2																				
MAMMARY GLAND		N	N	L	N	N	N	L	N	N	L	N	N	N	N	L	M	N	N	N	M	
Adenocarcinoma, solitary								P														
Malignant Lymphoma, mixed type																P						
Adenoma, solitary				P																		
Hyperplasia, cystic, diffuse											2											

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

* Died on Study or Moribund Sacrifice

FEMALE MICE

ORGAN Lesion	Accession Number	81-1176	81-1177	81-1178	81-1179	81-1180	81-1183*	81-1185	81-1186	81-1189	81-1193*	81-1194	Incidence
CECUM		N	N	N	N	N	N	N	N	N	N	N	(31)
Malignant Lymphoma, mixed type													1/31
COLON		N	N	N	N	N	N	N	N	N	N	L	(31)
Leiomyosarcoma, solitary													1/31
Malignant Lymphoma, mixed type													1/31
Malignant Lymphoma, lymphocytic type												P	2/31
RECTUM		N	N	N	N	N	N	N	N	N	N	N	(31)
Malignant Lymphoma, mixed type													1/31
SKIN		N	L	N	N	N	L	L	N	L	N	N	(31)
Melanoma, solitary													1/31
Keratoacanthoma, solitary													1/31
Dermatitis, chronic, diffuse			2				3	3		1			8/31
Dermatitis, chronic, multifocal										2			1/31
Dermatitis, chronic, focal													1/31
MAMMARY GLAND		L	N	N	M	N	M	N	N	N	N	L	(27)
Adenocarcinoma, solitary													1/27
Malignant Lymphoma, mixed type													1/27
Adenoma, solitary													1/27
Hyperplasia, cystic, diffuse		2										2	3/27

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1122	81-1124	81-1127*	81-1128	81-1129	81-1130	81-1135	81-1136*	81-1137	81-1138	81-1139	81-1140	81-1145	81-1146	81-1147*	81-1151	81-1152	81-1169	81-1171	81-1172*	Incidence
STERNUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
BONE MARROW		L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	
Malignant Lymphoma, mixed type														P								
Hyperplasia, myeloid, diffuse		2	3	2	2	2	2	3	3	1	2	2	2				2	2	2		2	
Myelofibrosis, multifocal		3	3	3	3	3	2	2	3	4	3	2	2		3	3	2	3	4	3	3	
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
GALL BLADDER		-	-	N	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	
HARDERIAN GLAND		-	-	-	-	-	-	-	-	-	L	-	-	-	-	L	-	-	-	-	-	
Adenoma, solitary											P											
Adenitis, chronic, diffuse																4						
INTERCOSTAL MUSCLES		-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	
Myositis, acute, diffuse									4													
LUMBAR LYMPH NODE		-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Hyperplasia, lymphoid, diffuse									3													

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1176	81-1177	81-1178	81-1179	81-1180	81-1183*	81-1185	81-1186	81-1189	81-1193*	81-1194	Incidence
STERNUM		N	N	N	N	N	N	N	N	N	N	N	(31)
BONE MARROW		L	L	L	L	L	N	L	L	L	L	L	(31)
Malignant Lymphoma, mixed type													1/31
Hyperplasia, myeloid, diffuse		2	2	2	2	1		2	2		2	2	25/31
Myelofibrosis, multifocal		4	2	3	3	3		2	3	2	4	3	29/31
LESIONS (TISSUES NOT SPECIFICALLY													
REQUIRED BY PROTOCOL)													
GALL BLADDER		-	-	-	-	-	-	-	-	-	-	-	(2)
HARDERIAN GLAND		-	-	-	-	-	-	-	-	-	-	L	(3)
Adenoma, solitary												P	2/3
Adenitis, chronic, diffuse													1/3
INTERCOSTAL MUSCLES		-	-	-	-	-	-	-	-	-	-	-	(1)
Myositis, acute, diffuse													1/1
LUMBAR LYMPH NODE		-	-	L	L	-	N	-	-	-	-	-	(4)
Malignant Lymphoma, mixed type				P	P								2/4
Hyperplasia, lymphoid, diffuse													1/4

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number: 81-1122	81-1124	81-1127*	81-1128	81-1129	81-1130	81-1135	81-1136*	81-1137	81-1138	81-1139	81-1140	81-1145	81-1146	81-1147*	81-1151	81-1152	81-1169	81-1171	81-1172*	Incidence
MANDIBULAR LYMPH NODE	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type						P															
PAROVARIAN TISSUE	L	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	
Malignant Lymphoma, mixed type	P																		P		
Malignant Lymphoma, lymphocytic type		P																			
PERIRENAL FAT	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Steatitis, chronic, focal						3															
RENAL LYMPH NODE	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																					
Hyperplasia, lymphoid, diffuse								3													
RESPIRATORY LYMPH NODE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																					
SALIVARY GLAND	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
SUBCUTANEOUS LYMPH NODE	-	-	-	-	-	-	-	-	-	-	L	L	L	-	-	-	-	-	L	-	
Malignant Lymphoma, mixed type													P						P		
Hyperplasia, lymphoid, diffuse											2	2									

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1176	81-1177	81-1178	81-1179	81-1180	81-1183*	81-1185	81-1186	81-1189	81-1193*	81-1194	Incidence
MANDIBULAR LYMPH NODE		-	-	L	-	-	-	-	-	-	-	-	(2)
Malignant Lymphoma, mixed type				P									2/2
PAROVARIAN TISSUE		-	-	-	-	-	-	-	-	-	L	L	(5)
Malignant Lymphoma, mixed type											P		3/5
Malignant Lymphoma, lymphocytic type												P	2/5
PERIRENAL FAT		-	-	-	-	-	-	-	-	-	-	-	(1)
Steatitis, chronic, focal													1/1
RENAL LYMPH NODE		-	-	L	-	-	-	-	-	-	-	-	(2)
Malignant Lymphoma, mixed type				P									1/2
Hyperplasia, lymphoid, diffuse													1/2
RESPIRATORY LYMPH NODE		-	-	L	-	-	-	-	-	-	-	-	(1)
Malignant Lymphoma, mixed type				P									1/1
SALIVARY GLAND		-	-	N	-	-	-	-	-	-	-	-	(2)
SUBCUTANEOUS LYMPH NODE		-	-	L	-	-	-	-	-	-	-	-	(5)
Malignant Lymphoma, mixed type				P									3/5
Hyperplasia, lymphoid, diffuse													2/5

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1122	81-1124	81-1127*	81-1128	81-1129	81-1130	81-1135	81-1136*	81-1137	81-1138	81-1139	81-1140	81-1145	81-1146	81-1147*	81-1151	81-1152	81-1169	81-1171	81-1172*	Incidence
SUBCUTIS		-	-	L	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type							P															
Hemangiosarcoma, metastatic				P																		
Hemangioma, solitary																						
THORACIC LYMPH NODE		-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Lymphadenitis, acute, diffuse							3															
THYMUS		-	-	-	-	-	L	-	-	-	-	-	-	-	N	-	N	-	-	L	-	
Malignant Lymphoma, mixed type							P													P		
VAGINA		N	N	N	N	N	N	N	N	N	N	N	N	L	N	N	N	N	-	N	N	
Malignant Lymphoma, mixed type														P								

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

FEMALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1176	81-1177	81-1178	81-1179	81-1180	81-1183*	81-1185	81-1186	81-1189	81-1193*	81-1194	Incidence
SUBCUTIS		-	-	-	-	-	-	L	-	-	-	-	(3)
Malignant Lymphoma, mixed type													1/3
Hemangiosarcoma, metastatic													1/3
Hemangioma, solitary								P					1/3
THORACIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	(1)
Lymphadenitis, acute, diffuse													1/1
THYMUS		-	-	-	-	-	-	N	-	-	-	-	(5)
Malignant Lymphoma, mixed type													2/5
VAGINA		N	N	N	N	N	N	N	N	N	N	N	(30)
Malignant Lymphoma, mixed type													1/30

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0447*	81-0448	81-0449*	81-0451*	81-0452	81-0453	81-0454	81-0455	81-0456	81-0457	81-0458	81-0459*	81-0462*	81-0463	81-0464*	81-0465*	81-0466*	81-0468	81-0469*	81-0470	Incidence
BRAIN		N	N	N	N	N	L	N	L	N	N	N	N	N	N	L	N	N	L	N	N	
Encephalomalacia, focal																						
Lymphocytosis, multifocal (Meninges)																						
Corpora amylacea, multifocal							2		3							2			2			
SPINAL CORD		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Axonal degeneration, multifocal																						
Lymphocytosis, multifocal (Meninges)																						
EYES		N	N	N	N	N	N	N	N	N	N	N	N	L	N	N	N	N	N	L	N	
Keratitis, acute, focal, unilateral														3								
Keratitis, chronic, multifocal,bilateral																				3		
Keratitis, chronic, focal, unilateral																						
Cataract, subcapsular, unilateral																						
OPTIC NERVES		M	N	N	N	M	N	M	N	N	N	N	N	N	M	N	N	N	N	M	N	
ADRENALS		N	N	N	N	N	N	N	N	L	N	N	N	N	N	N	N	N	N	N	N	
Pheochromocytoma, solitary																						
Cortical adenoma, solitary										P												
Hyperplasia, cortical, focal																						
Hyperplasia, medullary, multifocal																						
Hyperplasia, medullary, focal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which ca[illegible] be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0472	81-0473	81-0474	81-0475	81-0476	81-0477	81-0478	81-0479*	81-0480	81-0481	81-0483	81-0484	81-0485	81-0486	81-0487*	81-0488	81-0489	81-0490	81-0491	81-0492	Incidence
BRAIN		N	N	N	L	N	N	L	N	N	N	N	L	L	N	N	L	L	L	N	N	
Encephalomalacia, focal																		4				
Lymphocytosis, multifocal (Meninges)					1																	
Corpora amylacea, multifocal								1					2	2			2		2			
SPINAL CORD		N	N	N	L	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Axonal degeneration, multifocal					2																	
Lymphocytosis, multifocal (Meninges)					3																	
EYES		N	N	N	N	N	N	N	N	N	N	N	L	N	N	L	N	N	N	N	L	
Keratitis, acute, focal, unilateral																						
Keratitis, chronic, multifocal, bilateral																						
Keratitis, chronic, focal, unilateral																3						
Cataract, subcapsular, unilateral													3								4	
OPTIC NERVES		N	N	N	M	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
ADRENALS		N	N	N	N	N	N	N	N	N	N	L	N	N	L	N	L	N	L	L	N	
Pheochromocytoma, solitary															P							
Cortical adenoma, solitary																	P					
Hyperplasia, cortical, focal																				2		
Hyperplasia, medullary, multifocal												2										
Hyperplasia, medullary, focal																			2			

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which can be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0495	81-0496	81-0497	81-0498	81-0499	81-0500	81-0501*	81-0502	81-0505	81-0506	81-0509*	81-0510*	81-0511*	81-0512*	81-0513	81-0514	81-0515	81-0516	81-0517*	81-0518*	Incidence
BRAIN		N	N	N	N	N	L	N	L	N	N	N	N	N	N	L	L	N	N	N	L	
Encephalomalacia, focal																						
Lymphocytosis, multifocal (Meninges)																						
Corpora amylacea, multifocal							2		2							1	2				2	
SPINAL CORD		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Axonal degeneration, multifocal																						
Lymphocytosis, multifocal (Meninges)																						
EYES		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	L	N	N	N	N	
Keratitis, acute, focal, unilateral																						
Keratitis, chronic, multifocal,bilateral																						
Keratitis, chronic, focal, unilateral																						
Cataract, subcapsular, unilateral																	2					
OPTIC NERVES		N	M	N	N	N	N	M	M	N	N	N	N	N	N	N	N	N	N	N	N	
ADRENALS		N	N	N	N	L	L	N	N	L	N	N	N	N	N	L	L	N	N	N	N	
Pheochromocytoma, solitary							P															
Cortical adenoma, solitary																	P					
Hyperplasia, cortical, focal																2						
Hyperplasia, medullary, multifocal																						
Hyperplasia, medullary, focal						2	2			2												

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which ca)t be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0519*	81-0520*	81-0521																		Incidence
BRAIN		N	L	L																		(63)
Encephalomalacia, focal																						1/63
Lymphocytosis, multifocal (Meninges)																						1/63
Corpora amylacea, multifocal			1	2																		16/63
SPINAL CORD		N	N	N																		(63)
Axonal degeneration, multifocal																						1/63
Lymphocytosis, multifocal (Meninges)																						1/63
EYES		N	L	N																		(63)
Keratitis, acute, focal, unilateral																						1/63
Keratitis, chronic, multifocal, bilateral																						1/63
Keratitis, chronic, focal, unilateral																						1/63
Cataract, subcapsular, unilateral			3																			4/63
OPTIC NERVES		N	N	N																		(54)
ADRENALS		N	N	N																		(63)
Pheochromocytoma, solitary																						2/63
Cortical adenoma, solitary																						3/63
Hyperplasia, cortical, focal																						2/63
Hyperplasia, medullary, multifocal																						1/63
Hyperplasia, medullary, focal																						4/63

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0447*	81-0448	81-0449*	81-0451*	81-0452	81-0453	81-0454	81-0455	81-0456	81-0457	81-0458	81-0459*	81-0462*	81-0463	81-0464*	81-0465*	81-0466*	81-0468	81-0469*	81-0470	Incidence
SPLEEN		N	N	N	L	N	N	L	N	N	N	N	L	N	N	N	N	N	L	N	N	
Hemangiosarcoma, solitary																						
Malignant Lymphoma, mixed type					P														P			
Malignant Lymphoma, lymphocytic type													P									
Hyperplasia, lymphoid, diffuse								2														
Hematopoiesis, extramedullary, diffuse																						
PANCREAS		N	N	N	L	N	L	N	N	N	N	N	L	N	N	N	N	L	N	N	N	
Malignant Lymphoma, mixed type					P																	
Malignant Lymphoma, lymphocytic type													P									
Hyperplasia, acinar-cell, multifocal							2															
Hyperplasia, acinar-cell, focal																		2				
Hyperplasia, islet-cell, focal																						
Acinar atrophy, diffuse																						
Acinar atrophy, focal																						
MESENTERIC LYMPH NODE		N	N	N	L	L	N	M	N	L	N	L	L	M	L	L	N	N	L	L	N	
Malignant Lymphoma, mixed type					P														P			
Malignant Lymphoma, lymphocytic type													P									
Hyperplasia, lymphoid, diffuse						2				2		2										
Lymphadenitis, acute, diffuse																				3		

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0472	81-0473	81-0474	81-0475	81-0476	81-0477	81-0478	81-0479*	81-0480	81-0481	81-0483	81-0484	81-0485	81-0486	81-0487*	81-0488	81-0489	81-0490	81-0491	81-0492	Incidence
SPLEEN		L	N	N	N	N	N	N	L	N	N	N	L	N	N	L	N	L	L	L	L	
Hemangiosarcoma, solitary																					P	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
Hyperplasia, lymphoid, diffuse													2						2	2		
Hematopoiesis, extramedullary, diffuse		3							3							3		3				
PANCREAS		N	N	N	N	L	N	N	N	N	N	N	N	N	N	L	N	N	N	N	N	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
Hyperplasia, acinar-cell, multifocal						2																
Hyperplasia, acinar-cell, focal																						
Hyperplasia, islet-cell, focal																						
Acinar atrophy, diffuse																2						
Acinar atrophy, focal																						
MESENTERIC LYMPH NODE		L	N	N	N	L	L	N	L	L	N	L	L	N	L	L	L	N	L	L	N	
Malignant Lymphoma, mixed type																	P					
Malignant Lymphoma, lymphocytic type										P												
Hyperplasia, lymphoid, diffuse									2										2			
Lymphadenitis, acute, diffuse		4														2						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which ca t be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0495	81-0496	81-0497	81-0498	81-0499	81-0500	81-0501*	81-0502	81-0505	81-0506	81-0509*	81-0510*	81-0511*	81-0512*	81-0513	81-0514	81-0515	81-0516	81-0517*	81-0518*	Incidence
SPLEEN		N	L	N	N	N	N	N	N	N	L	L	N	L	N	L	N	L	N	N	L	
Hemangiosarcoma, solitary														P								
Malignant Lymphoma, mixed type											P											
Malignant Lymphoma, lymphocytic type																						
Hyperplasia, lymphoid, diffuse			2															2				
Hematopoiesis, extramedullary, diffuse												3				3					3	
PANCREAS		N	L	N	N	N	N	N	N	N	N	N	L	N	N	N	L	N	L	N	N	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
Hyperplasia, acinar-cell, multifocal																						
Hyperplasia, acinar-cell, focal																	2					
Hyperplasia, islet-cell, focal													2									
Acinar atrophy, diffuse																						
Acinar atrophy, focal			2																2			
MESENTERIC LYMPH NODE		N	N	N	N	L	N	L	M	N	L	L	L	L	N	L	N	N	L	M	L	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
Hyperplasia, lymphoid, diffuse						2						2										
Lymphadenitis, acute, diffuse																3					2	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which ca t be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0519*	81-0520*	81-0521																			Incidence
SPLEEN		L	L	N																			(63)
Hemangiosarcoma, solitary																							2/63
Malignant Lymphoma, mixed type																							3/63
Malignant Lymphoma, lymphocytic type																							1/63
Hyperplasia, lymphoid, diffuse																							6/63
Hematopoiesis, extramedullary, diffuse		3	3																				9/63
PANCREAS		N	N	N																			(63)
Malignant Lymphoma, mixed type																							1/63
Malignant Lymphoma, lymphocytic type																							1/63
Hyperplasia, acinar-cell, multifocal																							2/63
Hyperplasia, acinar-cell, focal																							2/63
Hyperplasia, islet-cell, focal																							1/63
Acinar atrophy, diffuse																							1/63
Acinar atrophy, focal																							2/63
MESENTERIC LYMPH NODE		L	L	L																			(59)
Malignant Lymphoma, mixed type			P																				4/59
Malignant Lymphoma, lymphocytic type																							2/59
Hyperplasia, lymphoid, diffuse		2		3																			9/59
Lymphadenitis, acute, diffuse																							5/59

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which ca t be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0447*	81-0448	81-0449*	81-0451*	81-0452	81-0453	81-0454	81-0455	81-0456	81-0457	81-0458	81-0459*	81-0462*	81-0463	81-0464*	81-0465*	81-0466*	81-0468	81-0469*	81-0470	Incidence
MESENTERIC LYMPH NODE (Con't.)		N	N	N	L	L	N	M	N	L	N	L	L	M	L	L	N	N	L	L	N	
Lymphadenitis, acute, focal																						
Congestion, diffuse															3	3				4		
Edema, diffuse																						
TESTES		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, lymphocytic type,																						
unilateral																						
PROSTATE		N	N	N	N	N	N	L	N	N	N	N	N	M	N	N	N	N	N	N	N	
Hyperplasia, glandular, multifocal																						
Prostatitis, chronic, active, focal								3														
EPIDIDYMIDES		L	N	N	N	N	N	N	N	N	N	N	N	M	N	N	N	N	N	N	N	
Sperm granuloma, solitary		3																				
Epididymitis, acute, focal																						
Epididymitis, chronic, focal																						
Mineralization, focal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which ca t be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0472	81-0473	81-0474	81-0475	81-0476	81-0477	81-0478	81-0479*	81-0480	81-0481	81-0483	81-0484	81-0485	81-0486	81-0487*	81-0488	81-0489	81-0490	81-0491	81-0492	Incidence
MESENTERIC LYMPH NODE (Con't.)		L	N	N	N	L	L	N	L	L	N	L	L	N	L	L	L	N	L	L	N	
Lymphadenitis, acute, focal																						
Congestion, diffuse						2	2			3		3	2		2							
Edema, diffuse																				2		
TESTES		L	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, lymphocytic type, unilateral		P																				
PROSTATE		N	N	N	N	N	N	N	N	N	N	N	N	N	L	N	N	N	N	N	N	
Hyperplasia, glandular, multifocal															2							
Prostatitis, chronic, active, focal																						
EPIDIDYMIDES		N	N	N	N	N	L	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Sperm granuloma, solitary																						
Epididymitis, acute, focal																						
Epididymitis, chronic, focal							3															
Mineralization, focal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which c[illegible]bt be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0495	81-0496	81-0497	81-0498	81-0499	81-0500	81-0501*	81-0502	81-0505	81-0506	81-0509*	81-0510*	81-0511*	81-0512*	81-0513	81-0514	81-0515	81-0516	81-0517*	81-0518*	Incidence
MESENTERIC LYMPH NODE (Con't.)		N	N	N	N	L	N	L	M	N	L	L	L	L	N	L	N	N	L	M	L	
Lymphadenitis, acute, focal																						
Congestion, diffuse								4			3		2	2					3			
Edema, diffuse																						
TESTES		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, lymphocytic type,																						
unilateral																						
PROSTATE		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Hyperplasia, glandular, multifocal																						
Prostatitis, chronic, active, focal																						
EPIDIDYMIDES		N	L	N	N	N	N	N	N	N	N	N	N	L	N	N	N	N	N	N	N	
Sperm granuloma, solitary																						
Epididymitis, acute, focal														3								
Epididymitis, chronic, focal																						
Mineralization, focal			1																			

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which ca[illegible]t be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I
MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0519*	81-0520*	81-0521																			Incidence
MESENTERIC LYMPH NODE (Con't.)		L	L	L																			(59)
Lymphadenitis, acute, focal				2																			1/59
Congestion, diffuse																							14/59
Edema, diffuse																							1/59
TESTES		N	N	N																			(63)
Malignant Lymphoma, lymphocytic type,																							
unilateral																							1/63
PROSTATE		N	N	N																			(62)
Hyperplasia, glandular, multifocal																							1/62
Prostatitis, chronic, active, focal																							1/62
EPIDIDYMIDES		N	N	N																			(62)
Sperm granuloma, solitary																							1/62
Epididymitis, acute, focal																							1/62
Epididymitis, chronic, focal																							1/62
Mineralization, focal																							1/62

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which ca)t be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion / Accession Number	81-0447*	81-0448	81-0449*	81-0451*	81-0452	81-0453	81-0454	81-0455	81-0456	81-0457	81-0458	81-0459*	81-0462*	81-0463	81-0464*	81-0465*	81-0466*	81-0468	81-0469*	81-0470	Incidence
URINARY BLADDER	N	N	N	N	N	N	N	L	N	L	N	N	M	N	L	L	N	L	N	L	
Hyperplasia, epithelial, diffuse																					
Cystitis, chronic, active, diffuse																					
Cystitis, chronic, diffuse																2				2	
Calculus								P		P					P			P			
LUNGS	L	N	N	L	N	L	N	N	L	N	L	L	L	N	L	N	L	N	L	N	
Alveolar/bronchiolar carcinoma,solitary						P															
Malignant Lymphoma, mixed type																					
Leukemia, myeloid																					
Hepatocellular carcinoma, metastatic																					
Fibrosarcoma, metastatic																					
Alveolar/bronchiolar adenoma, solitary									P				P				P		P		
Hyperplasia, alveolar/epithelium, focal																					
Hyperplasia, alveolar, focal																					
Bronchiolitis, acute, focal											2										
Histiocytosis, diffuse				2																	
Histiocytosis, focal																					
Hemorrhage, multifocal												2			2						
Hemorrhage, focal																					

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0472	81-0473	81-0474	81-0475	81-0476	81-0477	81-0478	81-0479*	81-0480	81-0481	81-0483	81-0484	81-0485	81-0486	81-0487*	81-0488	81-0489	81-0490	81-0491	81-0492	Incidence
URINARY BLADDER		L	N	N	N	N	N	N	N	N	L	N	L	N	N	N	N	N	N	N	N	
Hyperplasia, epithelial, diffuse																						
Cystitis, chronic, active, diffuse		3																				
Cystitis, chronic, diffuse													3									
Calculus		P									P		P									
LUNGS		N	L	N	L	N	N	N	L	N	N	N	L	N	N	N	L	N	N	L	L	
Alveolar/bronchiolar carcinoma,solitary																	P				P	
Malignant Lymphoma, mixed type																						
Leukemia, myeloid																						
Hepatocellular carcinoma, metastatic																				P		
Fibrosarcoma, metastatic									P													
Alveolar/bronchiolar adenoma, solitary													P									
Hyperplasia, alveolar/epithelium, focal			2																			
Hyperplasia, alveolar, focal																	2				2	
Bronchiolitis, acute, focal																						
Histiocytosis, diffuse																						
Histiocytosis, focal																					2	
Hemorrhage, multifocal			2		3																	
Hemorrhage, focal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which ca t be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0495	81-0496	81-0497	81-0498	81-0499	81-0500	81-0501*	81-0502	81-0505	81-0506	81-0509*	81-0510*	81-0511*	81-0512*	81-0513	81-0514	81-0515	81-0516	81-0517*	81-0518*	Incidence
URINARY BLADDER		L	L	N	N	N	N	N	L	L	N	L	N	N	N	N	N	N	N	N	N	
Hyperplasia, epithelial, diffuse												1										
Cystitis, chronic, active, diffuse																						
Cystitis, chronic, diffuse																						
Calculus		P	P						P	P												
LUNGS		N	N	N	N	L	L	L	L	N	N	N	N	N	N	N	N	L	N	N	N	
Alveolar/bronchiolar carcinoma,solitary																						
Malignant Lymphoma, mixed type																						
Leukemia, myeloid																						
Hepatocellular carcinoma, metastatic								P														
Fibrosarcoma, metastatic																						
Alveolar/bronchiolar adenoma, solitary																						
Hyperplasia, alveolar/epithelium, focal																						
Hyperplasia, alveolar, focal							2															
Bronchiolitis, acute, focal																						
Histiocytosis, diffuse																						
Histiocytosis, focal																						
Hemorrhage, multifocal									2													
Hemorrhage, focal						2																

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which c pt be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I
MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0519*	81-0520*	81-0521	Incidence
URINARY BLADDER		N	N	N	(62)
Hyperplasia, epithelial, diffuse					1/62
Cystitis, chronic, active, diffuse					1/62
Cystitis, chronic, diffuse					3/62
Calculus					11/62
LUNGS		L	L	N	(63)
Alveolar/bronchiolar carcinoma, solitary					3/63
Malignant Lymphoma, mixed type			P		1/63
Leukemia, myeloid		P			1/63
Hepatocellular carcinoma, metastatic					2/63
Fibrosarcoma, metastatic					1/63
Alveolar/bronchiolar adenoma, solitary		P			6/63
Hyperplasia, alveolar/epithelium, focal					1/63
Hyperplasia, alveolar, focal					3/63
Bronchiolitis, acute, focal					1/63
Histiocytosis, diffuse					1/63
Histiocytosis, focal					1/63
Hemorrhage, multifocal					5/63
Hemorrhage, focal					1/63

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which ca)t be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0447*	81-0448	81-0449*	81-0451*	81-0452	81-0453	81-0454	81-0455	81-0456	81-0457	81-0458	81-0459*	81-0462*	81-0463	81-0464*	81-0465*	81-0466*	81-0468	81-0469*	81-0470	Incidence
LUNGS (Con't.)		L	N	N	L	N	L	N	N	L	N	L	L	L	N	L	N	L	N	L	N	
Congestion, diffuse		2			2								3									
Congestion, multifocal																		2				
ESOPHAGUS		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
TRACHEA		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
THYROIDS		N	N	N	N	N	N	N	N	N	N	N	N	N	L	N	N	N	L	N	N	
Malignant Lymphoma, mixed type																			P			
Hyperplasia, follicular, multifocal																						
Thyroiditis, acute, focal																						
Follicular cysts, multifocal, bilateral																						
Follicular cysts, multiple, unilateral																						
Follicular cyst, solitary															2							
Follicular atrophy, multifocal, bilateral																						
Follicular atrophy, multifocal, unilateral																						
PARATHYROIDS		N	N	N	N	M	N	N	N	N	N	N	N	N	N	M	N	M	N	N	N	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0472	81-0473	81-0474	81-0475	81-0476	81-0477	81-0478	81-0479*	81-0480	81-0481	81-0483	81-0484	81-0485	81-0486	81-0487*	81-0488	81-0489	81-0490	81-0491	81-0492	Incidence
LUNGS (Con't.)		N	L	N	L	N	N	N	L	N	N	N	L	N	N	N	L	N	N	L	L	
Congestion, diffuse																						
Congestion, multifocal																						
ESOPHAGUS		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
TRACHEA		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
THYROIDS		L	N	N	N	N	N	N	L	L	L	N	L	N	L	N	L	L	N	L	L	
Malignant Lymphoma, mixed type																						
Hyperplasia, follicular, multifocal																						
Thyroiditis, acute, focal																						
Follicular cysts, multifocal,bilateral																						
Follicular cysts, multiple, unilateral													2		2							
Follicular cyst, solitary											2						2	2				
Follicular atrophy, multifocal,																						
bilateral		2							2	2											2	
Follicular atrophy, multifocal,																						
unilateral													2							2		
PARATHYROIDS		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	M	N	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0495	81-0496	81-0497	81-0498	81-0499	81-0500	81-0501*	81-0502	81-0505	81-0506	81-0509*	81-0510*	81-0511*	81-0512*	81-0513	81-0514	81-0515	81-0516	81-0517*	81-0518*	Incidence
LUNGS (Con't.)		N	N	N	N	L	L	L	L	N	N	N	N	N	N	N	N	L	N	N	N	
Congestion, diffuse																		2				
Congestion, multifocal																						
ESOPHAGUS		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
TRACHEA		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
THYROIDS		L	N	N	N	N	N	N	L	L	N	N	N	N	N	L	L	N	L	L	N	
Malignant Lymphoma, mixed type																						
Hyperplasia, follicular, multifocal		2																				
Thyroiditis, acute, focal																			2			
Follicular cysts, multifocal, bilateral																			2			
Follicular cysts, multiple, unilateral																						
Follicular cyst, solitary								2	2													
Follicular atrophy, multifocal,																						
bilateral																2				2		
Follicular atrophy, multifocal,																						
unilateral																	2					
PARATHYROIDS		M	N	N	N	M	M	N	N	N	N	N	M	M	M	M	M	M	N	N	N	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which c pt be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0519*	81-0520*	81-0521																			Incidence
LUNGS (Con't.)		L	L	N																			(63)
Congestion, diffuse																							4/63
Congestion, multifocal																							1/63
ESOPHAGUS		N	N	N																			(63)
TRACHEA		N	N	N																			(63)
THYROIDS		N	L	N																			(63)
Malignant Lymphoma, mixed type																							1/63
Hyperplasia, follicular, multifocal																							1/63
Thyroiditis, acute, focal																							1/63
Follicular cysts, multifocal, bilateral																							1/63
Follicular cysts, multiple, unilateral																							2/63
Follicular cyst, solitary																							6/63
Follicular atrophy, multifocal,																							
bilateral			2																				7/63
Follicular atrophy, multifocal,																							
unilateral																							3/63
PARATHYROIDS		N	N	M																			(49)

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which ca)t be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0447*	81-0448	81-0449*	81-0451*	81-0452	81-0453	81-0454	81-0455	81-0456	81-0457	81-0458	81-0459*	81-0462*	81-0463	81-0464*	81-0465*	81-0466*	81-0468	81-0469*	81-0470	Incidence
HEART		N	N	N	L	N	L	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Leukemia, myeloid																						
Myocarditis, acute, multifocal																						
Myocarditis, chronic, active, focal							2															
Myocarditis, chronic, multifocal																						
Myocarditis, chronic, focal																						
Thrombus, atrial					4																	
LIVER		N	N	L	L	L	L	N	N	L	L	L	L	N	N	N	N	L	L	L	L	
Hemangiosarcoma, solitary				P																		
Hepatocellular carcinoma, multifocal							P															
Hepatocellular carcinoma, solitary					P													P				
Leukemia, myeloid																						
Fibrosarcoma, metastatic																						
Hemangioma, solitary																						
Hepatocellular adenoma, multifocal																						
Hepatocellular adenoma, solitary										P	P	P									P	
Focal cellular change													P									
Lymphatic cysts, multiple																						
Hepatitis, acute, multifocal																				2		

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which ca t be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0472	81-0473	81-0474	81-0475	81-0476	81-0477	81-0478	81-0479*	81-0480	81-0481	81-0483	81-0484	81-0485	81-0486	81-0487*	81-0488	81-0489	81-0490	81-0491	81-0492	Incidence
HEART		N	N	N	N	N	N	N	L	N	N	N	N	N	N	N	N	L	N	N	N	
Leukemia, myeloid																						
Myocarditis, acute, multifocal									2													
Myocarditis, chronic, active, focal																						
Myocarditis, chronic, multifocal																						
Myocarditis, chronic, focal																		3				
Thrombus, atrial																						
LIVER		L	N	N	N	N	N	L	L	N	N	L	N	L	L	N	N	L	N	L	L	
Hemangiosarcoma, solitary																						
Hepatocellular carcinoma, multifocal																						
Hepatocellular carcinoma, solitary		P						P						P						P	P	
Leukemia, myeloid																						
Fibrosarcoma, metastatic									P													
Hemangioma, solitary																						
Hepatocellular adenoma, multifocal																						
Hepatocellular adenoma, solitary															P						P	
Focal cellular change												P		·								
Lymphatic cysts, multiple																						
Hepatitis, acute, multifocal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0495	81-0496	81-0497	81-0498	81-0499	81-0500	81-0501*	81-0502	81-0505	81-0506	81-0509*	81-0510*	81-0511*	81-0512*	81-0513	81-0514	81-0515	81-0516	81-0517*	81-0518*	Incidence
HEART		N	N	N	N	N	N	N	N	N	N	N	N	L	N	N	N	N	N	N	N	
Leukemia, myeloid																						
Myocarditis, acute, multifocal																						
Myocarditis, chronic, active, focal																						
Myocarditis, chronic, multifocal														2								
Myocarditis, chronic, focal																						
Thrombus, atrial																						
LIVER		L	L	L	L	N	N	L	N	N	N	L	N	N	N	N	L	L	L	N	N	
Hemangiosarcoma, solitary																						
Hepatocellular carcinoma, multifocal								P														
Hepatocellular carcinoma, solitary												P						P	P			
Leukemia, myeloid																						
Fibrosarcoma, metastatic																						
Hemangioma, solitary		P			P																	
Hepatocellular adenoma, multifocal																						
Hepatocellular adenoma, solitary																	P					
Focal cellular change																						
Lymphatic cysts, multiple				2																		
Hepatitis, acute, multifocal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

1000

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0519*	81-0520*	81-0521																		Incidence
HEART		L	L	N																		(63)
Leukemia, myeloid		P																				1/63
Myocarditis, acute, multifocal																						1/63
Myocarditis, chronic, active, focal																						1/63
Myocarditis, chronic, multifocal			2																			2/63
Myocarditis, chronic, focal																						1/63
Thrombus, atrial																						1/63
LIVER		L	L	L																		(63)
Hemangiosarcoma, solitary																						1/63
Hepatocellular carcinoma, multifocal																						2/63
Hepatocellular carcinoma, solitary			P																			11/63
Leukemia, myeloid		P																				1/63
Fibrosarcoma, metastatic																						1/63
Hemangioma, solitary																						2/63
Hepatocellular adenoma, multifocal				P																		1/63
Hepatocellular adenoma, solitary																						7/63
Focal cellular change				P																		3/63
Lymphatic cysts, multiple																						1/63
Hepatitis, acute, multifocal																						1/63

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0447*	81-0448	81-0449*	81-0451*	81-0452	81-0453	81-0454	81-0455	81-0456	81-0457	81-0458	81-0459*	81-0462*	81-0463	81-0464*	81-0465*	81-0466*	81-0468	81-0469*	81-0470	Incidence
LIVER (Con't.)		N	N	L	L	L	L	N	N	L	L	L	L	N	N	N	N	L	L	L	L	
Hepatitis, acute, focal																						
Hepatitis, periportal, chronic, focal																						
Hepatocytomegaly, multifocal																						
Fatty change, periacinar, diffuse																			2			
Fatty change, periacinar, multifocal																						
Fatty change, diffuse																						
Necrosis, periacinar, diffuse				2																		
Necrosis, periportal, multifocal																						
Necrosis, multifocal						2																
KIDNEYS		L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	
Malignant Lymphoma, mixed type																						
Fibrosarcoma, metastatic, bilateral																						
Metaplasia, osseous, focal																						
Renal cell adenoma, solitary																						
Hyperplasia, tubular, multifocal		2					1	1	1	1	2	2	1		1		1		2		2	
Hyperplasia, tubular, focal			2																			
Pyelitis, acute, diffuse, unilateral																						
Pyelonephritis, chronic, active, multifocal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0472	81-0473	81-0474	81-0475	81-0476	81-0477	81-0478	81-0479*	81-0480	81-0481	81-0483	81-0484	81-0485	81-0486	81-0487*	81-0488	81-0489	81-0490	81-0491	81-0492	Incidence
LIVER (Con't.)		L	N	N	N	N	N	L	L	N	N	L	N	L	L	N	N	L	N	L	L	
Hepatitis, acute, focal																						
Hepatitis, periportal, chronic, focal																						
Hepatocytomegaly, multifocal																						
Fatty change, periacinar, diffuse																						
Fatty change, periacinar, multifocal																						
Fatty change, diffuse																						
Necrosis, periacinar, diffuse																						
Necrosis, periportal, multifocal												2						2				
Necrosis, multifocal																						
KIDNEYS		L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	
Malignant Lymphoma, mixed type																						
Fibrosarcoma, metastatic, bilateral									P													
Metaplasia, osseous, focal												2										
Renal cell adenoma, solitary																						
Hyperplasia, tubular, multifocal			1	1	1	1	2				2	2	1	2			2		2	1		
Hyperplasia, tubular, focal																						
Pyelitis, acute, diffuse, unilateral		2																				
Pyelonephritis, chronic, active, multifocal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0495	81-0496	81-0497	81-0498	81-0499	81-0500	81-0501*	81-0502	81-0505	81-0506	81-0509*	81-0510*	81-0511*	81-0512*	81-0513	81-0514	81-0515	81-0516	81-0517*	81-0518*	Incidence
LIVER (Con't.)		L	L	L	L	N	N	L	N	N	N	L	N	N	N	N	L	L	L	N	N	
Hepatitis, acute, focal				2																		
Hepatitis, periportal, chronic, focal																						
Hepatocytomegaly, multifocal				2																		
Fatty change, periacinar, diffuse																						
Fatty change, periacinar, multifocal			1																			
Fatty change, diffuse																			2			
Necrosis, periacinar, diffuse												4										
Necrosis, periportal, multifocal																						
Necrosis, multifocal																						
KIDNEYS		L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	
Malignant Lymphoma, mixed type											P											
Fibrosarcoma, metastatic, bilateral																						
Metaplasia, osseous, focal												2										
Renal cell adenoma, solitary																						
Hyperplasia, tubular, multifocal		2	2	2		2	1			1	2	1	2	1		2	2	2	2		2	
Hyperplasia, tubular, focal																						
Pyelitis, acute, diffuse, unilateral																						
Pyelonephritis, chronic, active, multifocal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I
MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0519*	81-0520*	81-0521																		Incidence
LIVER (Con't.)		L	L	L																		(63)
Hepatitis, acute, focal																						1/63
Hepatitis, periportal, chronic, focal			2																			1/63
Hepatocytomegaly, multifocal																						1/63
Fatty change, periacinar, diffuse																						1/63
Fatty change, periacinar, multifocal																						1/63
Fatty change, diffuse																						1/63
Necrosis, periacinar, diffuse																						2/63
Necrosis, periportal, multifocal																						1/63
Necrosis, multifocal																						1/63
KIDNEYS		L	L	L																		(63)
Malignant Lymphoma, mixed type																						1/63
Fibrosarcoma, metastatic, bilateral																						1/63
Metaplasia, osseous, focal																						2/63
Renal cell adenoma, solitary		P																				1/63
Hyperplasia, tubular, multifocal				2																		40/63
Hyperplasia, tubular, focal																						1/63
Pyelitis, acute, diffuse, unilateral																						1/63
Pyelonephritis, chronic, active, multifocal			4																			1/63

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0447*	81-0448	81-0449*	81-0451*	81-0452	81-0453	81-0454	81-0455	81-0456	81-0457	81-0458	81-0459*	81-0462*	81-0463	81-0464*	81-0465*	81-0466*	81-0468	81-0469*	81-0470	Incidence
KIDNEYS (Con't.)		L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	
Pyelonephritis, chronic, active, diffuse																						
unilateral																						
Nephropathy, chronic, diffuse					2																	
Nephropathy, chronic, multifocal																						
Nephropathy, chronic, focal																			2			
Nephrocalcinosis, multifocal		2	1	1		2	1	2	2	1	2	2	1	1	1	1		1	2		1	
Nephrosis, tubular, diffuse				3																		
Necrosis, multifocal (Tubules)																						
Dilatation, diffuse (Tubules)																						
Hemorrhage, focal (Pelvis)											2											
Cytoplasmic vacuolization, diffuse,																						
(Tubules)		1	1	1	1	2	2	2	2	2	2	2	2	1	1		2	2	2	1	1	
STOMACH		N	N	N	N	L	N	N	N	L	N	N	N	N	N	N	L	N	L	N	N	
Gastritis, acute, focal						3																
Gastritis, acute, focal (Glandular)																						
Ulcer, acute, solitary																	3					
Degeneration, cystic, multifocal (Glandular)																			1			
Cyst, solitary (Glandular)										1												

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

1006

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0472	81-0473	81-0474	81-0475	81-0476	81-0477	81-0478	81-0479*	81-0480	81-0481	81-0483	81-0484	81-0485	81-0486	81-0487*	81-0488	81-0489	81-0490	81-0491	81-0492	Incidence
KIDNEYS (Con't.)		L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	
Pyelonephritis, chronic, active, diffuse																						
unilateral		4																				
Nephropathy, chronic, diffuse																						
Nephropathy, chronic, multifocal								2		2											2	
Nephropathy, chronic, focal																						
Nephrocalcinosis, multifocal			1	1	1		2			1	2	2	2	2	1		2		2	2	1	
Nephrosis, tubular, diffuse																						
Necrosis, multifocal (Tubules)																						
Dilatation, diffuse (Tubules)																2						
Hemorrhage, focal (Pelvis)																						
Cytoplasmic vacuolization, diffuse,																						
(Tubules)		1	2	1	2	2	2	2	1	2	1		1	2	2	2	2	2	1	1	1	
STOMACH		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	L	
Gastritis, acute, focal																						
Gastritis, acute, focal (Glandular)																					2	
Ulcer, acute, solitary																						
Degeneration, cystic, multifocal (Glandular)																						
Cyst, solitary (Glandular)																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0495	81-0496	81-0497	81-0498	81-0499	81-0500	81-0501*	81-0502	81-0505	81-0506	81-0509*	81-0510*	81-0511*	81-0512*	81-0513	81-0514	81-0515	81-0516	81-0517*	81-0518*	Incidence
KIDNEYS (Con't.)		L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	
Pyelonephritis, chronic, active, diffuse																						
unilateral																						
Nephropathy, chronic, diffuse																						
Nephropathy, chronic, multifocal																						
Nephropathy, chronic, focal																						
Nephrocalcinosis, multifocal		2	2	1	2		1		1	1	2	1	2	2	2	2	2	2	2	1	2	
Nephrosis, tubular, diffuse																						
Necrosis, multifocal (Tubules)							2									2						
Dilatation, diffuse (Tubules)																						
Hemorrhage, focal (Pelvis)																						
Cytoplasmic vacuolization, diffuse,																						
(Tubules)		2	2	2		1	2	2	2	1	2	1	2	2	1	1	1	1	1	1	2	
STOMACH		N	N	N	N	N	N	N	N	N	L	N	N	N	N	N	N	N	N	N	N	
Gastritis, acute, focal																						
Gastritis, acute, focal (Glandular)																						
Ulcer, acute, solitary																						
Degeneration, cystic, multifocal (Glandular)											2											
Cyst, solitary (Glandular)																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I
MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0519*	81-0520*	81-0521																		Incidence
KIDNEYS (Con't.)		L	L	L																		(63)
Pyelonephritis, chronic, active, diffuse																						
unilateral																						1/63
Nephropathy, chronic, diffuse																						1/63
Nephropathy, chronic, multifocal																						3/63
Nephropathy, chronic, focal																						1/63
Nephrocalcinosis, multifocal				2																		50/63
Nephrosis, tubular, diffuse																						1/63
Necrosis, multifocal (Tubules)																						2/63
Dilatation, diffuse (Tubules)																						1/63
Hemorrhage, focal (Pelvis)																						1/63
Cytoplasmic vacuolization, diffuse,																						
(Tubules)		1	2	2																		60/63
STOMACH		N	N	N																		(63)
Gastritis, acute, focal																						1/63
Gastritis, acute, focal (Glandular)																						1/63
Ulcer, acute, solitary																						1/63
Degeneration, cystic, multifocal (Glandular)																						2/63
Cyst, solitary (Glandular)																						1/63

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0447*	81-0448	81-0449*	81-0451*	81-0452	81-0453	81-0454	81-0455	81-0456	81-0457	81-0458	81-0459*	81-0462*	81-0463	81-0464*	81-0465*	81-0466*	81-0468	81-0469*	81-0470	Incidence
DUODENUM		N	N	N	N	N	N	N	N	N	N	N	Ni	N	N	N	N	N	N	N	N	
JEJUNUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	L	N	
Abscess, solitary																				4		
ILEUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, lymphocytic type																						
CECUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
COLON		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, lymphocytic type																						
RECTUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Fibrosarcoma, metastatic																						
SKIN		N	N	L	L	N	L	N	L	N	N	N	L	L	N	N	N	L	N	L	L	
Fibroma, solitary																						
Dermatitis, acute, ulcerative, focal																						
Dermatitis, acute, multifocal																						
Dermatitis, acute, focal																				2		
Dermatitis, acute, focal (Back)																						
Dermatitis, chronic, ulcerative, diffuse																						
Dermatitis, chronic, active, ulcerative, focal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0472	81-0473	81-0474	81-0475	81-0476	81-0477	81-0478	81-0479*	81-0480	81-0481	81-0483	81-0484	81-0485	81-0486	81-0487*	81-0488	81-0489	81-0490	81-0491	81-0492	Incidence
DUODENUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
JEJUNUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Abscess, solitary																						
ILEUM		N	N	N	N	N	N	N	N	L	N	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, lymphocytic type										P												
CECUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
COLON		N	N	N	N	N	N	N	N	L	N	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, lymphocytic type										P												
RECTUM		N	N	N	N	N	N	N	L	N	N	N	N	N	N	N	N	N	N	N	N	
Fibrosarcoma, metastatic									P													
SKIN		L	N	L	L	L	L	N	N	L	L	N	L	N	N	L	L	N	N	N	N	
Fibroma, solitary																						
Dermatitis, acute, ulcerative, focal																4						
Dermatitis, acute, multifocal																						
Dermatitis, acute, focal																2						
Dermatitis, acute, focal (Back)																3						
Dermatitis, chronic, ulcerative, diffuse				4																		
Dermatitis, chronic, active, ulcerative, focal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0495	81-0496	81-0497	81-0498	81-0499	81-0500	81-0501*	81-0502	81-0505	81-0506	81-0509*	81-0510*	81-0511*	81-0512*	81-0513	81-0514	81-0515	81-0516	81-0517*	81-0518*	Incidence
DUODENUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
JEJUNUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Abscess, solitary																						
ILEUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, lymphocytic type																						
CECUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
COLON		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, lymphocytic type																						
RECTUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Fibrosarcoma, metastatic																						
SKIN		N	N	L	L	L	L	L	N	N	L	N	N	N	L	N	L	N	N	N	N	
Fibroma, solitary																	P					
Dermatitis, acute, ulcerative, focal																						
Dermatitis, acute, multifocal							2															
Dermatitis, acute, focal																						
Dermatitis, acute, focal (Back)																						
Dermatitis, chronic, ulcerative, diffuse																						
Dermatitis, chronic, active, ulcerative, focal					4																	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0519*	81-0520*	81-0521																		Incidence
DUODENUM		N	N	N																		(63)
JEJUNUM		N	N	N																		(63)
Abscess, solitary																						1/63
ILEUM		N	N	N																		(63)
Malignant Lymphoma, lymphocytic type																						1/63
CECUM		N	N	N																		(63)
COLON		N	N	N																		(63)
Malignant Lymphoma, lymphocytic type																						1/63
RECTUM		N	N	N																		(63)
Fibrosarcoma, metastatic																						1/63
SKIN		N	N	N																		(63)
Fibroma, solitary																						1/63
Dermatitis, acute, ulcerative, focal																						1/63
Dermatitis, acute, multifocal																						1/63
Dermatitis, acute, focal																						2/63
Dermatitis, acute, focal (Back)																						1/63
Dermatitis, chronic, ulcerative, diffuse																						1/63
Dermatitis, chronic, active, ulcerative, focal																						1/63

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0447*	81-0448	81-0449*	81-0451*	81-0452	81-0453	81-0454	81-0455	81-0456	81-0457	81-0458	81-0459*	81-0462*	81-0463	81-0464*	81-0465*	81-0466*	81-0468	81-0469*	81-0470	Incidence
SKIN (Con't.)		N	N	L	L	N	L	N	L	N	N	N	L	L	N	N	N	L	N	L	L	
Dermatitis, chronic, active, diffuse																				4		
Dermatitis, chronic, active, multifocal																						
Dermatitis, chronic, active, focal							1															
Dermatitis, chronic, diffuse							3						3	3							3	
Dermatitis, chronic, diffuse (Dorsal)																						
Dermatitis, chronic, multifocal																		3				
Dermatitis, chronic, focal																						
Follicular atrophy, diffuse				2	3																	
Granulation tissue, focal									3													
MAMMARY GLAND		M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	
STERNUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Fibrosarcoma, invasive																						
BONE MARROW		L	N	N	N	L	L	L	N	L	L	N	L	N	L	N	N	N	L	N	N	
Leukemia, myeloid																						
Hyperplasia, myeloid, diffuse		2				2	2	2		2	1		2		2				2			

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0472	81-0473	81-0474	81-0475	81-0476	81-0477	81-0478	81-0479*	81-0480	81-0481	81-0483	81-0484	81-0485	81-0486	81-0487*	81-0488	81-0489	81-0490	81-0491	81-0492	Incidence
SKIN (Con't.)		L	N	L	L	L	L	N	N	L	L	N	L	N	N	L	L	N	N	N	N	
Dermatitis, chronic, active, diffuse		4																				
Dermatitis, chronic, active, multifocal																	1					
Dermatitis, chronic, active, focal																						
Dermatitis, chronic, diffuse					3	3	3			3	4		2									
Dermatitis, chronic, diffuse (Dorsal)						3																
Dermatitis, chronic, multifocal																						
Dermatitis, chronic, focal		3																				
Follicular atrophy, diffuse																						
Granulation tissue, focal																						
MAMMARY GLAND		M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	
STERNUM		N	N	N	N	N	N	M	N	N	N	N	N	N	N	N	N	N	N	N	N	
Fibrosarcoma, invasive																						
BONE MARROW		L	L	N	L	L	L	M	L	L	L	N	L	L	L	L	L	L	L	N	L	
Leukemia, myeloid																						
Hyperplasia, myeloid, diffuse		2	2		2	2	2		3	2	2		2	2	2	2	3	2	2		2	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0495	81-0496	81-0497	81-0498	81-0499	81-0500	81-0501*	81-0502	81-0505	81-0506	81-0509*	81-0510*	81-0511*	81-0512*	81-0513	81-0514	81-0515	81-0516	81-0517*	81-0518*	Incidence
SKIN (Con't.)		N	N	L	L	L	L	L	N	N	L	N	N	N	L	N	L	N	N	N	N	
Dermatitis, chronic, active, diffuse																						
Dermatitis, chronic, active, multifocal																						
Dermatitis, chronic, active, focal																	4					
Dermatitis, chronic, diffuse				3		3	3	2			2											
Dermatitis, chronic, diffuse (Dorsal)																						
Dermatitis, chronic, multifocal															3							
Dermatitis, chronic, focal																						
Follicular atrophy, diffuse																						
Granulation tissue, focal																	3					
MAMMARY GLAND		M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	
STERNUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	L	N	
Fibrosarcoma, invasive																				P		
BONE MARROW		N	L	L	L	L	L	L	L	L	L	N	L	N	L	L	L	L	L	L	L	
Leukemia, myeloid																						
Hyperplasia, myeloid, diffuse			2	2	2	2	2	2	2	2	2		2		3	2	2	2	2	2	2	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0519*	81-0520*	81-0521																		Incidence
SKIN (Con't.)		N	N	N																		(63)
Dermatitis, chronic, active, diffuse																						2/63
Dermatitis, chronic, active, multifocal																						1/63
Dermatitis, chronic, active, focal																						2/63
Dermatitis, chronic, diffuse																						15/63
Dermatitis, chronic, diffuse (Dorsal)																						1/63
Dermatitis, chronic, multifocal																						2/63
Dermatitis, chronic, focal																						1/63
Follicular atrophy, diffuse																						2/63
Granulation tissue, focal																						2/63
MAMMARY GLAND		M	M	M																		(0)
STERNUM		N	N	N																		(62)
Fibrosarcoma, invasive																						1/62
BONE MARROW		L	L	L																		(62)
Leukemia, myeloid		P																				1/62
Hyperplasia, myeloid, diffuse			3	2																		44/62

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion / Accession Number	81-0447*	81-0448	81-0449*	81-0451*	81-0452	81-0453	81-0454	81-0455	81-0456	81-0457	81-0458	81-0459*	81-0462*	81-0463	81-0464*	81-0465*	81-0466*	81-0468	81-0469*	81-0470	Incidence
LESIONS (TISSUES NOT SPECIFICALLY																					
REQUIRED BY PROTOCOL)																					
FEMUR	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
HEPATIC LYMPH NODE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																					
INGUINAL LYMPH NODE	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																					
Fibrosarcoma, metastatic																					
Hyperplasia, lymphoid, diffuse					4																
INTERCOSTAL MUSCLES	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Fibrosarcoma, invasive																					
Myositis, acute, diffuse				3																	
LUMBAR LYMPH NODE	L	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type												P									
Hyperplasia, lymphoid, diffuse	2																				
MANDIBULAR LYMPH NODE	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	
MESENTERIC FAT	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	
Steatitis, chronic, focal							3														

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0472	81-0473	81-0474	81-0475	81-0476	81-0477	81-0478	81-0479*	81-0480	81-0481	81-0483	81-0484	81-0485	81-0486	81-0487*	81-0488	81-0489	81-0490	81-0491	81-0492	Incidence
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
FEMUR		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
HEPATIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	
Malignant Lymphoma, mixed type																	P					
INGUINAL LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	L	-	-	-	
Malignant Lymphoma, mixed type																	P					
Fibrosarcoma, metastatic																		P				
Hyperplasia, lymphoid, diffuse																						
INTERCOSTAL MUSCLES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Fibrosarcoma, invasive																						
Myositis, acute, diffuse																						
LUMBAR LYMPH NODE		-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type																						
Hyperplasia, lymphoid, diffuse																						
MANDIBULAR LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
MESENTERIC FAT		-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	
Steatitis, chronic, focal										4												

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0495	81-0496	81-0497	81-0498	81-0499	81-0500	81-0501*	81-0502	81-0505	81-0506	81-0509*	81-0510*	81-0511*	81-0512*	81-0513	81-0514	81-0515	81-0516	81-0517*	81-0518*	Incidence
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
FEMUR		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
HEPATIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
INGUINAL LYMPH NODE		-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Fibrosarcoma, metastatic																						
Hyperplasia, lymphoid, diffuse						2																
INTERCOSTAL MUSCLES		-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	L	-	
Fibrosarcoma, invasive															P					P		
Myositis, acute, diffuse																						
LUMBAR LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type																						
Hyperplasia, lymphoid, diffuse																						
MANDIBULAR LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	
MESENTERIC FAT		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Steatitis, chronic, focal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I
MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0519*	81-0520*	81-0521																		Incidence
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
FEMUR		N	-	-																		(1)
HEPATIC LYMPH NODE		-	-	-																		(1)
Malignant Lymphoma, mixed type																						1/1
INGUINAL LYMPH NODE		-	-	-																		(4)
Malignant Lymphoma, mixed type																						1/4
Fibrosarcoma, metastatic																						1/4
Hyperplasia, lymphoid, diffuse																						2/4
INTERCOSTAL MUSCLES		-	-	-																		(3)
Fibrosarcoma, invasive																						2/3
Myositis, acute, diffuse																						1/3
LUMBAR LYMPH NODE		-	-	-																		(3)
Malignant Lymphoma, lymphocytic type																						1/3
Hyperplasia, lymphoid, diffuse																						1/3
MANDIBULAR LYMPH NODE		-	-	-																		(2)
MESENTERIC FAT		-	-	-																		(2)
Steatitis, chronic, focal																						2/2

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0447*	81-0448	81-0449*	81-0451*	81-0452	81-0453	81-0454	81-0455	81-0456	81-0457	81-0458	81-0459*	81-0462*	81-0463	81-0464*	81-0465*	81-0466*	81-0468	81-0469*	81-0470	Incidence
PANCREATIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type													P									
Hyperplasia, lymphoid, diffuse																						
PENIS		L	-	-	-	-	-	-	-	-	N	-	-	-	-	L	L	-	-	-	-	
Balanitis, acute, multifocal																						
Balanitis, acute, focal																	2					
Balanitis, chronic, active, diffuse																						
Balanitis, chronic, active, focal																						
Balanitis, chronic, multifocal																3						
Calculus		P																				
PREPUCE		L	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Posthitis, chronic, active, diffuse																						
Posthitis, chronic, active, multifocal		3																				
Posthitis, chronic, diffuse																						
Posthitis, chronic, focal					4																	
Abscess, solitary																						
PREPUTIAL GLAND		L	-	-	-	-	-	-	-	-	L	-	-	L	L	-	L	-	-	-	-	
Adenitis, chronic, active, diffuse											4											
Adenitis, chronic, diffuse														3	3		2					

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0472	81-0473	81-0474	81-0475	81-0476	81-0477	81-0478	81-0479*	81-0480	81-0481	81-0483	81-0484	81-0485	81-0486	81-0487*	81-0488	81-0489	81-0490	81-0491	81-0492	Incidence
PANCREATIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type																						
Hyperplasia, lymphoid, diffuse																						
PENIS		N	-	-	-	N	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	
Balanitis, acute, multifocal																						
Balanitis, acute, focal																						
Balanitis, chronic, active, diffuse																						
Balanitis, chronic, active, focal																						
Balanitis, chronic, multifocal																						
Calculus																						
PREPUCE		-	-	-	-	-	-	-	-	-	-	-	L	-	L	-	-	-	-	-	-	
Posthitis, chronic, active, diffuse															4							
Posthitis, chronic, active, multifocal																						
Posthitis, chronic, diffuse													3									
Posthitis, chronic, focal																						
Abscess, solitary																						
PREPUTIAL GLAND		L	L	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	
Adenitis, chronic, active, diffuse		3	4								4											
Adenitis, chronic, diffuse																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0495	81-0496	81-0497	81-0498	81-0499	81-0500	81-0501*	81-0502	81-0505	81-0506	81-0509*	81-0510*	81-0511*	81-0512*	81-0513	81-0514	81-0515	81-0516	81-0517*	81-0518*	Incidence
PANCREATIC LYMPH NODE		-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type																						
Hyperplasia, lymphoid, diffuse					3																	
PENIS		-	-	N	-	N	-	L	N	-	-	-	L	-	-	-	-	-	-	L	-	
Balanitis, acute, multifocal								3														
Balanitis, acute, focal																						
Balanitis, chronic, active, diffuse													2									
Balanitis, chronic, active, focal																				3		
Balanitis, chronic, multifocal																						
Calculus																						
PREPUCE		-	-	-	-	-	-	L	-	-	-	-	L	-	-	-	-	-	-	L	-	
Posthitis, chronic, active, diffuse													2									
Posthitis, chronic, active, multifocal																						
Posthitis, chronic, diffuse																						
Posthitis, chronic, focal																				3		
Abscess, solitary								4														
PREPUTIAL GLAND		-	-	L	-	L	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	
Adenitis, chronic, active, diffuse				4		2			4													
Adenitis, chronic, diffuse																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0519*	81-0520*	81-0521																		Incidence
PANCREATIC LYMPH NODE		-	-	-																		(2)
Malignant Lymphoma, lymphocytic type																						1/2
Hyperplasia, lymphoid, diffuse																						1/2
PENIS		-	-	-																		(13)
Balanitis, acute, multifocal																						1/13
Balanitis, acute, focal																						1/13
Balanitis, chronic, active, diffuse																						1/13
Balanitis, chronic, active, focal																						1/13
Balanitis, chronic, multifocal																						1/13
Calculus																						1/13
PREPUCE		-	-	-																		(7)
Posthitis, chronic, active, diffuse																						2/7
Posthitis, chronic, active, multifocal																						1/7
Posthitis, chronic, diffuse																						1/7
Posthitis, chronic, focal																						2/7
Abscess, solitary																						1/7
PREPUTIAL GLAND		N	-	-																		(12)
Adenitis, chronic, active, diffuse																						7/12
Adenitis, chronic, diffuse																						3/12

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0447*	81-0448	81-0449*	81-0451*	81-0452	81-0453	81-0454	81-0455	81-0456	81-0457	81-0458	81-0459*	81-0462*	81-0463	81-0464*	81-0465*	81-0466*	81-0468	81-0469*	81-0470	Incidence
PREPUTIAL GLAND (Con't.)		L	-	-	-	-	-	-	-	-	L	-	-	L	L	-	L	-	-	-	-	
Cystic duct		4																				
RENAL LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type													P									
RESPIRATORY LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type													P									
SALIVARY GLAND		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
SEMINAL VESICLES		L	N	N	N	N	N	N	N	N	-	N	N	-	N	-	N	-	N	N	-	
Calculus		P																				
SUBCUTANEOUS LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	
Malignant Lymphoma, mixed type																			P			
Fibrosarcoma, metastatic																						
Hyperplasia, lymphoid, diffuse																						
SUBCUTIS		-	-	-	-	L	L	-	-	L	-	-	-	L	L	-	L	-	L	-	-	
Undifferentiated Sarcoma, solitary																						
Neurofibrosarcoma, solitary														P								
Fibrosarcoma, multifocal																						
Fibrosarcoma, solitary						P											P					
Fibroma, solitary							P			P					P							

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0472	81-0473	81-0474	81-0475	81-0476	81-0477	81-0478	81-0479*	81-0480	81-0481	81-0483	81-0484	81-0485	81-0486	81-0487*	81-0488	81-0489	81-0490	81-0491	81-0492	Incidence
PREPUTIAL GLAND (Con't.)		L	L	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	
Cystic duct																						
RENAL LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type																						
RESPIRATORY LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type																						
SALIVARY GLAND		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
SEMINAL VESICLES		N	N	N	N	N	N	N	N	N	N	-	N	N	N	-	N	-	N	N	N	
Calculus																						
SUBCUTANEOUS LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	L	-	-	-	
Malignant Lymphoma, mixed type																						
Fibrosarcoma, metastatic																		P				
Hyperplasia, lymphoid, diffuse																						
SUBCUTIS		L	L	L	-	-	L	L	L	-	-	-	L	-	-	-	-	L	L	-	-	
Undifferentiated Sarcoma, solitary			P																			
Neurofibrosarcoma, solitary																						
Fibrosarcoma, multifocal									P													
Fibrosarcoma, solitary		P					P	P					P					P				
Fibroma, solitary				P															P			

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0495	81-0496	81-0497	81-0498	81-0499	81-0500	81-0501*	81-0502	81-0505	81-0506	81-0509*	81-0510*	81-0511*	81-0512*	81-0513	81-0514	81-0515	81-0516	81-0517*	81-0518*	Incidence
PREPUTIAL GLAND (Con't.)		-	-	L	-	L	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	
Cystic duct																						
RENAL LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type																						
RESPIRATORY LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type																						
SALIVARY GLAND		-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	
SEMINAL VESICLES		N	N	N	N	N	N	-	N	N	N	N	L	N	-	N	N	N	N	N	N	
Calculus													P									
SUBCUTANEOUS LYMPH NODE		-	-	L	-	-	-	-	L	L	-	-	-	-	-	-	-	-	N	-	-	
Malignant Lymphoma, mixed type																						
Fibrosarcoma, metastatic																						
Hyperplasia, lymphoid, diffuse				2					2	2												
SUBCUTIS		-	-	-	-	-	-	-	-	L	-	L	-	-	L	L	-	-	L	L	L	
Undifferentiated Sarcoma, solitary																			P			
Neurofibrosarcoma, solitary																						
Fibrosarcoma, multifocal																					P	
Fibrosarcoma, solitary															P	P				P		
Fibroma, solitary																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I
MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0519*	81-0520*	81-0521																			Incidence
PREPUTIAL GLAND (Con't.)		N	-	-																			(12)
Cystic duct																							1/12
RENAL LYMPH NODE		-	-	-																			(1)
Malignant Lymphoma, lymphocytic type																							1/1
RESPIRATORY LYMPH NODE		-	-	-																			(1)
Malignant Lymphoma, lymphocytic type																							1/1
SALIVARY GLAND		-	-	-																			(1)
SEMINAL VESICLES		N	N	N																			(53)
Calculus																							2/53
SUBCUTANEOUS LYMPH NODE		-	-	-																			(7)
Malignant Lymphoma, mixed type																							1/7
Fibrosarcoma, metastatic																							1/7
Hyperplasia, lymphoid, diffuse																							3/7
SUBCUTIS		L	L	-																			(25)
Undifferentiated Sarcoma, solitary		P																					3/25
Neurofibrosarcoma, solitary																							1/25
Fibrosarcoma, multifocal																							2/25
Fibrosarcoma, solitary			P																				11/25
Fibroma, solitary																							5/25

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0447*	81-0448	81-0449*	81-0451*	81-0452	81-0453	81-0454	81-0455	81-0456	81-0457	81-0458	81-0459*	81-0462*	81-0463	81-0464*	81-0465*	81-0466*	81-0468	81-0469*	81-0470	Incidence
SUBCUTIS (Con't.)		-	-	-	-	L	L	-	-	L	-	-	-	L	L	-	L	-	L	-	-	
Granuloma, solitary																						
Cellulitis, acute, focal																			4			
Abscess, solitary						4																
Edema, diffuse																						
THYMUS		-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	L	-	-	
Malignant Lymphoma, mixed type																			P			
Malignant Lymphoma, lymphocytic type													P									
URETHRA		L	-	-	-	-	L	-	-	-	L	-	-	-	-	-	-	L	-	-	-	
Urethritis, acute, focal		4																				
Calculus							P				P							P				

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0472	81-0473	81-0474	81-0475	81-0476	81-0477	81-0478	81-0479*	81-0480	81-0481	81-0483	81-0484	81-0485	81-0486	81-0487*	81-0488	81-0489	81-0490	81-0491	81-0492	Incidence
SUBCUTIS (Con't.)		L	L	L	-	-	L	L	L	-	-	-	L	-	-	-	-	L	L	-	-	
Granuloma, solitary																						
Cellulitis, acute, focal																						
Abscess, solitary																						
Edema, diffuse																						
THYMUS		-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
URETHRA		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	L	-	L	
Urethritis, acute, focal																						
Calculus																	P		P		P	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0495	81-0496	81-0497	81-0498	81-0499	81-0500	81-0501*	81-0502	81-0505	81-0506	81-0509*	81-0510*	81-0511*	81-0512*	81-0513	81-0514	81-0515	81-0516	81-0517*	81-0518*	Incidence
SUBCUTIS (Con't.)		-	-	-	-	-	-	-	-	L	-	L	-	-	L	L	-	-	L	L	L	
Granuloma, solitary										2												
Cellulitis, acute, focal																						
Abscess, solitary																						
Edema, diffuse												4										
THYMUS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
URETHRA		-	-	-	-	L	-	-	-	L	L	-	-	L	-	L	-	L	-	L	L	
Urethritis, acute, focal																						
Calculus						P				P	P			P		P		P		P	P	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 0.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP I
MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0519*	81-0520*	81-0521																		Incidence
SUBCUTIS (Con't.)		L	L	-																		(25)
Granuloma, solitary																						1/25
Cellulitis, acute, focal																						1/25
Abscess, solitary																						1/25
Edema, diffuse																						1/25
THYMUS		-	-	-																		(3)
Malignant Lymphoma, mixed type																						1/3
Malignant Lymphoma, lymphocytic type																						1/3
URETHRA		-	-	-																		(15)
Urethritis, acute, focal																						1/15
Calculus																						14/15

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0597	81-0598	81-0599	81-0601	81-0602	81-0603	81-0604	81-0605	81-0606	81-0607	81-0608	81-0609*	81-0611*	81-0612	81-0613*	81-0616	81-0617	81-0618*	81-0619*	81-0620*	Incidence
BRAIN		N	L	N	L	N	L	L	N	N	N	N	N	L	N	L	N	L	N	N	L	
Lymphocytosis, multifocal																		2				
Abscesses, multifocal																					3	
Corpora amylacea, multifocal			2		2		2	1						2		1						
SPINAL CORD		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
SPLEEN		N	L	L	L	L	L	L	L	N	N	L	L	L	L	L	L	L	L	N	L	
Hemangiosarcoma, solitary																						
Malignant Lymphoma, mixed type																						
Leukemia, myeloid																						
Hyperplasia, lymphoid, diffuse			2	2			2		2						2		2	2				
Hematopoiesis, extramedullary, diffuse					3	3		3				3	3	3		4			4		3	
HEART		N	N	N	N	L	N	L	N	N	N	N	N	L	N	L	L	N	L	L	L	
Leukemia, myeloid																						
Myocarditis, chronic, multifocal						2		2						2			1			2	2	
Mineralization, multifocal																2			2			
LIVER		L	L	L	L	N	L	L	N	L	L	L	L	L	N	N	L	L	L	L	N	
Hemangiosarcoma, solitary																	P					
Hepatocellular carcinoma, multifocal		P					P				P											
Hepatocellular carcinoma, solitary			P							P			P					P		P		

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II
MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion / Accession Number	81-0622*	81-0623*	81-0624*	81-0625	81-0626	81-0627*	81-0628	81-0629*	81-0630	81-0631*	81-0632*	81-0633	81-0634	81-0635	81-0636	81-0638*	81-0643	81-0644	81-0646*	81-0647	Incidence
BRAIN	L	N	L	L	N	N	N	L	L	N	L	N	N	L	L	N	N	N	L	N	
Lymphocytosis, multifocal																					
Abscesses, multifocal																					
Corpora amylacea, multifocal	1		2	2				2	2		2			2	2				2		
SPINAL CORD	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
SPLEEN	L	N	N	L	L	L	N	N	L	N	N	N	L	N	L	N	L	L	L	L	
Hemangiosarcoma, solitary																					
Malignant Lymphoma, mixed type																		P			
Leukemia, myeloid						P													P		
Hyperplasia, lymphoid, diffuse	2			2	2								2		2		2			2	
Hematopoiesis, extramedullary, diffuse									3												
HEART	N	N	L	N	L	L	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Leukemia, myeloid						P															
Myocarditis, chronic, multifocal			1		2																
Mineralization, multifocal																					
LIVER	L	L	L	L	N	L	N	L	N	N	L	L	N	N	N	N	N	L	L	L	
Hemangiosarcoma, solitary																					
Hepatocellular carcinoma, multifocal																				P	
Hepatocellular carcinoma, solitary	P	P	P	P				P				P						P			

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0648	81-0649	81-0650	81-0651	81-0652	81-0653	81-0654	81-0656	81-0657	81-0658*	81-0660*	81-0661	81-0663	81-0665	81-0666	81-0667*	81-0668	81-0669	81-0670*	81-0671	Incidence
BRAIN		N	N	L	L	N	L	N	N	N	N	N	L	L	L	N	L	N	N	N	L	(60)
Lymphocytosis, multifocal																						1/60
Abscesses, multifocal																						1/60
Corpora amylacea, multifocal				1	2		2						2	2	1		2				2	23/60
SPINAL CORD		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	(60)
SPLEEN		N	N	N	N	N	L	N	N	L	L	L	L	L	N	L	N	N	L	N	N	(60)
Hemangiosarcoma, solitary																P						1/60
Malignant Lymphoma, mixed type																P						2/60
Leukemia, myeloid																						2/60
Hyperplasia, lymphoid, diffuse							2						2	2					2			18/60
Hematopoiesis, extramedullary, diffuse										4	3	3										13/60
HEART		N	N	N	N	N	N	N	N	L	N	N	N	N	N	N	N	N	N	N	N	(60)
Leukemia, myeloid																						1/60
Myocarditis, chronic, multifocal																						8/60
Mineralization, multifocal										1												3/60
LIVER		L	L	L	L	L	N	L	N	L	L	L	N	N	L	L	L	N	N	L	L	(60)
Hemangiosarcoma, solitary								P												P		3/60
Hepatocellular carcinoma, multifocal											P											5/60
Hepatocellular carcinoma, solitary						P											P				P	15/60

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II
MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0597	81-0598	81-0599	81-0601	81-0602	81-0603	81-0604	81-0605	81-0606	81-0607	81-0608	81-0609*	81-0611*	81-0612	81-0613*	81-0616	81-0617	81-0618*	81-0619*	81-0620*	Incidence
LIVER (Con't.)		L	L	L	L	N	L	L	N	L	L	L	L	L	N	N	L	L	L	L	N	
Malignant Lymphoma, histiocytic type																						
Leukemia, myeloid																						
Hemangiosarcoma, metastatic																						
Hepatocellular adenoma, solitary												P							P			
Focal cellular change, solitary				P																		
Hepatitis, periportal, chronic, active, multifocal																			3			
Infarct, focal							4													4		
Hepatocytomegaly, multifocal																						
Necrosis, periacinar, multifocal														3								
Necrosis, focal																						
Fatty change, periacinar, multifocal																						
Hematopoiesis, extramedullary, diffuse																						
Hematopoiesis, extramedullary, multifocal					2			1														
KIDNEYS		L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	
Renal cell Carcinoma, solitary																						
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, histiocytic type																						
Leukemia, myeloid																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0622*	81-0623*	81-0624*	81-0625	81-0626	81-0627*	81-0628	81-0629*	81-0630	81-0631*	81-0632*	81-0633	81-0634	81-0635	81-0636	81-0638*	81-0643	81-0644	81-0646*	81-0647	Incidence
LIVER (Con't.)		L	L	L	L	N	L	N	L	N	N	L	L	N	N	N	N	N	L	L	L	
Malignant Lymphoma, histiocytic type																						
Leukemia, myeloid							P													P		
Hemangiosarcoma, metastatic																						
Hepatocellular adenoma, solitary																						
Focal cellular change, solitary																						
Hepatitis, periportal, chronic, active, multifocal																						
Infarct, focal																						
Hepatocytomegaly, multifocal																						
Necrosis, periacinar, multifocal												3										
Necrosis, focal																						
Fatty change, periacinar, multifocal												2										
Hematopoiesis, extramedullary, diffuse																						
Hematopoiesis,extramedullary,multifocal																						
KIDNEYS		L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	
Renal cell Carcinoma, solitary																						
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, histiocytic type																						
Leukemia, myeloid							P															

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0648	81-0649	81-0650	81-0651	81-0652	81-0653	81-0654	81-0656	81-0657	81-0658*	81-0660*	81-0661	81-0663	81-0665	81-0666	81-0667*	81-0668	81-0669	81-0670*	81-0671	Incidence
LIVER (Con't.)		L	L	L	L	L	N	L	N	L	L	L	N	N	L	L	L	N	N	L	L	(60)
Malignant Lymphoma, histiocytic type										P												1/60
Leukemia, myeloid																						2/60
Hemangiosarcoma, metastatic																P						1/60
Hepatocellular adenoma, solitary		P	P	P											P							6/60
Focal cellular change, solitary																						1/60
Hepatitis, periportal, chronic, active, multifocal																						1/60
Infarct, focal																						2/60
Hepatocytomegaly, multifocal											2											1/60
Necrosis, periacinar, multifocal																				2		3/60
Necrosis, focal												3					·					1/60
Fatty change, periacinar, multifocal																						1/60
Hematopoiesis, extramedullary, diffuse					2																	1/60
Hematopoiesis, extramedullary, multifocal																						2/60
KIDNEYS		L	L	L	L	L	L	L	L	L	N	N	L	L	L	L	L	L	L	L	L	(60)
Renal cell Carcinoma, solitary																		P				1/60
Malignant Lymphoma, mixed type																P						1/60
Malignant Lymphoma, histiocytic type										P												1/60
Leukemia, myeloid																						1/60

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0597	81-0598	81-0599	81-0601	81-0602	81-0603	81-0604	81-0605	81-0606	81-0607	81-0608	81-0609*	81-0611*	81-0612	81-0613*	81-0616	81-0617	81-0618*	81-0619*	81-0620*	Incidence
KIDNEYS (Con't.)		L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	
Hepatocellular carcinoma, metastatic																						
Hyperplasia, tubular, multifocal		2		2	2	2	2	1	2	2	1	2					2	2	2			
Pyelonephritis, acute, multifocal																			3			
Pyelonephritis,chronic,active,multifocal																						
Nephropathy, chronic, diffuse																						
Nephropathy, chronic, multifocal																						
Nephrocalcinosis, multifocal		1	1	2	1		1	1	2	1		1			1	2	1	1	2			
Necrosis, tubular, multifocal																						
Cyst, solitary (Cortex)																						
Abscesses, multifocal																					3	
Dilatation, multifocal (Tubules)													2							2		
Cytoplasmic vacuolization, diffuse, (Tubules)		1	1	1	1	1	1	2	1	1	1	1	1	1	1	1		1		1	1	
TESTES		N	N	N	N	N	L	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Hemangiosarcoma, solitary							P															
Degeneration, multifocal, unilateral																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion / Accession Number	81-0622*	81-0623*	81-0624*	81-0625	81-0626	81-0627*	81-0628	81-0629*	81-0630	81-0631*	81-0632*	81-0633	81-0634	81-0635	81-0636	81-0638*	81-0643	81-0644	81-0646*	81-0647	Incidence
KIDNEYS (Con't.)	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	
Hepatocellular carcinoma, metastatic																					
Hyperplasia, tubular, multifocal	2			2	2		2		2					2	2		2	2		2	
Pyelonephritis, acute, multifocal																					
Pyelonephritis, chronic, active, multifocal																3					
Nephropathy, chronic, diffuse																					
Nephropathy, chronic, multifocal												2									
Nephrocalcinosis, multifocal				2	1			1	1	1	1		1	2			2		1	1	
Necrosis, tubular, multifocal					2																
Cyst, solitary (Cortex)									2												
Abscesses, multifocal																					
Dilatation, multifocal (Tubules)	2					2															
Cytoplasmic vacuolization, diffuse, (Tubules)	1	1	1	1	1		1		1	2	1	2	1	2		2	1			2	
TESTES	N	N	N	N	N	N	N	N	N	N	N	N	N	L	N	N	N	N	N	N	
Hemangiosarcoma, solitary																					
Degeneration, multifocal, unilateral														2							

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0648	81-0649	81-0650	81-0651	81-0652	81-0653	81-0654	81-0656	81-0657	81-0658*	81-0660*	81-0661	81-0663	81-0665	81-0666	81-0667*	81-0668	81-0669	81-0670*	81-0671	Incidence
KIDNEYS (Con't.)		L	L	L	L	L	L	L	L	L	N	N	L	L	L	L	L	L	L	L	L	(60)
Hepatocellular carcinoma, metastatic																					P	1/60
Hyperplasia, tubular, multifocal			2	2	2		2		1				2	2	2	2				2	2	34/60
Pyelonephritis, acute, multifocal																						1/60
Pyelonephritis, chronic, active, multifocal																						1/60
Nephropathy, chronic, diffuse						4													3			2/60
Nephropathy, chronic, multifocal		2																				2/60
Nephrocalcinosis, multifocal		1		1	1		2		1				2	2	2	1		1				35/60
Necrosis, tubular, multifocal																						1/60
Cyst, solitary (Cortex)																						1/60
Abscesses, multifocal																						1/60
Dilatation, multifocal (Tubules)																	2					5/60
Cytoplasmic vacuolization, diffuse, (Tubules)		1	1	2	2	2	1	2					1	2	1			1	1	1	1	47/60
TESTES		N	N	N	L	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	(60)
Hemangiosarcoma, solitary																						1/60
Degeneration, multifocal, unilateral					2																	2/60

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number 81-0597	81-0598	81-0599	81-0601	81-0602	81-0603	81-0604	81-0605	81-0606	81-0607	81-0608	81-0609*	81-0611*	81-0612	81-0613*	81-0616	81-0617	81-0618*	81-0619*	81-0620*	Incidence
LESIONS (TISSUES NOT SPECIFICALLY																					
REQUIRED BY PROTOCOL)																					
ADRENALS	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	
COLON	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																					
EPIDIDYMIDES	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-	-	-	-	-	
Epididymitis, chronic, active, diffuse																					
EYES	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	
Keratitis, chronic, diffuse, unilateral								3													
GALL BLADDER	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
HARDERIAN GLAND	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	
Adenoma, solitary															P						
ILEUM	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																					
Hyperplasia, lymphoid, diffuse,																					
(Peyer's Patch)																					
Necrosis, focal (Peyer's Patch)																					
INGUINAL LYMPH NODE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion / Accession Number	81-0622*	81-0623*	81-0624*	81-0625	81-0626	81-0627*	81-0628	81-0629*	81-0630	81-0631*	81-0632*	81-0633	81-0634	81-0635	81-0636	81-0638*	81-0643	81-0644	81-0646*	81-0647	Incidence
LESIONS (TISSUES NOT SPECIFICALLY																					
REQUIRED BY PROTOCOL)																					
ADRENALS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	
COLON	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	
Malignant Lymphoma, mixed type																		P			
EPIDIDYMIDES	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	
Epididymitis, chronic, active, diffuse																					
EYES	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Keratitis, chronic, diffuse, unilateral																					
GALL BLADDER	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
HARDERIAN GLAND	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Adenoma, solitary																					
ILEUM	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	
Malignant Lymphoma, mixed type																		P			
Hyperplasia, lymphoid, diffuse,																					
(Peyer'sPatch)	3																				
Necrosis, focal (Peyer's Patch)	4																				
INGUINAL LYMPH NODE	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-	-	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0648	81-0649	81-0650	81-0651	81-0652	81-0653	81-0654	81-0656	81-0657	81-0658*	81-0660*	81-0661	81-0663	81-0665	81-0666	81-0667*	81-0668	81-0669	81-0670*	81-0671	Incidence
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
ADRENALS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(2)
COLON		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(1)
Malignant Lymphoma, mixed type																						1/1
EPIDIDYMIDES		-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	(3)
Epididymitis, chronic, active, diffuse									3													1/3
EYES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(1)
Keratitis, chronic, diffuse, unilateral																						1/1
GALL BLADDER		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	(1)
HARDERIAN GLAND		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(1)
Adenoma, solitary																						1/1
ILEUM		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(2)
Malignant Lymphoma, mixed type																						1/2
Hyperplasia, lymphoid, diffuse, (Peyers																						
Patch)																						1/2
Necrosis, focal (Peyer's Patch)																						1/2
INGUINAL LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(1)

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0597	81-0598	81-0599	81-0601	81-0602	81-0603	81-0604	81-0605	81-0606	81-0607	81-0608	81-0609*	81-0611*	81-0612	81-0613*	81-0616	81-0617	81-0618*	81-0619*	81-0620*	Incidence
JEJUNUM		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Hemorrhage, focal																						
LUMBAR LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	
Edema, diffuse														3								
LUNGS		-	-	L	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	L	
Undifferentiated Sarcoma, solitary																					P	
Alveolar/bronchiolar carcinoma,multifocal				P																		
Alveolar/bronchiolar carcinoma, solitary																						
Leukemia, myeloid																						
Bronchopneumonia, acute, multifocal																					3	
Histiocytosis, multifocal																						
Hemorrhage, multifocal																						
Congestion, diffuse																						
MANDIBULAR LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	
MESENTERIC FAT		-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Steatitis, chronic, multifocal																						
Steatitis, chronic, focal						3																

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0622*	81-0623*	81-0624*	81-0625	81-0626	81-0627*	81-0628	81-0629*	81-0630	81-0631*	81-0632*	81-0633	81-0634	81-0635	81-0636	81-0638*	81-0643	81-0644	81-0646*	81-0647	Incidence
JEJUNUM		-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	
Malignant Lymphoma, mixed type																			P			
Hemorrhage, focal				1																		
LUMBAR LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Edema, diffuse																						
LUNGS		L	L	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	L	-	-	
Undifferentiated Sarcoma, solitary																						
Alveolar/bronchiolar carcinoma,multifocal																						
Alveolar/bronchiolar carcinoma,solitary		P																	P			
Leukemia, myeloid							P															
Bronchopneumonia, acute, multifocal																						
Histiocytosis, multifocal																			3			
Hemorrhage, multifocal																						
Congestion, diffuse			3																			
MANDIBULAR LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
MESENTERIC FAT		-	-	-	L	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Steatitis, chronic, multifocal																						
Steatitis, chronic, focal					4	3																

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion / Accession Number	81-0648	81-0649	81-0650	81-0651	81-0652	81-0653	81-0654	81-0656	81-0657	81-0658*	81-0660*	81-0661	81-0663	81-0665	81-0666	81-0667*	81-0668	81-0669	81-0670*	81-0671	Incidence
JEJUNUM	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(2)
Malignant Lymphoma, mixed type																					1/2
Hemorrhage, focal																					1/2
LUMBAR LYMPH NODE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(1)
Edema, diffuse																					1/1
LUNGS	-	L	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	L	-	(10)
Undifferentiated Sarcoma, solitary																					1/10
Alveolar/bronchiolar carcinoma,multifocal																					1/10
Alveolar/bronchiolar carcinoma,solitary		P													P						4/10
Leukemia, myeloid																					1/10
Bronchopneumonia, acute, multifocal																					1/10
Histiocytosis, multifocal																					1/10
Hemorrhage, multifocal																			4		1/10
Congestion, diffuse																					1/10
MANDIBULAR LYMPH NODE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(1)
MESENTERIC FAT	-	L	-	-	-	-	-	-	L	-	-	-	-	-	-	L	-	-	-	-	(6)
Steatitis, chronic, multifocal																4					1/6
Steatitis, chronic, focal		4							3												5/6

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0597	81-0598	81-0599	81-0601	81-0602	81-0603	81-0604	81-0605	81-0606	81-0607	81-0608	81-0609*	81-0611*	81-0612	81-0613*	81-0616	81-0617	81-0618*	81-0619*	81-0620*	Incidence
MESENTERIC LYMPH NODE		L	-	L	-	L	-	-	-	L	-	L	-	L	-	L	L	-	-	-	-	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, histiocytic type																						
Hyperplasia, lymphoid, diffuse				2						4		3					3					
Lymphadenitis, acute, diffuse						4								3								
Hemorrhage, diffuse																						
Congestion, diffuse		2														3						
MESENTERY		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Hemorrhage, focal																						
OPTIC NERVE		-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	
PENIS		-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	L	
Squamous cell Carcinoma, solitary																						
Balanitis, chronic, diffuse																					3	
Balanitis, chronic, multifocal																						
Balanitis, chronic, focal																						
Calculus												P										
PITUITARY		-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	
PREPUCE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Posthitis, chronic, focal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0622*	81-0623*	81-0624*	81-0625	81-0626	81-0627*	81-0628	81-0629*	81-0630	81-0631*	81-0632*	81-0633	81-0634	81-0635	81-0636	81-0638*	81-0643	81-0644	81-0646*	81-0647	Incidence
MESENTERIC LYMPH NODE		L	-	L	-	L	-	-	-	-	L	-	-	-	-	-	-	-	L	-	-	
Malignant Lymphoma, mixed type																			P			
Malignant Lymphoma, histiocytic type																						
Hyperplasia, lymphoid, diffuse		3				3																
Lymphadenitis, acute, diffuse																						
Hemorrhage, diffuse				4																		
Congestion, diffuse		3				3					2											
MESENTERY		-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Hemorrhage, focal						3																
OPTIC NERVE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
PENIS		-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	L	-	-	-	L	
Squamous cell carcinoma, solitary																						
Balanitis, chronic, diffuse																					3	
Balanitis, chronic, multifocal																	1					
Balanitis, chronic, focal																						
Calculus																						
PITUITARY		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
PREPUCE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Posthitis, chronic, focal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0648	81-0649	81-0650	81-0651	81-0652	81-0653	81-0654	81-0656	81-0657	81-0658*	81-0660*	81-0661	81-0663	81-0665	81-0666	81-0667*	81-0668	81-0669	81-0670*	81-0671	Incidence
MESENTERIC LYMPH NODE		-	L	-	-	-	-	-	L	L	-	-	-	-	L	L	-	-	-	-	L	(19)
Malignant Lymphoma, mixed type																						1/19
Malignant Lymphoma, histiocytic type										P												1/19
Hyperplasia, lymphoid, diffuse									2							2						8/19
Lymphadenitis, acute, diffuse																						2/19
Hemorrhage, diffuse																						1/19
Congestion, diffuse			4						3						3						3	9/19
MESENTERY		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(1)
Hemorrhage, focal																						1/1
OPTIC NERVE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(1)
PENIS		-	L	L	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	(8)
Squamous cell carcinoma, solitary																	P					1/8
Balanitis, chronic, diffuse				3																		3/8
Balanitis, chronic, multifocal																						1/8
Balanitis, chronic, focal			2																			1/8
Calculus																						1/8
PITUITARY		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(1)
PREPUCE		-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(1)
Posthitis, chronic, focal				3																		1/1

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0597	81-0598	81-0599	81-0601	81-0602	81-0603	81-0604	81-0605	81-0606	81-0607	81-0608	81-0609*	81-0611*	81-0612	81-0613*	81-0616	81-0617	81-0618*	81-0619*	81-0620*	Incidence
PREPUTIAL GLAND		-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	L	-	-	L	L	
Adenitis, chronic, active, diffuse																	4			4	4	
Adenitis, chronic, active, focal																						
Adenitis, chronic, diffuse												3										
Dilated ducts																						
PROSTATE		-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	
Prostatitis, chronic,active,multifocal																						
RENAL LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Hemangiosarcoma, solitary																						
SEMINAL VESICLES		-	-	-	-	-	-	N	-	-	-	-	-	N	-	-	-	-	-	-	-	
SKIN		L	L	-	-	-	-	-	-	-	L	-	-	-	-	L	L	L	L	L	-	
Dermatitis, chronic, active, diffuse																						
Dermatitis, chronic, diffuse		2									3						3	3	2	3		
Dermatitis, chronic, multifocal																						
Dermatitis, chronic, focal			3													3						
Ulcers, acute, multifocal																						
Ulcers, chronic, multifocal																						
Ulcer, chronic, focal																						
Erosion, focal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion / Accession Number	81-0622*	81-0623*	81-0624*	81-0625	81-0626	81-0627*	81-0628	81-0629*	81-0630	81-0631*	81-0632*	81-0633	81-0634	81-0635	81-0636	81-0638*	81-0643	81-0644	81-0646*	81-0647	Incidence
PREPUTIAL GLAND	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	L	
Adenitis, chronic, active, diffuse																					
Adenitis, chronic, active, focal																				4	
Adenitis, chronic, diffuse																					
Dilated ducts		3														3					
PROSTATE	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	L	-	-	-	-	
Prostatitis, chronic, active, multifocal																3					
RENAL LYMPH NODE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	
Hemangiosarcoma, solitary															P						
SEMINAL VESICLES	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	N	-	-	-	-	
SKIN	L	L	-	L	-	-	L	N	-	L	-	L	-	-	L	L	-	-	-	-	
Dermatitis, chronic, active, diffuse																4					
Dermatitis, chronic, diffuse		3		3			4								4						
Dermatitis, chronic, multifocal												3									
Dermatitis, chronic, focal	4																				
Ulcers, acute, multifocal																4					
Ulcers, chronic, multifocal															4						
Ulcer, chronic, focal	4						2			3											
Erosion, focal										1											

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion / Accession Number	81-0648	81-0649	81-0650	81-0651	81-0652	81-0653	81-0654	81-0656	81-0657	81-0658*	81-0660	81-0661	81-0663	81-0665	81-0666	81-0667*	81-0668	81-0669	81-0670*	81-0671	Incidence
PREPUTIAL GLAND	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(7)
Adenitis, chronic, active, diffuse																					3/7
Adenitis, chronic, active, focal																					1/7
Adenitis, chronic, diffuse																					1/7
Dilated ducts																					2/7
PROSTATE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(3)
Prostatitis, chronic, active, multifocal																					1/3
RENAL LYMPH NODE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(1)
Hemangiosarcoma, solitary																					1/1
SEMINAL VESICLES	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	(5)
SKIN	L	L	-	L	-	-	L	-	-	-	-	L	-	-	-	-	-	L	-	-	(23)
Dermatitis, chronic, active, diffuse																					1/23
Dermatitis, chronic, diffuse	4	4		4			4														14/23
Dermatitis, chronic, multifocal																					1/23
Dermatitis, chronic, focal												2						4			5/23
Ulcers, acute, multifocal																					1/23
Ulcers, chronic, multifocal																					1/23
Ulcer, chronic, focal																					3/23
Erosion, focal																					1/23

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II
MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0597	81-0598	81-0599	81-0601	81-0602	81-0603	81-0604	81-0605	81-0606	81-0607	81-0608	81-0609*	81-0611*	81-0612	81-0613*	81-0616	81-0617	81-0618*	81-0619*	81-0620*	Incidence
STOMACH		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Gastritis, chronic, active, focal																						
SUBCUTANEOUS LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	
Hyperplasia, lymphoid, diffuse																						
SUBCUTIS		-	-	L	L	L	L	L	-	L	-	L	L	L	L	L	-	-	L	-	L	
Undifferentiated Sarcoma, solitary																						
Neurofibrosarcoma, solitary																						
Hemangiosarcoma, solitary														P								
Fibrosarcoma, multifocal								P														
Fibrosarcoma, solitary					P					P			P		P	P			P			
Fibroma, solitary				P			P					P			P	P						
Cellulitis, chronic, focal																						
Abscess, solitary																					4	
Granulation tissue, multifocal																						
Granulation tissue, focal																					3	
Hematoma, solitary						4																
URETHRA		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Calculus																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion / Accession Number	81-0622*	81-0623*	81-0624*	81-0625	81-0626	81-0627*	81-0628	81-0629*	81-0630	81-0631*	81-0632*	81-0633	81-0634	81-0635	81-0636	81-0638*	81-0643	81-0644	81-0646*	81-0647	Incidence
STOMACH	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	N	-	-	-	-	
Gastritis, chronic, active, focal											2										
SUBCUTANEOUS LYMPH NODE	-	-	N	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	
Hyperplasia, lymphoid, diffuse							3														
SUBCUTIS	L	-	-	-	L	L	L	-	L	-	-	L	-	-	-	-	L	-	L	-	
Undifferentiated Sarcoma, solitary									P												
Neurofibrosarcoma, solitary																					
Hemangiosarcoma, solitary																					
Fibrosarcoma, multifocal																					
Fibrosarcoma, solitary					P	P											P		P		
Fibroma, solitary												P									
Cellulitis, chronic, focal	3																				
Abscess, solitary																					
Granulation tissue, multifocal							3														
Granulation tissue, focal	3																				
Hematoma, solitary																					
URETHRA	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	
Calculus											P										

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion / Accession Number	81-0648	81-0649	81-0650	81-0651	81-0652	81-0653	81-0654	81-0656	81-0657	81-0658*	81-0660*	81-0661	81-0663	81-0665	81-0666	81-0667*	81-0668	81-0669	81-0670*	81-0671	Incidence
STOMACH	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(2)
Gastritis, chronic, active, focal																					1/2
SUBCUTANEOUS LYMPH NODE	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	(4)
Hyperplasia, lymphoid, diffuse								3													2/4
SUBCUTIS	-	-	L	-	-	L	-	-	-	L	L	-	-	-	-	-	-	-	L	-	(26)
Undifferentiated Sarcoma, solitary											P										2/26
Neurofibrosarcoma, solitary						P															1/26
Hemangiosarcoma, solitary																					1/26
Fibrosarcoma, multifocal																					1/26
Fibrosarcoma, solitary			P																		11/26
Fibroma, solitary			P																P		8/26
Cellulitis, chronic, focal																					1/26
Abscess, solitary										4											2/26
Granulation tissue, multifocal																					1/26
Granulation tissue, focal																					2/26
Hematoma, solitary																					1/26
URETHRA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(1)
Calculus																					1/1

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II
MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0597	81-0598	81-0599	81-0601	81-0602	81-0603	81-0604	81-0605	81-0606	81-0607	81-0608	81-0609*	81-0611*	81-0612	81-0613*	81-0616	81-0617	81-0618*	81-0619*	81-0620*	Incidence
URINARY BLADDER		-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-	-	-	-	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II
MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0622*	81-0623*	81-0624*	81-0625	81-0626	81-0627*	81-0628	81-0629*	81-0630	81-0631*	81-0632*	81-0633	81-0634	81-0635	81-0636	81-0638*	81-0643	81-0644	81-0646*	81-0647	Incidence
URINARY BLADDER		-	-	-	-	-	-	N	N	-	-	-	-	-	-	-	N	-	-	-	-	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP II

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0648	81-0649	81-0650	81-0651	81-0652	81-0653	81-0654	81-0656	81-0657	81-0658*	81-0660*	81-0661	81-0663	81-0665	81-0666	81-0667*	81-0668	81-0669	81-0670*	81-0671	Incidence
URINARY BLADDER		-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	(6)

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0747.	81-0748*	81-0749	81-0750*	81-0752	81-0753	81-0754*	81-0756*	81-0757*	81-0758	81-0759	81-0760	81-0761*	81-0762*	81-0763*	81-0764	81-0765	81-0767*	81-0768	81-0769*	Incidence
BRAIN		L	L	L	N	N	L	L	N	L	N	N	N	N	N	N	L	L	L	N	L	
Malignant Lymphoma, mixed type																			P			
Corpora amylacea, multifocal		2	2	2			2	2		1							2	2	2		2	
SPINAL CORD		N	N	N	N	N	N	N	N	N	N	N	N	N	N	L	N	N	N	N	N	
Malignant Lymphoma, mixed type																P						
SPLEEN		N	L	L	L	L	L	L	N	N	L	L	L	L	N	L	L	N	L	L	L	
Hemangiosarcoma, solitary																						
Malignant Lymphoma, mixed type				P		P										P			P			
Malignant Lymphoma, lymphocytic type					P																	
Malignant Lymphoma, histiocytic type			P																			
Hyperplasia, lymphoid, diffuse							2				2		2							2		
Hyperplasia, reticulum-cell, multifocal																						
Hematopoiesis, extramedullary, diffuse								3				3		3			3				2	
HEART		N	N	N	N	N	N	N	N	N	N	N	N	L	N	L	L	L	L	N	N	
Malignant Lymphoma, mixed type																			P			
Malignant Lymphoma, mixed type(Pericard.)																						
Fibrosarcoma, metastatic														P								
Myocarditis, acute, focal																						
Myocarditis, chronic, active, multifocal																		4				

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0770*	81-0771	81-0773	81-0774*	81-0775	81-0776	81-0777	81-0778	81-0779	81-0781	81-0782	81-0784	81-0786*	81-0787	81-0788	81-0789	81-0790*	81-0791	81-0792	81-0793	Incidence
BRAIN		L	N	L	L	L	L	N	L	L	L	L	L	N	L	N	L	N	L	L	N	
Malignant Lymphoma, mixed type																						
Corpora amylacea, multifocal		2		2	2	2	2		2	2	2	1	2		2		2		2	2		
SPINAL CORD		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, mixed type																						
SPLEEN		L	L	L	N	L	L	N	N	L	L	N	L	L	L	L	L	N	L	L	N	
Hemangiosarcoma, solitary															P							
Malignant Lymphoma, mixed type			P	P			P										P			P		
Malignant Lymphoma, lymphocytic type																						
Malignant Lymphoma, histiocytic type										P												
Hyperplasia, lymphoid, diffuse						2					2		2			2			2			
Hyperplasia, reticulum-cell, multifocal																						
Hematopoiesis, extramedullary, diffuse		3				3	3							3								
HEART		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, mixed type(Pericard.)																						
Fibrosarcoma, metastatic																						
Myocarditis, acute, focal																						
Myocarditis, chronic, active, multifocal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0794	81-0795	81-0796	81-0797	81-0798*	81-0799	81-0802	81-0804	81-0805	81-0806*	81-0807	81-0809*	81-0810*	81-0811	81-0812*	81-0813	81-0814*	81-0815*	81-0816*	81-0817	Incidence
BRAIN		L	N	L	L	L	N	L	L	N	N	L	L	L	L	N	L	L	L	L	L	
Malignant Lymphoma, mixed type																						
Corpora amylacea, multifocal		2		2	1	2		2	2			1	2	2	2		2	2	1	2	2	
SPINAL CORD		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, mixed type																						
SPLEEN		L	L	L	L	L	N	N	L	N	N	L	L	L	N	L	L	L	N	N	N	
Hemangiosarcoma, solitary																						
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
Malignant Lymphoma, histiocytic type																						
Hyperplasia, lymphoid, diffuse		2	2	2	2				2			2										
Hyperplasia, reticulum-cell, multifocal																	2					
Hematopoiesis, extramedullary, diffuse			3			3							3	3		2		3				
HEART		N	N	N	L	N	N	N	L	N	N	N	L	L	N	L	N	N	N	L	N	
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, mixed type(Pericard.)														P								
Fibrosarcoma, metastatic																P						
Myocarditis, acute, focal																				2		
Myocarditis, chronic, active, multifocal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number 81-0820	81-0821	Incidence
BRAIN	L	N	(62)
Malignant Lymphoma, mixed type			1/62
Corpora amylacea, multifocal	1		40/62
SPINAL CORD	N	N	(62)
Malignant Lymphoma, mixed type			1/62
SPLEEN	L	L	(62)
Hemangiosarcoma, solitary			1/62
Malignant Lymphoma, mixed type			9/62
Malignant Lymphoma, lymphocytic type			1/62
Malignant Lymphoma, histiocytic type			2/62
Hyperplasia, lymphoid, diffuse	2	2	17/62
Hyperplasia, reticulum-cell, multifocal			1/62
Hematopoiesis, extramedullary, diffuse			15/62
HEART	N	N	(62)
Malignant Lymphoma, mixed type			1/62
Malignant Lymphoma, mixed type(Pericard.)			1/62
Fibrosarcoma, metastatic			2/62
Myocarditis, acute, focal			1/62
Myocarditis, chronic, active, multifocal			1/62

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0747	81-0748*	81-0749	81-0750*	81-0752	81-0753	81-0754*	81-0756*	81-0757*	81-0758	81-0759	81-0760	81-0761*	81-0762*	81-0763*	81-0764	81-0765	81-0767*	81-0768	81-0769*	Incidence
HEART (Con't.)		N	N	N	N	N	N	N	N	N	N	N	N	L	N	L	L	L	L	N	N	
Myocarditis, chronic, multifocal																						
Myocarditis, chronic, focal																2						
Mineralization, multifocal																	2					
Mineralization, focal																						
LIVER		N	L	N	L	N	N	N	L	N	N	N	L	N	L	N	L	L	L	L	L	
Hemangiosarcoma, solitary																						
Hepatocellular carcinoma, multifocal									P								P					
Hepatocellular carcinoma, solitary													P		P					P		
Malignant Lymphoma, mixed type																			P			
Malignant Lymphoma, lymphocytic type					P																	
Malignant Lymphoma, histiocytic type			P																			
Osteosarcoma, metastatic, primary site																						
unknown																						
Hepatocellular adenoma, solitary																						
Necrosis, periacinar, diffuse																						
Necrosis, focal															3						2	
Hematopoiesis,extramedullary,multifocal																		1				

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0770*	81-0771	81-0773	81-0774*	81-0775	81-0776	81-0777	81-0778	81-0779	81-0781	81-0782	81-0784	81-0786*	81-0787	81-0788	81-0789	81-0790*	81-0791	81-0792	81-0793	Incidence
HEART (Con't.)		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Myocarditis, chronic, multifocal																						
Myocarditis, chronic, focal																						
Mineralization, multifocal																						
Mineralization, focal																						
LIVER		L	L	N	N	N	L	N	N	L	N	N	L	N	N	N	L	L	N	L	N	
Hemangiosarcoma, solitary		P																				
Hepatocellular carcinoma, multifocal			P							P										P		
Hepatocellular carcinoma, solitary							P						P					P				
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, lymphocytic type																						
Malignant Lymphoma, histiocytic type																						
Osteosarcoma, metastatic, primary site																						
unknown																						
Hepatocellular adenoma, solitary																						
Necrosis, periacinar, diffuse																						
Necrosis, focal																						
Hematopoiesis,extramedullary,multifocal																	1					

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III
MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0794	81-0795	81-0796	81-0797	81-0798*	81-0799	81-0802	81-0804	81-0805	81-0806*	81-0807	81-0809*	81-0810*	81-0811	81-0812*	81-0813	81-0814*	81-0815*	81-0816*	81-0817	Incidence
HEART (Con't.)		N	N	N	L	N	N	N	L	N	N	N	L	L	N	L	N	N	N	L	N	
Myocarditis, chronic, multifocal					1								1									
Myocarditis, chronic, focal																						
Mineralization, multifocal																						
Mineralization, focal									1													
LIVER		N	L	L	N	N	N	L	N	N	L	L	N	L	L	L	N	L	L	N	N	
Hemangiosarcoma, solitary			P																			
Hepatocellular carcinoma, multifocal				P				P				P							P			
Hepatocellular carcinoma, solitary											P											
Malignant Lymphoma, mixed type														P								
Malignant Lymphoma, lymphocytic type																						
Malignant Lymphoma, histiocytic type																						
Osteosarcoma, metastatic, primary site																						
unknown				P																		
Hepatocellular adenoma, solitary																		P				
Necrosis, periacinar, diffuse			4																			
Necrosis, focal																						
Hematopoiesis, extramedullary, multifocal															1	2						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0820	81-0821																				Incidence
HEART (Con't.)		N	N																				(62)
Myocarditis, chronic, multifocal																							2/62
Myocarditis, chronic, focal																							1/62
Mineralization, multifocal																							1/62
Mineralization, focal																							1/62
LIVER		N	N																				(62)
Hemangiosarcoma, solitary																							2/62
Hepatocellular carcinoma, multifocal																							9/62
Hepatocellular carcinoma, solitary																							7/62
Malignant Lymphoma, mixed type																							2/62
Malignant Lymphoma, lymphocytic type																							1/62
Malignant Lymphoma, histiocytic type																							1/62
Osteosarcoma, metastatic, primary site unknown																							1/62
Hepatocellular adenoma, solitary																							1/62
Necrosis, periacinar, diffuse																							1/62
Necrosis, focal																							2/62
Hematopoiesis, extramedullary, multifocal																							4/62

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion / Accession Number	81-0747	81-0748*	81-0749	81-0750*	81-0752	81-0753	81-0754*	81-0756*	81-0757*	81-0758	81-0759	81-0760	81-0761*	81-0762*	81-0763*	81-0764	81-0765	81-0767*	81-0768	81-0769*	Incidence
KIDNEYS	L	L	L	L	L	L	L	N	L	L	L	L	L	L	L	L	L	L	L	L	
Malignant Lymphoma, mixed type												P						P			
Fibrosarcoma, metastatic, unilateral																					
Hyperplasia, tubular, multifocal	2	2	2		2	2	2		2	2		1				2	2		2	2	
Pyelonephritis, acute, multifocal															3						
Pyelonephritis, chronic, active, multifocal																					
Pyelitis, acute, focal																					
Nephrocalcinosis, multifocal	2	2			1	1				1	1	1			2	1	2		2	1	
Nephropathy, chronic, diffuse				3																	
Nephropathy, chronic, multifocal																					
Necrosis, tubular, multifocal																	1				
Infarct, acute, focal																					
Infarcts, healed, multifocal (Cortex)																					
Infarct, healed, focal (Cortex)																					
Cyst, cortical, solitary																					
Atrophy, diffuse, unilateral							4														
Fibrosis, focal (Cortex)											1										
Congestion, diffuse																					
Cytoplasmic vacuolization, diffuse, (Tubules)	2	2	2		1	1	2		2		1	2	1	1	2	2	2		2		

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0770*	81-0771	81-0773	81-0774*	81-0775	81-0776	81-0777	81-0778	81-0779	81-0781	81-0782	81-0784	81-0786*	81-0787	81-0788	81-0789	81-0790*	81-0791	81-0792	81-0793	Incidence
KIDNEYS		L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	N	L	L	L	
Malignant Lymphoma, mixed type				P			P															
Fibrosarcoma, metastatic, unilateral																						
Hyperplasia, tubular, multifocal			2	2		2		1	2	2	1	2	1	2	2	3	2		2	2	2	
Pyelonephritis, acute, multifocal																						
Pyelonephritis,chronic,active,multifocal																						
Pyelitis, acute, focal		2																				
Nephrocalcinosis, multifocal			1	2	2	1		1	1	2		2			1		1		2	1	2	
Nephropathy, chronic, diffuse																						
Nephropathy, chronic, multifocal																						
Necrosis, tubular, multifocal						2																
Infarct, acute, focal																						
Infarcts, healed, multifocal (Cortex)														3								
Infarct, healed, focal (Cortex)												2										
Cyst, cortical, solitary																				2		
Atrophy, diffuse, unilateral		4																				
Fibrosis, focal (Cortex)																						
Congestion, diffuse																						
Cytoplasmic vacuolization, diffuse, (Tubules)		1	1	2		2	2	1	1	1	1	2	1	1	2	1	1		2	2	1	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion / Accession Number	81-0794	81-0795	81-0796	81-0797	81-0798*	81-0799	81-0802	81-0804	81-0805	81-0806*	81-0807	81-0809*	81-0810*	81-0811	81-0812*	81-0813	81-0814*	81-0815*	81-0816*	81-0817	Incidence
KIDNEYS	L	L	L	L	N	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	
Malignant Lymphoma, mixed type																					
Fibrosarcoma, metastatic, unilateral																	P				
Hyperplasia, tubular, multifocal	1	2		2			1	2	2		2	1				2	2			2	
Pyelonephritis, acute, multifocal																					
Pyelonephritis,chronic,active,multifocal											3										
Pyelitis, acute, focal																					
Nephrocalcinosis, multifocal	1	2		1		2		1	2		1		1	2	1	2	1		1	1	
Nephropathy, chronic, diffuse																					
Nephropathy, chronic, multifocal			3											2							
Necrosis, tubular, multifocal							2														
Infarct, acute, focal																	3				
Infarcts, healed, multifocal (Cortex)																					
Infarct, healed, focal (Cortex)																					
Cyst, cortical, solitary	2																				
Atrophy, diffuse, unilateral																					
Fibrosis, focal (Cortex)																					
Congestion, diffuse										3											
Cytoplasmic vacuolization, diffuse, (Tubules)	1	1	1	1			1	2	2	1	1	1			2	2	1	2	1	2	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0820	81-0821																			Incidence
KIDNEYS		L	L																			(62)
Malignant Lymphoma, mixed type																						4/62
Fibrosarcoma, metastatic, unilateral																						1/62
Hyperplasia, tubular, multifocal		1	1																			42/62
Pyelonephritis, acute, multifocal																						1/62
Pyelonephritis, chronic, active, multifocal																						1/62
Pyelitis, acute, focal																						1/62
Nephrocalcinosis, multifocal		1	1																			41/62
Nephropathy, chronic, diffuse																						1/62
Nephropathy, chronic, multifocal																						2/62
Necrosis, tubular, multifocal																						3/62
Infarct, acute, focal																						1/62
Infarcts, healed, multifocal (Cortex)																						1/62
Infarct, healed, focal (Cortex)																						1/62
Cyst, cortical, solitary			2																			3/62
Atrophy, diffuse, unilateral																						2/62
Fibrosis, focal (Cortex)																						1/62
Congestion, diffuse																						1/62
Cytoplasmic vacuolization, diffuse, (Tubules)		2	1																			51/62

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0747	81-0748*	81-0749	81-0750*	81-0752	81-0753	81-0754*	81-0756*	81-0757*	81-0758	81-0759	81-0760	81-0761*	81-0762*	81-0763*	81-0764	81-0765	81-0767*	81-0768	81-0769*	Incidence
TESTES		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	L	N	N	N	N	
Degeneration, diffuse, bilateral																	1					
Degeneration, multifocal, unilateral																						
Mineralization, multifocal, unilateral,																						
(Tubules)																						
Oligospermia, multifocal, unilateral																						
Hematoma, solitary, unilateral																						
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
ADRENALS		-	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	
Pheochromocytoma, solitary																						
AXILLARY LYMPH NODE		-	-	-	-	-	-	-	L	-	-	-	-	L	-	-	-	-	-	-	-	
Fibrosarcoma, metastatic									P					P								
CERVICAL LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
DUODENUM		-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	
Fibrosarcoma, metastatic														P								
Hemorrhage, focal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0770*	81-0771	81-0773	81-0774*	81-0775	81-0776	81-0777	81-0778	81-0779	81-0781	81-0782	81-0784	81-0786*	81-0787	81-0788	81-0789	81-0790*	81-0791	81-0792	81-0793	Incidence
TESTES		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Degeneration, diffuse, bilateral																						
Degeneration, multifocal, unilateral																						
Mineralization, multifocal, unilateral,																						
(Tubules)																						
Oligospermia, multifocal, unilateral																						
Hematoma, solitary, unilateral																						
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
ADRENALS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Pheochromocytoma, solitary																						
AXILLARY LYMPH NODE		-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Fibrosarcoma, metastatic							P															
CERVICAL LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
DUODENUM		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	
Fibrosarcoma, metastatic																						
Hemorrhage, focal																		4				

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion / Accession Number	81-0794	81-0795	81-0796	81-0797	81-0798*	81-0799	81-0802	81-0804	81-0805	81-0806*	81-0807	81-0809*	81-0810*	81-0811	81-0812*	81-0813	81-0814*	81-0815*	81-0816*	81-0817	Incidence
TESTES	N	N	N	N	N	N	N	N	N	N	L	N	L	N	L	N	N	N	L	N	
Degeneration, diffuse, bilateral																					
Degeneration, multifocal, unilateral											2										
Mineralization, multifocal, unilateral,																					
(Tubules)															2						
Oligospermia, multifocal, unilateral													3								
Hematoma, solitary, unilateral																			4		
LESIONS (TISSUES NOT SPECIFICALLY																					
REQUIRED BY PROTOCOL)																					
ADRENALS	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	
Pheochromocytoma, solitary							P														
AXILLARY LYMPH NODE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Fibrosarcoma, metastatic																					
CERVICAL LYMPH NODE	-	-	-	-	N	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
DUODENUM	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Fibrosarcoma, metastatic																					
Hemorrhage, focal																					

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0820	81-0821																			Incidence
TESTES		N	N																			(62)
Degeneration, diffuse, bilateral																						1/62
Degeneration, multifocal, unilateral																						1/62
Mineralization, multifocal, unilateral,																						
(Tubules)																						1/62
Oligospermia, multifocal, unilateral																						1/62
Hematoma, solitary, unilateral																						1/62
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
ADRENALS		-	-																			(3)
Pheochromocytoma, solitary																						1/3
AXILLARY LYMPH NODE		-	-																			(3)
Fibrosarcoma, metastatic																						3/3
CERVICAL LYMPH NODE		-	-																			(1)
DUODENUM		-	-																			(2)
Fibrosarcoma, metastatic																						1/2
Hemorrhage, focal																						1/2

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0747	81-0748*	81-0749	81-0750*	81-0752	81-0753	81-0754*	81-0756*	81-0757*	81-0758	81-0759	81-0760	81-0761*	81-0762*	81-0763*	81-0764	81-0765	81-0767*	81-0768	81-0769*	Incidence
EYES		-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Phthisis bulbi, unilateral						3																
EPIDIDYMIDES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Fibrosarcoma, metastatic																						
GALL BLADDER		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Hemorrhage, focal																						
HARDERIAN GLAND		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Adenoma, solitary																						
HEPATIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	
Malignant Lymphoma, mixed type																P						
INGUINAL LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Hyperplasia, lymphoid, diffuse																						
JEJUNUM		-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-	-	-	
Carcinoma, solitary																						
Hemorrhage, diffuse																						
LUMBAR LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	
Malignant Lymphoma, mixed type																P						
Hyperplasia, lymphoid, diffuse																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0770*	81-0771	81-0773	81-0774*	81-0775	81-0776	81-0777	81-0778	81-0779	81-0781	81-0782	81-0784	81-0786*	81-0787	81-0788	81-0789	81-0790*	81-0791	81-0792	81-0793	Incidence
EYES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	
Phthisis bulbi, unilateral																						
EPIDIDYMIDES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Fibrosarcoma, metastatic																						
GALL BLADDER		-	-	-	N	-	-	-	-	-	-	-	N	-	-	-	-	L	-	-	-	
Hemorrhage, focal																		3				
HARDERIAN GLAND		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	
Adenoma, solitary																				P		
HEPATIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
INGUINAL LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Hyperplasia, lymphoid, diffuse																						
JEJUNUM		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	
Carcinoma, solitary																						
Hemorrhage, diffuse																		3				
LUMBAR LYMPH NODE		L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Hyperplasia, lymphoid, diffuse		2																				

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be grade

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0794	81-0795	81-0796	81-0797	81-0798*	81-0799	81-0802	81-0804	81-0805	81-0806*	81-0807	81-0809*	81-0810*	81-0811	81-0812*	81-0813	81-0814*	81-0815*	81-0816*	81-0817	Incidence
EYES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Phthisis bulbi, unilateral																						
EPIDIDYMIDES		-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	L	-	-	-	
Fibrosarcoma, metastatic																		P				
GALL BLADDER		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Hemorrhage, focal																						
HARDERIAN GLAND		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Adenoma, solitary																						
HEPATIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
INGUINAL LYMPH NODE		-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Hyperplasia, lymphoid, diffuse					2																	
JEJUNUM		-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Carcinoma, solitary							P															
Hemorrhage, diffuse																						
LUMBAR LYMPH NODE		-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Hyperplasia, lymphoid, diffuse						2																

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0820	81-0821																				Incidence
EYES		-	-																				(2)
Phthisis bulbi, unilateral																							1/2
EPIDIDYMIDES		-	-																				(2)
Fibrosarcoma, metastatic																							1/2
GALL BLADDER		-	-																				(3)
Hemorrhage, focal																							1/3
HARDERIAN GLAND		-	-																				(1)
Adenoma, solitary																							1/1
HEPATIC LYMPH NODE		-	-																				(1)
Malignant Lymphoma, mixed type																							1/1
INGUINAL LYMPH NODE		-	-																				(1)
Hyperplasia, lymphoid, diffuse																							1/1
JEJUNUM		-	-																				(3)
Carcinoma, solitary																							1/3
Hemorrhage, diffuse																							1/3
LUMBAR LYMPH NODE		-	-																				(3)
Malignant Lymphoma, mixed type																							1/3
Hyperplasia, lymphoid, diffuse																							2/3

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0747	81-0748*	81-0749	81-0750*	81-0752	81-0753	81-0754*	81-0756*	81-0757*	81-0758	81-0759	81-0760	81-0761*	81-0762*	81-0763*	81-0764	81-0765	81-0767*	81-0768	81-0769*	Incidence
LUNGS		-	-	-	-	-	-	-	L	L	-	-	-	-	-	-	-	-	-	-	-	
Alveolar/bronchiolar carcinoma,																						
multifocal																						
Malignant Lymphoma, mixed type																						
Hepatocellular carcinoma, metastatic																						
Fibrosarcoma, metastatic																						
Hemorrhage, multifocal										3												
Congestion, diffuse									3													
MANDIBULAR LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	
Malignant Lymphoma, mixed type																P						
MEDIASTINUM		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Fibrosarcoma, metastatic																						
MESENTERIC FAT		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Steatitis, chronic, focal																						
MESENTERIC LYMPH NODE		-	L	-	-	L	-	-	L	L	-	L	L	-	N	-	-	-	-	-	L	
Malignant Lymphoma, mixed type						P							P									
Malignant Lymphoma, histiocytic type			P																			
Hyperplasia, lymphoid, diffuse										3												
Lymphadenitis, acute, diffuse												3										

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0770*	81-0771	81-0773	81-0774*	81-0775	81-0776	81-0777	81-0778	81-0779	81-0781	81-0782	81-0784	81-0786*	81-0787	81-0788	81-0789	81-0790*	81-0791	81-0792	81-0793	Incidence
LUNGS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Alveolar/bronchiolar carcinoma,																						
multifocal																						
Malignant Lymphoma, mixed type																						
Hepatocellular carcinoma, metastatic																						
Fibrosarcoma, metastatic																						
Hemorrhage, multifocal																						
Congestion, diffuse																						
MANDIBULAR LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
MEDIASTINUM		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Fibrosarcoma, metastatic																						
MESENTERIC FAT		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Steatitis, chronic, focal																						
MESENTERIC LYMPH NODE		L	-	-	-	-	-	-	-	L	-	-	L	-	-	-	L	-	L	-	-	
Malignant Lymphoma, mixed type																	P					
Malignant Lymphoma, histiocytic type										P												
Hyperplasia, lymphoid, diffuse		2											2						3			
Lymphadenitis, acute, diffuse																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0794	81-0795	81-0796	81-0797	81-0798*	81-0799	81-0802	81-0804	81-0805	81-0806*	81-0807	81-0809*	81-0810*	81-0811	81-0812*	81-0813	81-0814*	81-0815*	81-0816*	81-0817	Incidence
LUNGS		-	-	-	-	-	-	L	-	-	-	-	-	L	-	-	-	L	-	L	-	
Alveolar/bronchiolar carcinoma,																						
multifocal																				P		
Malignant Lymphoma, mixed type														P								
Hepatocellular carcinoma, metastatic								P														
Fibrosarcoma, metastatic																		P				
Hemorrhage, multifocal																						
Congestion, diffuse																						
MANDIBULAR LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
MEDIASTINUM		-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	
Fibrosarcoma, metastatic																P						
MESENTERIC FAT		-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	
Steatitis, chronic, focal																3						
MESENTERIC LYMPH NODE		-	-	-	-	L	-	L	L	-	-	-	-	L	-	L	-	L	L	-	-	
Malignant Lymphoma, mixed type														P								
Malignant Lymphoma, histiocytic type																						
Hyperplasia, lymphoid, diffuse						2										3						
Lymphadenitis, acute, diffuse																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0820	81-0821																				Incidence
LUNGS		-	-																				(6)
Alveolar/bronchiolar carcinoma,																							
multifocal																							1/6
Malignant Lymphoma, mixed type																							1/6
Hepatocellular carcinoma, metastatic																							1/6
Fibrosarcoma, metastatic																							1/6
Hemorrhage, multifocal																							1/6
Congestion, diffuse																							1/6
MANDIBULAR LYMPH NODE		-	-																				(2)
Malignant Lymphoma, mixed type																							1/2
MEDIASTINUM		-	-																				(1)
Fibrosarcoma, metastatic																							1/1
MESENTERIC FAT		-	-																				(1)
Steatitis, chronic, focal																							1/1
MESENTERIC LYMPH NODE		-	-																				(20)
Malignant Lymphoma, mixed type																							4/20
Malignant Lymphoma, histiocytic type																							2/20
Hyperplasia, lymphoid, diffuse																							6/20
Lymphadenitis, acute, diffuse																							1/20

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0747	81-0748*	81-0749	81-0750*	81-0752	81-0753	81-0754*	81-0756*	81-0757*	81-0758	81-0759	81-0760	81-0761*	81-0762*	81-0763*	81-0764	81-0765	81-0767*	81-0768	81-0769*	Incidence
MESENTERIC LYMPH NODE (Con't.)		-	L	-	-	L	-	-	L	L	-	L	L	-	N	-	-	-	-	-	L	
Necrosis, lymphoid, diffuse																					3	
Congestion, diffuse									3												3	
MESENTERY		-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type					P																	
Fibrosarcoma, metastatic																						
PANCREAS		-	-	-	-	-	-	-	-	N	-	-	-	L	N	L	-	-	-	-	-	
Fibrosarcoma, metastatic														P								
Acinar atrophy, focal																2						
PANCREATIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	
Malignant Lymphoma, mixed type																P						
PELVIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
PENIS		-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	
Balanitis, chronic, active, diffuse																						
Balanitis, chronic, diffuse								2														
Ulcers, chronic, multifocal																						
PERIRENAL LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
PITUITARY		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0770*	81-0771	81-0773	81-0774*	81-0775	81-0776	81-0777	81-0778	81-0779	81-0781	81-0782	81-0784	81-0786*	81-0787	81-0788	81-0789	81-0790*	81-0791	81-0792	81-0793	Incidence
MESENTERIC LYMPH NODE (Con't.)		L	-	-	-	-	-	-	-	L	-	-	L	-	-	-	L	-	L	-	-	
Necrosis, lymphoid, diffuse																						
Congestion, diffuse													3						3			
MESENTERY		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type																						
Fibrosarcoma, metastatic																						
PANCREAS		-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	
Fibrosarcoma, metastatic																						
Acinar atrophy, focal										2												
PANCREATIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
PELVIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
PENIS		-	-	-	N	L	-	-	-	-	-	N	-	-	-	-	N	-	-	-	-	
Balanitis, chronic, active, diffuse																						
Balanitis, chronic, diffuse						2																
Ulcers, chronic, multifocal																						
PERIRENAL LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
PITUITARY		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0794	81-0795	81-0796	81-0797	81-0798*	81-0799	81-0802	81-0804	81-0805	81-0806*	81-0807	81-0809*	81-0810*	81-0811	81-0812*	81-0813	81-0814*	81-0815*	81-0816*	81-0817	Incidence
MESENTERIC LYMPH NODE (Con't.)		-	-	-	-	L	-	L	L	-	-	-	-	L	-	L	-	L	L	-	-	
Necrosis, lymphoid, diffuse																						
Congestion, diffuse						3		4	3									3	4			
MESENTERY		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	
Malignant Lymphoma, lymphocytic type																						
Fibrosarcoma, metastatic																		P				
PANCREAS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	
Fibrosarcoma, metastatic																						
Acinar atrophy, focal																						
PANCREATIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
PELVIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	
PENIS		-	-	-	-	L	-	-	-	-	-	-	L	-	-	-	-	-	N	-	N	
Balanitis, chronic, active, diffuse						3							4									
Balanitis, chronic, diffuse																						
Ulcers, chronic, multifocal													4									
PERIRENAL LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type														P								
PITUITARY		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0820	81-0821																			Incidence
MESENTERIC LYMPH NODE (Con't.)		-	-																			(20)
Necrosis, lymphoid, diffuse																						1/20
Congestion, diffuse																						9/20
MESENTERY		-	-																			(2)
Malignant Lymphoma, lymphocytic type																						1/2
Fibrosarcoma, metastatic																						1/2
PANCREAS		-	-																			(6)
Fibrosarcoma, metastatic																						1/6
Acinar atrophy, focal																						2/6
PANCREATIC LYMPH NODE		-	-																			(1)
Malignant Lymphoma, mixed type																						1/1
PELVIC LYMPH NODE		-	-																			(1)
PENIS		N	-																			(10)
Balanitis, chronic, active, diffuse																						2/10
Balanitis, chronic, diffuse																						2/10
Ulcers, chronic, multifocal																						1/10
PERIRENAL LYMPH NODE		-	-																			(1)
Malignant Lymphoma, mixed type																						1/1
PITUITARY		-	-																			(1)

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0747	81-0748*	81-0749	81-0750*	81-0752	81-0753	81-0754*	81-0756*	81-0757*	81-0758	81-0759	81-0760	81-0761*	81-0762*	81-0763*	81-0764	81-0765	81-0767*	81-0768	81-0769*	Incidence
PREPUCE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Fibrosarcoma, metastatic (Subcutis)																						
Posthitis, chronic, active, diffuse																						
Posthitis, chronic, diffuse																						
Posthitis, chronic, focal																						
PREPUTIAL GLAND		-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	
Adenitis, chronic, active, focal																						
Adenitis, chronic, diffuse								3														
Adenitis, chronic, multifocal																						
Cystic duct, focal								3														
PROSTATE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
RENAL LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
RESPIRATORY LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
SALIVARY GLAND		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Sialadenitis, acute, multifocal																						
SEMINAL VESICLES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III
MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0770*	81-0771	81-0773	81-0774*	81-0775	81-0776	81-0777	81-0778	81-0779	81-0781	81-0782	81-0784	81-0786*	81-0787	81-0788	81-0789	81-0790*	81-0791	81-0792	81-0793	Incidence
PREPUCE		-	-	-	L	L	-	-	-	-	-	L	-	-	-	-	L	-	-	-	-	
Fibrosarcoma, metastatic (Subcutis)																						
Posthitis, chronic, active, diffuse					4							3					4					
Posthitis, chronic, diffuse																						
Posthitis, chronic, focal						3																
PREPUTIAL GLAND		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Adenitis, chronic, active, focal																						
Adenitis, chronic, diffuse																						
Adenitis, chronic, multifocal																						
Cystic duct, focal																						
PROSTATE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
RENAL LYMPH NODE		N	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
RESPIRATORY LYMPH NODE		-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	L	-	-	-	-	
Malignant Lymphoma, mixed type							P										P					
SALIVARY GLAND		-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	
Sialadenitis, acute, multifocal														3								
SEMINAL VESICLES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

1090

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0794	81-0795	81-0796	81-0797	81-0798*	81-0799	81-0802	81-0804	81-0805	81-0806*	81-0807	81-0809*	81-0810*	81-0811	81-0812*	81-0813	81-0814*	81-0815*	81-0816*	81-0817	Incidence
PREPUCE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	
Fibrosarcoma, metastatic (Subcutis)																			P			
Posthitis, chronic, active, diffuse																						
Posthitis, chronic, diffuse																			3			
Posthitis, chronic, focal																						
PREPUTIAL GLAND		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	
Adenitis, chronic, active, focal																					4	
Adenitis, chronic, diffuse																						
Adenitis, chronic, multifocal																						
Cystic duct, focal																						
PROSTATE		-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	
RENAL LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
RESPIRATORY LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
SALIVARY GLAND		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	
Sialadenitis, acute, multifocal																						
SEMINAL VESICLES		-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number 81-0820	81-0821																			Incidence
PREPUCE	-	-																			(5)
Fibrosarcoma, metastatic (Subcutis)																					1/5
Posthitis, chronic, active, diffuse																					3/5
Posthitis, chronic, diffuse																					1/5
Posthitis, chronic, focal																					1/5
PREPUTIAL GLAND	L	-																			(3)
Adenitis, chronic, active, focal																					1/3
Adenitis, chronic, diffuse																					1/3
Adenitis, chronic, multifocal	2																				1/3
Cystic duct, focal																					1/3
PROSTATE	-	-																			(1)
RENAL LYMPH NODE	-	-																			(1)
RESPIRATORY LYMPH NODE	-	-																			(2)
Malignant Lymphoma, mixed type																					2/2
SALIVARY GLAND	-	-																			(2)
Sialadenitis, acute, multifocal																					1/2
SEMINAL VESICLES	-	-																			(1)

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0747	81-0748*	81-0749	81-0750*	81-0752	81-0753	81-0754*	81-0756*	81-0757*	81-0758	81-0759	81-0760	81-0761*	81-0762*	81-0763*	81-0764	81-0765	81-0767*	81-0768	81-0769*	Incidence
SKIN		-	-	-	L	-	-	L	-	L	-	-	L	-	-	-	-	-	-	L	-	
Dermatitis, chronic, active, diffuse																						
Dermatitis, chronic, active, focal																						
Dermatitis, chronic, diffuse					3					3			4							2		
Dermatitis, chronic, multifocal																						
Dermatitis, chronic, focal								4												4		
Ulcers, chronic, multifocal										3												
Ulcer, chronic, focal													1							3		
Acanthosis, focal																						
Follicular atrophy, diffuse																						
STOMACH		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Gastritis, chronic, focal																						
SUBCUTANEOUS LYMPH NODE		-	-	L	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	L	-	
Malignant Lymphoma, mixed type				P																P		
Fibrosarcoma, metastatic									P													
Hyperplasia, lymphoid, diffuse																						
Edema, diffuse																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III
MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0770*	81-0771	81-0773	81-0774*	81-0775	81-0776	81-0777	81-0778	81-0779	81-0781	81-0782	81-0784	81-0786*	81-0787	81-0788	81-0789	81-0790*	81-0791	81-0792	81-0793	Incidence
SKIN		-	-	-	L	-	-	-	L	L	L	L	-	L	L	-	-	-	-	-	L	
Dermatitis, chronic, active, diffuse																						
Dermatitis, chronic, active, focal										4												
Dermatitis, chronic, diffuse					3				3					3	3							
Dermatitis, chronic, multifocal																						
Dermatitis, chronic, focal											4	4										
Ulcers, chronic, multifocal																						
Ulcer, chronic, focal										4												
Acanthosis, focal																						
Follicular atrophy, diffuse																					2	
STOMACH		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Gastritis, chronic, focal																						
SUBCUTANEOUS LYMPH NODE		L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	N	-	-	-	
Malignant Lymphoma, mixed type																	P					
Fibrosarcoma, metastatic																						
Hyperplasia, lymphoid, diffuse		2																				
Edema, diffuse																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0794	81-0795	81-0796	81-0797	81-0798*	81-0799	81-0802	81-0804	81-0805	81-0806*	81-0807	81-0809*	81-0810*	81-0811	81-0812*	81-0813	81-0814*	81-0815*	81-0816*	81-0817	Incidence
SKIN		L	L	L	-	-	-	L	-	L	L	L	L	-	-	L	-	-	L	L	-	
Dermatitis, chronic, active, diffuse																			3			
Dermatitis, chronic, active, focal																						
Dermatitis, chronic, diffuse		2						4		4	3	1								3		
Dermatitis, chronic, multifocal				3									3									
Dermatitis, chronic, focal																						
Ulcers, chronic, multifocal																						
Ulcer, chronic, focal													3									
Acanthosis, focal																						
Follicular atrophy, diffuse			3													3						
STOMACH		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	
Gastritis, chronic, focal																			2			
SUBCUTANEOUS LYMPH NODE		-	-	-	-	L	-	L	-	-	-	-	-	-	L	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Fibrosarcoma, metastatic																						
Hyperplasia, lymphoid, diffuse						2									2							
Edema, diffuse								3														

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number 81-0820	81-0821																				Incidence
SKIN	L	L																				(26)
Dermatitis, chronic, active, diffuse																						1/26
Dermatitis, chronic, active, focal	4																					2/26
Dermatitis, chronic, diffuse																						14/26
Dermatitis, chronic, multifocal																						2/26
Dermatitis, chronic, focal	2	4																				6/26
Ulcers, chronic, multifocal																						1/26
Ulcer, chronic, focal	3																					5/26
Acanthosis, focal		3																				1/26
Follicular atrophy, diffuse																						3/26
STOMACH	-	-																				(1)
Gastritis, chronic, focal																						1/1
SUBCUTANEOUS LYMPH NODE	N	-																				(10)
Malignant Lymphoma, mixed type																						3/10
Fibrosarcoma, metastatic																						1/10
Hyperplasia, lymphoid, diffuse																						3/10
Edema, diffuse																						1/10

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III
MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0747	81-0748*	81-0749	81-0750*	81-0752	81-0753	81-0754*	81-0756*	81-0757*	81-0758	81-0759	81-0760	81-0761*	81-0762*	81-0763*	81-0764	81-0765	81-0767*	81-0768	81-0769*	Incidence
SUBCUTIS		-	-	-	-	-	-	L	L	-	L	L	-	L	-	L	L	-	L	-	L	
Undifferentiated Sarcoma, multifocal																						
Neurofibrosarcoma, solitary								P														
Fibrosarcoma, multifocal														P								
Fibrosarcoma, solitary									P			P				P	P		P			
Fibroma, multifocal																						
Fibroma, solitary											P										P	
Cellulitis, acute, diffuse																						
Cellulitis, chronic, active, diffuse																						
Cellulitis, chronic, active, focal																						
Abscesses, multifocal																						
Abscess, focal																						
THYMUS		-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type					P																	
URETHRA		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Calculus																						
URINARY BLADDER		-	-	L	-	-	-	-	-	-	-	-	-	-	N	-	-	L	-	-	-	
Cystitis, chronic, diffuse																						
Calculi																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.1.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III
MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0770*	81-0771	81-0773	81-0774*	81-0775	81-0776	81-0777	81-0778	81-0779	81-0781	81-0782	81-0784	81-0786*	81-0787	81-0788	81-0789	81-0790*	81-0791	81-0792	81-0793	Incidence
SUBCUTIS		-	-	-	-	L	L	-	-	L	-	L	-	L	-	-	-	-	-	-	-	
Undifferentiated Sarcoma, multifocal						P																
Neurofibrosarcoma, solitary																						
Fibrosarcoma, multifocal																						
Fibrosarcoma, solitary							P															
Fibroma, multifocal																						
Fibroma, solitary																						
Cellulitis, acute, diffuse																						
Cellulitis, chronic, active, diffuse																						
Cellulitis, chronic, active, focal										3		3										
Abscesses, multifocal														4								
Abscess, focal																						
THYMUS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type																						
URETHRA		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Calculus																						
URINARY BLADDER		-	-	-	-	-	N	N	-	-	-	L	-	L	-	-	-	-	-	-	-	
Cystitis, chronic, diffuse												3		2								
Calculi												P		P								

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

*.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0794	81-0795	81-0796	81-0797	81-0798*	81-0799	81-0802	81-0804	81-0805	81-0806*	81-0807	81-0809*	81-0810*	81-0811	81-0812*	81-0813	81-0814*	81-0815*	81-0816*	81-0817	Incidence
SUBCUTIS		-	-	-	-	L	L	-	-	-	L	L	L	-	-	L	-	L	L	L	L	
Undifferentiated Sarcoma, multifocal																						
Neurofibrosarcoma, solitary																						
Fibrosarcoma, multifocal						P										P			P			
Fibrosarcoma, solitary							P											P		P		
Fibroma, multifocal																					P	
Fibroma, solitary							P					P										
Cellulitis, acute, diffuse																2						
Cellulitis, chronic, active, diffuse													3									
Cellulitis, chronic, active, focal																						
Abscesses, multifocal																						
Abscess, focal											4											
THYMUS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, lymphocytic type																						
URETHRA		-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	
Calculus															P							
URINARY BLADDER		-	N	-	-	-	N	-	-	-	-	-	-	-	L	-	-	-	-	-	-	
Cystitis, chronic, diffuse															3							
Calculi																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0820	81-0821																			Incidence
SUBCUTIS		-	-																			(24)
Undifferentiated Sarcoma, multifocal																						1/24
Neurofibrosarcoma, solitary																						1/24
Fibrosarcoma, multifocal																						4/24
Fibrosarcoma, solitary																						9/24
Fibroma, multifocal																						1/24
Fibroma, solitary																						4/24
Cellulitis, acute, diffuse																						1/24
Cellulitis, chronic, active, diffuse																						1/24
Cellulitis, chronic, active, focal																						2/24
Abscesses, multifocal																						1/24
Abscess, focal																						1/24
THYMUS		-	-																			(1)
Malignant Lymphoma, lymphocytic type																						1/1
URETHRA		-	-																			(1)
Calculus																						1/1
URINARY BLADDER		-	-																			(10)
Cystitis, chronic, diffuse																						3/10
Calculi																						2/10

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0747	81-0748*	81-0749	81-0750*	81-0752	81-0753	81-0754*	81-0756*	81-0757*	81-0758	81-0759	81-0760	81-0761*	81-0762*	81-0763*	81-0764	81-0765	81-0767*	81-0768	81-0769*	Incidence
URINARY BLADDER (Con't.)		-	-	L	-	-	-	-	-	-	-	-	-	-	N	-	-	L	-	-	-	
Calculus				P														P				

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0770*	81-0771	81-0773	81-0774*	81-0775	81-0776	81-0777	81-0778	81-0779	81-0781	81-0782	81-0784	81-0786*	81-0787	81-0788	81-0789	81-0790*	81-0791	81-0792	81-0793	Incidence
URINARY BLADDER (Con't.)		-	-	-	-	-	N	N	-	-	-	L	-	L	-	-	-	-	-	-	-	
Calculus																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0794	81-0795	81-0796	81-0797	81-0798*	81-0799	81-0802	81-0804	81-0805	81-0806*	81-0807	81-0809*	81-0810*	81-0811	81-0812*	81-0813	81-0814*	81-0815*	81-0816*	81-0817	Incidence
URINARY BLADDER (Con't.)		-	N	-	-	-	N	-	-	-	-	-	-	-	L	-	-	-	-	-	-	
Calculus																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP III

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0820	81-0821																			Incidence
URINARY BLADDER (Con't.)		-	-																			(10)
Calculus																						2/10

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

T.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion / Accession Number	81-0897*	81-0898	81-0900	81-0902	81-0903	81-0904	81-0905	81-0906	81-0907	81-0909*	81-0910	81-0912	81-0913	81-0914	81-0915	81-0917*	81-0918*	81-0919	81-0920	81-0921	Incidence
BRAIN	N	L	L	N	N	N	L	L	L	N	L	N	N	N	L	N	N	L	N	L	
Malignant Lymphoma, mixed type																					
Corpora amylacea, multifocal		1	2				1	2	2		2				2			2		1	
SPINAL CORD	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
SPLEEN	L	N	N	N	N	N	N	L	N	L	N	N	L	N	N	N	N	N	L	N	
Malignant Lymphoma, mixed type	P												P								
Hyperplasia, lymphoid, diffuse																			2		
Hyperplasia, reticulum-cell, multifocal																					
Angiectasis, multifocal																					
Hematopoiesis, extramedullary, diffuse								3		3											
HEART	N	N	N	N	N	N	N	N	N	L	N	N	L	N	N	N	N	N	N	N	
Fibrosarcoma, metastatic										P											
Myocarditis, acute, multifocal																					
Myocarditis, chronic, multifocal													1								
Myocarditis, chronic, focal																					
Necrosis, multifocal																					
Mineralization, multifocal																					
LIVER	L	N	L	L	L	L	L	L	N	N	N	L	L	L	N	L	L	N	L	L	
Hemangiosarcoma, multifocal																					

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

T.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0922	81-0923*	81-0924*	81-0926	81-0927	81-0928*	81-0929	81-0930	81-0931*	81-0932	81-0933	81-0934*	81-0935*	81-0936	81-0937*	81-0938*	81-0940*	81-0941	81-0943*	81-0944*	Incidence
BRAIN		N	N	N	N	N	L	N	N	L	N	N	L	N	N	N	N	N	N	N	N	
Malignant Lymphoma, mixed type													P									
Corpora amylacea, multifocal							2			1												
SPINAL CORD		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
SPLEEN		N	L	N	L	L	M	L	L	N	N	N	L	L	L	N	L	L	L	N	N	
Malignant Lymphoma, mixed type													P	P			P					
Hyperplasia, lymphoid, diffuse					1	2			2										2			
Hyperplasia, reticulum-cell, multifocal																						
Angiectasis, multifocal								2														
Hematopoiesis, extramedullary, diffuse			3												3			3				
HEART		N	N	N	L	N	N	N	N	N	N	N	N	N	N	N	N	L	N	L	N	
Fibrosarcoma, metastatic																						
Myocarditis, acute, multifocal																		1				
Myocarditis, chronic, multifocal																				2		
Myocarditis, chronic, focal					1																	
Necrosis, multifocal																						
Mineralization, multifocal																						
LIVER		N	L	L	N	N	N	L	L	N	N	N	L	L	L	L	L	L	L	N	N	
Hemangiosarcoma, multifocal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

N.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0945*	81-0946	81-0947*	81-0949*	81-0950*	81-0951	81-0952	81-0954*	81-0955	81-0956*	81-0957	81-0960	81-0961	81-0962	81-0964	81-0965	81-0966	81-0969*	81-0970*		Incidence
BRAIN		N	N	N	N	N	N	N	N	L	N	N	L	N	N	N	L	N	N	N		(59)
Malignant Lymphoma, mixed type																						1/59
Corpora amylacea, multifocal										2			1				2					14/59
SPINAL CORD		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N		(59)
SPLEEN		L	N	L	N	L	L	L	N	N	N	L	L	N	N	N	L	L	N	N		(58)
Malignant Lymphoma, mixed type		P																				6/58
Hyperplasia, lymphoid, diffuse							2	2				2	2									9/58
Hyperplasia, reticulum-cell, multifocal																	2					1/58
Angiectasis, multifocal																						1/58
Hematopoiesis, extramedullary, diffuse				3		3												3				8/58
HEART		L	N	L	N	N	N	N	N	N	L	N	N	N	N	N	N	N	N	L		(59)
Fibrosarcoma, metastatic				P																		2/59
Myocarditis, acute, multifocal																						1/59
Myocarditis, chronic, multifocal																				2		3/59
Myocarditis, chronic, focal																						1/59
Necrosis, multifocal											2											1/59
Mineralization, multifocal		1									2											2/59
LIVER		L	L	N	L	L	N	N	N	L	N	L	N	L	L	N	L	N	N	L		(59)
Hemangiosarcoma, multifocal			P																			1/59

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0897*	81-0898	81-0900	81-0902	81-0903	81-0904	81-0905	81-0906	81-0907	81-0909*	81-0910	81-0912	81-0913	81-0914	81-0915	81-0917*	81-0918*	81-0919	81-0920	81-0921	Incidence
LIVER (Con't.)		L	N	L	L	L	L	L	L	N	N	N	L	L	L	N	L	L	N	L	L	
Hemangiosarcoma, solitary								P														
Hepatocellular carcinoma, multifocal																						
Hepatocellular carcinoma, solitary				P		P	P		P					P	P		P	P		P		
Malignant Lymphoma, mixed type		P																				
Undifferentiated Sarcoma, metastatic																						
Hepatocellular adenoma, solitary					P								P									
Fatty change, focal					1																	
Necrosis, multifocal																						
Congestion, diffuse																						
Hematopoiesis,extramedullary,multifocal																					2	
KIDNEYS		L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	
Undifferentiated Sarcoma, solitary							P															
Malignant Lymphoma, mixed type		P																				
Alveolar/bronchiolar carcinoma, metastatic																						
Metaplasia, osseous, focal (Cortex)																						
Hyperplasia, tubular, multifocal			2	2	2	1	1	1	2	1	2	2	2	1	2	2			2	2	1	
Glomerulonephritis, acute, diffuse																	4					

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

T.I.T.R.I.
tudy No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion / Accession Number	81-0922	81-0923*	81-0924*	81-0926	81-0927	81-0928*	81-0929	81-0930	81-0931*	81-0932	81-0933	81-0934*	81-0935*	81-0936	81-0937*	81-0938*	81-0940*	81-0941	81-0943*	81-0944*	Incidence
LIVER (Con't.)	N	L	L	N	N	N	L	L	N	N	N	L	L	L	L	L	L	L	N	N	
Hemangiosarcoma, solitary																					
Hepatocellular carcinoma, multifocal							P							P							
Hepatocellular carcinoma, solitary			P												P		P	P			
Malignant Lymphoma, mixed type												P	P			P					
Undifferentiated Sarcoma, metastatic																	P				
Hepatocellular adenoma, solitary								P													
Fatty change, focal																					
Necrosis, multifocal													3								
Congestion, diffuse		2																			
Hematopoiesis,extramedullary,multifocal								1													
KIDNEYS	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	
Undifferentiated Sarcoma, solitary																					
Malignant Lymphoma, mixed type												P	P								
Alveolar/bronchiolar carcinoma, metastatic																					
Metaplasia, osseous, focal (Cortex)																					
Hyperplasia, tubular, multifocal	1	1		1	2		2	2		2	2		1	1		2	2	2			
Glomerulonephritis, acute, diffuse																					

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0945*	81-0946	81-0947*	81-0949*	81-0950*	81-0951	81-0952	81-0954*	81-0955	81-0956*	81-0957	81-0960	81-0961	81-0962	81-0964	81-0965	81-0966	81-0969*	81-0970*		Incidence
LIVER (Con't.)		L	L	N	L	L	N	N	N	L	N	L	N	L	L	N	L	N	N	L		(59)
Hemangiosarcoma, solitary					P																	2/59
Hepatocellular carcinoma, multifocal																						2/59
Hepatocellular carcinoma, solitary						P								P						P		16/59
Malignant Lymphoma, mixed type		P																				5/59
Undifferentiated Sarcoma, metastatic																						1/59
Hepatocellular adenoma, solitary										P		P			P		P					7/59
Fatty change, focal																						1/59
Necrosis, multifocal																						1/59
Congestion, diffuse																						1/59
Hematopoiesis,extramedullary,multifocal																						2/59
KIDNEYS		L	L	L	L	L	L	L	N	L	L	L	L	L	L	L	L	L	L	L		(59)
Undifferentiated Sarcoma, solitary																						1/59
Malignant Lymphoma, mixed type		P																				4/59
Alveolar/bronchiolar carcinoma, metastatic																				P		1/59
Metaplasia, osseous, focal (Cortex)				2													1					2/59
Hyperplasia, tubular, multifocal			2				2	2				2		2	2	1		2				38/59
Glomerulonephritis, acute, diffuse																						1/59

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

T.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0897*	81-0898	81-0900	81-0902	81-0903	81-0904	81-0905	81-0906	81-0907	81-0909*	81-0910	81-0912	81-0913	81-0914	81-0915	81-0917*	81-0918*	81-0919	81-0920	81-0921	Incidence
KIDNEYS (Con't.)		L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	
Nephropathy, chronic,diffuse,unilateral																						
Necrosis, tubular, diffuse, unilateral																						
Necrosis, tubular, multifocal											2											
Necrosis, tubular, focal																						
Nephrosis, diffuse																						
Nephrocalcinosis, multifocal			1	2	2	1	2	1	1	1	1	2	1			1		1	2	2	2	
Infarcts, healed, multifocal, bilateral																						
Infarct, healed, focal									3													
Cyst, cortical, solitary																						
Atrophy, diffuse, solitary							4															
Dilatation, diffuse (Tubules)																						
Dilatation, multifocal (Tubules)															2							
Congestion, diffuse																						
Cytoplasmic vacuolization, diffuse, (Tubules)			2	2	1	1	2	1	2	1	2	2	1		1	1	2	2	2	2	2	
TESTES		N	N	N	N	L	N	N	N	N	N	N	N	N	N	N	L	N	N	N	L	
Interstitial cell tumor, solitary																						
Sperm granuloma,multifocal,unilateral																					2	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

T.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0922	81-0923*	81-0924*	81-0926	81-0927	81-0928*	81-0929	81-0930	81-0931*	81-0932	81-0933	81-0934*	81-0935*	81-0936	81-0937*	81-0938*	81-0940*	81-0941	81-0943*	81-0944*	Incidence
KIDNEYS (Con't.)		L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	
Nephropathy,chronic,diffuse,unilateral																				3		
Necrosis, tubular, diffuse, unilateral																				4		
Necrosis, tubular, multifocal								2														
Necrosis, tubular, focal															2							
Nephrosis, diffuse																					3	
Nephrocalcinosis, multifocal				2	1	1	2	2	1	2	2	2	1	2		2	2					
Infarcts, healed, multifocal, bilateral																						
Infarct, healed, focal																						
Cyst, cortical, solitary										2												
Atrophy, diffuse, solitary																						
Dilatation, diffuse (Tubules)																						
Dilatation, multifocal (Tubules)																						
Congestion, diffuse			2																			
Cytoplasmic vacuolization, diffuse,																						
(Tubules)		2		2	2	1		1	2		2	2	2	2	2	2	2	1	1		1	
TESTES		N	N	N	N	N	N	L	N	N	N	N	N	N	N	N	N	N	N	L	N	N	
Interstitial cell tumor, solitary																						
Sperm granuloma, multifocal,unilateral																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV
MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0945*	81-0946	81-0947*	81-0949*	81-0950*	81-0951	81-0952	81-0954*	81-0955	81-0956*	81-0957	81-0960	81-0961	81-0962	81-0964	81-0965	81-0966	81-0969*	81-0970*		Incidence
KIDNEYS (Con't.)		L	L	L	L	L	L	L	N	L	L	L	L	L	L	L	L	L	L	L		(59)
Nephropathy, chronic, diffuse, unilateral																						1/59
Necrosis, tubular, diffuse, unilateral																						1/59
Necrosis, tubular, multifocal										2			2									4/59
Necrosis, tubular, focal																						1/59
Nephrosis, diffuse																						1/59
Nephrocalcinosis, multifocal		1	2	1	2		2	1		1		2		2	1	1	1	1				42/59
Infarcts, healed, multifocal, bilateral																				4		1/59
Infarct, healed, focal																						1/59
Cyst, cortical, solitary																						1/59
Atrophy, diffuse, solitary																						1/59
Dilatation, diffuse (Tubules)											3											1/59
Dilatation, multifocal (Tubules)																						1/59
Congestion, diffuse						3																2/59
Cytoplasmic vacuolization, diffuse, (Tubules)		1	2	2	2	1	2	1		1		2	1	2	2	1	1	2	1	2		51/59
TESTES		N	L	N	N	N	N	N	L	N	L	N	N	N	N	N	N	N	N	N		(59)
Interstitial cell tumor, solitary											P											1/59
Sperm granuloma, multifocal, unilateral																						1/59

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0897*	81-0898	81-0900	81-0902	81-0903	81-0904	81-0905	81-0906	81-0907	81-0909*	81-0910	81-0912	81-0913	81-0914	81-0915	81-0917*	81-0918*	81-0919	81-0920	81-0921	Incidence
TESTES (Con't.)		N	N	N	N	L	N	N	N	N	N	N	N	N	N	N	L	N	N	N	L	
Degeneration, diffuse, bilateral																	2					
Degeneration, diffuse, unilateral																						
Degeneration, multifocal, unilateral						2																
Mineralization, multifocal, unilateral																	2					
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
ADRENALS		-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Pheochromocytoma, solitary						P																
Malignant Lymphoma, mixed type																						
Alveolar/bronchiolar carcinoma,																						
metastatic																						
ANAL AREA		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
AXILLARY LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
COLON		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	
Necrosis, focal																		4				

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

T.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0922	81-0923*	81-0924*	81-0926	81-0927	81-0928*	81-0929	81-0930	81-0931*	81-0932	81-0933	81-0934*	81-0935*	81-0936	81-0937*	81-0938*	81-0940*	81-0941	81-0943*	81-0944*	Incidence
TESTES (Con't.)		N	N	N	N	N	N	L	N	N	N	N	N	N	N	N	N	N	L	N	N	
Degeneration, diffuse, bilateral																			3			
Degeneration, diffuse, unilateral								2														
Degeneration, multifocal, unilateral																						
Mineralization, multifocal, unilateral																						
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
ADRENALS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	
Pheochromocytoma, solitary																						
Malignant Lymphoma, mixed type																	P					
Alveolar/bronchiolar carcinoma,																						
metastatic																						
ANAL AREA		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	
AXILLARY LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	
Malignant Lymphoma, mixed type																	P					
COLON		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Necrosis, focal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion / Accession Number	81-0945*	81-0946	81-0947*	81-0949*	81-0950*	81-0951	81-0952	81-0954*	81-0955	81-0956*	81-0957	81-0960	81-0961	81-0962	81-0964	81-0965	81-0966	81-0969*	81-0970*		Incidence
TESTES (Con't.)	N	L	N	N	N	N	N	L	N	L	N	N	N	N	N	N	N	N	N		(59)
Degeneration, diffuse, bilateral																					2/59
Degeneration, diffuse, unilateral		3																			2/59
Degeneration, multifocal, unilateral								1													2/59
Mineralization, multifocal, unilateral																					1/59
LESIONS (TISSUES NOT SPECIFICALLY																					
REQUIRED BY PROTOCOL)																					
ADRENALS	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L		(4)
Pheochromocytoma, solitary																					1/4
Malignant Lymphoma, mixed type	P																				2/4
Alveolar/bronchiolar carcinoma,																					
metastatic																			P		1/4
ANAL AREA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		(1)
AXILLARY LYMPH NODE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		(1)
Malignant Lymphoma, mixed type																					1/1
COLON	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		(1)
Necrosis, focal																					1/1

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0897*	81-0898	81-0900	81-0902	81-0903	81-0904	81-0905	81-0906	81-0907	81-0909*	81-0910	81-0912	81-0913	81-0914	81-0915	81-0917*	81-0918*	81-0919	81-0920	81-0921	Incidence
DUODENUM		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Hemorrhage, focal																						
Congestion, diffuse																						
EYES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Cataract, subcapsular, unilateral																						
GALL BLADDER		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	
HARDERIAN GLAND		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	
Adenoma, solitary																					P	
HEPATIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
ILEUM		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Congestion, diffuse																						
INGUINAL LYMPH NODE		-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Hyperplasia, lymphoid, diffuse								3														
Lymphatic cyst, solitary																						
Congestion, diffuse																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0922	81-0923*	81-0924*	81-0926	81-0927	81-0928*	81-0929	81-0930	81-0931*	81-0932	81-0933	81-0934*	81-0935*	81-0936	81-0937*	81-0938*	81-0940*	81-0941	81-0943*	81-0944*	Incidence
DUODENUM		-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Hemorrhage, focal			2																			
Congestion, diffuse																						
EYES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Cataract, subcapsular, unilateral																						
GALL BLADDER		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
HARDERIAN GLAND		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Adenoma, solitary																						
HEPATIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	L	-	-	-	-	
Malignant Lymphoma, mixed type													P				P					
ILEUM		-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	
Malignant Lymphoma, mixed type																						
Congestion, diffuse			2																			
INGUINAL LYMPH NODE		L	-	-	-	L	-	-	-	-	-	-	-	-	-	-	L	-	L	-	-	
Malignant Lymphoma, mixed type																	P					
Hyperplasia, lymphoid, diffuse		3																	2			
Lymphatic cyst, solitary																			2			
Congestion, diffuse						2																

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

.I.T.R.I.
udy No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0945*	81-0946	81-0947*	81-0949*	81-0950*	81-0951	81-0952	81-0954*	81-0955	81-0956*	81-0957	81-0960	81-0961	81-0962	81-0964	81-0965	81-0966	81-0969*	81-0970*		Incidence
DUODENUM		L	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-		(3)
Malignant Lymphoma, mixed type		P																				1/3
Hemorrhage, focal																						1/3
Congestion, diffuse						2																1/3
EYES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-		(1)
Cataract, subcapsular, unilateral																		2				1/1
GALL BLADDER		-	-	-	N	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		(2)
HARDERIAN GLAND		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		(1)
Adenoma, solitary																						1/1
HEPATIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		(2)
Malignant Lymphoma, mixed type																						2/2
ILEUM		L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		(3)
Malignant Lymphoma, mixed type		P																				1/3
Congestion, diffuse																						1/3
INGUINAL LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		(5)
Malignant Lymphoma, mixed type																						1/5
Hyperplasia, lymphoid, diffuse																						3/5
Lymphatic cyst, solitary																						1/5
Congestion, diffuse																						1/5

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

T.I.T.R.I.
tudy No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0897*	81-0898	81-0900	81-0902	81-0903	81-0904	81-0905	81-0906	81-0907	81-0909*	81-0910	81-0912	81-0913	81-0914	81-0915	81-0917*	81-0918*	81-0919	81-0920	81-0921	Incidence
INTERCOSTAL MUSCLES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	
Alveolar/bronchiolar carcinoma,invasive																		P				
Fibrosarcoma, metastatic																						
JEJUNUM		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Congestion, diffuse																						
LUMBAR LYMPH NODE		L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type		P																				
Undifferentiated Sarcoma, metastatic																						
Fibrosarcoma, metastatic																						
Hyperplasia, lymphoid, diffuse																						
Edema, diffuse																						
LUNGS		L	-	L	-	-	-	-	L	-	-	-	-	-	-	-	L	L	-	-	L	
Alveolar/bronchiolar carcinoma,																						
multifocal																		P			P	
Alveolar/bronchiolar carcinoma,solitary				P																		
Malignant Lymphoma, mixed type		P																				
Hepatocellular carcinoma, metastatic																	P	P				
Fibrosarcoma, metastatic									P													
Alveolar/bronchiolar adenoma, solitary		P																				

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

T.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0922	81-0923*	81-0924*	81-0926	81-0927	81-0928*	81-0929	81-0930	81-0931*	81-0932	81-0933	81-0934*	81-0935*	81-0936	81-0937*	81-0938*	81-0940*	81-0941	81-0943*	81-0944*	Incidence
INTERCOSTAL MUSCLES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Alveolar/bronchiolar carcinoma,invasive																						
Fibrosarcoma, metastatic																						
JEJUNUM		-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Congestion, diffuse			2																			
LUMBAR LYMPH NODE		-	-	-	-	-	-	-	-	L	-	-	L	-	-	-	L	L	-	L	-	
Malignant Lymphoma, mixed type													P				P					
Undifferentiated Sarcoma, metastatic																		P				
Fibrosarcoma, metastatic																						
Hyperplasia, lymphoid, diffuse										2												
Edema, diffuse																				3		
LUNGS		L	L	-	L	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	
Alveolar/bronchiolar carcinoma, multifocal																						
Alveolar/bronchiolar carcinoma,solitary					P																	
Malignant Lymphoma, mixed type																						
Hepatocellular carcinoma, metastatic															P							
Fibrosarcoma, metastatic																						
Alveolar/bronchiolar adenoma, solitary																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0945*	81-0946	81-0947*	81-0949*	81-0950*	81-0951	81-0952	81-0954*	81-0955	81-0956*	81-0957	81-0960	81-0961	81-0962	81-0964	81-0965	81-0966	81-0969*	81-0970*		Incidence
INTERCOSTAL MUSCLES		-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		(2)
Alveolar/bronchiolar carcinoma,invasive																						1/2
Fibrosarcoma, metastatic				P																		1/2
JEJUNUM		-	-	-	-	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-		(1)
Congestion, diffuse																						1/1
LUMBAR LYMPH NODE		L	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		(8)
Malignant Lymphoma, mixed type		P																				4/8
Undifferentiated Sarcoma, metastatic																						1/8
Fibrosarcoma, metastatic				P																		1/8
Hyperplasia, lymphoid, diffuse																						1/8
Edema, diffuse																						1/8
LUNGS		-	-	L	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	L		(13)
Alveolar/bronchiolar carcinoma, multifocal																				P		3/13
Alveolar/bronchiolar carcinoma,solitary																						2/13
Malignant Lymphoma, mixed type																						1/13
Hepatocellular carcinoma, metastatic						P																4/13
Fibrosarcoma, metastatic				P																		2/13
Alveolar/bronchiolar adenoma, solitary																						1/13

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
-- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0897*	81-0898	81-0900	81-0902	81-0903	81-0904	81-0905	81-0906	81-0907	81-0909*	81-0910	81-0912	81-0913	81-0914	81-0915	81-0917*	81-0918*	81-0919	81-0920	81-0921	Incidence
LUNGS (Con't.)		L	-	L	-	-	-	-	L	-	-	-	-	-	-	-	L	L	-	-	L	
Histiocytosis, multifocal																						
Hemorrhage, multifocal																		3				
Hemorrhage, focal																						
Congestion, diffuse																						
MANDIBULAR LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
MESENTERIC FAT		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Steatitis, chronic, focal																						
MESENTERIC LYMPH NODE		L	-	-	L	L	-	-	-	L	-	-	-	L	-	-	-	L	L	L	-	
Malignant Lymphoma, mixed type		P			P															P		
Hyperplasia, lymphoid, diffuse						2				2									3			
Lymphadenitis, acute, diffuse																						
Lymphatic cyst, solitary														3								
Angiectasis, multifocal										2												
Hemorrhage, diffuse																		4				
Congestion, diffuse														2								

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

T.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0922	81-0923*	81-0924*	81-0926	81-0927	81-0928*	81-0929	81-0930	81-0931*	81-0932	81-0933	81-0934*	81-0935*	81-0936	81-0937*	81-0938*	81-0940*	81-0941	81-0943*	81-0944*	Incidence
LUNGS (Con't.)		L	L	-	L	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	
Histiocytosis, multifocal					3																	
Hemorrhage, multifocal																						
Hemorrhage, focal		2																				
Congestion, diffuse			4																			
MANDIBULAR LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	
Malignant Lymphoma, mixed type																	P					
MESENTERIC FAT		-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	
Steatitis, chronic, focal									3													
MESENTERIC LYMPH NODE		L	-	-	L	N	-	-	-	-	-	-	L	-	L	-	L	-	-	-	-	
Malignant Lymphoma, mixed type													P				P					
Hyperplasia, lymphoid, diffuse																						
Lymphadenitis, acute, diffuse																						
Lymphatic cyst, solitary																						
Angiectasis, multifocal																						
Hemorrhage, diffuse																						
Congestion, diffuse		3			3										4							

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
tudy No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0945*	81-0946	81-0947*	81-0949*	81-0950*	81-0951	81-0952	81-0954*	81-0955	81-0956*	81-0957	81-0960	81-0961	81-0962	81-0964	81-0965	81-0966	81-0969*	81-0970*		Incidence
LUNGS (Con't.)		-	-	L	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	L		(13)
Histiocytosis, multifocal																						1/13
Hemorrhage, multifocal																						1/13
Hemorrhage, focal																						1/13
Congestion, diffuse																						1/13
MANDIBULAR LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		(1)
Malignant Lymphoma, mixed type																						1/1
MESENTERIC FAT		-	-	L	-	-	-	-	-	-	-	L	-	-	-	-	-	L	-	-		(4)
Steatitis, chronic, focal				3								3						3				4/4
MESENTERIC LYMPH NODE		L	-	L	L	-	-	L	L	-	-	-	-	-	-	L	-	-	-	-		(20)
Malignant Lymphoma, mixed type		P														P						7/20
Hyperplasia, lymphoid, diffuse								2														4/20
Lymphadenitis, acute, diffuse				3																		1/20
Lymphatic cyst, solitary																						1/20
Angiectasis, multifocal																						1/20
Hemorrhage, diffuse																						1/20
Congestion, diffuse					3			2	3													7/20

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0897*	81-0898	81-0900	81-0902	81-0903	81-0904	81-0905	81-0906	81-0907	81-0909*	81-0910	81-0912	81-0913	81-0914	81-0915	81-0917*	81-0918*	81-0919	81-0920	81-0921	Incidence
MESENTERY		-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	L	L	-	-	-	
Hepatocellular carcinoma, invasive																	P	P				
Alveolar/bronchiolar carcinoma, metastatic																						
Hemorrhage, focal														3								
PANCREAS		-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	N	-	-	-	
Malignant Lymphoma, mixed type																						
Hyperplasia, acinar-cell, focal																						
Hyperplasia, islet-cell, focal																						
PANCREATIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	L	-	-	-	
Malignant Lymphoma, mixed type														P								
Alveolar/bronchiolar carcinoma, metastatic																		P				
PENIS		-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	
Balanitis, acute, diffuse																						
Balanitis, acute, multifocal																						
Balanitis, chronic, active, multifocal																						
Balanitis, chronic, diffuse								3														
Urethritis, acute, diffuse																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV
MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0922	81-0923*	81-0924*	81-0926	81-0927	81-0928*	81-0929	81-0930	81-0931*	81-0932	81-0933	81-0934*	81-0935*	81-0936	81-0937*	81-0938*	81-0940*	81-0941	81-0943*	81-0944*	Incidence
MESENTERY		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Hepatocellular carcinoma, invasive																						
Alveolar/bronchiolar carcinoma,																						
metastatic																						
Hemorrhage, focal																						
PANCREAS		-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Hyperplasia, acinar-cell, focal																						
Hyperplasia, islet-cell, focal																						
PANCREATIC LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Alveolar/bronchiolar carcinoma,																						
metastatic																						
PENIS		-	-	-	-	N	-	-	-	-	L	-	-	-	-	-	-	-	-	L	-	
Balanitis, acute, diffuse											4											
Balanitis, acute, multifocal																						
Balanitis, chronic, active, multifocal																						
Balanitis, chronic, diffuse																				3		
Urethritis, acute, diffuse																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
\- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number 81-0945*	81-0946	81-0947*	81-0949*	81-0950*	81-0951	81-0952	81-0954*	81-0955	81-0956*	81-0957	81-0960	81-0961	81-0962	81-0964	81-0965	81-0966	81-0969*	81-0970*		Incidence
MESENTERY	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L		(4)
Hepatocellular carcinoma, invasive																					2/4
Alveolar/bronchiolar carcinoma, metastatic																			P		1/4
Hemorrhage, focal																					1/4
PANCREAS	L	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N		(6)
Malignant Lymphoma, mixed type	P																				1/6
Hyperplasia, acinar-cell, focal			2																		1/6
Hyperplasia, islet-cell, focal			2																		1/6
PANCREATIC LYMPH NODE	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L		(4)
Malignant Lymphoma, mixed type	P																				2/4
Alveolar/bronchiolar carcinoma, metastatic																			P		2/4
PENIS	-	-	-	-	L	-	-	-	-	L	-	-	-	-	-	-	-	L	-		(7)
Balanitis, acute, diffuse																					1/7
Balanitis, acute, multifocal										4											1/7
Balanitis, chronic, active, multifocal					3																1/7
Balanitis, chronic, diffuse																					2/7
Urethritis, acute, diffuse																		2			1/7

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV
MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0897*	81-0898	81-0900	81-0902	81-0903	81-0904	81-0905	81-0906	81-0907	81-0909*	81-0910	81-0912	81-0913	81-0914	81-0915	81-0917*	81-0918*	81-0919	81-0920	81-0921	Incidence
PITUITARY		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
POPLITEAL LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
PREPUCE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Posthitis, chronic, active, diffuse																						
Abscess, solitary																						
PREPUTIAL GLAND		-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	
Adenitis, chronic, diffuse																						
Abscess, focal, solitary																						
Dilated ducts, multifocal								3														
PROSTATE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Prostatitis, chronic, active, diffuse																						
RENAL LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
RESPIRATORY LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
SALIVARY GLAND		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Sialadenitis, chronic, diffuse																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0922	81-0923*	81-0924*	81-0926	81-0927	81-0928*	81-0929	81-0930	81-0931*	81-0932	81-0933	81-0934*	81-0935*	81-0936	81-0937*	81-0938*	81-0940*	81-0941	81-0943*	81-0944*	Incidence
PITUITARY		-	-	-	-	-	-	-	M	-	-	-	-	-	-	-	-	-	-	-	-	
POPLITEAL LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	
Malignant Lymphoma, mixed type																	P					
PREPUCE		-	-	-	-	L	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	
Posthitis, chronic, active, diffuse						4																
Abscess, solitary											4											
PREPUTIAL GLAND		-	-	-	-	L	-	-	-	-	-	-	-	-	L	-	-	-	-	L	-	
Adenitis, chronic, diffuse						4																
Abscess, focal, solitary															4					4		
Dilated ducts, multifocal																						
PROSTATE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Prostatitis, chronic, active, diffuse																						
RENAL LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type													P									
RESPIRATORY LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	
Malignant Lymphoma, mixed type																	P					
SALIVARY GLAND		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Sialadenitis, chronic, diffuse																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
.- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV
MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0945*	81-0946	81-0947*	81-0949*	81-0950*	81-0951	81-0952	81-0954*	81-0955	81-0956*	81-0957	81-0960	81-0961	81-0962	81-0964	81-0965	81-0966	81-0969*	81-0970*		Incidence
PITUITARY		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		(0)
POPLITEAL LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		(1)
Malignant Lymphoma, mixed type																						1/1
PREPUCE		-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-		(3)
Posthitis, chronic, active, diffuse									4													2/3
Abscess, solitary																						1/3
PREPUTIAL GLAND		-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	L	-		(6)
Adenitis, chronic, diffuse																			2			2/6
Abscess, focal, solitary											4											3/6
Dilated ducts, multifocal																						1/6
PROSTATE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-		(1)
Prostatitis, chronic, active, diffuse																			4			1/1
RENAL LYMPH NODE		L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		(2)
Malignant Lymphoma, mixed type		P																				2/2
RESPIRATORY LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		(1)
Malignant Lymphoma, mixed type																						1/1
SALIVARY GLAND		-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-		(1)
Sialadenitis, chronic, diffuse											3											1/1

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0897*	81-0898	81-0900	81-0902	81-0903	81-0904	81-0905	81-0906	81-0907	81-0909*	81-0910	81-0912	81-0913	81-0914	81-0915	81-0917*	81-0918*	81-0919	81-0920	81-0921	Incidence
SEMINAL VESICLES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Seminal vesiculitis, chronic, active, multifocal																						
SKELETAL MUSCLE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
SKIN		L	-	-	-	-	-	-	-	N	-	-	-	L	L	-	-	L	L	L	L	
Keratoacanthoma, solitary (Prepuce)																						
Dermatitis, chronic, active, diffuse																						
Dermatitis, chronic, diffuse														3	3			2	3	4	3	
Dermatitis, chronic, multifocal																						
Dermatitis, chronic, focal																						
Ulcers, chronic, multifocal															4							
Ulcer, chronic, solitary														3								
Follicular atrophy, diffuse		3																4				
STOMACH		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
SUBCUTANEOUS LYMPH NODE		L	-	-	-	-	L	-	-	N	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type		P																				
Hyperplasia, lymphoid, diffuse							3															
Congestion, diffuse																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV
MALE MICE

* Died on Study
or
Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0922	81-0923*	81-0924*	81-0926	81-0927	81-0928*	81-0929	81-0930	81-0931*	81-0932	81-0933	81-0934*	81-0935*	81-0936	81-0937*	81-0938*	81-0940*	81-0941	81-0943*	81-0944*	Incidence
SEMINAL VESICLES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Seminal vesiculitis, chronic, active, multifocal																						
SKELETAL MUSCLE		-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	
SKIN		L	-	L	-	-	L	L	-	-	L	N	L	L	L	-	-	-	-	L	-	
Keratoacanthoma, solitary (Prepuce)															P							
Dermatitis, chronic, active, diffuse																				3		
Dermatitis, chronic, diffuse				2							3				3							
Dermatitis, chronic, multifocal							3															
Dermatitis, chronic, focal		4		2																		
Ulcers, chronic, multifocal																						
Ulcer, chronic, solitary								2														
Follicular atrophy, diffuse													3	2								
STOMACH		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
SUBCUTANEOUS LYMPH NODE		-	L	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Hyperplasia, lymphoid, diffuse											3											
Congestion, diffuse			2																			

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0945*	81-0946	81-0947*	81-0949*	81-0950*	81-0951	81-0952	81-0954*	81-0955	81-0956*	81-0957	81-0960	81-0961	81-0962	81-0964	81-0965	81-0966	81-0969*	81-0970*		Incidence
SEMINAL VESICLES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-		(1)
Seminal vesiculitis, chronic, active, multifocal																			3			1/1
SKELETAL MUSCLE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		(1)
SKIN		-	-	-	L	N	-	-	L	L	L	L	-	N	L	L	-	L	-	-		(28)
Keratoacanthoma, solitary (Prepuce)																						1/28
Dermatitis, chronic, active, diffuse																						1/28
Dermatitis, chronic, diffuse										3	3	4				3		4				14/28
Dermatitis, chronic, multifocal																						1/28
Dermatitis, chronic, focal					3				3						4							5/28
Ulcers, chronic, multifocal																						1/28
Ulcer, chronic, solitary																		3				3/28
Follicular atrophy, diffuse																						4/28
STOMACH		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N		(1)
SUBCUTANEOUS LYMPH NODE		-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-		(6)
Malignant Lymphoma, mixed type																						1/6
Hyperplasia, lymphoid, diffuse																						2/6
Congestion, diffuse																						1/6

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0897*	81-0898	81-0900	81-0902	81-0903	81-0904	81-0905	81-0906	81-0907	81-0909*	81-0910	81-0912	81-0913	81-0914	81-0915	81-0917*	81-0918*	81-0919	81-0920	81-0921	Incidence
SUBCUTIS		-	-	-	-	-	-	-	L	L	L	-	L	-	-	-	L	-	-	-	-	
Undifferentiated Sarcoma, solitary																						
Fibrosarcoma, multifocal																						
Fibrosarcoma, solitary									P	P	P						P					
Alveolar/bronchiolar carcinoma, metastatic																						
Fibroma, solitary													P									
Metaplasia, osseous, focal																						
Cellulitis, chronic, diffuse																						
THYMUS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malignant Lymphoma, mixed type																						
Fibrosarcoma, metastatic																						
URINARY BLADDER		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	
Cystitis, acute, diffuse																						
Cystitis, chronic, active, diffuse																						
Cystitis, chronic, diffuse																						
Hemorrhage, multifocal																						
Hemorrhage, focal																						
Calculus																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0922	81-0923*	81-0924*	81-0926	81-0927	81-0928*	81-0929	81-0930	81-0931*	81-0932	81-0933	81-0934*	81-0935*	81-0936	81-0937*	81-0938*	81-0940*	81-0941	81-0943*	81-0944*	Incidence
SUBCUTIS		-	-	-	-	-	-	L	-	-	-	-	-	L	-	L	-	L	-	-	-	
Undifferentiated Sarcoma, solitary																		P				
Fibrosarcoma, multifocal														P								
Fibrosarcoma, solitary																P						
Alveolar/bronchiolar carcinoma, metastatic																						
Fibroma, solitary								P														
Metaplasia, osseous, focal																						
Cellulitis, chronic, diffuse																						
THYMUS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	
Malignant Lymphoma, mixed type																	P					
Fibrosarcoma, metastatic																						
URINARY BLADDER		-	N	N	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	L	
Cystitis, acute, diffuse																						
Cystitis, chronic, active, diffuse																				3		
Cystitis, chronic, diffuse																						
Hemorrhage, multifocal																						
Hemorrhage, focal																					4	
Calculus					P																	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP IV

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-0945*	81-0946	81-0947*	81-0949*	81-0950*	81-0951	81-0952	81-0954*	81-0955	81-0956*	81-0957	81-0960	81-0961	81-0962	81-0964	81-0965	81-0966	81-0969*	81-0970*		Incidence
SUBCUTIS		-	L	L	-	L	-	-	-	-	L	-	L	-	-	L	L	L	-	L		(18)
Undifferentiated Sarcoma, solitary																						1/18
Fibrosarcoma, multifocal																						1/18
Fibrosarcoma, solitary				P							P		P					P				9/18
Alveolar/bronchiolar carcinoma,																						
metastatic																				P		1/18
Fibroma, solitary			P			P							P				P					6/18
Metaplasia, osseous, focal																3						1/18
Cellulitis, chronic, diffuse											3											1/18
THYMUS		-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		(2)
Malignant Lymphoma, mixed type																						1/2
Fibrosarcoma, metastatic				P																		1/2
URINARY BLADDER		-	-	-	-	L	-	N	L	N	-	N	-	-	-	-	-	-	-	L	-		(12)
Cystitis, acute, diffuse																				4		1/12
Cystitis, chronic, active, diffuse																						1/12
Cystitis, chronic, diffuse						3																1/12
Hemorrhage, multifocal									3													1/12
Hemorrhage, focal																						1/12
Calculus																						1/12

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1047*	81-1050	81-1053*	81-1056*	81-1058	81-1064	81-1071	81-1075	81-1076	81-1077*	81-1079	81-1083*	81-1085	81-1086	81-1088	81-1093	81-1097	81-1098	81-1099	81-1100	Incidence
BRAIN		L	L	L	L	L	L	L	N	N	L	N	N	L	L	L	N	L	N	L	N	
Hemorrhage, focal (Third Ventricle)					2																	
Corpora amylacea, multifocal		2	2	2	2	2	2	2			2			2	2	2		2		2		
SPINAL CORD		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
EYES		N	L	N	N	N	N	N	L	N	N	N	N	L	N	N	N	N	L	N	N	
Keratitis, acute, ulcerative, focal									4													
Mineralization, focal (Cornea)														1								
Cataract, subcapsular, unilateral -			3																2			
OPTIC NERVES		M	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
ADRENALS		N	N	N	N	L	N	L	N	N	N	N	N	N	L	N	N	L	L	L	N	
Pheochromocytoma, solitary																			P	P		
Hyperplasia, cortical, multifocal						2		2										2				
Hyperplasia, cortical, focal															2				2			
Hyperplasia, medullary, focal																						
SPLEEN		N	N	N	N	N	N	N	N	L	N	L	N	N	N	N	N	N	L	N	N	
Malignant Lymphoma, mixed type																						
Hyperplasia, lymphoid, diffuse																			3			
Hematopoiesis, extramedullary, diffuse										3		3										

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1101	81-1102*	81-1105	81-1106	81-1108	81-1119	81-1121	Incidence
BRAIN		L	L	L	L	L	L	L	(27)
Hemorrhage, focal (Third Ventricle)									1/27
Corpora amylacea, multifocal		2	2	2	2	2	2	2	20/27
SPINAL CORD		N	N	N	N	N	N	N	(27)
EYES		N	N	N	L	N	N	N	(27)
Keratitis, acute, ulcerative, focal									1/27
Mineralization, focal (Cornea)									1/27
Cataract, subcapsular, unilateral					2				3/27
OPTIC NERVES		N	N	N	N	N	N	N	(26)
ADRENALS		N	N	L	L	N	N	L	(27)
Pheochromocytoma, solitary									2/27
Hyperplasia, cortical, multifocal								2	4/27
Hyperplasia, cortical, focal									2/27
Hyperplasia, medullary, focal				2	2				2/27
SPLEEN		N	L	N	L	N	N	N	(27)
Malignant Lymphoma, mixed type			P		P				2/27
Hyperplasia, lymphoid, diffuse									1/27
Hematopoiesis, extramedullary, diffuse			3						3/27

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1047*	81-1050	81-1053*	81-1056*	81-1058	81-1064	81-1071	81-1075	81-1076	81-1077*	81-1079	81-1083*	81-1085	81-1086	81-1088	81-1093	81-1097	81-1098	81-1099	81-1100	Incidence
PANCREAS		N	N	N	N	N	N	N	N	N	N	L	L	N	N	N	N	N	N	N	N	
Acinar atrophy, multifocal												2	2									
MESENTERIC LYMPH NODE		M	L	N	L	N	L	L	N	L	N	L	L	L	N	L	L	L	L	L	N	
Malignant Lymphoma, mixed type			P																			
Hemangioma, solitary										P												
Hyperplasia, lymphoid, diffuse							2	2						1		2	3	2	2	2		
Lymphatic cysts, multifocal												3										
Congestion, diffuse					3								3							2		
TESTES		N	N	N	N	N	N	N	N	N	N	N	L	N	N	N	N	L	N	N	N	
Oligospermia, multifocal													2									
Atrophy, diffuse, unilateral																						
Degeneration, focal													2					1				
PROSTATE		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
EPIDIDYMIDES		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
URINARY BLADDER		N	N	N	N	N	N	N	N	N	L	N	L	L	N	L	N	N	N	N	N	
Cystitis, chronic, active, diffuse													4									
Cystitis, chronic, active, focal											3											
Calculus														P		P						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
'- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number: 81-1101	81-1102*	81-1105	81-1106	81-1108	81-1119	81-1121	Incidence
PANCREAS	N	N	N	N	N	N	N	(27)
Acinar atrophy, multifocal								2/27
MESENTERIC LYMPH NODE	L	L	N	L	L	N	N	(26)
Malignant Lymphoma, mixed type		P		P				3/26
Hemangioma, solitary								1/26
Hyperplasia, lymphoid, diffuse	2				2			10/26
Lymphatic cysts, multifocal								1/26
Congestion, diffuse	2							4/26
TESTES	L	N	L	N	N	N	N	(27)
Oligospermia, multifocal								1/27
Atrophy, diffuse, unilateral			2					1/27
Degeneration, focal	3							3/27
PROSTATE	N	N	N	N	N	N	N	(27)
EPIDIDYMIDES	N	N	N	N	N	N	N	(27)
URINARY BLADDER	N	N	L	N	N	N	N	(27)
Cystitis, chronic, active, diffuse								1/27
Cystitis, chronic, active, focal								1/27
Calculus			P					3/27

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
-- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1047*	81-1050	81-1053*	81-1056*	81-1058	81-1064	81-1071	81-1075	81-1076	81-1077*	81-1079	81-1083*	81-1085	81-1086	81-1088	81-1093	81-1097	81-1098	81-1099	81-1100	Incidence
LUNGS		N	L	L	L	N	L	N	N	N	L	N	N	N	N	N	N	N	N	N	N	
Alveolar/bronchiolar carcinoma,																						
multifocal					P																	
Alveolar/bronchiolar carcinoma,																						
solitary			P				P															
Alveolar/bronchiolar adenoma, solitary																						
Histiocytosis, multifocal			2																			
Thrombi, arterial, multiple				3																		
Hemorrhage, focal							1															
Congestion, diffuse											3											
ESOPHAGUS		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
TRACHEA		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
THYROIDS		M	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	L	N	
Follicular-cell adenoma, solitary																				P		
PARATHYROIDS		M	N	M	N	M	M	N	M	N	N	N	N	N	N	M	M	M	N	N	N	
HEART		M	N	N	N	N	N	N	N	L	N	N	N	N	N	N	N	N	N	N	N	
Myocarditis, chronic, focal										1												

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
-- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1101	81-1102*	81-1105	81-1106	81-1108	81-1119	81-1121	Incidence
LUNGS		L	N	N	L	L	N	N	(27)
Alveolar/bronchiolar carcinoma,									
multifocal					P				2/27
Alveolar/bronchiolar carcinoma,									
solitary		P							3/27
Alveolar/bronchiolar adenoma, solitary						P			1/27
Histiocytosis, multifocal		2			1				3/27
Thrombi, arterial, multiple									1/27
Hemorrhage, focal									1/27
Congestion, diffuse									1/27
ESOPHAGUS		N	N	N	N	N	N	N	(27)
TRACHEA		N	N	N	N	N	N	N	(27)
THYROIDS		N	N	N	N	N	N	N	(26)
Follicular-cell adenoma, solitary									1/26
PARATHYROIDS		N	N	N	N	M	N	N	(18)
HEART		N	N	N	N	N	N	N	(26)
Myocarditis, chronic, focal									1/26

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice

HISTOPATHOLOGY INCIDENCE TABLE

Dose (mg/kg/day): 175/100 mg/kg/day

GROUP V

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion / Accession Number	81-1047*	81-1050	81-1053*	81-1056*	81-1058	81-1064	81-1071	81-1075	81-1076	81-1077*	81-1079	81-1083*	81-1085	81-1086	81-1088	81-1093	81-1097	81-1098	81-1099	81-1100	Incidence
LIVER	N	L	L	N	N	N	N	N	L	L	L	L	N	N	L	N	L	L	L	L	
Hemangiosarcoma, multifocal			P																		
Hemangiosarcoma, solitary												P									
Hepatocellular carcinoma, multifocal		P																	P		
Hepatocellular carcinoma, solitary									P		P				P		P				
Hepatocellular adenoma, multifocal																				P	
Hepatocellular adenoma, solitary										P								P			
Necrosis, focal												2									
Hematopoiesis,extramedullary,multifocal																	1				
KIDNEYS	N	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	
Malignant Lymphoma, mixed type	·																				
Metaplasia, osseous, focal (Cortex)																		2			
Hyperplasia, tubular, multifocal		2			2	2	2	2	2				2	2	2	2	2	2	2	1	
Pyelonephritis, acute, diffuse, bact.et.										4											
Nephropathy, chronic, diffuse																					
Nephropathy, chronic, multifocal											2										
Nephrocalcinosis, multifocal		1	1	2	2	2	2	1				2	2		2	2	2	1	1	2	
Cortical cyst, solitary		2											2								
Infarct, cortical, focal							2										2				

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
. - = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1101	81-1102*	81-1105	81-1106	81-1108	81-1119	81-1121	Incidence
LIVER		L	N	L	N	L	N	L	(27)
Hemangiosarcoma, multifocal									1/27
Hemangiosarcoma, solitary									1/27
Hepatocellular carcinoma, multifocal									2/27
Hepatocellular carcinoma, solitary									4/27
Hepatocellular adenoma, multifocal		P							2/27
Hepatocellular adenoma, solitary				P		P		P	5/27
Necrosis, focal									1/27
Hematopoiesis,extramedullary,multifocal									1/27
KIDNEYS		L	L	L	L	L	L	L	(27)
Malignant Lymphoma, mixed type			P						1/27
Metaplasia, osseous, focal (Cortex)									1/27
Hyperplasia, tubular, multifocal		1	2		1	3	2	2	20/27
Pyelonephritis, acute, diffuse, bact.et.									1/27
Nephropathy, chronic, diffuse				3					1/27
Nephropathy, chronic, multifocal									1/27
Nephrocalcinosis, multifocal		1	2		1	2	2	2	21/27
Cortical cyst, solitary									2/27
Infarct, cortical, focal									2/27

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
– = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1047*	81-1050	81-1053*	81-1056*	81-1058	81-1064	81-1071	81-1075	81-1076	81-1077*	81-1079	81-1083*	81-1085	81-1086	81-1088	81-1093	81-1097	81-1098	81-1099	81-1100	Incidence
KIDNEYS (Con't.)		N	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	L	
Cholemic nephrosis, diffuse													3									
Necrosis, multifocal																						
Mineralization, multifocal											3											
Cytoplasmic vacuolization, diffuse,																						
(Tubules)			2		2	2	2	2	2	2		2	2	2	2	2	2	2	2	2	1	
STOMACH		N	N	N	N	N	N	N	N	N	N	N	L	N	N	N	N	N	N	N	N	
Degeneration, cystic, multifocal,																						
(Glandular)													1									
DUODENUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
JEJUNUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
ILEUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
CECUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
COLON		N	L	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
Malignant Lymphoma, mixed type			P																			
RECTUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
SKIN		N	L	L	N	N	L	L	N	L	L	L	N	N	N	L	N	L	N	L	L	
Fibroma, solitary																		P				
Epidermal inclusion cyst, solitary																					P	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1101	81-1102*	81-1105	81-1106	81-1108	81-1119	81-1121	Incidence
KIDNEYS (Con't.)		L	L	L	L	L	L	L	(27)
Cholemic nephrosis, diffuse									1/27
Necrosis, multifocal					1				1/27
Mineralization, multifocal									1/27
Cytoplasmic vacuolization, diffuse,									
(Tubules)		2	2	1	1	2	2	2	24/27
STOMACH		N	N	N	N	N	N	N	(27)
Degeneration, cystic, multifocal,									
(Glandular)									1/27
DUODENUM		N	N	N	N	N	N	N	(27)
JEJUNUM		N	N	N	N	N	N	N	(27)
ILEUM		N	N	N	N	N	N	N	(27)
CECUM		N	N	N	N	N	N	N	(27)
COLON		N	N	N	N	N	N	N	(27)
Malignant Lymphoma, mixed type									1/27
RECTUM		N	N	N	N	N	N	N	(27)
SKIN		L	L	L	L	N	N	N	(27)
Fibroma, solitary									1/27
Epidermal inclusion cyst, solitary									1/27

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice

HISTOPATHOLOGY INCIDENCE TABLE

Dose (mg/kg/day): 175/100 mg/kg/day GROUP V

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1047*	81-1050	81-1053*	81-1056*	81-1058	81-1064	81-1071	81-1075	81-1076	81-1077*	81-1079	81-1083*	81-1085	81-1086	81-1088	81-1093	81-1097	81-1098	81-1099	81-1100	Incidence
SKIN (Con't.)		N	L	L	N	N	L	L	N	L	L	L	N	N	N	L	N	L	N	L	L	
Dermatitis, chronic, active, ulcerative,																						
diffuse																						
Dermatitis, chronic, active, ulcerative,																						
focal							4															
Dermatitis, chronic, active, diffuse																					3	
Dermatitis, chronic, active, focal																						
Dermatitis, chronic, diffuse			3									3				3					3	
Dermatitis, chronic, multifocal								2			3											
Dermatitis, chronic, focal				3														3		3		
Follicular atrophy, diffuse								2		2												
Mineralization, multifocal				2																		
MAMMARY GLAND		M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	
STERNUM		N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
BONE MARROW		N	L	N	L	L	L	N	L	L	L	L	L	L	L	L	L	L	L	L	L	
Hyperplasia, myeloid, diffuse			2		2	2	2		2	2	2	2	2	2	2	2	2	2	2	2	2	
Myelofibrosis, focal			2																			

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1101	81-1102*	81-1105	81-1106	81-1108	81-1119	81-1121	Incidence
SKIN (Con't.)		L	L	L	L	N	N	N	(27)
Dermatitis, chronic, active, ulcerative,									
diffuse			3						1/27
Dermatitis, chronic, active, ulcerative,									
focal									1/27
Dermatitis, chronic, active, diffuse									1/27
Dermatitis, chronic, active, focal		1							1/27
Dermatitis, chronic, diffuse				3	3				6/27
Dermatitis, chronic, multifocal			2						3/27
Dermatitis, chronic, focal									3/27
Follicular atrophy, diffuse									2/27
Mineralization, multifocal									1/27
MAMMARY GLAND		M	M	M	M	M	M	M	(0)
STERNUM		N	N	N	N	N	N	N	(27)
BONE MARROW		L	L	N	L	L	L	L	(27)
Hyperplasia, myeloid, diffuse		2	2		2	2	2	2	23/27
Myelofibrosis, focal									1/27

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1047*	81-1050	81-1053*	81-1056*	81-1058	81-1064	81-1071	81-1075	81-1076	81-1077*	81-1079	81-1083*	81-1085	81-1086	81-1088	81-1093	81-1097	81-1098	81-1099	81-1100	Incidence
LESIONS (TISSUES NOT SPECIFICALLY																						
REQUIRED BY PROTOCOL)																						
ABDOMINAL CAVITY		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	
Pheochromocytoma, solitary																					P	
GALL BLADDER		N	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
HARDERIAN GLAND		-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Adenoma, solitary			P																			
LUMBAR LYMPH NODE		-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	
Hyperplasia, lymphoid, diffuse											2											
MANDIBULAR LYMPH NODE		N	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
MESENTERIC FAT		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	
Steatitis, chronic, focal																					3	
PENIS		-	L	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	
Urethritis, acute, focal											4											
Balanitis, chronic, active, diffuse			4																			
Balanitis, chronic, diffuse																						
Calculus											P											

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

* Died on Study or Moribund Sacrifice

MALE MICE

ORGAN Lesion	Accession Number	81-1101	81-1102*	81-1105	81-1106	81-1108	81-1119	81-1121	Incidence
LESIONS (TISSUES NOT SPECIFICALLY									
REQUIRED BY PROTOCOL)									
ABDOMINAL CAVITY		-	-	-	-	-	-	-	(1)
Pheochromocytoma, solitary									1/1
GALL BLADDER		-	-	-	-	-	-	-	(1)
HARDERIAN GLAND		-	-	-	-	-	-	-	(1)
Adenoma, solitary									1/1
LUMBAR LYMPH NODE		-	-	-	-	-	-	-	(1)
Hyperplasia, lymphoid, diffuse									1/1
MANDIBULAR LYMPH NODE		-	-	-	-	-	-	-	(1)
MESENTERIC FAT		-	-	-	-	-	-	-	(1)
Steatitis, chronic, focal									1/1
PENIS		-	N	-	L	-	-	-	(4)
Urethritis, acute, focal									1/4
Balanitis, chronic, active, diffuse									1/4
Balanitis, chronic, diffuse					2				1/4
Calculus									1/4

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1047*	81-1050	81-1053*	81-1056*	81-1058	81-1064	81-1071	81-1075	81-1076	81-1077*	81-1079	81-1083*	81-1085	81-1086	81-1088	81-1093	81-1097	81-1098	81-1099	81-1100	Incidence
PREPUCE		-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	
Posthitis, chronic, diffuse																						
Posthitis, chronic, multifocal											2											
PREPUTIAL GLAND		-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	
Dilated ducts, multifocal													3									
SEMINAL VESICLES		-	-	N	N	-	N	N	N	N	-	-	N	-	-	N	N	N	N	-	N	
SUBCUTANEOUS LYMPH NODE		-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	
Hyperplasia, lymphoid, diffuse									3													
SUBCUTIS		-	-	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	L	
Osteosarcoma, solitary																				P		
Fibrosarcoma, solitary				P																		
Fibroma, solitary																				P	P	
URETHRA		-	-	L	L	-	-	L	-	-	L	-	-	L	-	L	-	L	-	L	L	
Calculus				P	P			P			P			P		P		P		P	P	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 175/100 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

GROUP V

MALE MICE

* Died on Study or Moribund Sacrifice

ORGAN Lesion	Accession Number	81-1101	81-1102*	81-1105	81-1106	81-1108	81-1119	81-1121	Incidence
PREPUCE		-	L	-	-	-	-	-	(2)
Posthitis, chronic, diffuse			4						1/2
Posthitis, chronic, multifocal									1/2
PREPUTIAL GLAND		-	N	-	-	-	-	-	(2)
Dilated ducts, multifocal									1/2
SEMINAL VESICLES		N	-	N	-	-	N	-	(15)
SUBCUTANEOUS LYMPH NODE		-	-	-	-	-	-	-	(1)
Hyperplasia, lymphoid, diffuse									1/1
SUBCUTIS		L	-	-	-	-	-	-	(4)
Osteosarcoma, solitary									1/4
Fibrosarcoma, solitary									1/4
Fibroma, solitary		P							3/4
URETHRA		L	L	-	-	-	L	-	(12)
Calculus		P	P				P		12/12

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group MALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day
BRAIN		(63)	(60)	(62)	(59)	(27)	(65)	(62)	(64)	(64)	(31)
Malignant Lymphoma		0/63	0/60	1/62	1/59	0/27	2/65	2/62	1/64	2/64	1/31
Abscess		0/63	1/60	0/62	0/59	0/27	0/65	0/62	0/64	0/64	0/31
Compression		0/63	0/60	0/62	0/59	0/27	2/65	1/62	1/64	0/64	0/31
Corpora amylacea		16/63	23/60	40/62	14/59	20/27	36/65	35/62	18/64	38/64	9/31
Encephalomalacia		1/63	0/60	0/62	0/59	0/27	0/65	0/62	0/64	0/64	0/31
Hemorrhage		0/63	0/60	0/62	0/59	1/27	1/65	0/62	0/64	1/64	0/31
Lymphocytosis		1/63	1/60	0/62	0/59	0/27	2/65	3/62	7/64	1/64	0/31
Meningoencephalitis, acute		0/63	0/60	0/62	0/59	0/27	0/65	0/62	0/64	0/64	1/31
SPINAL CORD		(63)	(60)	(62)	(59)	(27)	(65)	(62)	(64)	(64)	(31)
Malignant Lymphoma		0/63	0/60	1/62	0/59	0/27	1/65	2/62	0/64	2/64	1/31
Hemangiosarcoma		0/63	0/60	0/62	0/59	0/27	0/65	1/62	0/64	0/64	0/31
Axonal degeneration		1/63	0/60	0/62	0/59	0/27	0/65	0/62	0/64	0/64	0/31
Hemorrhage		0/63	0/60	0/62	0/59	0/27	1/65	0/62	0/64	1/64	0/31
Lymphocytosis		1/63	0/60	0/62	0/59	0/27	3/65	5/62	11/64	1/64	0/31
Meningitis, acute		0/63	0/60	0/62	0/59	0/27	0/65	0/62	0/64	0/64	1/31

* Tissues not specifically required by protocol.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group MALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day
EYES		(63)	(*1)	(*2)	(*1)	(27)		(65)	(*3)	(*3)	(*1)	(31)
Malignant Lymphoma		0/63	0/1	0/2	0/1	0/27		0/65	1/3	0/3	0/1	0/31
Cataract, subcapsular		4/63	0/1	0/2	1/1	3/27		11/65	0/3	0/3	0/1	5/31
Hemorrhage		0/63	0/1	0/2	0/1	0/27		1/65	0/3	0/3	0/1	0/31
Keratitis, acute		1/63	0/1	0/2	0/1	1/27		0/65	0/3	0/3	0/1	0/31
Keratitis, chronic		2/63	1/1	0/2	0/1	0/27		2/65	0/3	1/3	0/1	1/31
Mineralization (Cornea)		0/63	0/1	0/2	0/1	1/27		1/65	0/3	0/3	0/1	0/31
Phthisis bulbi		0/63	0/1	1/2	0/1	0/27		2/65	2/3	2/3	0/1	2/31
OPTIC NERVES		(54)	(*1)	-	-	(26)		(63)	-	-	-	(28)
Neuritis, chronic		0/54	0/1	-	-	0/26		3/63	-	-	-	0/28
Perineuritis, acute		0/54	0/1	-	-	0/26		0/63	-	-	-	1/28
ADRENALS		(63)	(*2)	(*3)	(*4)	(27)		(65)	(*2)	(*3)	(*2)	(31)
Alveolar/bronchiolar Carcinoma,												
metastatic		0/63	0/2	0/3	1/4	0/27		0/65	0/2	0/3	0/2	0/31
Malignant Lymphoma		0/63	0/2	0/3	2/4	0/27		1/65	1/2	0/3	0/2	0/31
Cortical Adenoma		3/63	0/2	0/3	0/4	0/27		0/65	0/2	0/3	0/2	0/31
Fibroma		0/63	0/2	0/3	0/4	0/27		0/65	0/2	1/3	0/2	0/31
Pheochromocytoma		2/63	0/2	1/3	1/4	2/27		1/65	1/2	1/3	2/2	2/31
Hyperplasia, cortical		2/63	0/2	0/3	0/4	6/27		3/65	0/2	0/3	0/2	1/31
Hyperplasia, medullary		5/63	0/2	0/3	0/4	2/27		0/65	0/2	0/3	0/2	1/31

* Tissues not specifically required by protocol.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group	MALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day
SPLEEN		(63)	(60)	(62)	(58)	(27)	(64)	(62)	(64)	(64)	(31)
Granulosa-cell Carcinoma, metastatic		0/63	0/60	0/62	0/58	0/27	0/64	0/62	1/64	0/64	0/31
Hemangiosarcoma		2/63	1/60	1/62	0/58	0/27	0/64	2/62	0/64	3/64	2/31
Leukemia, myeloid		0/63	2/60	0/62	0/58	0/27	2/64	0/62	0/64	1/64	0/31
Malignant Lymphoma		4/63	2/60	12/62	6/58	2/27	27/64	17/62	15/64	19/64	11/31
Angiectasis		0/63	0/60	0/62	1/58	0/27	0/64	0/62	0/64	0/64	0/31
Hematopoiesis, extramedullary		9/63	13/60	15/62	8/58	3/27	2/64	5/62	11/64	5/64	2/31
Hyperplasia, lymphoid		6/63	18/60	17/62	9/58	1/27	18/64	29/62	30/64	24/64	7/31
Hyperplasia, reticulum-cell		0/63	0/60	1/62	1/58	0/27	1/64	0/62	0/64	0/64	0/31
Splenitis, acute		0/63	0/60	0/62	0/58	0/27	0/64	0/62	1/64	0/64	0/31
PANCREAS		(63)	-	(*6)	(*6)	(27)	(64)	(*10)	(*6)	(*4)	(31)
Fibrosarcoma, metastatic		0/63	-	1/6	0/6	0/27	0/64	0/10	0/6	0/4	0/31
Granulosa-cell Carcinoma, metastatic		0/63	-	0/6	0/6	0/27	0/64	0/10	1/6	0/4	0/31
Leukemia, myeloid		0/63	-	0/6	0/6	0/27	2/64	0/10	0/6	0/4	0/31
Malignant Lymphoma		2/63	-	0/6	1/6	0/27	12/64	6/10	4/6	1/4	3/31
Undifferentiated Sarcoma		0/63	-	0/6	0/6	0/27	0/64	1/10	0/6	0/4	0/31
Islet-cell Adenoma		0/63	-	0/6	0/6	0/27	2/64	0/10	0/6	0/4	0/31
Abscess		0/63	-	0/6	0/6	0/27	0/64	0/10	1/6	0/4	0/31
Acinar atrophy		3/63	-	2/6	0/6	2/27	0/64	0/10	0/6	1/4	1/31
Acinar hyperplasia		4/63	-	0/6	1/6	0/27	2/64	0/10	0/6	0/4	0/31

* Tissues not specifically required by protocol.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group MALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	175/100 mg/kg/day
PANCREAS (Con't.)		(63)	-	(*6)	(*6)	(27)	(64)	(*10)	(*6)	(*4)	(31)
Cystic duct		0/63	-	0/6	0/6	0/27	0/64	0/10	1/6	0/4	1/31
Dilated duct		0/63	-	0/6	0/6	0/27	0/64	0/10	0/6	1/4	0/31
Hyperplasia, islet-cell		1/63	-	0/6	1/6	0/27	0/64	0/10	0/6	0/4	0/31
Necrosis		0/63	-	0/6	0/6	0/27	0/64	0/10	1/6	0/4	0/31
Pancreatitis, chronic		0/63	-	0/6	0/6	0/27	1/64	0/10	0/6	0/4	0/31
MESENTERIC LYMPH NODE		(59)	(*19)	(*20)	(*20)	(26)	(62)	(*17)	(*13)	(*8)	(26)
Hemangiosarcoma		0/59	0/19	0/20	0/20	0/26	0/62	0/17	0/13	0/8	1/26
Leukemia, myeloid		0/59	0/19	0/20	0/20	0/26	2/62	0/17	0/13	0/8	0/26
Malignant Lymphoma		6/59	2/19	6/20	7/20	3/26	32/62	12/17	7/13	6/8	8/26
Renal-cell Carcinoma, metastatic		0/59	0/19	0/20	0/20	0/26	0/62	0/17	1/13	0/8	0/26
Undifferentiated Sarcoma		0/59	0/19	0/20	0/20	0/26	0/62	1/17	0/13	0/8	0/26
Hemangioma		0/59	0/19	0/20	0/20	1/26	0/62	0/17	0/13	0/8	0/26
Angiectasis		0/59	0/19	0/20	1/20	0/26	1/62	0/17	0/13	0/8	0/26
Congestion		14/59	9/19	9/20	7/20	4/26	1/62	0/17	1/13	0/8	0/26
Edema		1/59	0/19	0/20	0/20	0/26	0/62	0/17	1/13	0/8	0/26
Hemorrhage		0/59	1/19	0/20	1/20	0/26	0/62	0/17	0/13	0/8	0/26
Hyperplasia, lymphoid		9/59	8/19	6/20	4/20	10/26	12/62	4/17	3/13	0/8	7/26
Hyperplasia, reticulum-cell		0/59	0/19	0/20	0/20	0/26	0/62	0/17	0/13	1/8	0/26
Lymphadenitis, acute		1/59	2/19	1/20	1/20	0/26	0/62	0/17	0/13	0/8	0/26

* Tissues not specifically required by protocol.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group	MALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day
MESENTERIC LYMPH NODE (Con't.)		(59)	(*19)	(*20)	(*20)	(26)	(62)	(*17)	(*13)	(*8)	(26)
Lymphatic cyst		0/59	0/19	0/20	1/20	1/26	0/62	0/17	0/13	0/8	0/26
Necrosis, lymphoid		0/59	0/19	1/20	0/20	0/26	0/62	0/17	0/13	0/8	0/26
TESTES		(63)	(60)	(62)	(59)	(27)	-	-	-	-	-
Hemangiosarcoma		0/63	1/60	0/62	0/59	0/27					
Malignant Lymphoma		1/63	0/60	0/62	0/59	0/27					
Atrophy		0/63	0/60	0/62	0/59	1/27					
Degeneration		0/63	2/60	2/62	6/59	3/27					
Hematoma		0/63	0/60	1/62	0/59	0/27					
Interstitial cell Tumor		0/63	0/60	0/62	1/59	0/27					
Mineralization		0/63	0/60	1/62	1/59	0/27					
Oligospermia		0/63	0/60	1/62	0/59	1/27					
Sperm granuloma		0/63	0/60	0/62	1/59	0/27					
PROSTATE		(62)	(*3)	(*1)	(*1)	(27)	-	-	-	-	-
Hyperplasia, glandular		1/62	0/3	0/1	0/1	0/27					
Prostatitis, chronic		1/62	1/3	0/1	1/1	0/27					
EPIDIDYMIDES		(62)	(*3)	(*2)	-	(27)	-	-	-	-	-
Fibrosarcoma, metastatic		0/62	0/3	1/2	-	0/27					
Epididymitis, acute		1/62	0/3	0/2	-	0/27					
Epididymitis, chronic		1/62	1/3	0/2	-	0/27					

* Tissues not specifically required by protocol.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group MALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day
EPIDIDYMIDES (Con't.)		(62)	(*3)	(*2)	-	(27)		-	-	-	-	-
Mineralization		1/62	0/3	0/2	-	0/27						
Sperm granuloma		1/62	0/3	0/2	-	0/27						
OVARIES		-	-	-	-	-		(65)	(61)	(63)	(64)	(31)
Granulosa-cell Carcinoma								0/65	0/61	1/63	0/64	0/31
Hemangiosarcoma								2/65	0/61	0/63	0/64	0/31
Hemangiosarcoma, metastatic								0/65	1/61	0/63	0/64	0/31
Leukemia, myeloid								1/65	0/61	0/63	0/64	0/31
Malignant Lymphoma								6/65	4/61	6/63	5/64	2/31
Renal cell Carcinoma, metastatic								0/65	0/61	1/63	0/64	0/31
Undifferentiated Sarcoma								0/65	1/61	0/63	0/64	0/31
Cystadenoma								1/65	0/61	1/63	0/64	1/31
Granulosa-cell Tumor								0/65	1/61	0/63	0/64	0/31
Granulosa-thecal Tumor								0/65	0/61	1/63	0/64	0/31
Luteoma								0/65	0/61	0/63	1/64	0/31
Abscess								2/65	0/61	2/63	1/64	0/31
Follicular cyst								7/65	5/61	4/63	0/64	3/31
Hemorrhage								0/65	0/61	0/63	1/64	0/31
Hemorrhagic cyst								1/65	0/61	0/63	0/64	1/31
Hematoma								1/65	0/61	0/63	1/64	0/31

* Tissues not specifically required by protocol.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group MALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day
OVARIES (Con't.)		-	-	-	-	-	(65)	(61)	(63)	(64)	(31)
Keratinized cyst							0/65	0/61	1/63	0/64	0/31
Necrosis							0/65	1/61	0/63	0/64	0/31
Parovarian cyst							9/65	20/61	12/63	16/64	3/31
UTERUS		-	-	-	-	-	(65)	(48*)	(52*)	(50*)	(31)
Endometrial Stromal Sarcoma							1/65	1/48	0/52	0/50	1/31
Fibrosarcoma, metastatic							0/65	0/48	1/52	0/50	0/31
Hemangiosarcoma							1/65	0/48	2/52	0/50	0/31
Malignant Lymphoma							3/65	2/48	2/52	3/50	1/31
Renal cell Carcinoma, metastatic							0/65	0/48	1/52	0/50	0/31
Endometrial Stromal Polyp							0/65	0/48	1/52	0/50	1/31
Hemangioma							0/65	1/48	3/52	1/50	0/31
Endometritis, acute							8/65	2/48	1/52	1/50	5/31
Granuloma							0/65	0/48	0/52	0/50	1/31
Hematoma							0/65	2/48	0/52	1/50	0/31
Hemorrhage							1/65	0/48	0/52	0/50	1/31
Hydrometra							1/65	2/48	1/52	0/50	1/31
Hyperplasia, cystic, glandular							63/65	44/48	42/52	48/50	28/31
Metritis, acute							0/65	0/48	1/52	0/50	0/31
Mineralization							0/65	0/48	0/52	1/50	0/31

* Tissues not specifically required by protocol.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group	MALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day
UTERUS (Con't.)		-	-	-	-	-	(65)	(48*)	(52*)	(50*)	(31)
Squamous metaplasia							1/65	1/48	0/52	0/50	2/31
URINARY BLADDER		(62)	(*6)	(10*)	(12*)	(27)	(64)	(*1)	(*1)	-	(31)
Malignant Lymphoma		0/62	0/6	0/10	0/12	0/27	8/64	0/1	0/1	-	7/31
Renal cell Carcinoma, metastatic		0/62	0/6	0/10	0/12	0/27	0/64	0/1	1/1	-	0/31
Calculus		11/62	0/6	4/10	1/12	3/27	0/64	0/1	0/1	-	0/31
Cystitis, acute		0/62	0/6	0/10	1/12	0/27	0/64	0/1	0/1	-	0/31
Cystitis, chronic		4/62	0/6	3/10	2/12	2/27	0/64	0/1	0/1	-	1/31
Hemorrhage		0/62	0/6	0/10	2/12	0/27	0/64	0/1	0/1	-	0/31
Hyperplasia, epithelial		1/62	0/6	0/10	0/12	0/27	0/64	0/1	0/1	-	0/31
LUNGS		(63)	(10*)	(*6)	(13*)	(27)	(65)	(*7)	(10*)	(11*)	(31)
Alveolar/bronchiolar Carcinoma		3/63	5/10	1/6	5/13	5/27	3/65	0/7	1/10	2/11	4/31
Fibrosarcoma, metastatic		1/63	0/10	1/6	2/13	0/27	0/65	0/7	1/10	1/11	0/31
Granulosa-cell Carcinoma, metastatic		0/63	0/10	0/6	0/13	0/27	0/65	0/7	1/10	0/11	0/31
Hemangiosarcoma, metastatic		0/63	0/10	0/6	0/13	0/27	0/65	0/7	0/10	1/11	0/31
Hepatocellular Carcinoma, metastatic		2/63	0/10	1/6	4/13	0/27	0/65	0/7	0/10	0/11	0/31
Leukemia, myeloid		1/63	1/10	0/6	0/13	0/27	1/65	0/7	0/10	0/11	1/31
Malignant Lymphoma		1/63	0/10	1/6	1/13	0/27	18/65	3/7	1/10	5/11	8/31
Osteosarcoma		0/63	0/10	0/6	0/13	0/27	1/65	0/7	0/10	0/11	0/31
Renal cell Carcinoma, metastatic		0/63	0/10	0/6	0/13	0/27	0/65	0/7	1/10	0/11	0/31

* Tissues not specifically required by protocol.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	MALES RDX 0.0 mg/kg/day	MALES RDX 1.5 mg/kg/day	MALES RDX 7.0 mg/kg/day	MALES RDX 35 mg/kg/day	MALES RDX 175/100 mg/kg/day	FEMALES RDX 0.0 mg/kg/day	FEMALES RDX 1.5 mg/kg/day	FEMALES RDX 7.0 mg/kg/day	FEMALES RDX 35 mg/kg/day	FEMALES RDX 175/100 mg/kg/day
LUNGS (Con't.)	(63)	(*10)	(*6)	(*13)	(27)	(65)	(*7)	(*10)	(*11)	(31)
Undifferentiated Sarcoma	0/63	1/10	0/6	0/13	0/27	0/65	0/7	0/10	0/11	0/31
Alveolar/bronchiolar Adenoma	6/63	0/10	0/6	1/13	1/27	4/65	0/7	2/10	0/11	3/31
Bronchiolitis, acute	1/63	0/10	0/6	0/13	0/27	0/65	0/7	0/10	0/11	0/31
Bronchopneumonia, acute	0/63	1/10	0/6	0/13	0/27	0/65	0/7	0/10	0/11	0/31
Congestion	5/63	1/10	1/6	1/13	1/27	4/65	1/7	0/10	1/11	1/31
Edema	0/63	0/10	0/6	0/13	0/27	1/65	0/7	1/10	0/11	0/31
Hemorrhage	6/63	1/10	1/6	2/13	1/27	8/65	3/7	1/10	0/11	1/31
Histiocytosis	2/63	1/10	0/6	1/13	3/27	1/65	0/7	0/10	1/11	9/31
Hyperplasia, alveolar	4/63	0/10	0/6	0/13	0/27	0/65	0/7	0/10	0/11	0/31
Thrombus	0/63	0/10	0/6	0/13	1/27	0/65	0/7	0/10	0/11	0/31
TRACHEA	(63)	-	-	-	(27)	(65)	(*1)	(*1)	-	(31)
Hemorrhage	0/63	-	-	-	0/27	1/65	0/1	0/1	-	1/31
THYROIDS	(63)	-	-	-	(26)	(65)	(*2)	(*1)	-	(31)
Follicular Carcinoma	0/63	-	-	-	0/26	0/65	1/2	0/1	-	1/31
Leukemia, myeloid	0/63	-	-	-	0/26	1/65	0/2	0/1	-	0/31
Malignant Lymphoma	1/63	-	-	-	0/26	0/65	2/2	0/1	-	1/31
Follicular-cell Adenoma	0/63	-	-	-	1/26	0/65	0/2	0/1	-	0/31
Abscess	0/63	-	-	-	0/26	0/65	0/2	0/1	-	1/31
C-cell hyperplasia	0/63	-	-	-	0/26	2/65	0/2	0/1	-	0/31

* Tissues not specifically required by protocol.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group MALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/
THYROIDS (Con't.)		(63)	-	-	-	(26)	(65)	(*2)	(*1)	-	(31)
Follicular atrophy		10/63	-	-	-	0/26	6/65	0/2	0/1	-	0/31
Follicular cyst		9/63	-	-	-	0/26	12/65	0/2	0/1	-	0/31
Follicular hyperplasia		1/63	-	-	-	0/26	3/65	0/2	0/1	-	1/31
Thyroiditis, acute		1/63	-	-	-	0/26	0/65	0/2	0/1	-	0/31
Thyroiditis, chronic		0/63	-	-	-	0/26	1/65	0/2	0/1	-	0/31
PARATHYROIDS		(49)	-	-	-	(18)	(40)	(*1)	-	-	(20)
Adenoma		0/49	-	-	-	0/18	0/40	1/1	-	-	0/20
HEART		(63)	(60)	(62)	(59)	(26)	(65)	(62)	(64)	(64)	(31)
Fibrosarcoma, metastatic		0/63	0/60	2/62	2/59	0/26	0/65	0/62	0/64	0/64	0/31
Leukemia, myeloid		1/63	1/60	0/62	0/59	0/26	2/65	0/62	0/64	1/64	2/31
Malignant Lymphoma		0/63	0/60	2/62	0/59	0/26	1/65	4/62	1/64	2/64	1/31
Mineralization		0/63	3/60	2/62	2/59	0/26	0/65	0/62	0/64	0/64	1/31
Myocarditis, acute		1/63	0/60	1/62	1/59	0/26	0/65	1/62	0/64	1/64	0/31
Myocarditis, chronic		4/63	8/60	4/62	4/59	1/26	1/65	2/62	3/64	2/64	1/31
Necrosis		0/63	0/60	0/62	1/59	0/26	0/65	0/62	0/64	0/64	0/31
Thrombus		1/63	0/60	0/62	0/59	0/26	0/65	0/62	0/64	0/64	0/31
LIVER		(63)	(60)	(62)	(59)	(27)	(65)	(62)	(64)	(64)	(31)
Fibrosarcoma, metastatic		1/63	0/60	0/62	0/59	0/27	0/65	0/62	0/64	0/64	0/31
Hemangiosarcoma		1/63	3/60	2/62	3/59	2/27	0/65	1/62	0/64	0/64	0/31

* Tissues not specifically required by protocol.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group MALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day
LIVER (Con't.)		(63)	(60)	(62)	(59)	(27)	(65)	(62)	(64)	(64)	(31)
Hemangiosarcoma, metastatic		0/63	1/60	0/62	0/59	0/27	0/65	1/62	0/64	1/64	1/31
Hepatocellular Carcinoma		13/63	20/60	16/62	18/59	6/27	0/65	4/62	3/64	6/64	3/31
Leukemia, myeloid		1/63	2/60	0/62	0/59	0/27	2/65	0/62	0/64	1/64	2/31
Malignant Lymphoma		0/63	1/60	4/62	5/59	0/27	11/65	14/62	11/64	12/64	4/31
Osteosarcoma, metastatic		0/63	0/60	1/62	0/59	0/27	0/65	0/62	0/64	0/64	0/31
Undifferentiated Sarcoma		0/63	0/60	0/62	0/59	0/27	0/65	2/62	0/64	0/64	0/31
Undifferentiated Sarcoma, metastatic		0/63	0/60	0/62	1/59	0/27	0/65	0/62	0/64	0/64	0/31
Hemangioma		2/63	0/60	0/62	0/59	0/27	0/65	0/62	2/64	0/64	1/31
Hepatocellular Adenoma		8/63	6/60	1/62	7/59	7/27	1/65	1/62	6/64	6/64	3/31
Lipoma		0/63	0/60	0/62	0/59	0/27	1/65	0/62	0/64	0/64	0/31
Abscess		0/63	0/60	0/62	0/59	0/27	0/65	0/62	0/64	1/64	0/31
Angiectasis		0/63	0/60	0/62	0/59	0/27	0/65	1/62	0/64	0/64	0/31
Congestion		0/63	0/60	0/62	1/59	0/27	1/65	0/62	0/64	0/64	0/31
Fatty change		3/63	1/60	0/62	1/59	0/27	2/65	0/62	0/64	0/64	1/31
Focal cellular change		3/63	1/60	0/62	0/59	0/27	2/65	0/62	3/64	2/64	0/31
Hematopoiesis, extramedullary		0/63	3/60	4/62	2/59	1/27	10/65	4/62	5/64	13/64	3/31
Hepatitis, acute		2/63	0/60	0/62	0/59	0/27	0/65	0/62	0/64	0/64	0/31
Hepatitis, chronic		1/63	1/60	0/62	0/59	0/27	1/65	0/62	0/64	0/64	1/31
Hepatocytomegaly		1/63	1/60	0/62	0/59	0/27	0/65	0/62	0/64	0/64	0/31

* Tissues not specifically required by protocol.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group MALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day
LIVER (Con't.)		(63)	(60)	(62)	(59)	(27)	(65)	(62)	(64)	(64)	(31)
Infarct		0/63	2/60	0/62	0/59	0/27	1/65	0/62	1/64	0/64	0/31
Lymphatic cyst		1/63	0/60	0/62	0/59	0/27	0/65	0/62	0/64	0/64	0/31
Necrosis		4/63	4/60	3/62	1/59	1/27	1/65	0/62	0/64	0/64	1/31
KIDNEYS		(63)	(60)	(62)	(59)	(27)	(65)	(62)	(64)	(64)	(31)
Alveolar/bronchiolar Carcinoma, metastatic		0/63	0/60	0/62	1/59	0/27	0/65	0/62	0/64	0/64	0/31
Fibrosarcoma, metastatic		1/63	0/60	1/62	0/59	0/27	0/65	0/62	1/64	0/64	0/31
Hepatocellular Carcinoma, metastatic		0/63	1/60	0/62	0/59	0/27	0/65	0/62	0/64	1/64	0/31
Leukemia, myeloid		0/63	1/60	0/62	0/59	0/27	0/65	0/62	0/64	1/64	1/31
Malignant Lymphoma		1/63	2/60	4/62	4/59	1/27	12/65	11/62	8/64	9/64	8/31
Osteosarcoma, metastatic		0/63	0/60	0/62	0/59	0/27	1/65	0/62	0/64	0/64	0/31
Renal cell Carcinoma		0/63	1/60	0/62	0/59	0/27	0/65	0/62	2/64	0/64	0/31
Undifferentiated Sarcoma		0/63	0/60	0/62	1/59	0/27	0/65	1/62	0/64	0/64	0/31
Renal cell Adenoma		1/63	0/60	0/62	0/59	0/27	0/65	0/62	0/64	0/64	0/31
Abscess		0/63	1/60	0/62	0/59	0/27	0/65	0/62	0/64	0/64	0/31
Amyloidosis		0/63	0/60	0/62	0/59	0/27	0/65	0/62	0/64	0/64	1/31
Atrophy		0/63	0/60	2/62	1/59	0/27	0/65	0/62	0/64	0/64	0/31
Cholemic nephrosis		0/63	0/60	0/62	0/59	1/27	0/65	0/62	0/64	0/64	0/31
Congestion		0/63	0/60	1/62	2/59	0/27	1/65	0/62	1/64	1/64	0/31

* Tissues not specifically required by protocol.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group MALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day
KIDNEYS (Con't.)		(63)	(60)	(62)	(59)	(27)	(65)	(62)	(64)	(64)	(31)
Cortical cyst		0/63	1/60	3/62	1/59	2/27	0/65	0/62	1/64	0/64	0/31
Cytoplasmic vacuolization (Tubules)		60/63	47/60	51/62	51/59	24/27	9/65	5/62	10/64	7/64	4/31
Dilatation (Tubules)		1/63	5/60	0/62	2/59	0/27	0/65	2/62	0/64	3/64	1/31
Fibrosis		0/63	0/60	1/62	0/59	0/27	0/65	0/62	0/64	0/64	0/31
Glomerulonephritis, acute		0/63	0/60	0/62	1/59	0/27	0/65	0/62	0/64	0/64	0/31
Granuloma		0/63	0/60	0/62	0/59	0/27	0/65	0/62	0/64	1/64	0/31
Hemorrhage		1/63	0/60	0/62	0/59	0/27	0/65	0/62	0/64	0/64	0/31
Hydronephrosis		0/63	0/60	0/62	0/59	0/27	0/65	0/62	0/64	0/64	2/31
Hyperplasia, tubular		41/63	34/60	42/62	38/59	20/27	23/65	20/62	15/64	27/64	14/31
Infarct		0/63	0/60	3/62	2/59	2/27	1/65	1/62	1/64	1/64	1/31
Metaplasia, osseous (Cortex)		2/63	0/60	0/62	2/59	1/27	0/65	0/62	1/64	1/64	0/31
Mineralization		0/63	0/60	0/62	0/59	1/27	0/65	0/62	0/64	0/64	0/31
Necrosis, tubular		2/63	1/60	3/62	6/59	1/27	8/65	3/62	5/64	3/64	2/31
Nephrocalcinosis		50/63	35/60	41/62	42/59	21/27	9/65	2/62	6/64	1/64	5/31
Nephropathy, chronic		5/63	4/60	3/62	1/59	2/27	5/65	0/62	2/64	1/64	4/31
Nephrosis		1/63	0/60	0/62	1/59	0/27	0/65	0/62	0/64	0/64	0/31
Pigmentation		0/63	0/60	0/62	0/59	0/27	0/65	0/62	0/64	1/64	0/31
Pyelonephritis, acute		0/63	1/60	1/62	0/59	0/27	0/65	0/62	0/64	0/64	1/31
Pyelonephritis, acute, bacterial et.		0/63	0/60	0/62	0/59	1/27	0/65	0/62	0/64	0/64	0/31

* Tissues not specifically required by protocol.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group MALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day
KIDNEYS (Con't.)		(63)	(60)	(62)	(59)	(27)	(65)	(62)	(64)	(64)	(31)
Pyelitis, acute		1/63	0/60	1/62	0/59	0/27	0/65	0/62	0/64	0/64	0/31
Pyelonephritis, chronic		2/63	1/60	1/62	0/59	0/27	0/65	0/62	0/64	1/64	0/31
STOMACH		(63)	(*2)	(*1)	(*1)	(27)	(65)	(*4)	(*1)	(*1)	(31)
Leukemia, myeloid		0/63	0/2	0/1	0/1	0/27	1/65	0/4	0/1	0/1	0/31
Malignant Lymphoma		0/63	0/2	0/1	0/1	0/27	6/65	1/4	0/1	0/1	3/31
Undifferentiated Sarcoma		0/63	0/2	0/1	0/1	0/27	0/65	1/4	0/1	0/1	0/31
Cyst		1/63	0/2	0/1	0/1	0/27	3/65	1/4	0/1	0/1	0/31
Degeneration, cystic		2/63	0/2	0/1	0/1	1/27	5/65	0/4	0/1	0/1	0/31
Gastritis, acute		2/63	0/2	0/1	0/1	0/27	0/65	0/4	0/1	0/1	1/31
Gastritis, chronic		0/63	1/2	1/1	0/1	0/27	0/65	0/4	0/1	0/1	1/31
Lymphocytosis		0/63	0/2	0/1	0/1	0/27	0/65	0/4	0/1	0/1	1/31
Mineralization		0/63	0/2	0/1	0/1	0/27	0/65	0/4	0/1	0/1	2/31
Ulcer		1/63	0/2	0/1	0/1	0/27	1/65	0/4	0/1	0/1	0/31
DUODENUM		(63)	-	(*2)	(*3)	(27)	(65)	-	(*2)	(*2)	(31)
Fibrosarcoma, metastatic		0/63	-	1/2	0/3	0/27	0/65	-	0/2	0/2	0/31
Malignant Lymphoma		0/63	-	0/2	1/3	0/27	0/65	-	0/2	0/2	0/31
Amyloidosis		0/63	-	0/2	0/3	0/27	1/65	-	0/2	0/2	0/31
Congestion		0/63	-	0/2	1/3	0/27	0/65	-	0/2	0/2	0/31
Hemorrhage		0/63	-	1/2	1/3	0/27	0/65	-	0/2	1/2	0/31

* Tissues not specifically required by protocol.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group	MALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/
JEJUNUM		(63)	(*2)	(*3)	(*1)	(27)	(65)	(*2)	(*1)	(*2)	(31)
Carcinoma		0/63	0/2	1/3	0/1	0/27	0/65	0/2	0/1	0/2	0/31
Malignant Lymphoma		0/63	1/2	0/3	0/1	0/27	0/65	0/2	0/1	0/2	1/31
Abscess		1/63	0/2	0/3	0/1	0/27	0/65	0/2	0/1	0/2	0/31
Congestion		0/63	0/2	0/3	1/1	0/27	0/65	0/2	0/1	1/2	0/31
Hemorrhage		0/63	1/2	1/3	0/1	0/27	0/65	0/2	0/1	0/2	0/31
ILEUM		(63)	(*2)	-	(*3)	(27)	(65)	-	(*3)	(*3)	(31)
Malignant Lymphoma		1/63	1/2	-	1/3	0/27	4/65	-	3/3	1/3	3/31
Congestion		0/63	0/2	-	1/3	0/27	0/65	-	0/3	1/3	0/31
Hyperplasia, lymphoid		0/63	1/2	-	0/3	0/27	0/65	-	0/3	0/3	0/31
Necrosis		0/63	1/2	-	0/3	0/27	0/65	-	0/3	0/3	0/31
CECUM		(63)	-	-	-	(27)	(65)	(*1)	(*1)	(*1)	(31)
Malignant Lymphoma		0/63	-	-	-	0/27	0/65	1/1	0/1	0/1	1/31
Leiomyoma		0/63	-	-	-	0/27	0/65	0/1	1/1	0/1	0/31
Nematodiasis		0/63	-	-	-	0/27	1/65	0/1	0/1	0/1	0/31
COLON		(63)	(*1)	-	(*1)	(27)	(65)	(*1)	(*1)	(*2)	(31)
Leiomyosarcoma		0/63	0/1	-	0/1	0/27	0/65	0/1	0/1	0/2	1/31
Malignant Lymphoma		1/63	1/1	-	0/1	1/27	3/65	0/1	1/1	0/2	3/31
Colitis, acute		0/63	0/1	-	0/1	0/27	0/65	0/1	0/1	1/2	0/31
Necrosis		0/63	0/1	-	1/1	0/27	0/65	0/1	0/1	0/2	0/31

* Tissues not specifically required by protocol.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group	MALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/
COLON (Con't.)		(63)	(*1)	-	(*1)	(27)	(65)	(*1)	(*1)	(*2)	(31)
Nematodiasis		0/63	0/1	-	0/1	0/27	1/65	0/1	0/1	0/2	0/31
RECTUM		(63)	-	-	-	(27)	(65)	-	-	-	(31)
Fibrosarcoma, metastatic		1/63	-	-	-	0/27	0/65	-	-	-	0/31
Malignant Lymphoma		0/63	-	-	-	0/27	2/65	-	-	-	1/31
SKIN		(63)	(*23)	(*26)	(*28)	(27)	(65)	(*29)	(*42)	(*22)	(31)
Melanoma		0/63	0/23	0/26	0/28	0/27	0/65	0/29	0/42	0/22	1/31
Squamous cell Carcinoma		0/63	0/23	0/26	0/28	0/27	0/65	0/29	1/42	0/22	0/31
Fibroma		1/63	0/23	0/26	0/28	1/27	0/65	0/29	0/42	0/22	0/31
Keratoacanthoma		0/63	0/23	0/26	1/28	0/27	0/65	0/29	0/42	0/22	1/31
Squamous papilloma		0/63	0/23	0/26	0/28	0/27	0/65	1/29	0/42	0/22	0/31
Acanthosis		0/63	0/23	1/26	0/28	0/27	0/65	0/29	0/42	0/22	0/31
Dermatitis, acute		5/63	0/23	0/26	0/28	0/27	0/65	0/29	0/42	0/22	0/31
Dermatitis, chronic		26/63	21/23	25/26	21/28	16/27	35/65	22/29	34/42	19/22	10/31
Epidermal inclusion cyst		0/63	0/23	0/26	0/28	1/27	1/65	0/29	0/42	0/22	0/31
Erosion		0/63	1/23	0/26	0/28	0/27	0/65	0/29	0/42	0/22	0/31
Follicular atrophy		2/63	0/23	3/26	4/28	2/27	3/65	1/29	2/42	2/22	0/31
Granulation tissue		2/63	0/23	0/26	0/28	0/27	0/65	0/29	0/42	0/22	0/31
Mineralization		0/63	0/23	0/26	0/28	1/27	0/65	0/29	0/42	0/22	0/31
Ulcer		0/63	5/23	6/26	4/28	0/27	0/65	0/29	1/42	0/22	0/31

* Tissues not specifically required by protocol.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group MALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day
MAMMARY GLAND		-	-	-	-	-		(63)	(*18)	(*18)	(*6)	(27)
Adenocarcinoma		-	-	-	-	-		2/63	1/18	3/18	2/6	1/27
Fibrosarcoma, metastatic		-	-	-	-	-		0/63	0/18	1/18	0/6	0/27
Malignant Lymphoma		-	-	-	-	-		3/63	2/18	0/18	0/6	1/27
Adenoma		-	-	-	-	-		0/63	1/18	0/18	0/6	1/27
Adenoacanthoma		-	-	-	-	-		0/63	1/18	0/18	0/6	0/27
Fibroadenoma		-	-	-	-	-		0/63	2/18	0/18	0/6	0/27
Hyperplasia, cystic		-	-	-	-	-		6/63	1/18	3/18	0/6	3/27
STERNUM		(62)	-	-	-	(27)		(65)	-	-	-	(31)
Fibrosarcoma, invasive		1/62	-	-	-	0/27		0/65	-	-	-	0/31
BONE MARROW		(62)	-	-	-	(27)		(65)	-	-	-	(31)
Leukemia, myeloid		1/62	-	-	-	0/27		1/65	-	-	-	0/31
Malignant Lymphoma		0/62	-	-	-	0/27		2/65	-	-	-	1/31
Hyperplasia, myeloid		44/62	-	-	-	23/27		45/65	-	-	-	25/31
Myelofibrosis		0/62	-	-	-	1/27		55/65	-	-	-	29/31

* Tissues not specifically required by protocol.

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group	MALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/
LESIONS (TISSUES NOT SPECIFICALLY											
REQUIRED BY PROTOCOL)											
ABDOMINAL CAVITY		-	-	-	-	(1)	-	-	-	-	-
Pheochromocytoma		-	-	-	-	1/1	-	-	-	-	-
AXILLARY LYMPH NODE		-	-	(3)	(1)	-	(3)	(2)	(2)	(2)	-
Fibrosarcoma, metastatic		-	-	3/3	0/1	-	0/3	0/2	0/2	0/2	-
Malignant Lymphoma		-	-	0/3	1/1	-	3/3	2/2	2/2	2/2	-
COCCYGEAL VERTEBRAE		-	-	-	-	-	-	-	-	(1)	-
Malignant Lymphoma		-	-	-	-	-	-	-	-	1/1	-
GALL BLADDER		-	(1)	(3)	(2)	(1)	(2)	(1)	-	(2)	(2)
Hemorrhage		-	0/1	1/3	0/2	0/1	0/2	0/1	-	0/2	0/2
HARDERIAN GLAND		-	(1)	(1)	(1)	(1)	(1)	(5)	(2)	(1)	(3)
Adenocarcinoma		-	0/1	0/1	0/1	0/1	0/1	0/5	1/2	0/1	0/3
Adenoma		-	1/1	1/1	1/1	1/1	1/1	4/5	1/2	1/1	2/3
Adenitis, chronic		-	0/1	0/1	0/1	0/1	0/1	0/5	0/2	0/1	1/3
HEPATIC LYMPH NODE		(1)	-	(1)	(2)	-	(1)	(2)	(4)	-	-
Malignant Lymphoma		1/1	-	1/1	2/2	-	1/1	2/2	4/4	-	-
Hemorrhage		0/1	-	0/1	0/2	-	0/1	1/2	0/4	-	-

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group MALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day
LESIONS (TISSUES NOT SPECIFICALLY												
REQUIRED BY PROTOCOL) (Con't.)												
INGUINAL LYMPH NODE		(4)	(1)	(1)	(5)	-		(3)	(2)	(3)	-	-
Fibrosarcoma, metastatic		1/4	0/1	0/1	0/5	-		0/3	0/2	0/3	-	-
Malignant Lymphoma		1/4	0/1	0/1	1/5	-		2/3	2/2	2/3	-	-
Congestion		0/4	0/1	0/1	1/5	-		0/3	0/2	0/3	-	-
Hyperplasia, lymphoid		2/4	0/1	1/1	3/5	-		0/3	0/2	0/3	-	-
Lymphatic cyst		0/4	0/1	0/1	1/5	-		0/3	0/2	0/3	-	-
INTERCOSTAL MUSCLES		(3)	-	-	(2)	-		(4)	-	(1)	(1)	(1)
Alveolar/bronchiolar Carcinoma,												
invasive		0/3	-	-	1/2	-		0/4	-	0/1	0/1	0/1
Fibrosarcoma, invasive		2/3	-	-	0/2	-		0/4	-	0/1	0/1	0/1
Fibrosarcoma, metastatic		0/3	-	-	1/2	-		0/4	-	0/1	0/1	0/1
Granulosa-cell Carcinoma, metastatic		0/3	-	-	0/2	-		0/4	-	1/1	0/1	0/1
Leukemia, myeloid		0/3	-	-	0/2	-		1/4	-	0/1	0/1	0/1
Malignant Lymphoma		0/3	-	-	0/2	-		3/4	-	0/1	1/1	0/1
Myositis, acute		1/3	-	-	0/2	-		0/4	-	0/1	0/1	1/1

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group MALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day
LESIONS (TISSUES NOT SPECIFICALLY REQUIRED BY PROTOCOL) (Con't.)												
LUMBAR LYMPH NODE		(3)	(1)	(3)	(8)	(1)		(7)	(8)	(9)	(6)	(4)
Fibrosarcoma, metastatic		0/3	0/1	0/3	1/8	0/1		0/7	0/8	0/9	0/6	0/4
Leukemia, myeloid		0/3	0/1	0/3	0/8	0/1		1/7	0/8	0/9	1/6	0/4
Malignant Lymphoma		1/3	0/1	1/3	4/8	0/1		6/7	8/8	5/9	4/6	2/4
Undifferentiated Sarcoma, metastatic		0/3	0/1	0/3	1/8	0/1		0/7	0/8	0/9	0/6	0/4
Congestion		0/3	0/1	0/3	0/8	0/1		0/7	1/8	1/9	0/6	0/4
Edema		0/3	1/1	0/3	1/8	0/1		0/7	0/8	1/9	0/6	0/4
Hemorrhage		0/3	0/1	0/3	0/8	0/1		0/7	0/8	2/9	0/6	0/4
Hyperplasia, lymphoid		1/3	0/1	2/3	1/8	1/1		0/7	0/8	1/9	1/6	1/4
MANDIBULAR LYMPH NODE		(2)	(1)	(2)	(1)	(1)		(8)	(6)	(6)	(3)	(2)
Leukemia, myeloid		0/2	0/1	0/2	0/1	0/1		1/8	0/6	0/6	0/3	0/2
Malignant Lymphoma		0/2	0/1	1/2	1/1	0/1		7/8	6/6	4/6	3/3	2/2
Congestion		0/2	0/1	0/2	0/1	0/1		0/8	0/6	1/6	0/3	0/2
Hyperplasia, lymphoid		0/2	0/1	0/2	0/1	0/1		0/8	0/6	1/6	0/3	0/2
MEDIASTINUM		-	-	(1)	-	-		-	-	-	-	-
Fibrosarcoma, metastatic		-	-	1/1	-	-		-	-	-	-	-

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group MALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day
LESIONS (TISSUES NOT SPECIFICALLY REQUIRED BY PROTOCOL) (Con't.)											
MESENTERIC FAT		(2)	(6)	(1)	(4)	(1)	(2)	(1)	(5)	(2)	-
Hematoma		0/2	0/6	0/1	0/4	0/1	0/2	0/1	0/5	1/2	-
Hemorrhage		0/2	0/6	0/1	0/4	0/1	1/2	0/1	0/5	0/2	-
Steatitis, chronic		2/2	6/6	1/1	4/4	1/1	1/2	1/1	5/5	1/2	-
MESENTERY		-	(1)	(2)	(4)	-	(3)	(3)	-	(2)	-
Alveolar/bronchiolar Carcinoma, metastatic		-	0/1	0/2	1/4	-	0/3	0/3	-	0/2	-
Fibrosarcoma, metastatic		-	0/1	1/2	0/4	-	0/3	0/3	-	0/2	-
Hepatocellular Carcinoma, invasive		-	0/1	0/2	2/4	-	0/3	0/3	-	0/2	-
Malignant Lymphoma		-	0/1	1/2	0/4	-	1/3	1/3	-	2/2	-
Undifferentiated Sarcoma		-	0/1	0/2	0/4	-	0/3	1/3	-	0/2	-
Undifferentiated Sarcoma, metastatic		-	0/1	0/2	0/4	-	0/3	1/3	-	0/2	-
Hematoma		-	0/1	0/2	0/4	-	1/3	0/3	-	0/2	-
Hemorrhage		-	1/1	0/2	1/4	-	0/3	0/3	-	0/2	-
Lymphatic cyst		-	0/1	0/2	0/4	-	1/3	0/3	-	0/2	-
ORBITAL CAVITY		-	-	-	-	-	-	-	(1)	-	-
Granulosa-cell Carcinoma, metastatic		-	-	-	-	-	-	-	1/1	-	-

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group MALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day
LESIONS (TISSUES NOT SPECIFICALLY											
REQUIRED BY PROTOCOL) (Con't.)											
PANCREATIC LYMPH NODE		(2)	-	(1)	(4)	-	-	(4)	(2)	(2)	-
Alveolar/bronchiolar Carcinoma,											
metastatic		0/2	-	0/1	2/4	-	-	0/4	0/2	0/2	-
Malignant Lymphoma		1/2	-	1/1	2/4	-	-	3/4	2/2	2/2	-
Hyperplasia, lymphoid		1/2	-	0/1	0/4	-	-	1/4	0/2	0/2	-
PARIETAL PLEURA		-	-	-	-	-	-	-	-	(1)	-
Fibrosarcoma, metastatic		-	-	-	-	-	-	-	-	1/1	-
PAROVARIAN TISSUE		-	-	-	-	-	(6)	(9)	(4)	(4)	(5)
Malignant Lymphoma							6/6	9/9	4/4	4/4	5/5
PELVIC LYMPH NODE		-	-	(1)	-	-	-	(1)	-	-	-
Malignant Lymphoma		-	-	0/1	-	-	-	1/1	-	-	-
PENIS		(13)	(8)	(10)	(7)	(4)	-	-	-	-	-
Squamous cell Carcinoma		0/13	1/8	0/10	0/7	0/4					
Balanitis, acute		2/13	0/8	0/10	2/7	0/4					
Balanitis, chronic		3/13	5/8	4/10	3/7	2/4					
Calculus		1/13	1/8	0/10	0/7	1/4					
Ulcer		0/13	0/8	1/10	0/7	0/4					

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group MALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day
LESIONS (TISSUES NOT SPECIFICALLY											
REQUIRED BY PROTOCOL) (Con't.)											
PENIS (Con't.)		(13)	(8)	(10)	(7)	(4)	-	-	-	-	-
Urethritis, acute		0/13	0/8	0/10	1/7	1/4					
PERIRENAL FAT		-	-	-	-	-	-	-	-	-	(1)
Steatitis, chronic		-	-	-	-	-	-	-	-	-	1/1
PERIRENAL LYMPH NODE		-	-	(1)	-	-	-	-	-	-	-
Malignant Lymphoma		-	-	1/1	-	-	-	-	-	-	-
PERITONEUM		-	-	-	-	-	-	-	(1)	-	-
Renal cell Carcinoma, metastatic		-	-	-	-	-	-	-	1/1	-	-
PITUITARY		-	(1)	(1)	-	-	(6)	(11)	(6)	(4)	-
Adenocarcinoma		-	0/1	0/1	-	-	0/6	0/11	1/6	0/4	-
Adenoma		-	0/1	0/1	-	-	5/6	11/11	4/6	2/4	-
Congestion		-	0/1	0/1	-	-	0/6	0/11	1/6	0/4	-
Hyperplasia		-	0/1	0/1	-	-	0/6	0/11	0/6	1/4	-
PLEURA		-	-	-	-	-	-	-	(1)	-	-
Fibrosarcoma, metastatic		-	-	-	-	-	-	-	1/1	-	-
POPLITEAL LYMPH NODE		-	-	-	(1)	-	-	-	-	-	-
Malignant Lymphoma		-	-	-	1/1	-	-	-	-	-	-

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group MALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/
LESIONS (TISSUES NOT SPECIFICALLY											
REQUIRED BY PROTOCOL) (Con't.)											
PREPUCE		(7)	(1)	(5)	(3)	(2)	-	-	-	-	-
Fibrosarcoma, metastatic		0/7	0/1	1/5	0/3	0/2					
Abscess		1/7	0/1	0/5	1/3	0/2					
Posthitis, chronic		6/7	1/1	5/5	2/3	2/2					
PREPUTIAL GLAND		(12)	(7)	(3)	(6)	(2)	-	-	-	-	-
Abscess		0/12	0/7	0/3	3/6	0/2					
Adenitis, chronic		10/12	5/7	3/3	2/6	0/2					
Cystic duct		1/12	0/7	1/3	0/6	0/2					
Dilated duct		0/12	2/7	0/3	1/6	1/2					
RENAL LYMPH NODE		(1)	(1)	(1)	(2)	-	(10)	(7)	(9)	(3)	(2)
Hemangiosarcoma		0/1	1/1	0/1	0/2	-	0/10	0/7	0/9	0/3	0/2
Malignant Lymphoma		1/1	0/1	0/1	2/2	-	9/10	7/7	9/9	3/3	1/2
Congestion		0/1	0/1	0/1	0/2	-	0/10	1/7	0/9	0/3	0/2
Hyperplasia, lymphoid		0/1	0/1	0/1	0/2	-	0/10	0/7	0/9	0/3	1/2
RESPIRATORY LYMPH NODE		(1)	-	(2)	(1)	-	(7)	(5)	(10)	(3)	(1)
Malignant Lymphoma		1/1	-	2/2	1/1	-	7/7	5/5	9/10	3/3	1/1
Edema		0/1	-	0/2	0/1	-	0/7	0/5	1/10	0/3	0/1

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group MALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day
LESIONS (TISSUES NOT SPECIFICALLY												
REQUIRED BY PROTOCOL) (Con't.)												
SALIVARY GLAND		(1)	-	(2)	(1)	-		(2)	(5)	(3)	(2)	(2)
Malignant Lymphoma		0/1	-	0/2	0/1	-		1/2	3/5	1/3	2/2	0/2
Sialadenitis, acute		0/1	-	1/2	0/1	-		0/2	0/5	0/3	0/2	0/2
Sialadenitis, chronic		0/1	-	0/2	1/1	-		0/2	0/5	0/3	0/2	0/2
SEMINAL VESICLES		(53)	(5)	(1)	(1)	(15)		-	-	-	-	-
Calculus		2/53	0/5	0/1	0/1	0/15						
Seminal vesiculitis, chronic		0/53	0/5	0/1	1/1	0/15						
SKELETAL MUSCLE		-	-	-	(1)	-		(1)	(1)	-	(2)	-
Endometrial Stromal Sarcoma, invasive		-	-	-	0/1	-		1/1	0/1	-	0/2	-
Malignant Lymphoma		-	-	-	0/1	-		0/1	0/1	-	1/2	-
Myositis, chronic		-	-	-	0/1	-		0/1	1/1	-	0/2	-
SUBCUTANEOUS LYMPH NODE		(7)	(4)	(10)	(6)	(1)		(9)	(1)	(2)	-	(5)
Fibrosarcoma, metastatic		1/7	0/4	1/10	0/6	0/1		0/9	0/1	0/2	-	0/5
Malignant Lymphoma		1/7	0/4	3/10	1/6	0/1		7/9	1/1	1/2	-	3/5
Congestion		0/7	0/4	0/10	1/6	0/1		0/9	0/1	0/2	-	0/5
Edema		0/7	0/4	1/10	0/6	0/1		0/9	0/1	0/2	-	0/5
Hyperplasia, lymphoid		3/7	2/4	3/10	2/6	1/1		2/9	0/1	0/2	-	2/5

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group	MALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/
LESIONS (TISSUES NOT SPECIFICALLY REQUIRED BY PROTOCOL) (Con't.)											
SUBCUTIS		(25)	(26)	(24)	(18)	(4)	(2)	(2)	(6)	(1)	(3)
Alveolar/bronchiolar Carcinoma, metastatic		0/25	0/26	0/24	1/18	0/4	0/2	0/2	0/6	0/1	0/3
Fibrosarcoma		13/25	12/26	13/24	10/18	1/4	0/2	2/2	3/6	1/1	0/3
Hemangiosarcoma		0/25	1/26	0/24	0/18	0/4	0/2	0/2	0/6	0/1	0/3
Hemangiosarcoma, metastatic		0/25	0/26	0/24	0/18	0/4	0/2	0/2	0/6	0/1	1/3
Leukemia, myeloid		0/25	0/26	0/24	0/18	0/4	2/2	0/2	0/6	0/1	0/3
Malignant Lymphoma		0/25	0/26	0/24	0/18	0/4	0/2	0/2	0/6	0/1	1/3
Neurofibrosarcoma		1/25	1/26	1/24	0/18	0/4	0/2	0/2	0/6	0/1	0/3
Osteosarcoma		0/25	0/26	0/24	0/18	1/4	0/2	0/2	0/6	0/1	0/3
Undifferentiated Sarcoma		3/25	2/26	1/24	1/18	0/4	0/2	0/2	0/6	0/1	0/3
Fibroma		5/25	8/26	5/24	6/18	3/4	0/2	0/2	1/6	0/1	0/3
Hemangioma		0/25	0/26	0/24	0/18	0/4	0/2	0/2	1/6	0/1	1/3
Abscess		1/25	2/26	2/24	0/18	0/4	0/2	0/2	1/6	0/1	0/3
Cellulitis, acute		1/25	0/26	1/24	0/18	0/4	0/2	0/2	0/6	0/1	0/3
Cellulitis, chronic		0/25	1/26	3/24	1/18	0/4	0/2	0/2	0/6	0/1	0/3
Edema		1/25	0/26	0/24	0/18	0/4	0/2	0/2	0/6	0/1	0/3

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group MALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/
LESIONS (TISSUES NOT SPECIFICALLY											
REQUIRED BY PROTOCOL) (Con't.)											
SUBCUTIS (Con't.)		(25)	(26)	(24)	(18)	(4)	(2)	(2)	(6)	(1)	(3)
Granulation tissue		0/25	3/26	0/24	0/18	0/4	0/2	0/2	0/6	0/1	0/3
Granuloma		1/25	0/26	0/24	0/18	0/4	0/2	0/2	1/6	0/1	0/3
Hematoma		0/25	1/26	0/24	0/18	0/4	0/2	0/2	0/6	0/1	0/3
Metaplasia, osseous		0/25	0/26	0/24	1/18	0/4	0/2	0/2	0/6	0/1	0/3
THORACIC CAVITY		-	-	-	-	-	-	-	-	(1)	-
Alveolar/bronchiolar Carcinoma,											
metastatic		-	-	-	-	-	-	-	-	1/1	-
THORACIC LYMPH NODE		-	-	-	-	-	-	-	-	(1)	(1)
Lymphadenitis, acute		-	-	-	-	-	-	-	-	0/1	1/1
THYMUS		(3)	-	(1)	(2)	-	(5)	(2)	(6)	(6)	(5)
Fibrosarcoma, metastatic		0/3	-	0/1	1/2	-	0/5	0/2	0/6	1/6	0/5
Granulosa-cell Carcinoma, metastatic		0/3	-	0/1	0/2	-	0/5	0/2	1/6	0/6	0/5
Malignant Lymphoma		2/3	-	1/1	1/2	-	3/5	1/2	1/6	5/6	2/5
Renal cell Carcinoma, metastatic		0/3	-	0/1	0/2	-	0/5	0/2	1/6	0/6	0/5

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX

INCIDENCE COMPARISON TABLES

ORGAN lesion	Group	MALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day
LESIONS (TISSUES NOT SPECIFICALLY											
REQUIRED BY PROTOCOL) (Con't.)											
URETHRA		(15)	(1)	(1)	-	(12)	-	-	-	-	-
Calculus		14/15	1/1	1/1	-	12/12	-	-	-	-	-
Urethritis, acute		1/15	0/1	0/1	-	0/12	-	-	-	-	-
VAGINA		-	-	-	-	-	(62)	(14)	(10)	(12)	(30)
Malignant Lymphoma							1/62	0/14	0/10	1/12	1/30
VERTEBRAE		-	-	-	-	-	-	(1)	-	-	-
Hemangiosarcoma, invasive		-	-	-	-	-	-	1/1	-	-	-

I.I.T.R.I
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice

INCIDENCE OF LESIONS CONSIDERED TO BE TREATMENT RELATED

ORGAN Lesion	Group	MALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35 mg/kg/day	RDX 175/100 mg/kg
LIVER		(63)	(60)	(62)	(59)	(27)	(65)	(62)	(64)	(64)	(3
Hepatocellular Carcinoma		13/63	20/60	16/62	18/59	6/27	0/65	4/62	3/64	6/64	3/
Hepatocellular Adenoma		8/63	6/60	1/62	7/59	7/27	1/65	1/62	6/64	6/64	3/
TESTES		(63)	(60)	(62)	(59)	(27)					
Degeneration		0/63	2/60	2/62	6/59	3/27					

PATHOLOGY APPENDIX IV:

Statistical Evaluation

TABLE IV

TWENTY-FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY
OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE IN THE
MALE B6C3F1 MOUSE

Statistical Evaluation of Histopathologic Lesions[a]

DOSE (mg/kg/day):	0.0	1.5	7.0	35.0	175/100
SKIN, Chronic Dermatitis					
Present:	26	21*	25*	21*	16*
Absent:	37	2	1	7	11
SKIN, Ulcer					
Present:	0	5*	6*	4*	0
Absent:	63	18	20	24	27
LUNG, Alveolar/Bronchiolar Carcinoma					
Present:	3	6	3	7	5*
Absent:	60	54	59	52	22
LUNG, Alveolar/Bronchiolar Adenoma					
Present:	6	5	5	7	1
Absent:	57	55	57	52	26
LUNG, Alveolar/Bronchiolar Carcinoma and Adenoma (Combined)					
Present:	9	11	8	14	6*
Absent:	54	49	54	45	21
LUNG, Histiocytosis					
Present:	2	1	0	2	3
Absent:	61	59	62	57	24

[a]Statistical analyses were conducted on the combined data collected from animals which either spontaneously died or were sacrificed in a moribund state following the 12 month sacrifice and from animals at the 24 month scheduled sacrifice.

* = Significantly different from the control group, $p \leq 0.05$.

TABLE IV (Continued)

TWENTY-FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY
OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE IN THE
MALE B6C3F1 MOUSE

Statistical Evaluation of Histopathologic Lesions[a]

DOSE (mg/kg/day):	0.0	1.5	7.0	35.0	175/100
KIDNEY, Malignant Lymphoma					
Present:	1	2	4	4	1
Absent:	62	58	58	55	26
EYE, Subcapsular Cataract					
Present:	4	0	0	1	3
Absent:	59	1	2	0	24
LIVER, Malignant Lymphoma					
Present:	0	1	4	5*	0
Absent:	63	59	58	54	27
LIVER, Hepatocellular Carcinoma					
Present:	13	20	16	18	6
Absent:	50	40	46	41	21
LIVER, Hepatocellular Adenoma					
Present:	8	6	1	7	7
Absent:	55	54	61	52	20
LIVER, Hepatocellular Carcinoma and Adenoma (Combined)					
Present:	21	26	17	25	13
Absent:	42	34	45	34	14

[a]Statistical analyses were conducted on the combined data collected from animals which either spontaneously died or were sacrificed in a moribund state following the 12 month sacrifice and from animals at the 24 month scheduled sacrifice

* = Significantly different from the control group, $p < 0.05$.

TABLE IV (Continued)

TWENTY-FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY
OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE IN THE
MALE B6C3F1 MOUSE

Statistical Evaluation of Histopathologic Lesions[a]

DOSE (mg/kg/day):	0.0	1.5	7.0	35.0	175/100
SPLEEN, Lymphoid Hyperplasia					
Present:	6	18*	17*	9	1
Absent:	57	42	45	49	26
TESTES, Degeneration					
Present:	0	2	2	6*	3*
Absent:	63	58	60	53	24

[a]Statistical analyses were conducted on the combined data collected from animals which either spontaneously died or were sacrificed in a moribund state following the 12 month sacrifice and from animals at the 24 month scheduled sacrifice

* = Significantly different from the control group, $p < 0.05$.

TABLE V

TWENTY-FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY
OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE IN THE
FEMALE B6C3F1 MOUSE

Statistical Evaluation of Histopathologic Lesions[a]

DOSE (mg/kg/day):	0.0	1.5	7.0	35.0	175/100
LUNG, Alveolar/Bronchiolar Carcinoma					
Present:	3	1	3	3	4
Absent:	62	61	61	61	27
LUNG, Alveolar/Bronchiolar Adenoma					
Present:	4	2	5	9	3
Absent:	61	60	59	55	28
LUNG, Alveolar/Bronchiolar Carcinoma and Adenoma (Combined)					
Present:	7	3	8	12	7
Absent:	58	59	56	52	24
LUNG, Histocytosis					
Present:	1	1	3	3	9*
Absent:	64	61	61	61	22
LIVER, Hepatocellular Carcinoma					
Present:	0	4	3	6*	3*
Absent:	65	58	61	58	28
LIVER, Hepatocellular Adenoma					
Present:	1	1	6	6	3
Absent:	64	61	58	58	28

[a]Statistical analyses were conducted on the combined data collected from animals which either spontaneously died or were sacrificed in a moribund state following the 12 month sacrifice and from animals at the 24 month scheduled sacrifice.
* = Significantly different from the control group, $p < 0.05$.

TABLE V (Continued)

TWENTY-FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY
OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE IN THE
FEMALE B6C3F1 MOUSE

Statistical Evaluation of Histopathologic Lesions[a]

DOSE (mg/kg/day):	0.0	1.5	7.0	35.0	175/100
LIVER, Hepatocellular Carcinoma and Adenoma (Combined)					
Present:	1	5	9*	12*	6*
Absent:	64	57	55	52	25

[a]Statistical analyses were conducted on the combined data collected from animals which either spontaneously died or were sacrificed in a moribund state following the 12 month sacrifice and from animals at the 24 month scheduled sacrifice.
* = Significantly different from the control group, $p < 0.05$.

TABLE VI

TWENTY-FOUR MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY
OF HEXAHYDRO-1,3,5-TRINITRIO-1,3,5-TRIAZINE IN THE
FEMALE B6C3F1 MOUSE

Statistical Evaluation of Histopathologic Lesions[a] Fisher's Exact Test

	Incidence					
Dose (mg/kg/day):	0.0	1.5	7.0	35.0	175/100	Historical[b] Controls
LIVER, Hepatocellular Adenoma						
	1/65 (1.5%)	1/62 (1.6%)	6/64[d] (9.4%)	6/64[d] (9.4%)	3/31 (9.7%)	98/2469 (4.0%)
LIVER, Hepatocellular Carcinoma						
	0/65	4/62 (6.4%)	3/64 (4.7%)	6/64[c,d] (9.4%)	3/31[c] (9.75)	101/2469 (4.1%)
LIVER, Hepatocellular Carcinoma and Adenoma (Combined)						
	1/65[d] (1.5%)	5/62 (8.1%)	9/64[c] (14.1%)	12/64[c,d] (18.8%)	6/31[c,d] (19.4%)	196/2469[c] (7.9%)

[a]Statistical analyses were conducted on the combined data collected from animals which either spontaneously died or were sacrificed in a moribund state following the 12 month sacrifice and from animals at the 24 month scheduled sacrifice.

[b]NTP Bulletin #10.

[c] = Significantly different from the control group, $p < 0.05$.

[d] = Significantly different from historical control, $p < 0.05$.

IIT RESEARCH INSTITUTE

PATHOLOGY APPENDIX V:

Addendum - Histopathology Report

Lungs Sections

Histopathology Report:

Addendum - Lung Sections From

1.5, 7.0, and 35.0 mg/kg Dose Groups

Chronic Toxicity/Carcinogenicity Study

RDX in B6C3F1 Mice

24 Month Terminal Sacrifice

I.I.T.R.I. Project No. L 06121 Study No. 7

Sponsor Project No. DAMD-17-79-C-9161

Submitted by

John W. Sagartz, D.V.M.

Following the Sponsor's approval, all previously unexamined lung specimens from males and females of the 1.5, 7.0, and 35.0 mg/kg dose groups were sectioned and examined microscopically. Histopathologic findings for each animal were recorded on individual forms shown in Appendix A. These additional observations were tabulated on Histopathology Incidence Tables. These incidences were combined with those derived from the limited number of mice examined immediately following scheduled sacrifice. These combined incidences are recorded in the Incidence Comparison Table.

Noteworthy primary neoplastic lung lesions are shown in the following tabulation extracted from the Incidence Comparison Table:

	Males				
	0.0 mg/kg	1.5 mg/kg	7.0 mg/kg	35 mg/kg	175/100 mg/kg
No. Examined	(63)	(60)	(62)	(59)	(27)
Alveolar/ Bronchiolar Carcinoma	3/63	6/60	3/62	7/59	5/27
Alveolar/ Bronchiolar Adenoma	6/63	5/60	5/62	7/59	1/27
Alveolar/ Bronchiolar Carcinoma & Adenoma, Combined	9/63	11/60	8/62	14/59	6/27

	Females				
	0.0 mg/kg	1.5 mg/kg	7.0 mg/kg	35 mg/kg	175/100 mg/kg
No. Examined	(65)	(62)	(64)	(64)	(31)
Alveolar/ Bronchiolar Carcinoma	3/65	1/62	3/64	3/64	4/31
Alveolar/ Bronchiolar Adenoma	4/65	2/62	5/64	9/64	3/31
Alveolar/ Bronchiolar Carcinoma & Adenoma, Combined	7/65	3/62	8/64	12/64	7/31

The combined incidences of primary pulmonary neoplasms were increased in males of all dose groups and in females of the 7.0, 35.0, and 175/100 mg/kg dose groups. The occurrence of these neoplasms in mice of both sexes is regarded as random and of no biologic significance.

In males, malignant lymphoma was found in one control, 5 mice of the 7.0 mg/kg dose group, and 5 mice of the 35.0 mg/kg dose group. The increased incidences among the 7.0 and 35.0 mg/kg males are spontaneous and unrelated to the test compound.

As previously stated in the main report, the increased occurrence of pulmonary histiocytosis among females of the 175/100 mg/kg group was not regarded as treatment related.

A variety of other lung lesions were observed in treated mice of both sexes. These lesions are consistent in type and incidence with those commonly seen in mice of this age and strain, and are not considered related to the test compound.

In conclusion, microscopic examination of all remaining lung sections from male and female mice of the 1.5, 7.0, and 35.0 mg/kg dose groups revealed no compound-induced neoplastic or nonneoplastic lesions.

John W. Sagartz 2/25/84

John W. Sagartz, D.V.M. (Date)
Veterinary Pathologist

Cumulative Incidence Comparison Table

I.I.T.R.I.
Study No. L 06121 SN 7
Compound: RDX
Terminal Sacrifice

CUMULATIVE

INCIDENCE COMPARISON TABLE

ORGAN lesion	Group MALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35.0 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35.0 mg/kg/day	RDX 175/100 mg/kg/day
LUNGS		(63)	(60)	(62)	(59)	(27)		(65)	(62)	(64)	(64)	(31)
Alveolar/Bronchiolar Carcinoma		3/63	6/60	3/62	7/59	5/27		3/65	1/62	3/64	3/64	4/31
Fibrosarcoma, metastatic		1/63	0/60	4/62	2/59	0/27		0/65	0/62	1/64	1/64	0/31
Granulosa-cell Carcinoma, metastatic		0/63	0/60	0/62	0/59	0/27		0/65	0/62	1/64	0/64	0/31
Hemangiosarcoma, metastatic		0/63	0/60	0/62	0/59	0/27		0/65	1/62	0/64	1/64	0/31
Hepatocellular Carcinoma, metastatic		2/63	1/60	2/62	4/59	0/27		0/65	0/62	0/64	2/64	0/31
Leukemia, myeloid		1/63	3/60	0/62	3/59	0/27		1/65	0/62	0/64	1/64	1/31
Malignant Lymphoma		1/63	0/60	5/62	5/59	0/27		18/65	13/62	10/64	13/64	8/31
Mammary Adenocarcinoma, metastatic		0/63	0/60	0/62	0/59	0/27		0/65	0/62	1/64	0/64	0/31
Osteosarcoma		0/63	0/60	0/62	0/59	0/27		1/65	0/62	0/64	0/64	0/31
Pheochromocytoma, metastatic		0/63	0/60	0/62	0/59	0/27		0/65	0/62	0/64	1/64	0/31
Renal cell Carcinoma, metastatic		0/63	0/60	0/62	0/59	0/27		0/65	0/62	1/64	0/64	0/31
Squamous cell Carcinoma, metastatic		0/63	0/60	0/62	0/59	0/27		0/65	0/62	1/64	0/64	0/31
Undifferentiated Sarcoma		0/63	1/60	0/62	0/59	0/27		0/65	0/62	0/64	0/64	0/31
Alveolar/Bronchiolar Adenoma		6/63	5/60	5/62	7/59	1/27		4/65	2/62	5/64	9/64	3/31
Bronchiolitis, acute		1/63	0/60	0/62	0/59	0/27		0/65	0/62	0/64	0/64	0/31
Bronchopneumonia, acute		0/63	1/60	0/62	0/59	0/27		0/65	0/62	0/64	0/64	0/31
Congestion		5/63	6/60	9/62	5/59	1/27		4/65	1/62	6/64	2/64	1/31
Edema		0/63	0/60	0/62	0/59	0/27		1/65	0/62	1/64	0/64	0/31
Hemorrhage		6/63	4/60	4/62	7/59	1/27		8/65	4/62	3/64	0/64	1/31

I.I.T.R.I.
Study No. L 06121 SN 7
Compound: RDX
Terminal Sacrifice

CUMULATIVE
INCIDENCE COMPARISON TABLE

ORGAN lesion	Group MALES	RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35.0 mg/kg/day	RDX 175/100 mg/kg/day	FEMALES RDX 0.0 mg/kg/day	RDX 1.5 mg/kg/day	RDX 7.0 mg/kg/day	RDX 35.0 mg/kg/day	RDX 175/100 mg/kg/day
LUNGS (Continued)		(63)	(60)	(62)	(59)	(27)	(65)	(62)	(64)	(64)	(31)
Histiocytosis		2/63	1/60	0/62	2/59	3/27	1/65	1/62	3/64	3/64	9/31
Hyperplasia, alveolar		4/63	2/60	0/62	1/59	0/27	0/65	1/62	0/64	1/64	0/31
Lymphocytic Inflammatory Infiltrate		0/63	0/60	0/62	0/59	0/27	0/65	1/62	0/64	1/64	0/31
Mineralization		0/63	0/60	0/62	0/59	0/27	0/65	0/62	0/64	1/64	0/31
Thrombus		0/63	0/60	0/62	0/59	1/27	0/65	0/62	0/64	0/64	0/31

Histopathologic Incidence Table

I .R...
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5 mg/kg/day

HISTOPATHOLOGY INCIDENCE TABLE

Male Mice

Group II

ORGAN / Lesion	Accession Number	81-0597	81-0598	81-0601	81-0602	81-0603	81-0604	81-0605	81-0606	81-0607	81-0608	81-0609	81-0611	81-0612	81-0616	81-0617	81-0618	81-0619	81-0624	81-0625	81-0626	Incidence
LUNGS		N	N	N	L	N	N	N	N	L	N	N	N	N	L	N	N	L	L	N	N	
Alveolar/Bronchiolar Carcinoma, solitary																						
Hepatocellular Carcinoma, metastatic															.			P				
Leukemia, myeloid																						
Alveolar/Bronchiolar Adenoma, solitary					P																	
Congestion, diffuse																		3				
Congestion, multifocal										2												
Hemorrhage, multifocal															2				3			
Hyperplasia, alveolar, focal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5

HISTOPATHOLOGY INCIDENCE TABLE

Male Mice

Group II (Con't.)

ORGAN Lesion	Accession Number	81-0628	81-0629	81-0630	81-0631	81-0632	81-0633	81-0634	81-0635	81-0636	81-0638	81-0643	81-0646	81-0647	81-0648	81-0650	81-0651	81-0652	81-0653	81-0654	81-0656	Incidence
LUNGS		N	L	L	L	N	N	N	L	N	L	N	L	L	N	N	N	N	N	N	N	
Alveolar/Bronchiolar Carcinoma, solitary													P									
Hepatocellular Carcinoma, metastatic																						
Leukemia, myeloid													P									
Alveolar/Bronchiolar Adenoma, solitary			P	P					P													
Congestion, diffuse					2						3											
Congestion, multifocal			2																			
Hemorrhage, multifocal														2								
Hyperplasia, alveolar, focal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5

HISTOPATHOLOGY INCIDENCE TABLE

Male Mice

Group II (Con't.)

ORGAN Lesion	Accession Number	81-0657	81-0658	81-0660	81-0661	81-0663	81-0665	81-0667	81-0668	81-0669	81-0671											Incidence
LUNGS		N	N	L	L	L	N	N	L	N	N											(50)
Alveolar/Bronchiolar Carcinoma, solitary																						1/50
Hepatocellular Carcinoma, metastatic																						1/50
Leukemia, myeloid				P																		2/50
Alveolar/Bronchiolar Adenoma, solitary									P													5/50
Congestion, diffuse																						3/50
Congestion, multifocal																						2/50
Hemorrhage, multifocal																						3/50
Hyperplasia, alveolar, focal					2	2																2/50

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0

HISTOPATHOLOGY INCIDENCE TABLE

Male Mice

Group III

ORGAN Lesion	Accession Number	81-0747	81-0748	81-0749	81-0750	81-0752	81-0753	81-0754	81-0758	81-0759	81-0760	81-0761	81-0762	81-0763	81-0764	81-0765	81-0767	81-0768	81-0769	81-0770	81-0771	Incidence
LUNGS		N	N	N	L	N	L	N	L	N	L	L	L	N	L	N	L	N	N	N	N	
Alveolar/Bronchiolar Carcinoma, solitary									P													
Fibrosarcoma, metastatic												P			P							
Hepatocellular Carcinoma, metastatic																						
Malignant Lymphoma, lymphocytic type					P																	
Malignant Lymphoma, mixed type																	P					
Alveolar/Bronchiolar Adenoma, solitary							P															
Congestion, multifocal												2										
Congestion, diffuse											2											
Hemorrhage, multifocal													2									

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

1200

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0

HISTOPATHOLOGY INCIDENCE TABLE

Male Mice

Group III (Con't.)

ORGAN Lesion	Accession Number	81-0773	81-0774	81-0775	81-0776	81-0777	81-0778	81-0779	81-0781	81-0782	81-0784	81-0786	81-0787	81-0788	81-0789	81-0790	81-0791	81-0792	81-0793	81-0794	81-0795	Incidence
LUNGS		L	L	N	L	N	L	N	N	N	L	L	N	N	L	N	N	N	N	N	N	
Alveolar/Bronchiolar Carcinoma, solitary							P															
Fibrosarcoma, metastatic																						
Hepatocellular Carcinoma, metastatic											P											
Malignant Lymphoma, lymphocytic type																						
Malignant Lymphoma, mixed type					P										P							
Alveolar/Bronchiolar Adenoma, solitary			P												P							
Congestion, multifocal			2																			
Congestion, diffuse		2																				
Hemorrhage, multifocal												2										

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0

HISTOPATHOLOGY INCIDENCE TABLE

Male Mice

Group III (Con't.)

ORGAN Lesion	Accession Number	81-0796	81-0797	81-0798	81-0799	81-0804	81-0805	81-0806	81-0807	81-0809	81-0811	81-0812	81-0813	81-0815	81-0817	81-0820	81-0821					Incidence
LUNGS		L	N	L	N	N	N	L	N	L	N	L	L	L	L	N	N					(56)
Alveolar/Bronchiolar Carcinoma,solitary																						2/56
Fibrosarcoma, metastatic												P			.							3/56
Hepatocellular Carcinoma, metastatic																						1/56
Malignant Lymphoma, lymphocytic type																						1/56
Malignant Lymphoma, mixed type																						3/56
Alveolar/Bronchiolar Adenoma, solitary						.							P		P							5/56
Congestion, multifocal																						2/56
Congestion, diffuse		2		2				2						3								6/56
Hemorrhage, multifocal										2												3/56

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0

HISTOPATHOLOGY INCIDENCE TABLE

Male Mice

Group IV

ORGAN Lesion	Accession Number	81-0898	81-0902	81-0903	81-0904	81-0905	81-0907	81-0909	81-0910	81-0912	81-0913	81-0914	81-0915	81-0919	81-0920	81-0924	81-0927	81-0928	81-0929	81-0930	81-0931	Incidence
LUNGS		N	L	N	L	N	L	N	N	N	L	N	L	N	N	L	N	L	N	N	L	
Alveolar/Bronchiolar Carcinoma, solitary																						
Leukemia, myeloid															.	P						
Malignant Lymphoma, mixed type																						
Alveolar/Bronchiolar Adenoma, solitary					P		P				P		P									
Congestion, diffuse																					2	
Congestion, multifocal																						
Hemorrhage, focal																						
Hemorrhage, multifocal			2															3				
Histiocytosis, multifocal																						
Hyperplasia, alveolar, focal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0

HISTOPATHOLOGY INCIDENCE TABLE

Male Mice

Group IV (Con't.)

ORGAN / Lesion	Accession Number	81-0932	81-0933	81-0934	81-0935	81-0937	81-0938	81-0940	81-0941	81-0943	81-0944	81-0945	81-0946	81-0949	81-0951	81-0952	81-0954	81-0955	81-0956	81-0957	81-0960	Incidence
LUNGS		N	N	L	L	L	L	L	N	L	N	L	N	L	N	L	N	L	L	L	L	
Alveolar/Bronchiolar Carcinoma, solitary							P															
Leukemia, myeloid						P		P														
Malignant Lymphoma, mixed type				P	P		P					P										
Alveolar/Bronchiolar Adenoma, solitary																P		P				
Congestion, diffuse																			2			
Congestion, multifocal														2								
Hemorrhage, focal										2												
Hemorrhage, multifocal																				2		
Histiocytosis, multifocal																						
Hyperplasia, alveolar, focal																					1	

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0

HISTOPATHOLOGY INCIDENCE TABLE

Male Mice

Group IV (Con't.)

ORGAN Lesion	Accession Number	81-0961	81-0962	81-0964	81-0965	81-0966	81-0969														Incidence
LUNGS		N	L	N	N	L	L														(46)
Alveolar/Bronchiolar Carcinoma,solitary			P																		2/46
Leukemia, myeloid																					3/46
Malignant Lymphoma, mixed type																					4/46
Alveolar/Bronchiolar Adenoma, solitary																					6/46
Congestion, diffuse							2														3/46
Congestion, multifocal																					1/46
Hemorrhage, focal						2															2/46
Hemorrhage, multifocal																					3/46
Histiocytosis, multifocal			2																		1/46
Hyperplasia, alveolar, focal																					1/46

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5

HISTOPATHOLOGY INCIDENCE TABLE

Female Mice

Group II

ORGAN Lesion	Accession Number	81-0674	81-0675	81-0676	81-0677	81-0678	81-0679	81-0680	81-0682	81-0683	81-0684	81-0686	81-0688	81-0689	81-0690	81-0691	81-0693	81-0694	81-0695	81-0696	81-0698	Incidence
LUNGS		N	L	N	N	N	L	L	N	L	L	L	L	N	N	N	N	L	N	N	N	
Alveolar/Bronchiolar Carcinoma,solitary								P														
Hemangiosarcoma, metastatic																						
Malignant Lymphoma, lymphocytic type							P															
Malignant Lymphoma, mixed type										P	P	P	P					P				
Malignant Lymphoma, plasmacytic type																						
Alveolar/Bronchiolar Adenoma, solitary			P																			
Hemorrhage, focal																						
Histiocytosis, focal																						
Hyperplasia, alveolar, focal													2									
Lymphocytic Inflammatory Infiltrate																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 00121 SN
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5

HISTOPATHOLOGY INCIDENCE TABLE

Female Mice

Group II (Con't.)

ORGAN Lesion	Accession Number	81-0699	81-0702	81-0703	81-0704	81-0706	81-0707	81-0709	81-0710	81-0711	81-0712	81-0713	81-0714	81-0716	81-0718	81-0719	81-0720	81-0722	81-0723	81-0724	81-0725	Incidence
LUNGS		L	N	N	L	N	N	N	N	N	N	N	L	N	N	N	N	N	L	N	N	
Alveolar/Bronchiolar Carcinoma, solitary																						
Hemangiosarcoma, metastatic																						
Malignant Lymphoma, lymphocytic type																			P			
Malignant Lymphoma, mixed type																						
Malignant Lymphoma, plasmacytic type		P																				
Alveolar/Bronchiolar Adenoma, solitary																						
Hemorrhage, focal					1																	
Histiocytosis, focal																						
Hyperplasia, alveolar, focal																						
Lymphocytic Inflammatory Infiltrate													2									

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

I.I.T.R.I.
Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 1.5

HISTOPATHOLOGY INCIDENCE TABLE

Female Mice

Group II (Con't.)

ORGAN Lesion	Accession Number	81-0727	81-0729	81-0730	81-0731	81-0732	81-0733	81-0735	81-0736	81-0737	81-0738	81-0739	81-0742	81-0743	81-0745	81-0746						Incidence
LUNGS		N	L	N	L	N	N	L	N	N	L	L	N	N	N	N						(55)
Alveolar/Bronchiolar Carcinoma, solitary																						1/55
Hemangiosarcoma, metastatic					P																	1/55
Malignant Lymphoma, lymphocytic type																						2/55
Malignant Lymphoma, mixed type								P				P										7/55
Malignant Lymphoma, plasmacytic type																						1/55
Alveolar/Bronchiolar Adenoma, solitary			P																			2/55
Hemorrhage, focal																						1/55
Histiocytosis, focal											1											1/55
Hyperplasia, alveolar, focal																						1/55
Lymphocytic Inflammatory Infiltrate																						1/55

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0

HISTOPATHOLOGY INCIDENCE TABLE

Female Mice

Group III

ORGAN Lesion	Accession Number	81-0823	81-0824	81-0825	81-0826	81-0828	81-0829	81-0830	81-0831	81-0833	81-0834	81-0836	81-0838	81-0839	81-0840	81-0841	81-0843	81-0844	81-0846	81-0847	81-0848	Incidence
LUNGS		N	N	N	N	N	N	N	N	N	N	L	L	L	N	N	N	L	L	L	N	
Alveolar/Bronchiolar Carcinoma, solitary																						
Malignant Lymphoma, mixed type														P				P				
Mammary Adenocarcinoma, metastatic																						
Squamous Cell Carcinoma, metastatic																						
Alveolar/Bronchiolar Adenoma, solitary													P									
Congestion, multifocal												2										
Congestion, diffuse																			2	2		
Hemorrhage, focal																						
Histiocytosis, focal																						
Histiocytosis, multifocal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0

HISTOPATHOLOGY INCIDENCE TABLE

Female Mice

Group III (Con't.)

ORGAN Lesion	Accession Number	81-0850	81-0851	81-0853	81-0855	81-0856	81-0857	81-0858	81-0859	81-0860	81-0861	81-0863	81-0864	81-0866	81-0867	81-0869	81-0871	81-0872	81-0873	81-0874	81-0875	Incidence
LUNGS		N	L	L	L	N	L	L	L	L	L	N	N	L	N	N	N	N	N	N	L	
Alveolar/Bronchiolar Carcinoma, solitary														P								
Malignant Lymphoma, mixed type			P					P		P	P										P	
Mammary Adenocarcinoma, metastatic					P																	
Squamous Cell Carcinoma, metastatic																						
Alveolar/Bronchiolar Adenoma, solitary				P						P												
Congestion, multifocal						.	2	2														
Congestion, diffuse									3													
Hemorrhage, focal																						
Histiocytosis, focal										2												
Histiocytosis, multifocal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 7.0

HISTOPATHOLOGY INCIDENCE TABLE

Female Mice

Group III (Con't.)

ORGAN Lesion	Accession Number	81-0876	81-0877	81-0879	81-0880	81-0881	81-0882	81-0885	81-0888	81-0890	81-0892	81-0893	81-0894	81-0895	81-0896						Incidence
LUNGS		L	L	N	L	N	N	N	L	L	N	L	N	L	N						(54)
Alveolar/Bronchiolar Carcinoma, solitary					P																2/54
Malignant Lymphoma, mixed type		P										P									9/54
Mammary Adenocarcinoma, metastatic																					1/54
Squamous Cell Carcinoma, metastatic														P							1/54
Alveolar/Bronchiolar Adenoma, solitary																					3/54
Congestion, multifocal																					3/54
Congestion, diffuse																					3/54
Hemorrhage, focal			2							2											2/54
Histiocytosis, focal									1												2/54
Histiocytosis, multifocal					2																1/54

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0

HISTOPATHOLOGY INCIDENCE TABLE

Female Mice

Group IV

ORGAN Lesion	Accession Number	81-0973	81-0974	81-0975	81-0976	81-0977	81-0978	81-0980	81-0981	81-0982	81-0983	81-0985	81-0986	81-0987	81-0989	81-0990	81-0991	81-0994	81-0995	81-0999	81-1000	Incidence
LUNGS		N	N	L	N	N	L	N	L	L	L	N	L	N	N	N	L	L	N	L	N	
Alveolar/Bronchiolar Carcinoma, solitary																						
Hepatocellular Carcinoma, metastatic											P											
Leukemia, myeloid																						
Malignant Lymphoma, histiocytic type				P																		
Malignant Lymphoma, lymphocytic type																		P				
Malignant Lymphoma, mixed type																	P					
Pheochromocytoma, metastatic																						
Alveolar/Bronchiolar Adenoma, solitary							P		P				P									
Alveolar/Bronchiolar Adenoma, multifocal																						
Congestion, diffuse										2												
Histiocytosis, focal																						
Histiocytosis, multifocal									2													
Hyperplasia, alveolar, focal																						
Lymphocytic Inflammatory Infiltrate																						
Mineralization, focal																				1		

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN (
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0

HISTOPATHOLOGY INCIDENCE TABLE

Female Mice

Group IV (Con't.)

ORGAN Lesion	Accession Number	81-1001	81-1003	81-1004	81-1005	81-1006	81-1007	81-1008	81-1010	81-1013	81-1014	81-1015	81-1016	81-1018	81-1020	81-1021	81-1022	81-1024	81-1025	81-1026	81-1027	Incidence
LUNGS		N	L	N	L	L	N	N	N	N	L	N	N	N	N	L	N	N	L	L	N	
Alveolar/Bronchiolar Carcinoma, solitary																						
Hepatocellular Carcinoma, metastatic			P																			
Leukemia, myeloid																						
Malignant Lymphoma, histiocytic type																						
Malignant Lymphoma, lymphocytic type						P																
Malignant Lymphoma, mixed type					P											P						
Pheochromocytoma, metastatic																						
Alveolar/Bronchiolar Adenoma, solitary																				P		
Alveolar/Bronchiolar Adenoma, multifocal																P						
Congestion, diffuse																						
Histiocytosis, focal																			2			
Histiocytosis, multifocal																						
Hyperplasia, alveolar, focal																			2			
Lymphocytic Inflammatory Infiltrate											3											
Mineralization, focal																						

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded

Study No.: L 06121 SN 7
Compound: RDX
Terminal Sacrifice
Dose (mg/kg/day): 35.0

HISTOPATHOLOGY INCIDENCE TABLE

Female Mice

Group IV (Con't.)

ORGAN Lesion	Accession Number	81-1028	81-1031	81-1032	81-1035	81-1036	81-1037	81-1039	81-1040	81-1041	81-1042	81-1043	81-1044	81-1045								Incidence
LUNGS		L	L	L	L	N	N	L	N	N	L	N	L	L								(53)
Alveolar/Bronchiolar Carcinoma, solitary														P								1/53
Hepatocellular Carcinoma, metastatic																						2/53
Leukemia, myeloid								P														1/53
Malignant Lymphoma, histiocytic type																						1/53
Malignant Lymphoma, lymphocytic type																						2/53
Malignant Lymphoma, mixed type		P												P								5/53
Pheochromocytoma, metastatic					P																	1/53
Alveolar/Bronchiolar Adenoma, solitary			P	P							P		P									8/53
Alveolar/Bronchiolar Adenoma, multifocal																						1/53
Congestion, diffuse																						1/53
Histiocytosis, focal																						1/53
Histiocytosis, multifocal																						1/53
Hyperplasia, alveolar, focal																						1/53
Lymphocytic Inflammatory Infiltrate																						1/53
Mineralization, focal																						1/53

Symbols: N = Within Normal Limits
L = Lesion Present
M = Tissue Not Present
- = Tissue Not Applicable

Severity: 1 = Minimal
2 = Mild
3 = Moderate
4 = Marked
P = Presence of lesion which cannot be graded